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.
Part I. The first enantiospecific, stereospecific total synthesis of ervincidine 89 has been
accomplished from commercially available D-(+)-tryptophan 37 which has served both as
the chiral auxiliary and the starting material. Moreover, this is the first synthesis which
unequivocally sets the stereochemistry of the hydroxyl group at C-6 in sterospecific
fashion, as well as the C-16 hydroxy methyl group. The stereospecific conversion of D(+)-tryptophan 37 into the key template (−)-Na-H, Nb-benzyl tetracyclic ketone 49 via the
asymmetric Pictet-Spengler reaction (600 gram scale) and Dieckmann cyclization on
multi-hundred gram scale was reduced to only two reaction vessels. The optically active
tetracyclic ketone 49 was converted into the core pentacyclic framework 56 using the
intramolecular palladium-mediated enolate cross coupling reaction which was developed
ii

here in Milwaukee to afford the core pentacylic framework 56. This robust reaction could
be scaled up to multigram scale in this series. Important to success here were the
sequence of chemical reactions which included a Wittig reaction, a regioselective
hydroboration and protection/deprotection steps in order to provide regiospecific
oxidation at C-6. The IBX mediated oxidation and the Luche reduction using CeCl3.
7H20 in the presence of NaBH4 afforded the first enantiospecific, stereospecific total
synthesis of ervincidine 89. The indole alkaloid ervincidine 89 could be prepared from D(+)-tryptophan 37 in 13 reaction vessels in 19.2% overall yield. Another important
experiment was the epimerization of the C-6 alcohol with 0.2N HCl which indicated that
care must be employed in isolation of these alkaloids which contain a benzylic hydroxyl
group. This research process developed here also provides a general entry to the C-6
hydroxy substituted indole alkaloids of either alpha or beta stereochemistry. Two other
diasteromers were made to rule them out as potential structures. This research corrects
the errors in Glasby’s book and Lousnamma’s review and clarifies the work of Yunusov
et al. as well as providing the correct absolute configuration of the C-6 hydroxyl function
in ervincidine 89.
Part.II..GABAA/BzR

chloride

ion

channels

comprise

the

major

inhibitory

neurotransmitter system in the CNS. This central role carries with it a direct influence on
many diseases of the CNS. Inverse agonists acting at α5 subunits containing GABAA
receptors are thought to act as cognitive enhancers while eliminating unwanted side
effects associated with non-selective compounds. From the recent work of Rowlett, Cook
et.al. it was demonstrated that novel α5 selective inverse agonist PWZ-029 was evaluated
as a cognitive enhancer in rhesus monkeys in the CANTAB paradigm. This ligand had

iii

the ability to reverse cholinergic deficits in performance induced by the antimuscarinic
scopolamine under mixed trial conditions. In the ORD task, PWZ-029 showed only a
modest trend for enhancement of performance, but when task difficulty was increased by
testing with difficult trials only, PWZ-029 robustly increased performance.

This

enhancement was reversed by administration of the α5 GABA (A) subtype selective
antagonist XLi-093 and this antagonism in turn was reversed by increasing the dose of
PWZ-029. In addition, PWZ-029 enhanced performance in the DNMS task using the 10
minute delay with distracters. This ligand also exhibited anxiolytic activity in some
primates and was an orally active anticonvulsant in rats. These findings are consistent
with a key role for α5 GABAA receptors in the treatment of age-associated memory
impairment and Alzheimer’s disease.
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I. THE FIRST ENANTIOSPECIFIC, STEREOSPECIFIC TOTAL
SYNTHESIS OF THE INDOLE ALKALOID ERVINCIDINE

2

1. Introduction
1.1. Classification and biological activity of the sarpagine/macroline related indole
alkaloids
Alkaloids are of importance due to their biological activity. They are distributed diversely
and have been isolated from plant and animal sources worldwide.1-5 Indole alkaloids are
of prominence because of the similarity with tryptophan which is an essential amino acid.
The medicinal properties6 of these indole alkaloids remain of great interest as well as the
nature of their structure and stereochemistry. From the synthetic point of view, these
complex molecules remain of paramount significance. The enantiospecific and
regiospecific synthesis of alkaloids or their enantiomers has always been a challenge to
the synthetic chemist.7-9 Synthetic routes are designed and revised continually in order to
provide material for testing and for commercial uses. For all of these reasons, indole
alkaloids play an important role in organic chemistry. This chapter includes the various
classes of ajmaline and sarpagine-related indole alkaloids and also provides the previous
synthetic methods to construct these molecules.10
Biological activity of sarpagine/macroline related indole alkaloids
Indole alkaloids of the sarpagine/macroline/ajmaline type comprise one of the largest
groups of structurally related indole natural products.10 These indole alkaloids are
primarily

isolated

from

three

plant

families:

Apocynaceae,

Rubiaceae

and

Loganiaceae.11-13 Interest in the macroline/sarpagine alkaloids originated as a result of
folk tales that described the medicinal properties of the plants from which these alkaloids
were isolated.9,14 Various species of Rauwolfia which are broadly distributed among Asia

3

and Africa

15-20

are widely used in traditional Chinese medicine for the treatment of

neuralgia, migraine21 and hypertension.18,20,22
As early as 1958,23 and later in 196724 the bisindole macralstonine 1a (Figure 1), which
had been isolated from Alstonia macrophylla Wall and Alstonia muelleriana Domin, was
shown to exhibit potent hypotensive activity.
Nine alkaloids from Alstonia angustifolia were tested by Wright et al.25 for antiprotozoal
activity against Entamoeba histolytica and Plasmodium falciparum in vitro (Table 1).
Three dimeric alkaloids, macralstonine O-acetate 1b,26 (-)-macrocarpamine 2a,27 and (+)villalstonine 3a28,

29

(Figure 1) were found to possess significant activity against both

protozoa. Macrocarpamine 2a was found to be the most active antiamoebic compound
with an antiamoebic activity one fourth that of the standard drug emetine. Villalstonine
3a was found to be the most potent alkaloid against P. falciparum, and was about fifteen
Figure 1. Bisindoles
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times less active than the antimalarial drug chloroquine. The acetate of macralstonine 1b
was much more active against both protozoa when compared with the parent
macralstonine 1a. The monomeric alkaloids were found to be considerably less active
than the bisindoles. These results were in agreement with the studies carried out later by
Houghton et al. (Tables 2 and 3).30 The results of these in vitro studies provide some
basis for the traditional use of the plant extract from Alstonia angustifolia for the
treatment of amoebic dysentery and malaria by the people of the Malay peninsula.31,32
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Table 1. Antiamoebic and Antimalarial Activity of Selected Alstonia Alkaloids25
Alkaloids

E. histolytica

P. falciparum

ED50(95% C. I.) µM

ED50(95% C. I.) µM

alstonerine

75.3(65.0-85.6)

46.3(27.7-77.3)

alstophylline

67.7(57.2-78.2)

82.3(65.9-102)

macralstonine

inactive at 70

inactive at 178

O-acetyl macralstonine

15.51(14.78-16.24)

3.43(1.86-6.34)

villalstonine

11.8(11.7-12.0)

2.92(1.11-3.14)

pleiocarpamine

47.4(46.8-52.90)

20.5(12.6-33.17)

macrocarpamine

8.21(7.76-8.48)

9.36(7.20-12.1)

11-methoxyakuammicine

70.5(65.3-75.6)

41.3(26.5-64.3)

norfurocurarine

84.1(82.9-89.6)

129(70.2-239)

vincamajine

inactive at 70

138(79.3-238)

ED50: Effective dose at 50% inhibition. See Table 2 for source of P.falciparum

The bisindole alkaloid accedinisine 4a was first reported to be isolated from the root of
epithelium T. accedens in 1976.33

Later in 1994,

accedinisine 4a and N′-

demethylaccedinisine 4b were isolated from Peschiera van heurkii. These two bisindole
alkaloids exhibited potent antileishmanial and antibacterial activities.34 Dimeric alkaloids
are often more potent in vivo than their monomeric progenitors. Much of the early
isolation and structural work on the Alstonia alkaloids was performed in the laboratories
of Elderfield35 and Schmid36,37 and was followed by the biomimetic interconversions of
LeQuesne et al.26,28,29,38-40
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Table 2. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 and T9-96
strains)30
Alkaloids

K1 (μM, n = 3)

T9-96 (μM, n = 3)

K1/T9-96 ratio

O-acetyl macralstonine

0.53 ± 0.09

12.4 ± 1.6

0.04

villalstonine

0.27 ± 0.06

0.94 ± 0.07

0.29

alstomacroline

1.12 ± 0.35

10.2 ± 0.4

0.11

macrocarpamine

0.36 ± 0.06

>39*

<0.009

chloroquine diphosphate

0.20 ± 0.07

0.019 ± 0.002

10.53

K1: the multi-drug resistant strain, which is highly resistant to chloroquine; T9-96: the chloroquine
sensitive strain; n: number of independent experiments; *: % inhibition at 39 µM (7.5 µg/mL), the highest
concentration tested was 32.6 ± 4.1 µM. The experiment was done with infected human red blood cells.

During the structure determination of Alstonia bisindole alkaloids by Schmid et al.36,37
macroline 6 (Figure 3) was obtained as a degradation product from villalstonine 3a. To
date, macroline 6 has not been isolated as a natural product but it is believed to be a
biomimetic precursor to many Alstonia alkaloids.26,28,29,38,39
Studies on individual sarpagine/ajmaline indole alkaloids have shown normacusine B
exhibited sedative and ganglion blocking activity,41 lochnerine elicited hypoglycemic
activity,42 pericyclivine has been shown to exhibit weak cytotoxic activity against P-388
leukemia,43 while gardnutine, gardnerine, and hydroxygardnutine have been shown to
elicit ganglion blocking effects as well as anticancer activity.44-46 The mixture of
constituents (normacusine B, affinisine, Na-methylpericyclivine, and voachalotine)
present in Peschiera van Heurckii from the tropical rain forest in Bolivia is known for its
alleged leishmanicidal and bactericidal activity.34 Like many quaternary alklaoids, the

7

major quaternary sarpagine alkaloid from Strychnos angolensis, 11-methylmacusine A,
demonstrated muscle relaxant
Table 3. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 strain)47
ALKALOID

n

IC50 (µg/mL)

talcarpine

3

40.3 ± 2.9

pleiocarpamine

2

6.44 ± 0.98

alstoumerine

2

13.1 ± 2.7

20-epi-antirhine

3

7.51 ± 1.17

alstonerine

2

9.67 ± 3.57

alstophylline

2

12.7 ± 1.7

macralstonine

3

8.92 ± 2.95

O-methylmacralstonine

2

0.85 ± 0.20

O-acetylmacralstonine

3

0.53 ± 0.09

alstomacrophylline

2

1.10 ± 0.30

villalstonine

3

0.27 ± 0.06

villalstonine Nb-oxide

2

10.7 ± 1.9

alstomacroline

3

1.12 ± 0.35

macrocarpamine

3

0.36 ± 0.06

chloroquine diphosphate

3

0.20 ± 0.07

K1 strain: multidrug resistant strain; n: number of independent experiments. The test was done with
infected human red blood cells.

activity.48 The crude mixture of nine alkaloids present in Ervatamia yunnanesis is used in
Chinese folk medicine for the treatment of hypertension.22 Scientists have begun to
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evaluate these alkaloids for activity against cancer49,50 and HIV,51,52 however, the paucity
of isolable material from these plants has retarded in depth evaluation.
Figure 2. Dimeric Indole Alkaloids accedinisine and N′-demethylaccedinisine
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The number of macroline-related alkaloids which have been isolated has increased
rapidly. At this time, the group contains more than 150 alkaloids, of which over a 100 are
monomeric indoles. The remainder belongs to the bisindole class of alkaloids.40,53-55 The
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sarpagine group of alkaloids (represented by 7, Figure 3) is the largest class of natural
products related to the macroline bases and both series originate from common biogenetic
intermediates. Illustrated in Figure 3 are the basic macroline and sarpagine skeletons. The
biogenetic numbering of LeMen and Taylor56 is used throughout this chapter. Note the
four stereocenters at C-3, C-5, C-15 and C-16 in macroline. The β-hydrogen atom at C-15
of this group, as well as the chiral centers at C-3, C-5 and C-16 are the same for the
sarpagine series. The two classes can be related in a synthetic sense by a Michael addition
of the nitrogen atom of N-4 of macroline 6 to the α, β-unsaturated carbonyl system at C21, or by direct 1, 2 addition of N-4 to the ketone at C-19, as illustrated in Figure 4.54,55
Conversely, sarpagine can be converted into macroline 6 by a retro-Michael reaction or
Hoffmann elimination of the Nb-methyl intermediate, as demonstrated earlier by
LeQuesne et al.38 (see Figure 4).
Figure 4. Biosynthetic Relationship Between Macroline and Sarpagine
H

H
H
N
Me

ref. 23

N

H
OR

1, 2

d it i
- ad

on

20
H

H 19
O
6, R = H, macroline
9, R = TBS

1,

4-

ad

dit

N
Me

OH
R''

N
H

H R'
12, R' = (=CH2)
13, R'' = OH, CH3
H

ion

N
Me

H

OR

N
H

O
H
H

23

R = TBS
retro Michael reaction or
Hoffmann elimination

10, R = H
11, R = TBS

10

The macroline/sarpagine alkaloids bear important structural similarities to the ajmaline
alkaloids, the latter of which are well known for their biological activity.57 Ajmaline 8, is
a clinically important indole alkaloid with historical significance.58,59 Both these bases are
structurally related by the presence of the quinuclidine ring and the C-5―C-16 bond
linkage. The absolute configurations of the stereogenic centers at C-3, C-5 and C-15 of
both series are identical, except at C-16 which is antipodal to the sarpagine series. The
biogenetic connection between the sarpagine and ajmaline alkaloids proposed earlier60-62
was confirmed by Stöckigt et al.63-66 by conversion of 16-epi-vellosimine 14 into
deacetylvinorine 16 in the presence of the enzyme, acetyl-CoA dependent vinorine
synthase (see Figure 5).
Figure 5. Biosynthetic Relationship Between Sarpagine and Ajmaline Type Alkaloids
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Table 4. Sarpagine Indole Alkaloids (1)40

Structure

Alkaloid

R'
H

H
CHO

N
R

N
H

H

H
N
R

H

OR'

N
H

H

R1O
H
N
R

H

OR2

N
H

H

R2
H

CO2CH3
H

N
R1

N
H

H

Refs.

R=H, R'=H, vellosimine

(40)

R=Me, R'=H, Na-methylvellosimine

(40)

R=H, R'=OMe, 10-methoxyvellosimine

(40)

R=Me , R'=OMe, majvinine

(40)

R=H, R'=H, normacusine B

(40)

R=H, R'=Ac, O-acetylnormacusine B

(40)

R=H, R'=COPh, O-benzoyl
normacusine B

(40)

R=H, R'=Me, O-methylnormacusine B

(40)

R=Me, R'=H, affinisine

(40)

R=R1=R2=H, sarpagine

(40)

R=H, R1=Me, R2=H, lochnerine

(40)

R=R1=H, R2=Ac, O-acetylsarpagine

(40)

R=Me, R1=R2=H, Na-methylsarpagine

(40)

R1=R2=H, pericyclivine

(40)

R1=CH3, R2=H,
Na-methylpericyclivine

(40)

R1=H, R2=OH, 10-hydroxy
pericyclivine

(40)

R1=H, R2=OMe, 10-methoxy
pericyclivine

(40)

R1=Me, R2=OH, 10-hydroxyNa-methylpericyclivine

(40)

R1=Me, R2=OMe, 10-methoxyNa-methylpericyclivine

(40)
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Table 4. Sarpagine Indole Alkaloids (2) 67-69

Structure

Alkaloid

R2

OH
H

R3

H

R1=R3=H, R2=OH, 16-episarpagine

(40)

R1=R3=H, R2=OMe, lochvinerine

(40)

R1=R2=H, R3=OCH3, gardnerine

(40)

R'=OMe, R= H, 18-hydroxy
lochnerine

(40)

R'=H, R=Me, 18-hydroxy
affinisine

(40)

18-hydroxygardnerine

(40)

11-methoxy-Na-methyldihydropericyclivine

(68)

R=H, R'=CH=CHCOCH3, difforine

(40, 69)

R=CH3, R'=CO2CH3
Na-methyl-16-epipericyclivine

(40, 70)

N

N
R1

H

H

Refs.

R'
H
N
R

H

OH

N
H

H
OH
OH
H

H3CO

H
N
H

N
H

H
OH

H

H3CO

CO2CH3
H

N
Me

N
H

H

H

H
R'

N
R

N
H

H
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Table 4. Sarpagine Indole Alkaloids (3)

Structure

Alkaloid

Refs.

R1
H
R2
N
H

H

H

OH
O

N

H

H

R1=OH, R2=CH3
verticillatine (Cl salt)

(40)

R1=H, peraksine
(vomifoline)

(40)

macrosalhine bromide

(40)

O-acetylpreperakine

(40)

H

H

H
O

N

N
Me

OH

H

H

H
H

Br

H

H
CH2OAc

N
H

N
H

H

CHO

R1
H
N
H

H

H

CH2OH

H

(40)

R1=OH, R2=CH2OH,
10-hydroxy-19(S),20(R)dihydroperaksine

(40)

R1=H, R2=CHO,
19(S),20(R)-dihydroperaksine-17al

(40)

H
R2

N
H

R1=H, R2=CH2OH,
19(S),20(R)-dihydroperaksine

R'

R=R"=H, R'=CH2OH,
16-epinormacusine B

(40)

R=Me, R'=CH2OH, R"=H,
16-epiaffinisine

(40)

R"
N
R

N
H

H

R=Me, R'=CH2OAc, R"=H,
O-acetyl-16-epiaffinisine

(40)
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Table 4. Sarpagine Indole Alkaloids (4)

Structure
H
N
Me

Alkaloids

Refs.

voacoline

(40)

trinervine

(40)

venecurine

(40)

CO2CH3
O

N

OH

H

H

Me
H

H
N
H

H
O

N
H

OH
H

Me
H

H
N
H

H
O

N

OH

H

H

Me
H

R
H
N
R'

H

N
H

R=H, R'=Me, talpinine

(40)

R=OMe, R'=H, 21-hydroxy
cyclolochnerine

(40)

OH O
H
H

H
N
H

CO2CH3
O

N
H

H
OH

eburnaphylline

(40)

15

Table 4. Sarpagine Indole Alkaloids (5)70-73

Structure

Alkaloid

Refs.

neo-sarpagine

(71)

HO
H

H

OH

N

N
H

H

H
H

R
H

H

OH

N

N
H HO

R=OH, 3-hydroxysarpagine

H

OH H
H

H

ervincidine

(73)

(40, 138,139)

H

O
H

H

R2

(72)

OH

N

N
H

R=H,
Na-demethylaccedine
(amerovolfine)

R1=CH3, R2=H, R3=CH3,
dehydro-16-epiaffinisine

(40)

R1=H, R2=OCH3, R3=CH3,
gardnutine

(40)

R1=H, R2=OCH3, R3=CH2OH,
18-hydroxygardnutine

(40, 74)

R=H, dehydrovoachalotine

(40)

R=OH, 17-hydroxydehydrovoachalotine

(40)

H
N

N
R1

H

H
R3
R

O
H

H
CO2Me

N
Me

N
H

H
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Table 4. Sarpagine Indole Alkaloids (6)

Structure
H

H
N
Me

Refs.

alstoumerine

(40)

koumidine

(40)

OH

N
H

Alkaloid

H

H

OH

OH
H
H
N
H

N
H

H

H

R2

R1=H, R2=CHO,
polyneuridine aldehyde

(40)

R1=H, R2=CH2OH, polyneuridine

(40)

R1=CH3, R2=CHO, voachalotinal

(40)

CO2CH3
N
R1

N
H

H

R1=CH3, R2=CH2OH, voachalotine

R2
H

CO2CH3
R3

N
R1

N
H

(40)

R1=R2=H, R3=CH2OH,
E-akuammidine

(40)

R1=R2=H, R3=CH2OAc,
acetylakuammidine

(40)

H

(40)
R1=CH3, R2=OCH3, R3=CH2OH,
10-methoxy-Na-methylakuammidine
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Table 4. Sarpgine Indole Alkaloids (7)

Structure

H

Refs.

panarine

(40)

H
CO2

N

N
H

H

H

H

R2
R1

N
H

Alkaloid

N

Cl

H

H

R'O
H
N
R

H

N
H

R1=CH2OH, R2=H, macusine B

(40)

R1=CH2OCH3, R2=H,
O-methylmacusine B

(40)

R1=CO2CH3, R2=H, alkaloid Q3

(40)

R1=H, R2=CH2OCH3,
O-methyl-16-epimacusine B

(40)

R1=H, R2=CO2-, 16-epipanarine

(40)

R1=CO2CH3, R2=CH2OH
macusine A

(40)

R1=CH2OH, R2=CO2CH3,
Nb-methylakuammidine

(40)

R=H, R'=H, spegatrine

(40)

R=H, R'=Me, lochneram

(40)

R=Me, R'=H,
Na-methylsarpagine metho salt

(40)

OH
Cl

H

OH
H

R2O

CO2CH3
N
R1

N
H

H

R1=CH3, R2=H,
Na-methyl-11-hydroxymacusine A

(40)

R1=H, R2=CH3,
11-methoxymacusine A

(40)
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Table 4. Sarpgine Indole Alkaloids (8)

Structure

Alkaloids

H

R1
R2

H3CO

N

N
Me

H

H
N
H

H

R1=H, R2=CO2Et, fuchsiaefoline

(40)

R1=CH2OH, R2=CO2Me,
12-methoxy-Nb-methylvoachalotine

(40)

R1=CH2OH, R2=CO2Et
12-methoxy-Nb-methylvoachalotine
ethyl ester

H

Refs.

(40)

OMe

19,20-dihydro-O-methylmacusine B

(40)

R1=H, R2=CO2CH3, R3=CH2OH,
19,20-dihydroakuammidine

(40)

R1=H, R2=CH2OH, R3=CO2CH3,
19,20-dihydropolyneuridine

(40)

R1=CH3, R2=CH2OAc, R3=CO2CH3,
17-O-acetyl-19,20-dihydrovoachalotine

(40)

R1=CH3, R2=H, affinisine Nb-oxide

(40)

R1=H, R2=CH3,
O-methylnormacusine B Nb-oxide

(40)

N
H

H
H

H

R2
R3

N
R1

N
H

H
H

H
O
N
R1

H

OR2

N

H

H

OH
H
CO2CH3
N
Me

N
H

OH
H

21-hydroxyvoachalotine

(40)
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Table 4. Sarpagine Indole Alkaloids (9)74-78

Structure

Alkaloid

Refs.

R1
H
N
H O

H

OR

N
H

R =R1=H, 16-epiaffinine

(75)

R =Me, R1 =H, hystrixnine

(76)

R =H, R1 =OMe, pelirine

(77)

OH
H
H
N
H O

N

affinine

(78)

H

OR

R=H, 19E, gelsempervine-A

(79)

R=Ac, 19E, gelsempervine-B

(79)

R=H, 19Z, gelsempervine-C

(79)

R=Ac, 19Z, gelsempervine-D

(79)

19Z, 19Z-16-epivoacarpine

(79)

19ZE, 19E-16-epivoacarpine

(79)

H
CO2CH3
N
H O

N
H
19

OH
H
CO2CH3
N
H HO

N
H
19
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Table 4. Sarpagine Indole Alkaloids (10)71,79-82

Structure
H

H
N
H O

Alkaloid
OH

erichsonine

N

(80)

H

H

H

Refs.

OH

CO2CH3
O

pagicerine

(81)

N

N
H O

H

R
H

H

R =H, amerovolficine
O

N

N
H O

H

H

(72)

R =OMe,
10-methoxy-16-de(methoxycarbonyl) (82)
pagicerine

CO2CH3
H

N
H S

NH2

pagisulfine

N
H

(83)
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Table 5. Macroline Related Indole Alkaloids (1) 83-87

Structure
R2
R1

Alkaloid

H

H

R1

H
Me

R3

R2

H

R2

H
O
H

R1=OMe, R2=H2, alstophylline

(85)

R1=OMe, R2=O, 6-oxoalstophylline

(85)

R1=OMe, R2=H, R3=H2,
19,20-dehydro,10-methoxytalcarpine

(27)

R1=H, R2=OMe, R3=H2, alstophyllal

(85)

R1=H, R2=OMe, R3=O, 6-oxo-alstophyllal (85)
R1=H, R2=H, R3=H2, alstonerinal

R1=H, R2=CHO, talcarpine

(85, 86)

R1=H, R2=CH2OH, macrocarpine A

(85, 86)

R1=OH, R2=CH2OH, alstohentine

(85)

R=CHO, secotalcarpine

(86)

R=CH2OH, macrocarpine B
R=CH2OAc, macrocarpine C

R

(85, 88)

(85, 86)
(86)

H
O

N
H

O
Me

N

H

CHO

R1
H

H

Me

H

N

H

N
Me

O
H

H

(84)

H

H

H

R1= R2=H2, alstonerine

O

N

N
Me

N
Me

O

N

N
Me

N
Me

H

Refs.

H

H
OH

alstomacroine

(87)
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Table 5. Macroline Related Indole Alkaloids (2)88

Structure

Alkaloid

Refs.

O
H3C
H

R

H
N
Me

R=H, alstonisine
H
H

O
Me

R1=H, alstonal

O

H
N
Me

R=OCH3, Nb-demethylalstophylline
oxindole

NH

OHC
H

R

(89)

O

NH

(89)

R1=OCH3, Nb-demethylalstophyllal
oxindole

H
H
O
O
H3C
H

R

O

H
N
Me

NH
OH
H

R=OCH3, 16-hydroxy-Nb-demethyl
alstophylline oxindole

(89)

R1=H, 16-hydroxyalstonal

(89)

Me
O

H

N
Me

(89)

O
OHC
H

R

R=H, 16-hydroxyalstonisine

NH
OH
H

R1=OCH3, 16-hydroxy-Nb-demethyl
alstophyllal oxindole

(89)

O
O

R

H

N
Me

H
N

OH
H
H

O

H

macroxine

(89)
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Table 5. Macroline Related Indole Alkaloids (3) 89

Structure
H
N
Me

Alkaloids

H
O

N
H

Refs.

H

Me
O OH

H

macrodasine A

(86, 90)

macrodasine B

(86)

alstomicine

(85)

O
CH2OH

H
N
Me

H
O

N
H

H

Me
O O

H
O

CH2OH

H
N
Me

H

N
H

H

OH
O
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Table 6. Bisindole Alkaloids (1)

Structure
H

Alkaloid

Refs.

CO2CH3
H

R
N
H

N

R =H, N'-demethylaccedinisine

(40)

R =CH3, accedinisine

(40)

R =H, desformoundulatine

(40)

R =CH2OH, undulatine

(40)

macralstonidine

(40)

H
H

H
CH2OH

N
Me

H

N
H

H

H

CO2CH3
R

N
Me

N
H

H
CO2CH3
N
H
Me

MeO

H

Me
N

H
O
Me

H
O

2Cl

H

N
H

N Me
H
OH

H
H
N
N
Me H

H
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Table 6. Bisindole alkaloids (2)90,91

Structure

Alkaloid
CO2CH3

H
H

H
Me

N

N
H

Refs.

H

vobatracine

(91)

vobasonidine

(91)

macrospegatrine

(92)

N

N
H

H
CHO

H
H
N
H

HO

OH
Me

N

H

OH

H

N

N

Me

CO2CH3

H

H
CO2CH3

H
H
O H
Me
O

HH
N

N

H

H

H

H
H

OH

N
N
H

H

H
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Table 6. Bisindole Alkaloids (3)92-94

Structure

Alkaloid

Refs.

O
N

HN
H
H
H
O
N
H

H
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Table 6. Bisindole Alkaloids (4)
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Table 6. Bisindole Alkaloids (5)95

Structure
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Table 6. Bisindole Alkaloids (6)

Structure

Alkaloid

Refs.
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Table 6. Bisindole Alkaloids (7)

Alkaloid
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Table 6. Bisindole Alkaloids (8)96,97

Structure

Alkaloid

Refs.

flexicorine

(97)

CO2Me

O

N

N

H
O

MeO

N
HH
Me

CO2Me

MeO
N
Me

RO
MeO

N

N
H
Me H

N

(98)

R =Ac,
11-methoxy-10-(11'-vincorinyl)-vincamedine

(98)

H

CO2CH3
N

CO2Me

MeO
N
Me

N
H

CO2CH3
MeO

R =H,
11-methoxy-10-(11'-vincorinyl)-vincamajine

OH N
N
HH
Me

11-methoxy-10-(11'-vincorinyl)
-17-epivincamajine

(98)

32

Table 6. Bisindole Alkaloids (9)98,99

Alkaloid

Structure
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CO2Me

MeO

N

N
H
Me

N
H
Me H

N

H
Me
N
Me

( 99)

CO2CH3

HO
MeO

11-methoxy-10-[11'(10'-methoxy
-cathafolinyl)]vincamajine

H

H
O

N

H

H

pandicine
N

(100)

O

HO
H
MeO

H
H

HO

N
OMe H

CO2Me

H
N

N

OH

OH H
H
H
H HO

2Cl
N

N
H

H

H

dispegatrine

(40)

33

Table 7. Degradation Products of Alstonia Alkaloids100

Structure
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1.2. Previous approaches to the tetracyclic azabicyclo [3.3.1] nonane core framework

5 of the sarpagine/macroline related indole alkaloids
As illustrated in Figure 3, as well as Tables 4, 5, and 7, a core tetracyclic system (rings A,
B, C and D) appears to be a common structural feature of the macroline related sarpagine
and ajmaline alkaloids. A general approach to the synthesis of these macroline–related
alkaloids should involve enantiospecific synthesis of this core structure with the correct
configurations at stereocenters C-3, and C-5 and the appropriate functional groups at C15/C-16 for further transformations. The racemic azabicyclo [3.3.1] nonane has been
prepared in the late 1970’s by Yoneda,101 Mashimo,102 Kluge103 and Hobson,104 and was
later improved by Soerens105 on a kilogram scale. In 1988, Zhang et al.106 achieved the
synthesis of the optically active tetracyclic ketone 25 in a stereospecific fashion by
employing the asymmetric Pictet-Spengler reaction. Many improvements have been
made to prepare both the Na-H and the Na-CH3 tetracyclic ketones. Other recent routes
toward the formation of the tetracyclic core, which deserve mention, include the racemic
synthesis by Rassat,107,108 the aza Diels-Alder approach by Kuethe,109 the olefin
metathesis process of Martin110 and the cis-Pictet-Spengler approach by Bailey111 and
Magnus.112
1.2.1. A racemic synthesis by Rassat et al. 59, 60
In 2000, Rassat et al.107,

108

designed the synthesis of 2,6-dihyroxy-9-azabicyclo[3.31]-

nonane 25 from the bis epoxide 18 (Scheme 1), which could be carried out on large
scale. The bis epoxide 18 was easily converted into a 1:1 mixture of regioisomeric diols
19 and 20 via transannular cyclization with benzylamine in refluxing water. The
undesired diol 20 was then converted into 19 by reacting it with trifluroacetic anhydride
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in refluxing dichloromethane, followed by hydrolysis with sodium hydroxide to furnish
19 in 95% yield (from 18). This bicyclic nonane 19, was then converted into 25, as
illustrated in Scheme 1.
Scheme 1
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Monoprotection of the diol 19 with tert-butyldimethylsilyl chloride, followed by
replacement of the N-benzyl group with the N-benzoyl group gave the desired monol 22.
Swern oxidation of the alcohol 22, followed by removed of the silyl group gave 23 in
95% yield (2 steps). Fischer indole cyclization of 23 with N-methyl, N-phenylhydrazine
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in refluxing methanolic HCl led to the indole, which on reduction with LiAlH4 provided
the Nb-benzyl derivative 24. The racemic tetracyclic ketone 25 could then be obtained by
Swern oxidation of 24 in 73% yield.
1.2.2. Approach to the core tetracyclic structure via the aza-Diels Alder/intramolecular Heck cyclization by Kuethe et al.61
Scheme 2
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Keuthe and co-workers adopted a [4+2] annulation strategy for construction of the
tetracyclic cores 30a,b. As illustrated in Scheme 2, indoles 26a,b on treatment with nBuLi or LDA in refluxing MTBE, followed by addition of iodine furnished the iodo
compounds 27a,b individually. Dess-Martin oxidation of the primary alcohol provided
the aldehydes 28a,b. The aza-Diels Alder reaction of 28a,b with the Danishefsky diene
provided 29a,b, which was subjected to an intramolecular Heck cyclization to furnish the
desired cyclized indole scaffolds in both series 30a,b. Although this route requires
stoichiometric amounts of palladium in the Heck coupling reaction, it does provide the
tetracyclic framework in five steps, albeit the carbonyl group is not in an ideal position
for regiospecific transformations.
1.2.3. Approach to the core structure 36 via a ring-closing olefin metathesis by
Martin et al.110
During their extensive study on the use of olefin metathesis reactions for the synthesis of
various azabicyclo structures with the nitrogen in the one-atom bridge, Martin et al.110
were able to construct the tetracyclic core (ABCD rings), necessary for the synthesis of
the macroline/sarpagine alkaloids. As illustrated in Scheme 3, the dihydro-β-carboline 31
(obtained from L-tryptophan) was N-protected with Cbz-Cl, followed by esterification to
provide a diastereomeric mixture of aminals 32. This diastereomeric mixture of aminals
32 was then treated with allyltrimethylsilane and boron-trifluoride etherate to afford the
cis-tetrahydro-β-carboline 33 as a mixture of two compounds in a 5.5:1 diastereomeric
ratio which must be separated. Selective reduction of the ester, followed by a Wittig
reaction yielded the alkyne 34 in a one-pot procedure. Treatment of the alkyne 34 with
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Scheme 3
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Grubb’s first generation catalyst promoted the enyne metathesis to furnish the tetracyclic
diene 35 in essentially quantitative yield. Selective oxidation of the exocylic olefin
provided the aldehyde 36 in 54% yield (two steps).
1.2.4. Synthesis of the tetracyclic core 42 via the cis-selective Pictet-Spengler reaction by Bailey et al.111
Bailey employed the cis-selective Pictet-Spengler reaction to synthesize the tetracyclic
intermediate 42. As Illustrated in Scheme 4, the synthesis began with L-(-)-tryptophan
37' which was converted into the homologated nitrile 38 via the reduction/

39

activation/replacement sequence in 50% overall yield. The homologated nitrile 38 was
then treated with methyl propynoate in refluxing chloroform for 100 hours to afford the
enamines 39a and 39b, after which the mixture was directly added to excess
trifluoroacetic acid at 0 °C to provide a mixture of cis and trans diastereomers (40a and
40b) in the ratio of 77:23. The diastereomeric mixture was then converted into the Nbbenzyl compound, which was further methylated to provide 41 in 39% yield (2 steps).
The ring closure was mediated by the action of lithium diethylamide at -78 °C on ester 41
to afford the tetracyclic core in 42 in 90% yield. Although the tetracyclic ketone 42 can
be synthesized by this method, this route suffers due to the number of steps involved in
comparison to other routes and also from the poor diastereoselectivity obtained in the
Pictet-Spengler reaction.
Scheme 4
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1.2.5. Synthesis of the tetracyclic core 48 by Magnus et al.64
In 1989, Magnus et al.64 reported the synthesis of the Na-H tetracyclic ketone 49 from L(-)-tryptophan 37' which he employed for the total synthesis of (+)-koumine, (+)taberpsychine and (+)-koumidine. Illustrated in Scheme 5 is the cis-selective PictetSpengler reaction, which began with L-(-)-tryptophan37'.
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The L-(-)-tryptophan 37' was converted into the Na-benzyl, tryptophan methyl ester 43 by
first benzylation with sodium amide/PhCH2Cl in 92% yield, followed by Fischer
esterification of the alkylated L-(+)-tryptophan in 68% yield. This ester 43 was then
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reacted with benzaldehyde at 22 °C and the imine which resulted was reduced with
sodium borohydride in methanol to provide Na-benzyl, Nb-benzyl tryptophan methyl ester
44 in 95% yield. This intermediate was then converted into a mixture of diastereomeric
acids 45a/45b, by employing the conditions of the Pictet-Spengler reaction as developed
by Zhang et al.106 Esterification of this mixture with MeOH/ClSiMe3 provided the esters
46a/46b (2:1) in 80% yield. The major cis-diastereomer 46a was isolated in 58% yield by
crystallization from methanol and carried through to the tetracyclic ketone 48 via a
Dieckmann cyclization and acid-mediated decarboxylation, as illustrated in Scheme 5
following the route developed in Milwaukee and reported in the racemic series by
Yoneda et al.101
1.3. Previous syntheses of sarpagine/macroline related indole alkaloids
1.3.1. Synthesis of sarpagine/macroline related indole alkaloids in Milwaukee113
Vellosimine 14a and normacusine B are the simplest representatives of the family of
sarpagine indole alkaloids. Until 2000, no enantiospecific total synthesis of members of
the sarpagine series was reported. The partial total synthesis of (-)-koumidine [which is
similar in structure to 14a, except it has a more stable Z-ethylidene double bond and the S
configuration at C-16], was first reported by Sakai.114 Magnus later synthesized the
enantiomer of (-)-koumidine via a Pictet- Spengler reaction. However, establishment of
the double bond (Z:E=1:5.7) was not stereospecific112 and the reaction was hampered by
poor diasteroselectivity in the Pictet-Spengler reaction. Entry into the pentacyclic
sarpagine skeleton in Milwaukee for the total synthesis of ajmaline previously, was
through a macroline framework which did not have the potential for incorporation of the
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E-ethylidene double bond sterospecifically and also involved a large number of steps.
Martin reported the total synthesis of geissoschizine with stereoselective establishment of
the E-ethylidene double bond by an elimination process.115 Furthermore Rawal116 and
Bosch117 reported the total synthesis of Strychnos alkaloids with stereocontrolled
establishment of the double bond by a Heck coupling reaction.
1.3.1.1. The enantiospecific total synthesis of (+)-vellosimine by Wang10,118,119
In 2000 Wang reported an efficient, enantiospecific total synthesis of (+)-vellosimine 14a
with the first stereospecific establishment of the ethylidene double bond by a key
palladium (enolate-mediated) carbon-carbon bond forming process. This key reaction
provided a very efficient approach and allowed a direct entry to the basic pentacylic
skeleton of the sarpagine alkaloid system, and permitted introduction of the C-19—C-20
olefinic bond with the E configuration, stereospecifically. The synthesis began with the
tetracyclic ketone 49, which was subjected to the conditions of catalytic hydrogenation to
provide the Na-H, Nb-H tetracyclic ketone 50 in 95% yield. Alkylation of the secondary
amine in 50 with Z-1-bromo-2-iodo-2-butene 51, a unit prepared by Ensley et al.120 and
employed by Rawal,116 Bosch117 and Kuehne121 provided the Nb-Z-2'-iodo-2'-butenyl
tetracyclic ketone 52 in 87% yield. This Z-olefin 51 can now be prepared on a 500 gram
scale in a regiospecific fashion in three steps from crotonaldehyde.122 Ketone 52 was then
converted into the α, β-unsaturated aldehyde 53 in high yield (see Scheme 6).
Numerous attempts to effect the intramolecular Michael addition in α,β-unsaturated
aldehyde 53 by generating a vinyl anion, followed by cyclization failed to give the
desired product.10,119 Radical-mediated cyclization121 was then attempted on 53 by
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treating it with Bu3SnH/AIBN in refluxing benzene. A mixture of (+)-vellosimine 14a,
accompanied by the undesired Z-olefinic isomer 54 in a 1:3 (E/Z) ratio was obtained in
40% overall yield. The olefinic bond had isomerized under the radical conditions to
provide the thermodynamically more stable olefin as the major isomer.10 Attempts to
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carry out the Heck reaction under the conditions developed by Rawal,123 as well as under
modified conditions did not provide the desired E-olefin.
Muratake and Natsume124 had reported a direct palladium-mediated arylation at the γposition of a simple α, β-unsaturated aldehyde under basic conditions in high yield. When
the α, β-unsaturated aldehyde 53 was stirred under similar conditions, the C-14 insertion
product (aldehyde 55) was isolated in 71% yield. With the formation of this product it
was felt a similar mechanism could be envisaged to occur with iodo olefin 52. The
relative acidity inherent at the α-position of the ketone in 52 would facilitate the enolate
mediated Pd(0)-cyclization into the desired sarpagine system in 14a. When iodo olefin 52
was subjected to the optimized conditions of the intramolecular palladium-mediated cross
coupling reaction (3 mol% Pd(OAc)2, 30 mol% PPh3),10 it furnished the cyclized product
56 stereospecifically in 80% yield. Wittig reaction of this ketone was followed by
hydrolysis to provide the thermodynamically more stable α-aldehyde in 14a.
Consequently, the first total synthesis of the Na-H substituted sarpagine indole alkaloid
(+)-vellosimine 14a was accomplished from commercially available D-(+)-tryptophan
methyl ester 107 (Scheme 16) in seven reaction vessels in 27% overall yield. With the
success achieved in stereospecific construction of the sarpagine skeleton via the enolate
mediated palladium cross coupling reaction, a similar strategy was employed for the
synthesis of the related sarpagine alkaloids in the Na-H as well as Na-methyl series.113
1.3.1.2. Total synthesis of the enantiomer of macroline, the Na-H analog of macroline
and trinervine via a regiospecific hydroboration process by Liu et al.125-127
From the earlier work of LeQuesne et al.,38 the biogenetic origin of macroline 6 could be
envisaged to arise from affinisine (enantiomer of 57', see Scheme 7) via a retro Michael
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reaction (Figure 4). Consequently, the total synthesis of the enantiomer of macroline 6'
was designed based on this approach. Shortly after the synthesis of (+)-vellosimine 14a,
Liu125-127 followed the same strategy (from L-tryptophan 37') to provide the enantiomer
of affinisine 57'.
Scheme 7
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The hydroxyl group of the enantiomer of affinisine 57' was protected as the tbutyldimethylsilyl ether to afford olefin 58' (Scheme 7). Hydroboration of olefin 58' with
1 equivalent of BH3·THF at 0 °C resulted in the formation of the Nb-BH3 complex 59'.
Further addition of 5 equivalents of BH3·THF at 0 °C afforded a mixture of the secondary
alcohols 60a',b' and undesired tertiary alcohol 61' in a ratio of 7:3.125 The poor yield
(49% of the desired secondary alcohols 60a',b'), as well as the formation of the undesired
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tertiary alcohol 61' prompted a more detailed study of this process (see Scheme 8). After
executing various reaction conditions,127 which involved the use of hindered boranes and
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a change of the reaction temperature as well as the use of a bulkier TIPS protecting
group, the desired secondary alcohols could be prepared (the TIPS group was employed
because it was found to be more stable and bulkier than the TBDMS). As illustrated in
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Scheme 8, the TIPS group was used to protect the alcohol 57' to provide the ether 62' in
90% yield. Hydroboration of olefin 62' under the modified conditions with 9 equivalents
of BH3/DMS at room temperature provided the desired secondary alcohols 63a' and 63b'
in 80% yield after oxidative workup.126,127
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Swern oxidation of this mixture of secondary alcohols furnished the ketones 64a',b' in
85% yield. This mixture of ketones was heated in THF in the presence of 1.5 equivalents
of HCl (1N aqueous) for 3 hours, after which ketone 65', which was devoid of the boron
species, was obtained in 90% yield. The methylation of 65' with methyl iodide gave the
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Nb-methiodide salt which was subjected to the modified conditions for ring cleavage (tBuOK in refluxing THF/EtOH [6:1]) to provide the enantiomer 66' of the macroline
equivalent. Deprotection of the TIPS group in 66' with TBAF in THF afforded the
enantiomer 6' of macroline in 86% yield (see Scheme 8).
Normacusine B 67 was converted into the Na-H analog of macroline 71 (Scheme 9)
following the same sequence of steps as outlined for 6' in Scheme 8. Trinervine 69,
which retained the basic sarpagine skeleton, and contained a unique hemiketal ring
formed between the C-17 (OH group) and the ketone at C-19 was synthesized from
intermediate 68 on stirring it with 10 equivalents of 1 N aqueous HCl in refluxing THF
(80% yield). The acidic conditions at reflux released the free amine, cleaved the TIPS
group, as well as catalyzed the hemiketal formation. The total synthesis of trinervine 69
was, therefore, completed in enantiospecific fashion in an overall yield of 20% (from the
ketone 50, see Scheme 6) in 10 reaction vessels (see Scheme 9).
1.3.1.3. Improved total synthesis of macroline by Liao et al.128
In an effort to decrease the amount of phosphine ligand employed for the cross coupling
process, the Buchwald-Hartwig α-arylation129 conditions were studied. The original
Buchwald conditions129 were modified by introducing DPEphos, a bidentate ligand with a
large bite angle, a stronger base such as NaO-t-Bu and Pd(dba)2 as the catalyst. The
improved route toward the synthesis of macroline is illustrated in Scheme 10.
Previous to this, the same sequence of steps was carried out as depicted in Scheme 8,
albeit under modified reaction conditions. The Na-methylvellosimine 74 was converted
into affinisine 58 (Scheme 7) by NaBH4/EtOH reduction in 90% yield. Protection of the
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OH group was carried out using TIPSOTf/2,6-lutidine in CH2Cl2 to provide the ether 62.
Hydroboration followed by oxidation provided the secondary alcohols 75a and 75b. The

Scheme 10
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Nb-BH3 complex was cleaved by refluxing with 2 equivalents of acetic acid in THF to
provide the free amine 75a,b. Because of the inconsistent results obtained in the Swernoxidation of the secondary alcohols 75a,b130, Dess Martin oxidation was employed to
furnish the desired ketone 65 in 82% yield. Treatment with methyl iodide in THF
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provided the quaternary salt, which underwent a retro-Michael reaction to provide the
macroline equivalent 66 in 20.4% overall yield from tryptophan methyl ester (not shown
in Scheme). Removal of the TIPS group with TBAF monohydrate, provided 6 in 86%
yield.
1.3.2. A biomimetic total synthesis of (+)-Na-methyl vellosimine 74 by Martin et al.
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van Tamelen62,131 reported a biogenetic-type synthesis of ajmaline 8 in which the key step
was the conversion of acid 76 into a mixture of epimeric aldehydes represented by 74
(Scheme 11). A proposition supported by a subsequent report of a biogenetic type
synthesis of ajmaline was made later by van Tamelen and Olivier.132,133 This seminal
cyclization to furnish the sarpagine skeleton proceeded via the proposed iminium ion 77,
which was generated by decarbonylation of an activated form of the carboxyl group in
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76. Aldehyde 74 was then converted into a relay compound which eventually was
transformed into ajmaline 8. Twenty-five years after van Tamelen’s original work,
Lounasmaa and coworkers reinvestigated this biogenetic-type cyclization.134 They did not
observe the expected “biogenetic-type” cyclization of a related iminium ion.
Consequently, Lounasmaa et al.134 reported they could not execute this type of
cyclization and cast doubt on the biogenetic hypothesis of van Tamelen. It must be
pointed out; however, Lounasmaa et al.134 did not employ the exact substrate of van
Tamelen. The group in Milwaukee as well as Martin and coworkers realized that
Lounasmaa’s work was not executed with the same substrate as van Tamelen. In order to
solve this controversy, Martin et al.135 developed a biogenetic entry into Na-methyl
vellosimine 74 which employed an iminium ion mediated cyclization similar to van
Tamelen’s original proposal.
As shown in Scheme 12, dihydrocarboline 31, which was readily obtained from
commercially available D-tryptophan 37, was allowed to react with the vinyl ketene
acetal to afford a single product and then directly converted into the t-butyl ester 78. The
Nb-acylation of amine 78 with diketene furnished an intermediate β-keto amide that
underwent facile cyclization via an intramolecular Michael reaction upon addition of
potassium tert-butoxide to give keto amide 79.
The E-ethylidene side chain in amide 80 was obtained in good yield by following the
reduction/activation/elimination sequence to give a single geometric isomer, as depicted
in Scheme 12. The lactam 80 was then methylated at the Na-indole position, after which
the Na-methyl amide was reduced to the amine 81 in 90% yield. This was followd by
selective acid catalyzed ester hydrolysis in the presence of methyl thioanisole which
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proceeded smoothly to give the acid 82. The acid moiety in 82 was then transformed into
the amide with NH4OH in the presence of EDCl in 86% yield followed by dehydration of
the amide with trifluoroacetic anhydride to provide the nitrile 83 in 90% yield. The ester
group in 83 was selectively reduced in the presence of the cyano group by reaction with
lithium borohydride in THF and the subsequent oxidation of the hydroxyl group with
Dess-Martin periodionane gave the aldehyde 84 in 83% yield. The aldehyde 84 was then
converted into the silyl enol ether 85 with TBDMSCl in the presence of NaH. The αaminonitrile 85 was then treated with BF3·OEt2 in benzene and this was followed by
exposure to aqueous potassium hydroxide in MeOH. The Na-methylvellosimine 74 was
obtained in 54% yield. This biomimetic total synthesis of Na-methylvellosimine 74
provided experimental support for the cyclization step originally proposed by van
Tamelen as one of the key steps in the biosynthesis of the sarpagine and ajmaline
alkaloids. It also illustrated the Lounasmaa’s criticism of the cyclization process134 may
be unfounded since he did not use the exact same substrate as van Tamelen.131
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2. Objectives and synthetic approach
The unique and complex architecture of the indole alkaloids coupled with their largely
unexplored potential in medicine or as tools for biological studies make these compounds
attractive targets for total synthesis. The sarpagine alkaloids contain the common
structural element of the parent pentacyclic sarpagan ring system.57 These indole
alkaloids contain a double bond at C19-C20 and lack functionality at the C-21 position.
In all known sarpagine indole alkaloids the stereochemistry at C-3 (S), C-5 (R) and C -15
(R) has been established.These three stereochemical centers have a fixed configuration
because of the rigid framework of the molecule. The double bond at C19-C20 has an Econfiguration. The alkaloid ervincidine belongs to the sarpagine class and has been
isolated from the epigeal part of Vinca erecta Rgl. et Schmalh.

136

The UV spectrum is

characteristic for indole bases. The IR spectrum has a broad band at 3000-3330 cm-1 due
to the presence of OH and NH groups connected by a hydrogen bond. This alkaloid
belongs to the akuammidine subgroup and is a hydroxyl derivative of tombosine. 136
Figure 6. Sarpagine Type Indole Alkaloids
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According to Glasby’s book of alkaloids 137 and the review by Lounasmaa,57 the structure
of ervincidine has four stereocenters C-3 (S), C-5 (R) , C -15 (R) and C -16(R). The
stereochemistry of the alcohol at the C-6 position was not assigned. The paper published
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by Yunusov etal.,136 has reported the structure of ervincidine similar to that of the
polyneuridine subclass with four stereocenters C-3(S), C-5(R), C-15(R) and C-16(S). But
again the stereochemistry of the C-6 alcohol was not assigned. As illustrated in Figure 7,
the proposed structure of ervincidine by Glasby5 and Lousnamaa57 has the functional
group at C-16 (R) with the alpha stereochemistry and that of Yunusov136 has the
functional group at C-16 (S) with the less stable beta stereochemistry which stimulated
the interest in this indole alkaloid. The synthesis of this natural product was also
challenging because the only information from the literature136 was the optical rotation
which was +29.5°(c 0.6, MeOH).
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No unequivocal spectral information (NMR, CHN

analysis) was given. Another aspect which made the synthesis of this molecule important
was the establishment of the stereochemistry of the C-6 alcohol function. Examination of
both the reports from the literature40,136 did not assign the stereochemistry to the C-6
alcohol. The mass spectrum and the molecular ion peak of ervincidine
the spectra of the sarpagine and tombosine alkaloids.

139

136

was similar to

The difference of 16 m/e units

indicated the presence of a hydroxyl group in ervincidine. The presence of an m/e ion
peak at 169 in the mass spectrum suggested the presence of the hydroxyl group in the
aliphatic part of the molecule possibly in ring C. On the basis of the comparison of the
mass spectrum of ervincidine with that of tombosine, akuammidine and gardenine and
with the proposed biogenentic interrelationship with gardnutine and hydroxygardnutine,
140

the position of the hydroxyl group in ervincidine was probably at C-6.136
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Figure 7. The Indole Alkaloid Ervincidine
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The objective of this research was to complete the first enantiospecific , stereospecific
total synthesis of the indole alkaloid ervincidine and correct the stereochemical ambiguity
reported in the literature. This ambiguity as pointed out was because the stereochemistry
of the CH2OH group at C-16 was not assigned unequivocally and neither was the
hydroxyl group at C-6 position. Moreover, the design of a synthetic entry into the C-6
alcohol stereospecifically, as well as an assessment (thermodynamic stability) of the
stability of the C-6 hydroxyl group was of significant importance in indole alkaloid
chemistry. As shown in Scheme 13, in a retrosynthetic sense, both the diastereomers 88
and 89 might be available via a common intermediate, pentacyclic ketone 56. The
chirality of 56 was to be employed to introduce the correct stereocenters in the target
alkaloids 88 or 89.
The ketone 56 could presumably be converted into vellosomine 14a, which could be
employed as an intermediate in the total synthesis of 88. The synthesis of the axial
alcohol E-16-epinormacusine B 112 could be achieved by a hydroboration/oxidation
process. This intermediate once obtained, might further provide 6-hydroxy-16
demethoxycarbonyl polyneuridine 89 via protection/deprotection of hydroxyl group,
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selective oxidation by IBX at C-6 and a reduction. The chirality of 56 was to be
employed to introduce the correct stereocenters in the target alkaloids 88 or 89.

Scheme 13. Retrosynthetic Analysis of ervincidine 88 and 89
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The important initial stereogenic centers would be established from the 1, 3 trans transfer
of chirality in the asymmetric Pictet-Spengler reaction.141-146 The retrosynthetic strategy
rests on the general approach which has been used to synthesize the macroline-sarpagine
type alkaloids in Milwaukee. The thermodynamically stable α-aldehyde 14a would arise
via Wittig reaction on the pentacylic ketone 56. The Na-H, Nb-H tetracyclic ketone 50
should be available from D-(+)-tryptophan 37 on a large scale via the asymmetric PictetSpengler reaction and the Dieckmann reaction as key steps.147-149 This synthetic strategy
was an efficient way to provide 56 in gram quantities. The less stable β-axial alcohol
could be synthesized using the pentacyclic ketone 56 via a Wittig reaction coupled with a
hydroboration/oxidation following the published procedure. 122,150,151

H
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3. Results and Discussion
3.1. The First enantiospecific, stereospecific total synthesis of the sarpagine alkaloids
related to structures of the proposed ervincidine (88 and 89) including ervindicine
3.1.1. Synthesis of the (−)-Na-H, Nb-H tetracyclic ketone 50 on large scale
As planned, the synthesis of isomers of ervincidine 88 and 89 began with the preparation
of the (−)-Na-H, Nb-benzyl tetracyclic ketone 49 as the key building block on large scale
following the procedure developed in Milwaukee. As illustrated in Scheme 14, Fischer
esterification of (+)-37 with methanolic hydrogen chloride gave the methyl ester 90 on
400 gram scale. This was then converted into Nb-benzyltryptophan methyl ester 91 on
stirring with benzaldehyde (1.1 equivalents) at room temperature (6 hours), followed by
reduction of the imine which resulted in situ with sodium borohydride [-10 oC to –8 oC
(2-5 hours, according to the scale)]. The optical purity of the Nb-benzyltryptophan methyl
ester 91 prepared in this manner was found to be greater than 98% ee as determined by
comparison to data from authentic samples.149
To introduce the desired stereocenter at C-1 the asymmetric Pictet-Spengler reaction141146

was employed with methyl 4,4-dimethoxy-butyrate 95,146 (which can be prepared on a

kilogram scale) and Nb-benzyl tryptophan 91 to provide the trans diester 92b as a single
diastereomer in 92% yield. This process was scaled up to the 400 gram level and
purification was achieved by recrystallization from ethanol. As shown in Scheme 15, the
lone pair of electrons of the Nb-nitrogen atom of 91 (Scheme 15) presumably attacked the
oxonium ion and this was followed by loss of the elements of methanol to form the
iminium ion intermediate 96. Attack of the iminium ion at the indole C-3 position could
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form either the anti spiroindolenine 98b or the syn spiroindolenine 98a intermediate. The
anti intermediate 98b could rearrange directly into the desired trans diester 91b;
however, in the case of the disfavored syn spiroindolenine 98a,152 it was felt the
rearrangement to the cis diester 92a would occur followed by the acid-catalyzed
isomerization at C-1 to afford the more stable trans diester 92b.141 Consequently, during
the process of this Pictet-Spengler reaction, the cis diester 92a derived from 97a was
indeed detected by TLC but was converted entirely into the trans diester 92b, presumably
via the carbocationic intermediate143 III as planned. After work up, the trans diester 92b
was obtained as the only diastereomer in greater than 98% ee and high yield on 100 gram
scale.
When the trans diester 92b was treated with three equivalents of sodium hydride in the
presence of excess methanol in refluxing toluene,106 the trans diester 92b was converted
entirely into trans δ-lactam 100. No further change was observed (Scheme 16) on
prolonged heating. However, when diester 92b was treated with nine equivalents of
sodium hydride in the presence of excess methanol in refluxing toluene under these same
reaction conditions for an extended period of time (72 hours), the desired Dieckmann βketoester 102 was obtained in 88% yield. Presumably, the δ-lactam 100 formed and then
underwent ring-opening10,101 to provide the trans diester 92b under these conditions. This
diester 101a was in equilibrium with the cis intermediate 101b and the latter material was
eventually converted into β-ketoester 102 via the Dieckmann process.
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Scheme 16
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It was felt the δ-lactam 100 was favored in the equilibrium over intermediates 101a and
101b; however, the irreversible formation of the enolate (see 102) in the Dieckmann
cyclization gradually promoted completion of the process to provide the β-ketoester 102,
exclusively (Scheme 16). Hydrolysis of the β-ketoester 102 and decarboxylation under
acidic conditions was achieved in one step to provide the template (-)-Na-H, Nb-benzyl
tetracyclic ketone 49 in 90% yield. The enantiomeric purity of ketone 49 was determined
to be greater than 98% ee by conversion of it into (-)-Na-methyl, Nb-benzyl tetracyclic
ketone 25 whose enantiomeric purity had been determined previously by Zhang.10,106,153
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D-(+)-Tryptophan methyl ester 90 can also be diastereospecifically converted (via 92b)
into azabicyclononone 49 in greater than 98% ee in a two pot process on multihundred
gram scale, as depicted in Scheme 17. More specifically, after Nb-benzylation of 90 with
benzaldehyde and sodium borohydride (1 eq) in methanol was completed, trifluoroacetic
acid (TFA) was added to the reaction vessel at 0 oC to neutralize the alkaline mixture.
After removal of the solvent under reduced pressure, CH2Cl2, TFA and acetal 95 were
added to the vessel at 0 oC and the modified Pictet-Spengler reaction (600 g scale) was
carried out to provide the trans diester 92b in 83% crystalline yield. In the second
sequence (150 g scale), the Dieckmann cyclization was completed and the reaction
solution was then cooled to 0 oC after which it was carefully quenched with glacial acetic
acid. After removal of the solvent under reduced pressure, concentrated glacial acetic
acid, aqueous hydrochloric acid and water were added to the residue in the same vessel at
0 oC. The acidic hydrolysis and decarboxylation of 102 was then executed at reflux to
provide (-)-49 in 80% crystalline yield in greater than 98% ee.10 The benzyl group in
tetracyclic ketone 49 was removed by converting 49 first into its hydrochloride salt. The
HCl salt of 49 was then subjected to the conditions of catalytic debenzylation [Pd/C, H2
(1 atm), bench top] to furnish the Na-H, Nb-H tetracyclic ketone 50 in 95% yield (Scheme
17).
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In conclusion, the basic tetracyclic core of the Na-H, Nb-H tetracyclic ketone 50, which
contained rings ABCD required for the synthesis of the C-19 methyl substituted
sarpagine indole alkaloids was constructed enantiospecifically and stereospecifically via
the asymmetric Pictet-Spengler/Dieckmann protocol on large scale.119,147,148
3.1.2. Synthesis of the -Na-H pentacyclic ketone 56
Nb-alkylation of the secondary amine 50 with (Z)-1-bromo-2-iodo-2-butene 51 under the
conditions developed in Milwaukee (dry THF/K2CO3/ reflux)122

118,154

led to the

formation of the desired product 52, but was very sluggish, and led to considerable
formation of baseline impurities. Since substitution by amines on bromides was clearly
an SN2 type process, it was then decided to increase the nucleophilicity of the amine by
employing a more polar aprotic solvent. It was well known that the nucleophilic strength
was dependent on the solvent employed in the SN2 reaction. Dry acetonitrile on the other
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hand proved to be the most suitable solvent for this process for the reaction went to
completion at room temperature to give 52 in 76% yield. In order to increase the yield,
vinyl iodide 51 was used in excess (3-4 equivalents). But this reaction condition did not
improve the yield but increased the base line impurities.
Initially, the vinyl iodide 51 required for this route was synthesized according to a
literature procedure.120 However, the free-radical hydrostannation of the propargyl
alcohol was difficult and the desired iodide was extremely hard to purify. Importantly, as
illustrated in Scheme 18, an improved method was recently developed122 to prepare 51 via
α-iodination of an α,β-unsaturated aldehyde 103 under the conditions of Kraft82,155 which
exclusively formed only the Z-isomer 104. This material without further purification
underwent the subsequent reduction83 to provide the desired alcohol 105 in 97% overall
yield. This alcohol 105 was treated with PBr3 in dry ether at 0 °C for 12 hours to provide
the desired bromide 51 in 93% yield . The sequence was scaled up to the 200 g level
scale starting from crotonaldehyde 103 to obtain the desired allylic bromide 51 on a large
scale as well.
The ketone 52 was initially converted into the desired ketone 56 in 80% yield via an
intramolecular palladium (enolate mediated) cross-coupling reaction analogous to the
process developed by Wang et al.118,156,157 Further development for this palladiummediated cross coupling reaction was achieved when ketone 52 was subjected in
combination with 5.0 mol% Pd2(dba)3 , 7.0 mol% DPEphos as a ligand and 1.5 equivalent
of NaOtBu as a base in THF at 80 °C for 5 hours. The desired ketone 56 was obtained in
83% yield which was superior to the previously reported results (Scheme 5).
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A plausible Hartwig-Buchwald catalytic cycle for the enolate-driven palladium catalyzed
α-vinylation reaction is illustrated in Scheme 19. It was felt the active Pd(0)L2 species
was generated primarily by reduction of Pd(OAc)2 with triphenylphosphine in this
phosphine-assisted catalytic cycle.158,159 The active Pd(0)L2 species could then undergo
oxidative addition on the vinyl iodide to form a vinylpalladium(II) iodide complex.
Ligation to the oxygen and rearrangement to the carbon atom at C(15) can then occur.
Finally, reductive elimination of the carbon bound Pd(II) intermediate would furnish the
desired E-olefin 56 while regenerating the active Pd(0)L2 species. A key to the success of
this Pd-mediated cross coupling reaction rested on the enolate concentration. This must
be high enough to permit ligand substitution to occur.125 It was well known that vinyl
iodides would be quite reactive in the oxidative-addition step. If nucleophilic substitution
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of the iodide by the nucleophilic enolate in the coupling process was comparably slow, the
rate of byproduct formation would be significant. Eventually, a highly reproducible yield
could be obtained by employing an excess of the phosphine ligand.160 In the case of
different substrates, sometimes it was necessary to carry out the reaction with a 10:1 ratio
of PPh3 (30 mol%) to Pd(OAc)2 (3 mol%). The process then took three days to go to
completion in comparison to that of five hours required under the original conditions, but
the amount of byproducts (Scheme 19) was decreased. The yield of the sequence in this
series was 81%. Furthermore, the best solvent system to date was DMF/H2O (9/1), as
compared to CH3CN, pure DMF, or DMF/H2O (4/1) which resulted in no reaction or low
yields.127 Because the conditions employed for the enolate driven palladium coupling
process were different from the recent Buchwald-Hartwig arylation reactions,160 efforts
were directed toward intramolecular α-vinylation under the conditions of the arylation
process.160 This might permit lower catalyst loading160 and be effective for both E and Z
ethylidenes. The homogenous reaction conditions might permit a faster rate and thereby
facilitate scaleup. In fact, Liao first reported a Pd(0) catalyzed α-vinylation process in
which the cheaper DPEphos was employed in the case of a Z-ethylidene130 for the
synthesis of (-)-koumidine.150 Moreover, utilization of this ligand for the synthesis of the
E-ethylidene 56 was also executed by Liao et al. in 80% yield.150 However, a related
approach has also been effective based on a palladium-catalyzed coupling of aminotethered vinyl halides with ketones reported by Solé, Bonjoch et al.161,162 In addition,
another process was also carried out with ketone 52 in the presence of 6.0 mol%
Pd(PPh3)4 and a base PhOK (which was generated previously in the reaction vessel from
2.0 equivalent of PhOH and 1.5 equivalent of KOtBu). The most notable aspect of the

68

Scheme 19
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Different trace byproducts 52, 50 or 106 are ocassionally observed depending on what catalyst was
employed and how much base was used.

latter attempt was that it did not require an additional ligand. The intramolecular
cyclization took place to afford ketone 56 in 80% yield again in stereospecific fashion.
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The use of the weaker potassium phenolate base limited the presence of any acetylene
byproduct formed from loss of HI from the halide 52.
Ketone 56 was then subjected to the Wittig reaction with methoxymethyl
triphenylphosphonium chloride and anhydrous potassium tert-butoxide to provide a
mixture of two stereoisomeric enol ethers (not shown). After a short wash column, the
mixture of enol ethers was hydrolyzed under acidic conditions to provide vellosimine 14a
in 90% yield (overall yield for two steps). Since the aldehyde at C(16) was in the more
stable alpha configuration because of a syn pentane interaction with the indole methylene
bridge, the mixture was simply stirred until all of the β-epimer was converted into the
more stable, natural epimer present in (+)-vellosimine 14a. The aldehyde function of 14a
was then reduced with sodium borohydride to provide the alcohol normacusine B 106,
the spectral data of which are in complete agreement with the natural product. The C (17)
functionalized alcohol was then protected as the trisopropylsilyl ether employing 2,6
lutidene as the base to provide the ether 107. Repeated attempts to oxidize the C-6
position by DDQ on 108 were unsuccessful. The conditions employed with the first
equivalent of DDQ deprotected the TIPS functional group forming alcohol 107 and the
second equivalent oxidized the alcohol 107 to aldehyde 14a. Finally, the oxidation at the
C (6) position was successfully accomplished by oxidation using IBX at 80°C (radical
process as shown in Scheme 21) to form the desired ketone 108.130,163
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The silyl analogue was then stirred in THF with tetrabutyl-ammonium fluoride
monohydrate to provide the C-16 substituted monol 110. Illustrated in Figure 8 is the
ORTEP view of the crystal structure of ketone 110.
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Scheme 21
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Figure 8. ORTEP View of the Crystal Structure of the monol 110

3.1.3. Completion of the regiospecific, stereospecific total synthesis of ervincidine
proposed by Glasby and Lousnamaa
The selective reduction of the ketone 110 was done by a Luche reduction164 using sodium
borohydride in combination with cerium chloride heptahydrate to afford the final product
88 with C-3 (S), C-5 (R) , C-6 (R), C -15 (R) and C -16(R) stereochemistry as a single
diastereomer. Luche reduction is a selective reduction of 1,2 enones using NaBH4 in
combination with CeCl3. For the methanolysis of NaBH4, CeCl3 which is a lewis acid
catalyst is selected. The harder reducing agent (see Scheme 22) favor 1, 2 reduction thus
leading to the formation of a single diastereomer regiospecifically. Illustrated in Figure
9 is the ORTEP view of the crystal structure of 88. However, the optical rotation of this
diastereomer 88 was [α]26D +79° (c 0.6, in methanol) which is not in agreement with the
value reported by Yunusov in the literature.40,137 The diastereomer 88 was stirred in 0.2N
HCl at 0°C. Examination by TLC (silica gel; CH2Cl2: MeOH 9:1; Rf: 0.73) showed a
new spot at lower Rf value (0.73) which indicated the complete epimerization of 111 at

73

the C-6 position. Unfortunately the new spot could not be isolated due to shortage of the
material at this point. It is felt the C-6 alpha hydroxyl group is presumably the
thermodynamically more stable isomer based on this preliminary experiment.
Scheme 22
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Figure 9. ORTEP View of the Crystal Structure of the Diol 88 which shows the alpha
hydrogen at C-6 with C-5

Since the optical rotation of diastereomer 88 obtained was not in agreement with the
literature which was +29.540,136,137 the focus of this research turned towards the synthesis
of the Na-H axial alcohol at the C-16 position proposed by Yunusov136 in order to
construct the diastereomer with the polyneuridine-related stereochemistry in an
enantiospecific fashion.
3.1.4.

Completion of the regiospecific, stereospecfic total synthesis of ervincidine

proposed by Yunusov136
The synthesis of E-16-epinormacusine B 112 began with the pentacyclic ketone 56. The
E-16-epinormacusine B 112 was obtained from 56 via a Wittig reaction which was
carried out with triphenylphosphonium bromide in benzene, in the presence of potassium
t-butoxide to afford the diene 111 in 90% yield. When the two double bonds in the diene
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111 are compared it was felt the less hindered double bond at C(16)-C(17) , relative to
the ethylidene at C(19)-C(20) would be more easily oxidized with a hindered
hydroborating reagent. This was in agreement with the earlier work of Magnus and Cook
et al. Treatment of diene 111 with the 9-BBN reagent was chosen as the hydroborating
agent to facilitate attack from the less hindered face of the C(16)-C(17) double bond
relative to the C(19)-C(20) site. This also hinders the formation of the Nb-9-BBN
complex which might hinder attack from the alpha face of the molecule. If it became
important to obtain the alcohol with the alpha stereochemistry at C-6, simple
epimerization (H+) should be effective based on the previous results shown here for the
epimerization of 111.

Scheme 23
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The synthesis of ketone 114 from alcohol 112 was carried out analogous to the previous
preparation of the TIPS derivative 108 from alcohol 107 in 90% yield. The oxidation of
the C-6 position was achieved by radical oxidation using IBX165,166 in 85% yield.
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As shown in Scheme 25, the silyl group from ketone 114 was removed by treatment with
wet TBAF in THF to give 115 in 90% yield. The selective reduction of the ketone 115
was done by a Luche reduction to achieve the stereospecific synthesis of the natural
product ervincidine 89 as a single diastereomer in 90% yield. The optical rotation of 89
[α]26D +29.00° (c 0.6, in methanol) was in agreement with that of the literature136 [α]26D
+29.5° (c 0.6, in methanol) which completed the first enantiospecific, stereospecific total
synthesis of the natural product ervincidine 89 (Scheme 25). The analysis of the spectral
data of the alkaloid 89 follows here.
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Figure 10: Proton spectrum of natural product Ervincidine 89
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Figure 11: Carbon spectrum of natural product ervincidine 89
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To assign the stereochemistry of the C-6 alcohol a detailed study of the 1D and 2D
NOESY experiments were carried out on the synthetic diol 89. The methyl group (3H-18)
detected as a three proton doublet showed strong connectivity only to H-19. The proton
of the aromatic ring at H-9 and H-6, showed a weak NOE. No NOEs were found between
H-15 and H-6. The protons of H-15 exhibited a strong NOE with H-17, H-16, H-14 and
H-18. The proton of H-6 showed strong NOE with H-5. A weak NOE was observed
between the protons labeled H-6 and H-3.

Figure 12. Selected NOEs of ervincidine 89
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Figure 13. 1D NOEs Observed after Irradiation of Protons at H-3
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Analysis of the 2D NOESY experiments (Figure 12) further confirmed, the result
obtained by the 1D NOESY experiments. Good NOEs were found between H-3 and H-5
(strong) and H-14 (strong). The irradiation of the proton at C-3 resulted in the
enhancement of the signals at H-5 and H-14, indicating that the protons at H-3 and H-5
(see Figure 13) were located in the pseudo axial position. These results were supported
by examination of the 2D NOE spectrum for H-6 which exhibited cross peaks at H-5
(strong).

Figure 14. 1D NOEs Observed after Irradiation of Protons at H-15
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The 1D NOE signals were observed between H-15 and H-18 (strong), H-17 (strong), H16 (strong) and H-14 (strong). The strong NOE between H-15 and with one of the H-17
protons and not an NOE with the other proton at H-17 indicated that one proton at C-17
was located in the α position while the other proton located at C-17 was found to be β.
The NOE signals between H-15 and H-18 (strong), H-19 (weak) and H-5 (weak) were in
agreement with the assignment.
Figure 15. 1D NOEs Observed after Irradiation of Protons at H-17
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The 2D NOE signals observed between the two proton at C-17 were very strong. The
signals between H-17 and H-15 (strong), H-17 and H16 (strong) and H-17 and H-14
(strong) were also strong.
Figure 16. 1D NOEs Observed after Irradiation of Protons at H-6
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The 1D NOE signal observed between H-6 and H-5 was very strong and the NOE
between H-6 and H-3 was weak. No NOE is seen between H-6 and H-15. Weak NOE
signals are found between H-6 and H-9 as well as H-6 and H-18. The NOE signal
between H-5 and H-16 was strong with a coupling constant of 9.8 Hz, consequently the
dihedral angle between the protons at H-5 and H-16 was close to 0˚ (eclipsed
conformation). A weak NOE was observed between H-3 and H-6. The coupling constant
between H-5 and H-6 was 5.1 Hz which indicated that both the protons were cis to each
other. The angle between both the H-5 and H-6 protons was about 60 ˚ (staggered
conformation) from models. Both the alcohol at C (17) and the proton at the C-6 position
are trans to each other. If the OH were axial and the proton at H-6 were equatorial, a
strong NOE would have been observed with H-15 which in this case was not seen. In
summary, the 2D COSY, NOESY and 1D NOE experiments support the structure of
ervincidine 89, as indicated in Scheme 25.
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Figure 17. 1D NOE data H-15 irradiated
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Figure 18. 2D NOESY of ervincidine 89
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3.1.5. Completion of the regiospecific, stereospecfic total synthesis of the
diasteromer (118) of Ervincidine
To synthesize the diastereomer with the opposite stereochemistry to that of ervincidine 89
at the C-6 position, diene 111 was treated with IBX to give the ketone 117 at the C-6
position in 80% yield. In order to shorten the synthetic route and also synthesize the other
isomer, 9-BBN was chosen which reduces the C-6 keto group to the alcohol and also acts
as a hydroborating agent. 167,168 Since 9-BBN is a bulky group the attack might take place
from the top face of the molecule. The boron might coordinate with the C-6 carbonyl
oxygen as well as the Nb nitrogen atom thus leading to the formation of the alpha
diastereomer 118. This process was executed as shown in scheme 26 in 70% yield The
optical rotation of 118 [α]26D +17.00° (c 0.6, in methanol) was not in agreement with the
literature.

40,137

It is entirely possible that 9-BBN complexed127,169 with the Nb-nitrogen

function and blocked the attack from the bottom face of the ketone so that the carbonyl
reduction occurred from the top face to give 118.
Scheme 26
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4. Conclusion
In conclusion, the first enantiospecific, stereospecific total synthesis of ervincidine 89
has been accomplished from commercially available D-(+)-tryptophan 37 which has
served both as the chiral auxiliary and the starting material. Moreover, this is the first
synthesis which unequivocally sets the stereochemistry of the hydroxyl group at C-6 in
sterospecific fashion, as well as the C-16 hydroxy methyl group. The stereospecific
conversion of D-(+)-tryptophan 37 into the key template (−)-Na-H, Nb-benzyl tetracyclic
ketone 49 via the asymmetric Pictet-Spengler reaction (600 gram scale) and Dieckmann
cyclization on multi-hundred gram scale was reduced to only two reaction vessels. The
optically active tetracyclic ketone 49 was converted into the core pentacyclic framework
56 using the intramolecular palladium-mediated enolate cross coupling reaction which
was developed here in Milwaukee130 to afford the core pentacylic framework 56. This
robust reaction could be scaled up to multigram scale in this series. Important to success
here were the sequence of chemical reactions which included a Wittig reaction, a
regiospecific hydroboration and protection/deprotection steps in order to provide
regiospecific oxidation at C-6. The IBX mediated oxidation and the Luche reduction
using CeCl3. 7H20 in the presence of NaBH4 afforded the first enantiospecific,
stereospecific total synthesis of ervincidine 89. The indole alkaloid ervincidine 89 could
be prepared from D-(+)-tryptophan 37 in 13 reaction vessels in 19.2% overall yield.
Another important experiment was the epimerization of the C-6 alcohol with 0.2N HCl
which indicated the care that must be employed in isolation of these alkaloids which
contain a benzylic hydroxyl group. This research process developed here also provides a
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general entry into C-6 hydroxy substituted indole alkaloids either alpha or beta
stereochemistry.
Two other diasteromers were made to rule them out as potential structures. This research
corrects the errors in Glasby’s book137 and Lousnamma’s review 40 and clarifies the work
of Yunusov et al as well as providing the correct absolute configuration of the C-6
hydroxyl function in ervincidine 89. 136

5. Experimental Details
General Experimental Considerations:
All reactions were carried out under an argon atmosphere with dry solvents using
anhydrous conditions unless otherwise stated. Tetrahydrofuran (THF) and diethyl ether
were freshly distilled from Na/benzophenone ketyl prior to use. Dichloromethane was
distilled from calcium hydride prior to use. Methanol was distilled over magnesium
sulfate prior to use. Benzene and toluene were distilled over Na prior to use. Acetonitrile
was distilled over CaH2 prior to use. Reagents were purchased of the highest commercial
quality and used without further purification unless otherwise stated. Thin layer
chromatography (TLC) was performed using Dynamic Adsorbents Inc. UV active silica
gel, 200 µm, plastic backed plates or; Dynamic Adsorbents Inc. UV active alumina N,
200 µm, F-254 plastic backed plates. Flash and gravity chromatography were performed
using silica gel P60A, 40-63 µm purchased from Silicycle. Basic alumina (Act I, 50-200
µm) for chromatography was purchased from Dynamic Adsorbents. Neutral alumina
(Brockman I, ~150 mesh) for chromatography was purchased from Sigma-Aldrich. TLC
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plates were visualized by exposure to short wavelength UV light (254 nm). Indoles were
visualized with a saturated solution of ceric ammonium sulfate in 50% sulfuric acid.170
Elemental analyses were performed on a Carlo Erba model EA-1110 carbon, hydrogen,
and nitrogen analyzer. All samples submitted for CHN analyses were first dried under
high vacuum for a minimum of six hours using a drying pistol with isopropyl alcohol or
benzene as the solvent with potassium hydroxide pellets in the drying bulb. Melting
points were taken on a Stuart melting point apparatus SMP3 manufactured by Barloworld
Scientific US Ltd. Proton (1H NMR) and carbon high resolution nuclear magnetic
resonance spectra (13C NMR) were obtained on a Bruker 300-MHz or a GE 500-MHz
NMR spectrometer. 1H NMR data are reported as follows: chemical shift, multiplicity (s
= singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of
triplets, ddd = doublet of doublet of doublet, td = triplet of doublets, qd = quartet of
doublets, sex = sextet, m = multiplet), integration, and coupling constants (Hz). 13C NMR
data are reported in parts per million (ppm) on the δ scale. The low resolution mass
spectra (LRMS) were obtained as electron impact (EI, 70eV), which were recorded on a
Hewlett-Packard 5985B gas chromatography-mass spectrometer, while high resolution
mass spectra (HRMS) were recorded on a VG Autospec (Manchester, England) mass
spectrometer. HRMS recorded by electrospray ionization (ESI) methods were performed
at the Laboratory for Biological Mass Spectrometery at Texas A&M University on a API
QStar Pulsar model, manufactured by MDS Sciex. Optical rotations were measured on a
JASCO Model DIP-370 digital polarimeter. Infra-red spectra were recorded on a Thermo
Nicolet Nexus 870 FT-IR or a Perkin Elmer 1600 series FT-IR spectrometer.
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D-(-)-Tryptophan methyl ester 90
To a round bottom flask (5000 mL) which contained a freshly saturated solution of
anhydrous methanolic hydrogen chloride (2500 mL), D-(+)-tryptophan 37 (400 g, 1.96
mol) was added. The mixture which resulted was heated to reflux for 8 h and then
allowed to cool to rt. The crystalline product which formed upon cooling was collected
by filtration and washed with cold ether to provide D-(-)-tryptophan methyl ester.HCl.
The free base 90 was prepared by treatment of the corresponding HCl salt with cold aq
NH4OH (10%), followed by extraction with CH2Cl2 in methanol (4:1, 3 x 1000 mL). The
solvent was evaporated under reduced pressure, after which the solid was redissolved in
CH2Cl2 and dried (K2CO3). The DCM layer was removed under reduced pressure to
provide D-(-)-tryptophan methyl ester 90 (392 g, 91%). mp 92-93 °C (free base); [α]D27
1

= -37.2 (c 1.0 in MeOH); IR (KBr) 1730 cm-1; H NMR (250 MHz, CDCl3, free base) δ
1.62 (2H, s), 3.05 (1H, dd, J = 14.5, 7.5 Hz), 3.29 (1H, dd, J = 14.6, 5.8 Hz), 3.74 (3H, s),
3.86 (1H, dd, J = 7.5, 4.8 Hz), 7.04-7.23 (3H, m), 7.35 (1H, d, J = 7.5 Hz), 7.61 (1H, d, J
13

= 7.5 Hz), 8.24 (1 H, s); C NMR (62.8 MHz, CDCl3, free base) δ 30.83, 51.86, 55.06,
111.19, 118.73, 119.49, 122.11, 122.87, 127.57, 136.37, 175.71; EIMS (m/e, relative
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intensity) 218 (M+, 78), 159 (57), 130 (100), 117 (33). Anal. Calcd. for C12H14O2N2: C,
66.06; H, 6.42, N, 12.84. Found: C, 66.14; H, 6.33; N, 12.77.
CO2Me
NH2
N
H

CO2Me

PhCHO/CH3OH, rt, 6 h;
NaBH4, -10 °C, 4 h,
90% (one vessel)

90

HN

Ph

N
H
91

D-(+)-Nb-Benzyltryptophan methyl ester 91
To a round bottom flask (3000 mL) which contained a solution of D-(-)-tryptophan
methyl ester 90 (408 g, 2.0 mol) in dry CH3OH (1500 mL), benzaldehyde (260.0 g, 2.3
mol) was added. The solution which resulted was stirred with an overhead stir for 6 h at
22 °C, until examination by TLC (silica gel) indicated the disappearance of 90. The
mixture was then cooled in an ice-salt bath to -5 °C [It was much easier to maintain the
inside temperature between -10˚C to -5˚C by the employment of a dry ice bath (without
solvent)]. If the temperature falls below -15˚C, a large amount of solid will appear and it
is too difficult to stir the reaction mixture. Sodium borohydride (42 g, 1.1 mol) was then
added portionwise at -5 °C over a period of 2.5 h [The slow addition and lower
temperature of this process are critical to avoid racemization of the chiral center]. The
solution was allowed to stir for 3 h and then followed by the addition of ice water (50
mL). The solvent was removed under reduced pressure. The residue was dissolved in
CHCl3 (2000 mL) and washed with brine (2 x 500 mL). The organic layer was dried
(K2CO3) and the solvent was removed under reduced pressure to give the free base 3 (525
g, 90%) which could be further purified by crystallization from EtOH. mp 109-110 °C;
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[α]D22 = + 9.07° (c 1.0 in CH3OH), [lit.152 [α]D22 = +8.65° (c 1.0 in CH3OH)]; IR (film)
-1 1

1745 cm ; H NMR (250 MHz, CDCl3) δ 2.10 (1H, s), 3,15 (2H, m), 3.65 (3H, s), 3.75
(3 H, s), 3.80 (3H, m), 6.90 (1H, s), 7.10 (1H, t, J = 8.2 Hz), 7.25 (5H, m), 7.55 (1H, d, J
= 8.2 Hz);
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C NMR (62.8 MHz, CDCl3) δ 29.35, 51.68, 52.20, 61.38, 111.18, 111.38,

118.84, 119.45, 122.07, 122.88, 127.03, 127.62, 128.19, 128.32, 136.30, 139.79, 175.36;
EIMS (m/e, relative intensity) 308 (M+, 28), 249 (22), 178 (57), 130 (100).
Anal. Calcd. for C19H20O2N2: C, 74.03; H, 6.49; N, 9.08. Found: C, 73.99; H, 6.56; N,
8.99.
CO2Me
0.6 N aq NaOH,
93
2.1 kg

CH3NO2, CH2Cl2,
rt, 48 h, 30%

O2N

CO2Me
94

NaH, MeOH,
0 °C,
H2SO4/MeOH,
MeO
- 45 °C to - 50 °C,
2 h, 90%

OMe
CO2Me
95

Preparation of methyl 4,4-dimethoxybutyrate 95171
To a round bottom flask (12 L) equipped with an overhead stir which contained a
solution of methyl acrylate 93 (1075 g, 12.5 mol) and nitromethane (762.5 g, 12.5 mol) in
CH2Cl2 (2500 mL) at 0 °C, was added a solution of NaOH (60 g) in water (2500 mL) at 0
°C. The mixture which resulted was stirred at rt for 48 h. The organic layer was separated
and washed with water (2 x 500 mL) and dried (MgSO4). The solvent was then removed
under reduced pressure and the residue was distilled under reduced pressure (95-100 °C/8
mm of Hg) to give the pure methyl γ-nitro butyrate 94 (540 g, 30%). This was dissolved
in methanolic sodium methoxide [5400 mL, 0.8 N, freshly prepared from 173 g of NaH
(60% dispersion in mineral oil)] and the solution which resulted was added dropwise with
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an overhead sitr at a rate of 1 drop per second to a round bottom flask (12 L) which
contained a solution of conc sulfuric acid (1350 mL) in methanol (4050 mL) at -45 to –50
°C. After the addition was completed, the reaction mixture was poured into CH2Cl2 (8 L).
The organic layer was separated and washed with ice water (2 x 1000 mL), aq 4 N NaOH
(2 x 600 mL) and dried (K2CO3). The solvent was removed under reduced pressure and
the residue was distilled (110-115 °C/8 mm of Hg) to provide methyl 4,41

dimethoxybutyrate 95 (540 g, 90%). H NMR (250 MHz, CDCl3) δ 1.92 (2H, q, J = 7.5
Hz), 2.37 (2H, t, J = 7.5 Hz), 3.31 (6H, s), 3.66 (3H, s), 4.38 (1H, t, J = 15.8 Hz);
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C

NMR (62.8 MHz, CDCl3) δ 27.92, 29.07, 51.45, 53.14, 103.14; CIMS (m/e, relative
intensity) 375 (M+ + 1, 100). The spectral data for 95 were identical to the published
values. 171
CO2Me
HN
N
H

Ph

(CH3O)2CHCH2CH2CO2CH3 (95)
TFA (2.4 eq), CH2Cl2,
rt, 10 d, 92%
or CHCl3, reflux, 12h
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CO2Me
N
H H

N

Ph

MeO2C
92b
trans diester only, > 98% de

Diastereospecific preparation of the trans-(1S,3R)-(-)-2-benzyl-3-methoxycarbonyl1-methoxycarbonylethyl-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole (92b) via the
newly modified Pictet-Spengler reaction.
To a round bottom flask (5000 mL) which contained a solution of optically active Nbbenzyl-D-tryptophan methyl ester 90 (400 g, 1.3 mol) in CH2Cl2 (2500 mL) was added
methyl 4,4-dimethoxybutyrate acetal 95 (315 g, 1.9 mol) and TFA (180 g, 2.4 eq) at 0 ˚C
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with stirring. The reaction mixture which resulted was allowed to stir at rt for 10 d and
then cooled in an ice bath and brought to pH = 8 with a cold aq solution of NaOH (3 N).
The aq layer was separated and extracted with CH2Cl2 (3 x 1500 mL). The combined
organic layers were washed with brine (2 x 600 mL) and dried (K2CO3). The volume of
the solution was reduced to 300 mL under reduced pressure and EtOAc (100 mL) and
hexanes (300 mL) were added to the above solution. The solution was cooled to –20 ˚C.
The trans diester 109b (402 g, 76%) precipitated out as white crystals and the mother
liquor was concentrated. The residue which resulted was purified by flash
chromatography (silica gel, EtOAc/hexane, 1/4) to provide additional 109b (83 g, 16%).
The combined yield of 92b (485 g) was 92%. mp 152-153 °C; [α]D27 = -35.7° (c 1.4, in
-1

1

CHCl3), [lit.114[α]D27=-38.0˚ (c 1.0 in CHCl3)]; IR (film) 3310, 1731, 1707 cm ; H
NMR (250 MHz, CDCl3) δ 1.85-2.15 (2H, m), 2.20-2.50 (2H, m), 3.03 (1H, dd, J = 15.8,
5.3 Hz), 3.12 (1H, dd, J = 15.8, 8.8 Hz), 3.48 (3H, s), 3.59 (1H, d, J = 13.6 Hz), 3.75 (3H,
s), 3.84 (1H, d, J = 13.6 Hz), 3.87-3.93 (1H, m), 3.98 (1H, dd, J = 8.8, 5.3 Hz), 7.07-7.35
(8H, m), 7.43 (1H, d, J = 7.2 Hz), 7.98 (1H, s);
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C NMR (62.8 MHz, CDCl3) δ 21.39,

28.94, 29.88, 51.45, 51.85, 53.51, 54.81, 56.79, 107.51, 110.99, 118.16, 119.51, 121.77,
127.08, 127.13, 128.28, 129.13, 134.26, 136.50, 139.41, 173.42, 174.18; EIMS (m/e,
relative intensity) 406 (M+, 60), 347 (45), 319 (100), 169 (50).
Anal. Calcd. for C24H26O4N2: C, 70.91; H, 6.45; N, 6.89. Found: C, 70.88; H, 6.47; N,
6.91.
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H

CO2Me
N

N
H
MeO2C
92b

Ph

OH
reflux, 3 d, 88%

N
H

N
CO2Me

H
Ph

102

Dieckmann cyclization of the Na-H diester 92b to provide (6S,10S)-(-)-methyl-9-oxo12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b]indole-8-carboxy-late
102
To a round bottom flask (5000 mL) which contained a solution of Na-H, trans diester 92b
(100 g, 0.25 mol) in toluene (3000 mL), which had been predried by azeotropic removal
of H2O by a DST (refluxed 6 h), was added sodium hydride (88.7 g, 2.2 mol, 60%
dispersion in mineral oil) at 0 ˚C. Anhydrous CH3OH (174 mL, 4.3 mol) was then added
into the above mixture dropwise under Ar at 0 ˚C. The solution which resulted was held
at reflux for 72 h (the flask was covered with aluminum foil on the top to keep the
temperature at reflux without carbonizing any compound on the sides of the flask).
The reaction was quenched with ice. The aq layer was extracted with CH2Cl2 (3 x 1 L).
The combined organic extracts were washed with brine and dried (K2CO). The solvent
was removed under reduced pressure and the mineral oil was separated by decantation.
The residue which resulted was purified by flash chromatography (silica gel,
EtOAc/hexane, 1/4) to provide the Na-H, β-ketoester 102 (82 g, 88%). mp 149-150 °C;
-1

1

[α]D27 = -177.4° (c, 1.0 in CHCl3); IR (KBr) 1670, 1630cm ; H NMR (250M Hz,
CDCl3) δ 2.30 (1H, d, J = 15.6 Hz), 2.82 (1H, dd, J = 15.5, 5.6 Hz), 2.90 (1H, d, J = 15.3
Hz), 3.18 (1H, dd, J = 15.9, 5.9 Hz), 3.66 (3H, s), 3.71 (1H, d, J = 13.4 Hz), 3.77 (1H, d,
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J = 5.3 Hz), 3.82 (1H, d, J = 13.4 Hz), 3.98 (1H, d, J = 5.4 Hz), 7.11 (1H, t, J = 7.1 Hz),
7.16 (1H, t, J = 7.0 Hz), 7.24-7.39 (6H, m), 7.50 (1H, d, J = 7.1 Hz), 7.63 (1H, s), 11.98
(1H, s);
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C NMR (75.5 MHz, CDCl3) δ 22.2, 28.6, 49.7, 51.3, 55.2, 55.9, 94.3, 106.2,

110.8, 118.1, 119.5, 121.6, 127.0, 127.2, 128.4, 128.7, 133.4, 135.7, 138.3, 171.6, 172.5;
CIMS (CH4) (m/e, relative intensity) 389 (M+ + 1, 100).
Anal. Calcd. for C23H22N2O3: C, 73.78; H, 5.92; N, 7.48. Found: C, 74.19; H, 6.23; N,
7.35.
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H
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N
H

CO2Me

H
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O
HOAc, HCl, H2O, reflux, 8 h

N

91%, > 98% ee

N
H

Ph

N
H
Ph

49

Preparation of (6S,10S)-(-)-9-oxo-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5Hcyclo-oct[b]indole 49 via acid mediated hydrolysis of the Na-H, β-ketoester 102
To a round bottom flask (500 mL) which contained the Na-H, β-ketoester 102 (45.0 g,
0.12 mol) was added glacial acetic acid (167 mL), aq hydrochloric acid (245 mL, conc.)
and water (65 mL) with stirring (magnetic stir). The solution which resulted was heated
at reflux for 8 h. After removal of the solvent under reduced pressure, the residue was
brought to pH = 9 with a cold aq solution of NaOH (3 N). The mixture which resulted
was extracted with CH2Cl2 (4 x 250 mL) and the combined organic extracts were washed
with a saturated aq solution of NH4Cl (100 mL), brine (2 x 100 mL) and dried (K2CO3).
Removal of the solvent under reduced pressure afforded an oil. After a short wash
column on silica gel, the Na-H, Nb-benzyltetracyclic ketone 49 (24.5 g, 64%) was
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crystallized from EtOAc/ hexane (1:4, 30 mL). The mother liquor was concentrated under
reduced pressure and the residue was chromatographed on silica gel with EtOAc/hexane
(1:4) to provide additional ketone 49 (10.5 g, 27%). The combined yield of 49 (35.0 g)
-1 1

was 91%. [α]D27 = -246.7˚ (c 1.05 in CHCl3); IR (KBr) 2933, 1715 cm ; H NMR (250
MHz, CDCl3) δ 2.02(1H, m), 2.15 (1H, m), 2.49 (2H, m), 2.71 (1H, d, J = 16.9 Hz), 3.27
(1H, dd, J = 16.9, 6.8 Hz), 3.78 (2H, s), 3.80 (1H, s), 4.02 (1H, s), 7.17 (1H, dt, J = 7.3,
1.0 Hz), 7.23 (1H, dt, J = 7.6, 1.0 Hz), 7.30-7.38 (6H, m), 7.54 (1H, d, J = 7.6 Hz), 7.81
(1 H, s);
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C NMR (62.8 MHz, CDCl3) δ 20.40, 30.37, 34.51, 49.40, 56.13, 65.22,

106.73, 110.94, 118.21, 119.72, 122.01, 126.86, 127.42, 128.43, 128.60, 131.98, 135.85,
138.25, 210.40; CIMS (m/e, relative intensity) 317 (M+ + 1).
Anal. Calcd. for C21H20N2O: C, 79.72; H, 6.37; N, 8.85. Found: C, 79.51; H, 6.37; N,
8.85.
CO2Me

CO2Me

PhCHO/CH3OH, rt, 6 h;
NaBH4, -10 °C, 4 h;

NH2
N
H

(CH3O)2CHCH2CH2CO2CH3
TFA(2.4 eq), CH2Cl2, rt,
10 d, 83% one pot
600 g scale

90

N

N
H H
MeO2C

Ph

92b

toluene, NaH (8 eq),
dry CH3OH, reflux, 72 h;
HOAc, HCl, H2O, reflux,
10 h, 80% overall yield
(150 g scale)
H
O
N
H
H
50

NH

sat HCl/EtOH,
Pd/C (5 mol%),
H2 (1 atm), EtOH,
10 h, 95%

H
O
N
H

N
H

49, >98% ee

Ph
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One pot process for converting D-(-)-tryptophan methyl ester 90 into trans-(1S,3R)(-)-2-benzyl-3-methoxycarbonyl-1-methoxycarbonylethyl-1,2,3,4-tetrahydro-9Hpyrido-[3,4-b]indole 92b10
To a round bottom flask (12 L) which contained a solution of D-(-)-tryptophan methyl
ester 90 (400 g, 1.83 mol) in CH3OH (5000 mL) was added benzaldehyde (230 g, 2.2
mol) with stirring (overhead stir). The solution which resulted was stirred for 6 h at rt.
The mixture was then cooled to –10 ˚C and sodium borohydride (55 g, 1.3 mol) was
added portionwise over a period of 3 h. The internal pot temperature was kept between 10 ˚C and -5 ˚C with a dry ice bath (solid dry ice). After analysis by TLC (silica gel,
EtOAc/hexane, 1/1) indicated the disappearance of imine, the mixture was allowed to stir
for an additional 0.5 h followed by the slow addition of CF3COOH (260 mL) at 0 ˚C. The
solvent was removed under reduced pressure and the residue was dissolved in CH2Cl2
(3000 mL). After the solution which resulted was cooled to 0 ˚C, methyl 4,4dimethoxybutyrate acetal 95 (324 g, 2.0 mol) and TFA (500 g, 2.4 eq) were added to this
vessel at 0 ˚C. The reaction mixture was stirred at rt for 10 d, after which it was cooled in
an ice bath and brought to pH = 8 with a cold aq solution of NaOH (3 N). The aq layer
was separated and extracted with CH2Cl2 (3 x 5000 mL). The combined organic layers
were washed with brine (2 x 200 mL) and dried (K2CO3). The volume of the solution was
reduced to 300 mL under reduced pressure and EtOAc (100 mL) and hexanes (300 mL)
were added to the above solution. The solution was cooled to –20 ˚C. The trans diester
92b (510 g, 69%) precipitated as white crystals and the mother liquor was concentrated
and the residue which resulted was purified by flash chromatography (silica gel,
EtOAc/hexane, 1/4) to provide additional 92b (114 g, 14%). The combined yield of 92b
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(624 g) was 83% and the solid was identical to the trans diester 92b obtained from Nbbenzyl-D-tryptophan methyl ester 90 in an earlier experiment.
One pot process for converting trans-(1S,3R)-(-)-2-benzyl-3-methoxy carbonyl-1methoxycarbonylethyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole 92b into (6S,10S) (-)-9-oxo-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b] indole 49 10
The trans diester 92b (150 g, 246 mmol) was dissolved in dry toluene (3500 mL) in a
round bottom flask (5000 mL) equipped with an overhead stirrer, Dean Stark trap (DST)
and a reflux condenser. The solution which resulted was heated to reflux for 6 h with
stirring. The above predried solution was cooled to 0 ˚C and sodium hydride (150 g of
60% dispersion NaH in mineral oil) was added to the above vessel under an atmosphere
of Ar. Dry CH3OH (170 mL) was added carefully (a large amount of H2 was evolved at
this point). The mixture was stirred at rt for 0.5 h, and then heated to reflux for an
additional 72 h. Note: The top of the flask was covered with aluminium foil to keep
the reflux and prevent carbonization of the lactam intermediate during the
Dieckmann process. After analysis by TLC (silica gel, EtOAc/hexane, 1/4) indicated the
disappearance of 92b, the reaction mixture was cooled to 0 ˚C and then quenched
carefully with glacial acetic acid (300 mL). The solvent was removed under reduced
pressure and glacial acetic acid (480 mL), aq hydrochloric acid (750 mL, conc.) and
water (200 mL) were added to the above vessel. The mixture which resulted was heated
at reflux for 8 h. After removal of the solvent under reduced pressure, the residue was
brought to pH = 9 by addition of an aq solution of cold NaOH (3 N). The mixture which
resulted was extracted with CH2Cl2 (4 x 1000 mL) and the combined organic extracts
were washed with brine (2 x 500 mL) and dried (K2CO3). Removal of the solvent under
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reduced pressure afforded an oil which was chromatographed on silica gel with
EtOAc/hexane (3:7) to provide the tetracyclic ketone 50 (90 g, 80%), which was identical
to the ketone obtained from ketoester 102 (see above). Note: A lactam intermediate is
formed first in the Dieckmann reaction which must open up to isomerize and
undergo the Dieckmann reaction. Do not mistake this first product (lactam) for the
β-keto ester intermediate by TLC.
H
N
H

O

sat HCl/EtOH,
Pd/C (5 mol%),

Ph

H2 (1 atm), EtOH,
10 h, 95%

N
H

49, >98% ee

H
O
N
H
H
50

NH

Catalytic debenzylation of 49 to provide (6S,10S)-(-)-9-oxo-12-H-6,7,8,9,10,11hexahydro-6,10-imino-5H-cyclooct[b]indole 50 over Pd/C/H2
Tetracyclic ketone 49 (40 g, 127 mmol) was dissolved in anhydrous ethanol (1300 mL).
A saturated solution of EtOH/HCl (g) was then added dropwise into the above mixture
until the solid completely dissolved. The solvent was then removed under reduced
pressure to furnish an HCl salt. The residue was then dissolved in dry ethanol (1000 mL)
and the solvent was removed under reduced pressure to remove the excess HCl. This
process was repeated 3 times to make sure there was no excess HCl. The HCl salt was
degassed under reduced pressure at rt and back filled with argon (2 times). Dry Pd/C
(10% by wt, 8.1 g, 60 mmol) was added to the above HCl salt, followed by addition
(slow addition, initially) of dry ethanol (1300 mL). The mixture was degassed under
reduced pressure at rt and back filled with H2 (3 times). The mixture which resulted was
allowed to stir on bench top at rt under an atmosphere of H2 (balloon) for 10 h. Analysis
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by TLC (silica gel plate was exposed to NH3 vapours) indicated the absence of starting
ketone 49. The catalyst was removed by filtration (Celite) and washed with ethanol (3 x
100 mL). The solvent was removed under reduced pressure. The residue was dissolved in
a mixture of CHCl3 and brought to pH = 8 with 10% aq NH4OH. The aq layer was
extracted with CHCl3 (3 x 400 mL). The combined organic layers were washed with
brine (2 x 200 mL) and dried (K2CO3). The solvent was removed under reduced pressure
to afford the crude amine which was chromatographed (flash) on silica gel (CHCl3/EtOH,
9/1) to provide pure Na-H, Nb-H tetracyclic ketone 50 (27.2 g, 95%). FTIR (NaCl) 3393,
3382, 1705 cm-1, 1H NMR (300 MHz, CDCl3) δ 2.08-2.15 (2H, m), 2.36-2.50 (3H, m),
2.80 (1H, d, J = 16.4 Hz), 3.09 (1H, dd, J = 16.5, 6.8 Hz), 3.92 (1H, d, J = 6.7 Hz), 4.27
(1H, d, J = 3.9 Hz), 7.10 (1H, d, J = 7.4 Hz), 7.16 (1H, d, J = 7.4 Hz), 7.29 (1H, d, J = 7.9
Hz), 7.44 (1H, d, J = 7.62 Hz), 8.06 (1H, bs),
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C NMR (75.5 MHz, CDCl3) 211.0,

135.7, 134.0, 126.9, 122.1, 119.7, 118.1, 110.9, 107.5, 59.8, 46.1, 35.0, 32, 25.8; CIMS
(m/e, relative intensity) 227 (M++1, 100%).
Anal. Calcd. For C14H14N2O: C, 74.31%; H, 6.24%; N, 12.38%. Found: C, 74.39%; H,
6.35%; N, 12.41%.
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Pd2(dba)3 (5 mol %), DPEPhos
(7 mol %), t-BuONa (1.5 equiv),
THF, 80 °C, 5 h, 83%
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THF-H2O (1:1)
0°C-rt, 5h

H
I
104

NaBH4, THF-H2O (9:1)
0°C, 97% overall yield
in two steps

Br
PBr3, Et2O

I
CH3

105

I
0°C-rt, 93%

CH3
51

(Z)-1-bromo-2-iodobut-2-ene 51155
A solution of crotonaldehyde 103 (300mL. 3.63 mol) in THF-H2O (1:1, 1500mL) was
cooled to -15 to -20 °C (dry ice). To the cold solution was added K2CO3 (600g, 4.45 mol,
1.2 equiv), I2 (1383g, 5.45 mol, 1.5 equiv) and DMAP (88.6g, 0.726 mol, 0.2 equiv)
successively (the temperature was increased, controlled by the rate of addition of I2). The
reaction was allowed to stir for 12 h until the disappearance of starting material (TLC,
silica gel, I2) during which the temperature was allowed to increase to rt. Then solid
Na2S2O3 (600g) and a saturated solution of Na2S2O3 (about 5L) was added until the
reaction mixture became colorless. The mixture was extracted with EtOAc (3x8L) and
the organic layers were combined. The majority of the solvent was removed under
reduced pressure. The residue 104 was dissolved in THF-H2O (9:1, 8L) and cooled to -5
to -10 °C (dry ice) after which NaBH4 (70g, 1.8 mol, 0.5 equiv) was added in portions
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and the temperature maintained at 0°C. The mixture was extracted with EtOAc (3x8L)
and dried (MgSO4). The solvent was removed under reduced pressure to provide a brown
oil. After a simple wash column to remove some baseline material, iodide 105 was
obtained as light yellow oil 105 (650g, 90%). 1H NMR (300 MHz, CDCl3) δ 6.02 (q, 1H,
J =3.9Hz), 4.30 (s, 2H), 1.85 (t, 3H, J=6.3Hz). The spectral properties of this iodide were
identical to the published values.120 (Z)-2-Bromo-2-buten-1-ol 105 (2 g, 10 mmol) was
dissolved in anhydrous ethyl ether (20 mL). Phosphorus tribromide (0.380 mL, 4 mmol)
was added dropwise to this solution at 0°C. This reaction mixture which resulted was
stirred for 18 h at rt. The reaction was quenched with a cold aq solution of K2CO3 and
extracted with ethyl ether after which it was washed with brine. The organic layer was
dried (Na2SO4) and concentrated in vacuuo to give 51 (2.45 g, 93% yield) which was
directly used in the next step.172 1H NMR: 6.08 (q, J = 6.4 Hz, 1H); 4.36 (s, 2H); 1.81 (d,
J = 6.4 Hz, 3H). The spectral properties of this bromide were identical to the published
values.121 This was directly used in the following alkylation.
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Alkylation of (6S,10S)-(-)-9-oxo-12-H-6,7,8,9,10,11-hexahydro-6,10-imino-5Hcyclooct[b] indole (50) to provide (6S,10S)-(-)-9-oxo-12-(Z-2' -iodo-2' -butenyl)6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b] indole 52
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A solution of the Na-H, Nb-H tetracyclic ketone 50 (1.5g, 6.637mmol) was dissolved in
dry CH3CN (20mL). To this mixture, K2CO3 (3.66g, 26.54 mmol) and Z-1-bromo-2iodo-2-butene 51 (2.6g, 9.95mmol) were added. This reaction mixture was stirred for 14h
at rt. Analysis by TLC indicated the absence of tetracyclic ketone. The K2CO3 was
removed by passing the mixture through a bed of celite with EtOAC. After removal of
the solvent under reduced pressure, the crude product was purified by flash
chromatography (silica gel, hexane:EtOAC = 9:1) to provide Nb-Z-2′-iodo-2′-butenyl
tetracyclic ketone 52 (2.04g, 76%). FTIR (NaCl) 3393, 1705, 1450cm-1; 1H NMR (300
MHz, CDCl3) δ 1.73 (3H, d, J=6.27Hz), 2.19-2.05 (2H, m), 2.37-2.47 (2H,m), 2.65(1H,
d, J=16.87Hz), 3.05 (1H, dd, J=16.94, 6.72 Hz), 3.19-3.37 (2H,m), 3.64 (1H, d,
J=6.37Hz), 3.96 (1H, bs), 5.76 (1H, q, J=6.17Hz), 6.97-7.16 (2H, m), 7.25 (1H, d,
J=7.72Hz), 7.40 (1H, d, J=7.52Hz), 8.05 (1H, bs); 13C NMR (75.5 MHz, CDCl3) δ 20.60,
21.71, 30.35, 34.49, 49.73, 63.36, 64.07, 106.69, 108.47, 110.94, 118.09, 119.62, 121.97,
125.72, 132.11, 132.76, 135.79, 210.40; CIMS (m/e, relative intensity) 407 (M++1,
100%). Anal. Calcd. For C18H19N2O: C, 53.22%; H, 4.71%; N, 6.90%. Found: C,
53.15%; H, 4.80%; N, 6.64%.
O
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Palladium catalyzed cyclization of (6S, 10S)-(-)-9-oxo-12-(Z-2’-iodo-2’butenyl)6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct [b] indole (52) to provide
pentacyclic ketone (56)
The Nb-Z-2' -iodo-butenyl tetracyclic ketone 52 (1 g, 2.46 mmol) was dissolved in
anhydrous THF (20mL). To this mixture NaOtBu (0.354 g, 3.69 mmol), DPEphos
(0.0927 g, 7.0 mol %) and Pd2 (dba)3 (0.112g, 5.0 mol %) was added. This reaction
mixture was degassed 3-4 times under vacuum and back filled with argon and placed in a
preheated oil bath at 80 °C for 5hrs. The reaction was quenched with water and ethyl
acetate. The organic layer was separated and dried (Na2SO4). The EtOAc was then
removed under reduced pressure and the residue was flash chromatographed with
CH2Cl2/MeOH (4.5:0.5) to provide the coupling product 56 (0.569g, 83% yield).

1

H

NMR (300 MHz, CDCl3) δ 1.63 (3H, J=6.86 Hz, d), 2.15-2.20 (1H, m), 2.38 (1H, t,
J=9.9 Hz), 2.97 (1H, dd, J=15.58, 6.20 Hz), 3.27 (1H, d, J=14.43 Hz), 3.37 (1H, bs),
3.59 (1H, d, J=5.70 Hz), 3.78 (2H, bs), 4.26 (1H, d, J=59.11 Hz), 5.49 (1H, q, J=6.85
Hz), 7.05-7.15 (2H, m), 7.25 (1H, d, J=7.25Hz), 7.47 (1H, d, J=4.7Hz), 7.93 (s, 1H); 13C
NMR (75.5 MHz, CDCl3) δ 12.68, 22.39, 36.40, 44.55, 50.83, 55.24, 64.17, 105.62, 110.
89, 118.54, 119.69, 121. 26, 122.00, 126.88, 131.88, 135.87, 136. 34, 217.00; CIMS
(m/e, relative intensity) 291 (M+ +1, 100%); EIMS (m/e, relative intensity) 278 (M+ ,
10%), 250 ,75%), 249 (85%), 182 (6%), 169 (100%), 168 (5%). HRMS C18H18N2O:
calcd. 278.1419; found 278.1437. This material was used directly in the next step.

110

H
N
H

O

N
H
56

H

CH3OCH2PPh3Cl (7.3
equiv), t-BuOK (7.9
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Conversion of the pentacyclic ketone (56) into (+)-3-ethylidene-1,3,4,7,12,12bhexahydro-2H, 6H- 2,6-methano-indole[2,3,-α]-quinolizine-13-carboxaldehyde[(+)vellosimine, 14a] via the Wittig reaction followed by acid mediated hydrolysis.
A mixture of anhydrous potassium t-butoxide (12.8g, 0.114 mol) and methoxylmethyl
triphenylphosphonium chloride (36g, 0.105 mol) in dry benzene (500mL) was allowed to
stir at rt for 1h. The pentacyclic ketone 56 (4g, 14.4mmol) in THF (160mL) was then
added into the above orange colored solution dropwise at rt. The mixture which resulted
was stirred at rt for 24h. The mixture was diluted with EtOAc (3x700mL), washed with
H2O (3x50mL), brine (50mL) and dried (K2CO3). The solvent was removed under
reduced pressure to afford an oil. The solvent was removed under reduced pressure and
the residue was dissolved (without further purification) in a solution of aq HCl (2N) in
H2O-THF (1:1, 400mL). The solution which resulted was refluxed 55 °C (oil bath
temperature) under an atmosphere of argon for 6h. The reaction mixture was brought to rt
and concentrated under reduced pressure. The reaction mixture was diluted with water
and extracted with ether to remove the triphenyl phosphine oxide. The aq layer was
brought to pH 8 with an ice cold aq solution of NaOH (1N). The aq layer was extracted
with CH2Cl2 and the combined organic layers were washed with H2O (3x100mL), brine
(100mL) and dried (K2CO3). The solvent was removed under reduced pressure to afford
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an oil which was crystallized to provide the aldehyde 14a (3.78g, 90%). The spectral
data for (+)-vellosimine 14a were in good agreement with the published values.19,173
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mediated

reduction

of

(+)-3-ethylidene-1,3,4,7,12,12b-

hexahydro-2H,6H-2,6-methano-indole[2,3-α]-quinolizine-13-carboxaldehyde[(+)vellosimine, 14a] to provide the (+)-3-ethylidene-1,3,4,7,12,12b-hexahydro-13hydroxymethyl-2H,6H-2,6-methano-indole [2,3-α]-quinolizine [(+)-normacusine B,
107].
The (+)-vellosimine 14a (100mg, 0.34mmol) was dissolved in EtOH (5mL). The NaBH4
(12mg, 0.33 mmol) was added to the above solution at 0 °C in one portion. The mixture
was then stirred for 8 h. The reaction mixture was diluted with CH2Cl2 (50mL) and
poured into cold water (10mL). The aq layer was extracted with additional CH2Cl2
(3x20mL) and the combined organic layers were washed with brine (10mL) and dried
(K2CO3). The solvent was removed under reduced pressure to afford the crude product
which was chromatographed to provide normacusine B 107 (90mg, 90%). [α]D28 = +40.5
° (c=0.75, C2H5OH); lit [α]D =+42 ° (c=1.0, C2H5OH)174: FTIR (NaCl) 3198 cm-1; 1H
NMR (300 MHz, CDCl3) δ 1.57 (3H, d, J=6.76 Hz), 1.66 (1H, dt, J =12.54, 3.69 Hz),
1.78 (1H, q, J=7.49 Hz), 1.93 (1H, t, J=10.00Hz), 2.61(1H, d, J=15.37Hz), 2.72 (1H, s),
2.74 (1H, d, J=6.51 Hz), 3.03 (1H, dd, J=15.39, 5.10 Hz), 3.43-3.49 (4H, m), 4.07 (1H, d,
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J=10.29Hz), 5.26 (1H, q, J=6.68Hz), 7.03-7.14 (1H, m), 7.28 (1H, d, J=6.00Hz), 7.42
(1H, d, J=7.00Hz), 8.22 (1H, s);

13

C NMR (75.5 MHz, CDCl3) δ 12.75, 26.95, 27.58,

33.37, 44.14, 050/48, 54.47, 55.85, 64.90, 0104.52, 110.99, 116.84, 118.07,
119.35,121.44, 127.59, 135.33, 136.33, 137.80; EIMS (m/e, relative intensity) 294 (M+,
84%), 293 (85%), 279 (10%), 263 (30%), 169 (100%), 168 (79%). HRMS C19H22N2O:
calcd. 294.1732; found 294.1705. The spectral data were identical to that reported in the
literature.174
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Synthesis of 3-ethylidiene-13-(triisopropylsilanyloxymethyl)-1,3,4,7,12,12bhexahydro-2H,6H-2,6-methano-indolo [2,3-α] quinolizine 108 from normacusine B
107 with 2,6-lutidine and triisopropylsilyl chloride.
A solution of normacusine B 107 (1.0g, 3.4mmol) was stirred in dry CH2Cl2 (30mL) in a
125mL round bottom flask. At 0 °C, 2, 6–lutidine (1.58mL, 13.6mmol), followed by
triisopropylsilyl chloride (1.82mL, 6.8mmol) were added. The reaction mixture was
allowed to stir for 2h until analysis of the mixture by TLC indicated the absence of
starting material. Water (50.0mL) was added to the solution to quench the reaction
mixture and it was extracted with CH2Cl2 (3x200mL). The organic layer was separated
and dried (Na2SO4). The organic layer was removed under reduced pressure and the
residue was purified by flash chromatography (silica gel, CH2Cl2/MeOH (95:5) to
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provide 108 (1.38g, 90%). [α]D = +45.14 ° (c=0.14 in CH2Cl2); 1H NMR (300 MHz,
CDCl3) δ 1.05 (m, 21H), 1.62 (d, 3H, J=6.7Hz), 1.74 (m, 2H), 2.05 (t, 1H, J=10.1Hz),
2.70 (d, 1H, J=15.5Hz), 2.79 (m, 2H), 3.08 (dd, 1H, J=15.3 and 5.3Hz), 3.60 (m, 4H),
4.17 (d, 1H, J=7.5Hz), 5.39 (q, 1H, J=6.8Hz), 7.13 (m, 2H), 7.34 (d, 1H, J=7.5Hz), 7.48
(d, 1H, J=7.4Hz), 8.03(br, 1H);

13

C NMR (75.5 MHz, CDCl3) δ 11.83, 12.73, 17.96,

27.10, 27.29, 33.56, 44.26, 50.55, 54.93, 56.05, 65.56, 104.72, 110.76, 116.44, 118.03,
119.20, 121.23, 127.74, 135.48, 136.18, 137.87; MS (EI) m/e (relative intensity) 450 (M+,
16), 263 (45), 182 (31), 169 (89), 168 (100). Anal.Calcd. for C28H42N2OSi: C, 74.61; H,
9.39; N, 6.22. Found: C, 74.46; H, 9.31, N, 6.06
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IBX mediated oxidation to provide (6S,11S,11aR,E)-9-ethylidene-11((triisopropylsilyl)oxy)methyl)-6,8,9,10,11,11a-hexahydro-6,10-methanoindolo[3,2b]quinolizin-12(5H)-one (109) 130
To a solution of triisopropylsilyl ether 108 (100mg, 0.22mmol) in EtOAc/DMSO
(10mL/5mL) was added IBX (0.552mg, 0.88mmol) in one portion at rt. The mixture
which resulted was stirred at 80°C overnight and the reaction progress was monitored by
TLC (silica gel, EtOAc). The reaction mixture was cooled at 0 °C and quenched with a
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saturated solution of aq NaHCO3 (4mL), followed by treatment with a saturated solution
of aq Na2S2O3 (5mL). After this, the mixture was stirred for an additional 10min at 0°C.
The aq layer was extracted with additional amounts of EtOAc (3x10mL) and the
combined organic layers was washed with brine (10mL) and dried (K2CO3). The solvent
was removed under reduced pressure to provide the crude oil which was purified by flash
chromatography [silica gel, hexane: EtOAc (1:1)] to provide the benzylic ketone 109
(87mg, 85%). 1H NMR (300 MHz, CDCl3) δ 1.05 (m, 21H), 1.66 (d, 3H, J=6.3Hz), 1.82
(d, 1H, J=6.3Hz), 2.13 (t, 1H, J=9.9Hz), 2.86 (d, 1H, J=7Hz), 3.17 (s, 1H), 3.5 (m, 3H),
3.8 (dd, 1H, J1=9.6Hz, J2=4.2Hz ), 4.3 (d, 1H, J=8.4Hz), 5.47 (q, 1H, J=7Hz), 7.39 (t,
2H, J=7Hz ), 7.49 (t, 1H, J=7Hz), 7.96 (d, 1H, J=7Hz), 8.14 (d, 1H, J=7.2Hz ), 9.6 (br,
1H);

13

C NMR (75.5 MHz, CDCl3) δ 11.91, 12.97, 18.03, 29.72, 32.50, 42.63, 50.48,

54.85, 63.92, 64.60, 106.49, 111.64, 118.52, 121.64, 122.74, 123.61, 124.47, 132.30,
136.14, 154.67, 192.01; HRMS (ESI) calculated for C28H41N2O2Si : 465.2937; found :
465.2950.
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Synthesis of (6S,11R,11aR,E)-9-ethylidene-11-(hydroxymethyl)-6,8,9,10,11,11ahexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (110)
A solution of benzylic ketone 109 (20mg, 0.043mmol) was stirred in THF (1 mL) in a
5mL round bottom flask. At 0°C, excess TBAF hydrate was then added to the mixture and it
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was allowed to warm to rt. The reaction mixture was stirred for 2h until analysis of the

mixture by TLC indicated the absence of starting material. The reaction was quenched
with water (10mL) and extracted with EtOAc (3x10mL), washed with brine and dried
(Na2SO4). After removal of the solvent under reduced pressure, the residue was purified
by flash chromatography [EtOAc : hexane (4:1)] to provide the target monol 110 (0.011g,
85%) . 1H NMR (300 MHz, CDCl3) δ 1.68 (d, 3H, J=6Hz), 1.87 (d, 1H, J=12Hz), 2.12
(br, 1H), 2.28 (t, 1H, J=12Hz), 2.84 (d, 1H, J=6 Hz), 3.25 (s, 1H), 3.66 (m, 5H), 4.35
(dd, 1H, J1=9Hz, J2=3Hz ), 5.55 (q, 1H, J=7.5Hz), 7.25 (m, 2H ), 7.43 (d, 1H, J=7Hz),
7.98 (d, 1H, J=8.4Hz);

13

C NMR (75.5 MHz, CDCl3) δ 11.60, 12.52, 19.30, 29.17,

42.58, 50.19, 54.38, 63.17, 64.32, 105.38, 111.63, 117.97, 120.54, 122.24, 123.19,
124.29, 133.29, 136.80, 156.43, 193.70; HRMS (ESI) calculated for C19H21N2O2 :
309.1603; found : 309.1588. This material was used in a later step. The structure of
ketone 110 was confirmed by X-ray analysis (see Figure 8).
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Preparation of (6S,11R,11aR,12R,E)-9-ethylidene-11-(hydroxymethyl)5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (88)
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A solution of alcohol 110 (15mg, 0.049mmol) was stirred in MeOH (1 mL) in a 5mL
flask. At -78°C, CeCl3.7H20 (19mg, 0.054mmol) and NaBH4 (2mg, 0.049mmol) was
added to the mixture and it was allowed to warm to rt. The reaction mixture was stirred
for 3h until analysis of the mixture by TLC indicated the absence of starting material. The
reaction was quenched with aq NH4Cl (5mL) and extracted with CH2Cl2 (3x10mL),
washed with brine and dried (Na2SO4). After removal of the solvent under reduced
pressure, the residue was purified by flash chromatography [CH2Cl2 : MeOH (90:10)] to
provide the target diol 88 (13mg, 90%) ; Rf 0.75 (silica gel, CH2Cl2/MeOH, 9 : 1); [α]25D
+79° (c 0.6 MeOH); 1H NMR (300 MHz, CDCl3) δ 1.67 (d, 3H, J=6.6Hz), 1.80 (td, 1H,
J1=12.6Hz, J2=6Hz), 2.13 (m, 1H), 2.2 (m, 1H), 2.7 (t, 1H, J=6.6 Hz), 3.01 (s, 1H), 3.5
(m, 3H), 3.6 (m, 2H), 4.10 (d, 1H, J=8Hz ), 5.23 (d, 1H, J=6Hz), 5.47 (q, 1H, J=6.6 Hz),
7.04 (m, 2H), 7.3 (d, 1H, J=7.8Hz), 7.78 (d, 1H, J=7.8Hz);

13

C NMR (75.5 MHz,

CDCl3) δ 11.60, 27.20, 32.46, 39.18, 50.16, 55.58, 59.71, 63.85, 65.98, 102.27, 110.61,
116.86, 118.64, 119.18, 120.78, 126.51, 135.19, 136.91, 138.54; HRMS (ESI) calculated
for C19H23N2O2 : 311.1760; found : 311.1758. The structure of diol 88 was confirmed by
X-ray analysis (see Figure 9).
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Synthesis of (+)-3-ethylidene-12-methyl-1,3,4,7,12,12b-hexahydro-2H,6H-2,6methano-13-methylene-indole[2,3-a]quinolizine (111) via the Wittig reaction.
A mixture of anhydrous potassium tert-butoxide (3.24g,-2.75mmol) and
methyltriphenylphosphonium bromide (8.93 g, 2.5 mmol) in dry benzene (150 mL) was
allowed to stir at rt for 1 h. The pentacyclic ketone 56 (1.46 g, 0.50 mmol) in THF (50
mL) was then added into the above orange-colored solution dropwise at rt. The mixture
which resulted was stirred at rt for 4 h. The mixture was diluted with EtOAc (500 mL),
washed with H2O (3 x 50 mL), brine (100 mL), and dried (K2CO3). The solvent was
removed under reduced pressure and the oil which resulted was flash chromatographed
(silica gel, CHCl3/MeOH ) 40:1) to provide the olefin 111 (1.30 g, 90%): FTIR (CHCl3)
3439 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.67 (dt, 3H, J = 6.8, 1.8 Hz), 1.87 (dt, 1H, J
= 9.2, 2.8 Hz), 2.25 ( ddd, 1 H, J = 11.8, 10.0, 1.7 Hz), 3.02 (dd, 1 H, J = 15.4, 1.3 Hz),
3.24 (dd, 1 H, J = 15.5, 5.2 Hz), 3.35 (m, 1 H), 3.60 (s, 3 H), 3.84 (m, 2 H), 3.93 (m, 1
H), 4.35 (dd, 1 H, J = 9.9, 2.3 Hz), 4.86 (t, 2 H, J = 2.4 Hz, 5.34 (q, 1 H, J =7.0 Hz),
7.08 (td, 1 H, J = 6.9, 1.2 Hz), 7.20 (td, 1 H, J = 6.9, 1.1 Hz), 7.27 (d, 1 H, J = 7.6 Hz),
7.50 (td, 1 H, J = 7.6 Hz); 13C NMR (75.5 MHz, CDCl3) δ 12.4, 26.2, 29.2, 35.3, 36.3,
49.6, 56.1, 56.8, 103.8, 105.4, 108.7, 115.4, 118.1, 118.8, 120.9, 127.0, 136.4, 137.3,
138.2, 151.6; EIMS (m/z, relative intensity) 290 (M+, 100), 275 (13), 182 (76). Anal.
Calcd for C20H22N2: C, 82.72; H, 7.04; N, 9.65. Found: C, 82.84; H, 7.29; N, 9.46.
OH
9-BBN (5 equiv), 0 °C to rt,
1.5 h; NaBO3⋅4H2O,
0 °C to rt, 2 h
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Synthesis of (E) 16-epinormacusine B 112 from (+)-3-ethylidene-12-methyl1,3,4,7,12,12b-hexahydro-2H,6H-2,6-methano-13-methylene-indole[2,3-a]quinolizine
(111)
To a solution of olefin 111 (200 mg, 0.72 mmol) in THF (20 mL) was added 9-BBN (0.5
M in THF, 7.23 mL, 3.6 mmol) dropwise at 0 °C. The solution was allowed to warm to rt
and stirred for 1.5 h. The reaction mixture was then cooled to 0 °C and NaBO3· 4H2O
(1.67g, 10.8mmol) was added (Kabalka process) and the reaction temperature allowed to
warm to rt. The mixture which resulted was stirred for 2 h at rt, diluted with CH2Cl2 (200
mL), washed with H2O (3 x 50 mL) as well as brine (100 mL), and dried (K2CO3). The
solvent was removed under reduced pressure and the residue was chromatographed
(silica gel, CH2Cl2/MeOH; 9:1) to provide alcohol 112 (149 mg, 70%). FTIR (CHCl3)
3200, 2918 cm-1; [α]D = +6.92° (c 0.25, MeOH) [lit.1 [α]D = +3° (c 0.25, MeOH)]; 1H
NMR (300 MHz, CDCl3) δ 1.64 (dt, 3 H, J = 6.8, 1.8 Hz), 1.84 (m, 2 H), 2.24 (m, 1 H),
2.89 (q, 1 H, J = 2.8 Hz), 3.01 (m, 2 H), 3.27 (dd, 1 H, J = 10.5, 8.5 Hz), 3.48-3.76 (m, 4
H), 4.22 (dd, 1 H, J = 9.0, 4.2 Hz), 5.23 (q, 1 H, J = 6.8 Hz), 7.08 (td, 1 H, J = 7.1, 1.3
Hz), 7.16 (td, 1 H, J = 7.1, 1.3 Hz), 7.36 (d, 1 H, J =7.3 Hz), 7.49 (d, 1 H, J =7.3 Hz), 8.60
(s, 1 H); 13C NMR (75.5 MHz, CDCl3) δ 12.7, 22.3, 26.1, 27.0, 41.8, 50.1, 52.8, 55.9,
60.9, 105.6, 111.2, 114.9, 118.1, 119.3, 121.7, 126.0, 135.6, 136.4, 137.4; Anal. Calcd
for C19H22N2O: C, 77.52; H, 7.53; N, 9.52. Found: C, 77.80; H, 7.79; N, 9.34
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Preparation.of.(6S,11S,11aS,E)-9-ethylidene-11-(((triisopropylsilyl)oxy)methyl)-5, 6,
8, 9, 10, 11, 11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizine (113)
The synthesis of 113 (TIPS derivative) from monol 112 was carried out analogous to
the preparation of 108 from 107 in 90% yield. 1H NMR (300 MHz, CDCl3) δ 1.03 (d,
21H, J=3Hz), 1.57 (d, 3H, J=6Hz), 2.01 (m, 1H), 2.08 (m, 1H), 2.26 (t, 1H, J=12Hz),
2.81 (s, 1H), 2.97 (d, 1H, J=15Hz), 3.30 (m, 3H), 3.57 (m, 3H), 4.76 (d, 1H, J=9Hz),
5.21 (q, 1H, J=9Hz), 7.28 (m, 2H), 7.45 (d, 1H, J=9Hz), 9.88 (br, 1H); 13C NMR (75.5
MHz, CDCl3) δ 12.69, 22.80, 26.53, 27.44, 42.99, 50.12, 52.25, 56.65, 61.76, 106.78,
110.55, 112.93, 118.21, 121.23, 126.73, 136.38, 137.26, 141.34; HRMS (ESI) calculated
for C28H43N2OSi : 451.3145; found : 451.3172. This material was employed directly in
the next step.

OTIPS

OTIPS
H
N
H

H
EtOAc:DMSO

N
H
113

O

H

IBX, 80°C, 8h, 85%

N
H

H

H

N
H
114

H
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Preparation of (6S,11S,11aR,E)-9-ethylidene-11-((triisopropylsilyl)oxy)methyl)6,8,9,10,11,11a-hexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (114)
The synthesis of ketone 114 from TIPS derivative 113 was carried out analogous to
the preparation of 109 from 108 in 85% yield. 1H NMR (300 MHz, CDCl3) δ 0.96 (d,
21H, J=2.7Hz), 1.66 (d, 3H, J=7Hz), 1.81 (t, 1H, J=11Hz), 2.06 (dd, 1H, J1=9.9Hz,
J2=3.3Hz), 2.25 (m, 1H), 3.35 (d, 1H, J=2), 3.47 (t, 1H, J=11), 3.74 (d, 2H, J=2.4Hz),
3.78 (s, 1H), 3.84 (dd, 1H, J1=10.2Hz, J2=4.8), 4.14 (dd, 1H, J1=10.5Hz, J2=4.5), 5.32
(q, 1H, J=6.9Hz), 7.27 (m, 3H), 8.13 (d, 1H, J=6.9Hz), 8.9 (br, 1H);

13

C NMR (75.5

MHz, CDCl3) δ 11.85, 12.72, 17.94, 25.99, 27.81, 38.52, 50.07, 55.52, 59.87, 63.54,
108.57, 111.27, 114.29, 121.77, 122.82, 123.50, 123.88, 135.75, 139.17, 155.29, 191.47;
HRMS (ESI) calculated for C28H41N2OSi : 465.2937; found : 465.2914. This material
was employed directly in the next step.

OH

OTIPS
O

N
H

H

H

N
H

O

H

H

THF, TBAF.H2O
N
H

O°C-rt, 85%
H

N
H

H

115

114

Preparation of (6S,11S,11aR,E)-9-ethylidene-11-(hydroxymethyl)-6,8,9,10,11,11ahexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (115)
The synthesis of monol 115 from TIPS derivative 114 was carried out analogous to
the preparation of 110 from 109 in 85% yield

H NMR δ 1.68 (td, 3H, J1=6.6Hz,

13
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J2=3.9Hz), 2.06 (m, 2H), 2.26 (m, 1H), 3.3 (m, 1H), 3.67 (dd, 1H, J1=11Hz, J2=5Hz),
3.77 (m, 3H), 4.28 (dd, 1H, J1=11Hz, J2=5Hz ), 5.4 (q, 1H, J=6Hz), 7.27 (m, 2H ), 7.47
(m, 1H), 8.01 (m, 1H);

13

C NMR (75.5 MHz, CD3OD) δ 11.47, 24.85, 27.60, 38.07,

49.51, 54.62, 58.32, 63.23, 107.63, 111.63, 114.36, 120.63, 122.40, 123.30, 123.48,
136.70, 138.16, 156.29, 191.83 ; HRMS (ESI) calculated for C19H21N2O2 : 309.1603;
found : 309.1588. This material was employed directly in the next step.
OH
O

N
H

H

H
MeOH, CeCl3.7H20

N
H
115

OH
OH
H

H

NaBH4, -78°C-rt, 90%

N
H

H

N
H

H
89

Preparation of (6S,11S,11aR,12R,E)-9-ethylidene-11-(hydroxymethyl)5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (89)
The synthesis of 89 from 115 was carried out analogous to the preparation of 88
from 110 in 85% yield. Rf 0.71 (silica gel, CH2Cl2/MeOH, 9 : 1); [α]25D +29.0° (c 0.6 in
MeOH); [lit.136 [α]D22 = +29.5° (c 0.6 in CH3OH)]; 1H NMR (300 MHz, CD3OD) δ 1.70
(d, 3H, J=6.9Hz), 1.94 (m, 2H), 2.26 (m ,1H), 2.9 (q, 1H, J=2.4 Hz), 3.14 (dd, 1H,
J1=11.4Hz, J2=6Hz), 3.61 (dd, 1H, J1=10Hz, J2=5.4Hz ), 3.6 (s, 3H), 3.8 (m, 1H), 4.2
(dd, 1H, J1=8.4Hz, J2=4Hz ), 5.4 (m, 2H), 7.0 (t, 1H, J=7Hz ), 7.08 (t, 1H, J=7Hz), 7.32
(d, 1H, J=8.1Hz ), 7.76 (d, 1H, J=7.8Hz); 13C NMR (300MHz, CD3OD) δ 11.48, 26.31,
28.15, 42.53, 50.10, 55.66, 58.72, 61.00, 67.33, 110.22, 110.58, 114.22, 118.64, 119.68,
120.85, 125.04, 136.17, 136.99, 138.87; HRMS (ESI) calculated for C19H23N2O2:
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311.1760; found : 311.1773. The optical rotation and mass spectrum were in excellent
agreement with the natural product. 136
O

H
N
H

EtOAc:DMSO

N
H

H

IBX, 80°C, 8h, 80%

111

N
H

H
N

H

H

116

Synthesis of (6S,11aR,E)-9-ethylidene-11-methylene-6,8,9,10,11,11a-hexahydro-6,10methanoindolo[3,2-b]quinolizin-12(5H)-one (116)
To a solution of diene 111 (100mg, 0.36mmol) in EtOAc/DMSO (5mL/2.5mL) was
added IBX (0.225mg, 1.44mmol) in one portion at rt. The mixture was stirred at 80°C
overnight and the reaction progress was monitored by TLC (silica gel, EtOAc). The
reaction mixture was cooled at 0 °C and quenched with a saturated solution of aq
NaHCO3 (4mL), followed by treatment with a saturated solution of aq Na2S2O3 (5mL).
After this, the mixture was stirred for an additional 10min at 0°C. The aq layer was
extracted with additional amounts of EtOAc (3x10mL) and the combined organic layers
was washed with brine (10mL) and dried (K2CO3). The solvent was removed under
reduced pressure to provide the crude oil which was purified by chromatography [silica
gel, hexane: EtOAc (3:1)] to provide the benzylic ketone 116 (84mg, 80%). 1H NMR
(300 MHz, CDCl3) 1.66 (d, 3H, J=6Hz), 1.9 (m, 1H), 2.36 (m, 1H), 3.6 (m, 3H), 4.0 (m,
1H), 4.9 (d, 1H, J=2Hz), 5.0 (d, 1H, J=2Hz), 5.39 (q, 1H, J=6.8Hz), 7.27 (m, 2H), 7.4
(m, 1H), 7.6 (m, 2H), 8.0 (m, 1H); 13C NMR (75.5 MHz, CDCl3) δ 11.13, 34.44, 38.50,
50.13, 54.41, 67.44, 105.89, 106.23, 124.30, 128.49, 128. 65, 131.60, 131.74, 132.39,
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135.75, 136.72, 145.10, 155.95, 190.17; HRMS (ESI) calculated for C19H19N2O :
291.1497; found : 291.1513. This material was employed directly in the next step.

O

N
H

OH
H

9-BBN (5 equiv), 0 °C to rt,
1.5 h; NaBO3⋅4H2O,
0 °C to rt, 2 h

N
H

H

116

OH

70%

N
H

H

H

N
H

H
117

Preparation of (6S,11S,11aR,12S,E)-9-ethylidene-11-(hydroxymethyl)5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (117)
To a solution of olefin 116 (100 mg, 0.344 mmol) in THF (10 mL) was added 9-BBN
(0.5 M in THF, 1.63 mL, 1.72 mmol) dropwise, at 0 °C. The solution was allowed to
warm to rt and stirred for 1.5 h. The reaction mixture was then cooled to 0 °C and
NaBO3· 4H2O (0.795g, 5.16mmol) was added and the reaction temperature allowed to
warm to rt. The mixture which resulted was stirred for 2 h at rt, diluted with CH2Cl2 (50
mL), washed with H2O (3 x 50 mL) as well as brine (50 mL), and dried (K2CO3). The
solvent was removed under reduced pressure and the residue was chromatographed
(silica gel, CH2Cl2/MeOH; 9:1) to provide alcohol 117 (74mg, 70% yield). Rf 0.73 (silica
gel, CH2Cl2/CH3OH, 9 : 1); [α]25D = +17.0° (c 0.6 in CH3OH); [lit.136 [α]D22 = +29.5° (c
0.6 in CH3OH)]; 1H NMR (300 MHz, CD3OD) δ 1.70 (d, 3H, J=6Hz), 1.92 (m, 2H),
2.27 (m ,1H), 2.9 (s, 1H), 3.16 (dd, 1H, J1=11.4Hz, J2=6Hz), 3.61 (m, 3H), 3.8 (m, 1H),
4.2 (m, 1H), 5.3 (q, 1H, J=6.6Hz), 5.36 (d, 1H, J=4.8Hz), 7.0 (m, 2H), 7.35 (s, 1H), 7.82
(d, 1H, J=7.5Hz );

13

C NMR (300MHz, CD3OD) δ 11.48, 26.35, 28.22, 42.59, 50.06,
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55.69, 58.72, 59.17, 61.07, 67.42, 110.23, 110.57, 114.09, 118.62, 119.67, 120.81,
125.07, 136.35, 136.98, 139.12; HRMS (ESI) calculated for C19H22N2O2 : 311.1760;
found : 311.1748
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II. THE SYNTHESIS OF ALPHA 5 SUBTYPE SELECTIVE LIGANDS FOR
GABA (A) /BENZODIAZEPINE RECEPTORS
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1. Introduction
The GABAA /benzodiazepine receptor (BzR) is the major neurotransmitter in the central
nervous system which is inhibitory in action.1 This receptor is involved in many
functions of the CNS as well as in many diseases.2 Many of these diseases occur due to
the improper balance of neurotransmitters which can be restored using therapeutics. The
benzodiazepines continue to be the most widely used drug to treat various disorders such
as anxiety disorders3 and epilepsy4 but they have side effects including muscle
relaxant/ataxic, sedative-hypnotic effects, hypersensitive behavior, phobias, along with
effects which lead to or complicate drug abuse5.
The γ-aminobutyric acid (GABAA) receptors are heteroligomeric membrane-bound
protein complexes that are composed of several subunits and are termed type A, type B
and type C. In the case of type A receptors, the inhibitory effects of GABA mediated by
these receptors can be modulated by a number of pharmacological agents that selectively
bind to allosteric sites on these ion channels.6-9 GABAA receptors are pentameric
assemblies of proteins derived from a family of subunits (6α3β3γ1δ1π1θ1ε and 3ρ)
which form the chloride ion channel. The most common form of native GABAA
receptors contains α, β, and γ subunits in a 2:2:1 stoichiometry.10-12 It has been shown
that recombinant receptors which contain these subunits most closely mimic the
biological, electrophysiological and pharmacological properties of native GABAA
receptors which contain a benzodiazepine recognition site (GABAA/Bz receptors).13The
benzodiazepine binding site is located at the interface between

14,15

α and γ subunits.16

While it is clear the γ subunit is also required for benzodiazepine binding,11,13 the fact
that most native GABAA receptors contain a γ2 subunit is in agreement with the α
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subunit as the key determinant of benzodiazepine binding and efficacy. However, it is
clear the gamma subunit is also required for benzodiazepine binding (see Figure 1) was
mentioned. Recent advances in molecular biology have identified 21 subunits which
comprise a series of GABAA/BzR subtypes (ion channels).17-21 Importantly, it has now
been found that certain disease states, as well as tolerance and dependence are related to
the up or down regulation of specific subunits.

Figure 1. Absolute subunit arrangement of the α1β2γ2 GABAA receptor when viewed
from the synaptic cleft.

The GABA binding sites are located at the β+α− subunit

interfaces and the modulatory Bz BS (Bz) is located at the α+γ subunit interface. 22,23
1.2. Benzodiazepine pharmacology
Ligands that bind to the BZ site can influence the binding of GABA to its receptor and
thereby alter the flux of chloride ions through the ion channel.24 Ligands at the BZ site
are categorized as agonists, inverse agonists, or antagonists. Agonists enhance the
effects of GABA by increasing the frequency of channel opening to provide a net
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hyperpolarization of the neuron and a decreased excitability. BZ inverse agonists have
the opposite effect and decrease the flow of chloride ions (negative modulators, NAM)
which results in a depolarization and an increased neuronal excitability. Between the
two efficacy extremes, there is a continuum of partial agonists and partial inverse
agonists as well as antagonists, the latter of which do not alter chloride flow and are
functionally silent. These different efficacies are reflected in different behavioral effects
of BzR site ligands in mammalian species. The schematic diagram of subunits and
ligands of the benzodiazepine-GABA receptor-chloride channel complex can be seen in
Figure 2.

Figure 2. The schematic diagram of subunits and ligands of the benzodiazepine-GABA
receptor-chloride channel complex. Reprinted with permission of the author.

142

The interaction with benzodiazepines (BZ, Figure 3) has been a major influence in
studies on GABA receptors because of the long history of the therapeutic application of
BZs as anxiolytics, anticonvulsants, sedative-hypnotics, and muscle relaxants.9,25
Although the BZs were first introduced into clinical practice in the early 1960s, it was
not until 1975 that these drugs were shown to act by potentiating the inhibitory
actions of GABA in the brain.

1,25

The presence of high-affinity specific binding sites

for BZs in the mammalian brain was then demonstrated by Squires, Haefely et al.

6,26,27

Converging lines of evidence established that these sites were contained in the same
macromolecule as the GABA sites and the chloride channel, moreover, that all three
elements were coupled allosterically.28-30 The term "GABA/BZ receptor" came into use
for this complex (and is still encountered). Until recently, progress in this field was
driven by the synthesis of a vast range of BZs and BZ-like drugs, which acted at the
allosteric BZ sites in the brain. GABAA receptors exhibited clinical anxiolytic or
sedative properties which correlated to their binding potencies in the CNS.31 The
structures of some ligands which act at the BZ site are shown in Figure 3.
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Figure 3. GABA, diazepam, triazolam and midazolam.
BDZs, such as diazepam(2), are the most potent anticonvulsent, muscle relaxant,
sedative-hypnotic and anxiolytic compounds in clinical use.32 They do not substitute for
GABA, but instead enhance the inhibitory effects of GABA. BDZ’s allosterically bind
to the receptor at a different location than GABA does and enhance the chloride
channels conductance by increasing the frequency of gated channel opening.33-37 BDZ
and compounds interacting with the benzodiazepine site of GABAA receptors can only
modulate ongoing GABAergic activity (see Figure 4). These compounds cannot elicit
chloride ion flux in the absence of GABA33,37 and thus can exhibit an extremely low
degree of toxicity. Many different classes of compounds have been shown to interact
with the BDZ binding site of GABAA receptors.38-42 In each of these classes, compounds
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could be identified that enhanced or reduced the action of GABA on GABAA receptors,
as mentioned above.

Figure 4: Mode of action of benzodiazepines. Reprinted with permission of the author

1.3. Molecular Modeling
An extensive study of the BzR pharmacophore has been carried out in Milwaukee.42-47
Based on data from at least 166 ligands at BzR, a unified BzR pharmacophore receptor
model of the BDZ receptor has been developed. Outlined in Figure 5 are the proposed
descriptors required for high affinity binding to the inclusive pharmacophore.43,48 The
important points of the model include three anchor points which were termed L1, H1, and
H2; region L1 represents a center of lipophilic interaction with the ligands, while H1, H2
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and A2 represent two hydrogen bond donor sites and one hydrogen bond acceptor site on
the receptor protein, respectively, in the receptor binding domain.49 Three additional
lipophilic regions were also proposed, termed L2, L3 and LDi, which are important for
binding affinity and selectivity as well as efficacy of ligands. It is noteworthy to mention
that lipophilic interactions between a ligand and the receptor include vander Waals
interactions, as well as potential π-π and p-π stacking between the aromatic moieties of
the ligand and groups on the receptor protein.

Figure 5. Diazepam in the Pharmacophore/Receptor Model for the BzR Site.
Pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), a diazadiindole (thin line), and
diazepam (thick line) fitted to the inclusive pharmacophore model for the BzR. Sites H1
and H2 represent hydrogen bond donor sites on the receptor protein complex, while A2
represents a hydrogen bond acceptor site necessary for potent inverse activity in vivo.
L1, L2, L3 and LDi are four lipophilic regions in the binding pharmacophore.
Descriptors S1, S2, and S3 are regions of negative steric repulsion.
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Areas of negative steric repulsion with the protein are described as S1, S2, and S3.
Examination of the included volumes indicated that the shapes of binding pockets for
α1, α2 and α3 subtypes are very similar to each other. Region L2 for the α5 containing
subtype appeared to be larger in size than the analogous region of the other receptor
subtypes. The LDi region in contrast appeared to be larger in the α1 subtype than in the
other subtypes. 50 The receptor subtype descriptor termed the DI site is related to α4 and
α6 BzR, which is devoid of or has a very small lipophilic pocket L3 in comparison to the
other four (α1, α2, α3, and α5) subtypes The DI region appears to be near the outside of
the receptor binding cleft and may be important as well for interactions at the α1 subtype
which results sometimes in increased α1 subtype selective affinity. With the aid of these
models,

several

series

of

ligands

have

been

synthesized

and

evaluated

pharmacologically to determine the interaction with the GABA/benzodiazepine receptor
subtype selective ligands.

2. Objective of this research
Benzodiazepines and related drugs have been documented to disrupt memory in human
and non-human subjects.

10,13,47,51

Broadly stated, administration of Bz-type drugs can

result in a loss of the ability to form new memories. The memory deficits induced by
Bz-type drugs are strikingly similar to those associated with lesions of the
hippocampus.52 Neurons in the hippocampus express structurally diverse GABAA
receptors.53,54 The highest density of α5GABAA receptors is found in the hippocampus
proper (see Figure 6) and these receptors are mostly extra-synaptic.53 The distribution of
α5GABAA receptors in the hippocampus raises the possibility that this subtype plays a
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distinct role in memory deficits induced by Bz-type drugs.55 While memory deficits
induced by Bz-type drugs represent a clinical burden, understanding the mechanisms
underlying these deficits might represent a therapeutic boon.

Figure 6: Distribution of α5 receptor in the Hippocampus. Reprinted with permission of
author.

In this regard, there is increasing evidence that inverse agonists with selectivity for the
α5GABAA receptor subtype may enhance cognition.56 Since α5 GABAA subtypes
modulate memory processes, the specific aim of this research is to synthesize α5
subtype selective ligands which can be used to treat disorders such as cognitive
dysfunction which includes Alzheimer’s disease devoid of side effects (sedative,
addictive, hypnotic, muscle relaxant and convulsant effects). A key rationale for this
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approach is that GABA neurons in the hippocampus and temporal cortical areas are
largely preserved in patients

57,58

with Alzheimer’s disease (AD), and these preserved

neurons contain α5GABAA receptor subtypes that are only moderately reduced in
number in AD.58
Another critical therapeutic goal of this research is to synthesize ligands which would
also reduce anxiety. In fact, BZ-type drugs are commonly given to dementia patients
exhibiting “agitation” (usually defined as “inappropriate verbal, vocal, or motor activity
not explainable by apparent needs or confusion”).59 Thus, in addition to enhancing
cognition, it would be advantageous to develop analogs which may provide a unique
approach to reduce agitation/anxiety in patients with cognitive disorders.

3. Results and Discussion
3.1. Synthesis of α5 selective 1, 4 benzodiazepines
The need for α5 selective ligands to study the hippocampus, as well as results based on
previous structure-activity relationships60-64 prompted a study of agonist selectivity by
modification of 7-substituted benzodiazepines.60-63 Earlier in this laboratory,49,62-66 a
series of acetylene based α5 selective inverse agonists were prepared.67 These agents
were among the most α5 selective ligands ever reported.67 Because the acetylene
function (interaction in lipophilic pocket L2) enhanced selectivity at α5 BzR, it was
decided to effect a similar change with orally active benzodiazepines to extend the SAR.
In the past two decades computer modeling has evolved into a full-fledged discipline
independent from traditional structure-activity-relationships (SAR) and molecular

149

biology and proven to be a valuable tool in drug discovery.68-76 This technique was
important in the development of selective ligands for GABA/BzR subtypes due to the
diversity of structural classes of active ligands which bound to these subtypes.31,74,76 For
this the unified pharmacophore/receptor model (see Figure 5) which was described
previously was used.
In order to develop orally active high affinity selective ligands for α5 containing
isoforms at the BzR, diazepam was chosen as the starting point. According to classical
structure-activity-relationships,77 diazepam does not bind to α4 and α6 containing
isoforms (these are termed “diazepam insensitive sites”),77,78 consequently, interaction at
α4 and α6 sites was retarded from the beginning. It was felt diazepam bound to all
diazepam sensitive (DS) receptor subtypes at the three anchor points: H1, H2 and
L1.65,71,79 The imine nitrogen atom was believed to be hydrogen bonded to a hydrogen
bond donor site on the receptor protein(H2), the carbonyl oxygen was felt to be hydrogen
bonded to another hydrogen bonding descriptor(H1), while the benzene A-ring interacted
with the receptor protein at a lipophilic site (L1). In addition, it was felt diazepam also
interacted in lipophilic pockets L2 and L3, as shown in Figure 7. Lipophilic pocket L3
was believed to be very small in α4 and α6 containing isoforms which retarded affinity
of 1,4-benzodiazepines at these subtypes.49,79,80 When the agonist QH-II-066 11 was
aligned in the included volume of pharmacophore/receptor for α2β3γ2 and α5β3γ2
subtypes, the fit was excellent (Figure 9 and Figure 10) respectively.
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Figure 7. Diazepam (2) aligned in the pharmacophore model.75,81
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Figure 8: The ligand QH-II-66, (11, a 7-acetylenyl-1, 4-benzodiazepine, in black), was
designed to offer better occupation of this region and exhibit α5 selectivity. Note that
diazepam shown in the Figure was intentionally offset from its original position, which
had overlapped completely with QH-II-066, solely for the sake of visualization.65,66
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Figure 9. The ligand, QH-II-66 11, aligned in the included volume of the
pharmacophore/receptor model for the α2β3γ2 subtype.

Figure 10. The ligand, QH-II-66 11, aligned in the included volume of the
pharmacophore/receptor model for the α5β3γ2 subtype.
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Based on the findings at α5 containing isoforms64,74,76,81 and the results in the
imidazobenzodiazepine series described previously,61-63 a diazepam analog with an
acetylenic function at position-7(QH-II-066, 11) was prepared, and better selectivity in
vitro for α5 containing isoforms was immediately achieved in the agonist series.74-76,82 It
was felt that lipophilic pocket L2 was larger in α5 containing subtypes as compared to
α1 containing isoforms,47,74-76 hence the α5 subtype tolerated a larger lipophilic group
in region L2. To develop ligands more selective for α5 containing BzR subtypes,
interactions at H1, H2 or L3 must be modified since not many changes can be done at the
L2 pocket.

3.1.2. Synthesis of gram quantities of the 1, 4 benzodiazepine (QH-II066)
The large scale synthesis here of this α5β3γ2 selective ligand 11 (Scheme 1), which
began from 2-aminobenzophenone 5 and followed the classic work of Fryer, Sternbach
et al.83,84 as modified by Huang and Liu, was carried out.65,85 Benzophenone 5 was
acylated on 100 gram scale by bromoacetylbromide. The bromoacetamide 6 which
resulted was then treated with a saturated solution of ammonia (gas) in methanol at
reflux to afford benzodiazepine 7 in 99% yield. Regioselective bromination84 of this
ligand at position-7 was realized after treatment with 2 equivalents of bromine in acetic
acid in the presence of 2 equivalents of concentrated sulfuric acid at room temperature.
After the reaction was allowed to stir for seven days, ninety percent of the
monobrominated benzodiazepine 8 was obtained after alkaline workup. It was necessary
to stir the reaction with only 2 equivalents of bromine for several days to prevent
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dibromination. Attempts to use additional bromine or to heat the reaction mixture
resulted in polybromination. It was difficult to remove the dibrominated side product
from the desired 1, 4-benzodiazepine 8, consequently, the reaction was run over several
days. The bromide 8 then was reacted with trimethylsilyacetylene in the presence of a
palladium catalyst to provide trimethylsilyl analog 9.62,86,87 This TMS-protected material
9 was then methylated with methyl iodide/sodium hydride to give the N-methyl
benzodiazepine 10. In this manner the acetylenic function was not methylated. This
material was subjected to fluoride-mediated disilation on 20 g scale to furnish gram
quantities of 11 (QH-II-066) for studies in rodents and primates.
In agreement with the molecular modeling, QH-II-066 11 indeed bound more potently to
α5β3γ2 subtypes than to α1β3γ2 GABA/BzR receptor sites. This important result
indicated that perhaps QH-II-066 might exhibit anxiolytic activity but would exert less
sedative-hypnotic, muscle relaxant or ataxic effects when compared to the control
(diazepam 2).

Scheme 1: Synthesis of QH-II-066
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Table 1. In Vitro Receptor Binding Data of Diazepam (2) and QH-II-066 (11). Binding
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM)
Compound

α1

α2

α3

α4

α5

α6

Diazepam (2)

14

7.8

13.9

NDa

13.4

NDa

QH-II-066 (11)

76.3

42.1

47.4

NDa

6.8

>3000

ND: not determined yet. aBinding at α4 and α6 subtypes has not been determined, but since the 6-phenyl
group is present, the ligand will not bind to α4 and α6 subtypes.

Studies by Lelas and Cook et al.88 reflect that QH-II-066 11 has functional selectivity in
vivo with diazepam-like efficacy at α5 and partial efficacy at the α1 subtype. This study
showed that QH-II-066 had anxiolytic activity with reduced sedative effects compared
to diazepam 2. This study also indicated that the 7-acetyleno substituted diazepam
analog exhibited less potency against ECS induced seizures relative to diazepam than
against PTZ-induced seizures. Hence α1 subtype may play an important role in ECSinduced seizures than in PTZ-induced seizures (see Appendix II).
Recent studies by Weiss and Cook et al.89 show that activation of GABA (A) receptors
induces apoptosis in neuroblastoma. The mechanism by which GABA-A activation
inhibited the growth of neuroblastoma cells was assessed. To enhance the signal readout
of this pathway, α5 selective GABA-A receptor agonist QH-II-066 was used. Apoptosis
was induced in both LAN-5 (high GABA-A expression levels) and Kelly cells (low
GABA-A expression levels) (Figure 11 A and B), as assessed by annexin V flow
cytometry.

Immunoblotting revealed that upon addition of GABA and QH-II-066,
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cleaved PARP, an indicator of apoptosis, was increased.

Notably, immunoblotting

revealed a decrease in activity of the PI3K/AKT and MAPK pro-growth and survival
pathways, indicated by decreased phosphorylation levels of Akt and Erk, respectively
(Figure 11 C). Together these data suggest that specific activation of the GABA-A
receptor decreases cell viability, induces apoptosis, and suppresses pro-growth and
survival signaling pathways in neuroblastoma cell lines (see Appendix III).

Figure 11. GABA activation decreases viability and induces apoptosis in
neuroblastoma cells (A) Lan5 and Kelly cells were treated with GABA 100 μM or
the selective ligand for GABA (QH-II-066, 11) 1 μM or both and analyzed by annexin
V-FITC flow cytometry for apoptosis after 72h. (B) Percentages of positive cells for
apoptotic marker annexin V are mean ± s.e. for triplicate samples with treatments
indicated. (C) Cells analyzed by immunoblot using antisera indicated show decreased
phosphorylation of Akt and Erk.
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3.1.3. Synthesis of PS-1-37
Since the α5 in vitro selectivity and efficacy of QH-II-066 11 was increased in regard to
the potent controls, it was decided to maintain the acetylenic function at C (7) and
determine this potential effect at L2 of other orally active BZ agonists.
PS-I-37 is a stable analog of XHe-II-053 related to an agonist developed by Upjohn, and
was prepared for study. A mixture of the bromo benzodiazepine 3 was taken up in
pyridine and phosphorous pentasulfide to form the thione 12. This was further reacted
with glycine, Na2CO3 in ethanol and a water mixture to form acid 13 as a yellow solid.
This was suspended in dry CH2Cl2 and DCC was added. The suspension which resulted
was stirred at 40°C for 2hrs. The solvent was removed under vacuum to give the ketone
14 as brown oil. The cyclized product was dissolved in benzene, after which
dimethylformamide diethyl acetal and triethyl amine were added. The residue was then
crystallized from ethyl acetate to give amine 15. A solution of 15 in dry toluene was
treated with 1-methyl piperazine and refluxed for 5hrs and then the solvent was removed
under vacuum to give a gum which was crystallized to furnish 16. To the suspension of
compound 16 in acetonitrile and triethyl amine was added bis(triphenylphosphine)
palladium(II) acetate to furnish the trimethylsilyl analogue 17. The trimethyl silyl was
removed using TBAF in THF to provide the acetylenic product 18 (PS-I-37) and this
material was anxiolytic in monkeys (Dr.Rowlett, Harvard).
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Scheme 2: Synthesis of PS-1-37
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Table 2. In Vitro Receptor Binding Data on Diazepam (2) and PS-1-37 (18). Binding
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM)
Compound

α1

α2

α3

α4

α5

α6

Diazepam (2)

14

7.8

13.9

NDa

13.4

NDa

PS-1-37 (18)

193

35

435

NDa

22

5000

ND: not determined yet. aBinding at α4 subtypes has not been determined, but since the 6-phenyl
group is present, the ligand will not bind to α4 and α6 subtypes.

CH3
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Figure 12. The Oocyte Efficacy Data on PS-1-37(18).
Table 3. EC50 and Hill Slope for Modulation of Control GABA EC3 by PS-1-37 (18) in
Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results Represent
EC50 (95% Confidence Interval for EC50) and Hill Slope (Nh) ± SD from at Least Four
Cells from Two Batches.

EC50
PS-I-37

95%CI
Nh

α1β 3γ2

α2β 3γ2

α3β 3γ2

>1,1µM

>228nM

>2,3µM

α4β 3γ2

α5β 3γ2
87nM
48-158

α6β 3γ2
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Table 4. Modulation of Control GABA EC3 by Diazepam and PS-1-37 (18) on Xenopus
Oocytes Expressing Different GABAA Receptor Subtypes. Values are Presented as
Mean ± SEM of at Least Four Oocytes from at Least Two Batches
α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

10nM

135±4%

193±5%

167±8%

160±2%

100nM

246±16%

400±22%

461±34%

322±7%

1µM

345±27%

508±29%

776±44%

420±12%

10µM

366±27%

520±14%

749±29%

377±14%

10nM

114±2%

119%

ns

136±1%

100nM

144±1 %

172±3%

ns

259±16%

1µM

272±3 %

271±15%

324±9%

438±12%

10µM

402±12%

311±1%

402±29%

345±4%

Diazepam(2)

PS-1-37 (18)

All the above values were significantly different from the respective control currents (p<0.01, Student’st-test) except where indicated (n.s.). NS means not significant.

3.1.4. Synthesis of 8-substituted imidazobenzodiazepines
As mentioned above, the α5 subtypes are primarily found in the hippocampus90 which is
important for memory and learning91. Studies done by Mohler et al.

92

on α5 knockin

mice provided strong evidence that hippocampal extrasynaptic α5 GABAA receptors
play a critical role in associative learning.92 The 8-substituted imidazobenzodiazepines
such as RY-23 and RY-24 exhibited a greater affinity and selectivity at the α5 subtype.
Previously, the subtype selective inverse agonist activity60-64,85 of a series of α5 subtype
selective ligands [(20, RY-023), (21, RY-024), (22, RY-079) and (23, RY-080)] was
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reported. The design was based on the structure of 19 (Ro 15-4513) and, in addition,
McKernan, Atack et al. (see 24) reported several related ligands as well.93,94 These
ligands are BzR inverse agonists in vivo and have been shown to enhance cognition.17-21
One of these ligands was shown by Bailey et al.

91

to be important in the acquisition of

fear conditioning and provided further evidence for the involvement of hippocampal
GABAA/benzodiazepine receptors in learning and anxiety. This was supported by the
work of DeLorey et al.95 in a memory model with a ligand closely related to α5 subtype
selective inverse agonists 20 and 21.
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(CH3)3 Si
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H3CO
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Figure 13. Ro 15-4513 (19), RY-023 (20), RY-024 (21), RY-079 (22), RY-80
(23) and the Merck compound (24).

The ligands 20-23 and 24 depicted in Figure 13 were 40-70 fold more selective for α5
subtypes in comparision to α1 subtypes; however, better selectivity remains a goal of
paramount importance. In collaboration with Sieghart et al. the efficacy of inverse
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agonist RY 24 (21) was determined (Figure 46). It was demonstrated that RY 24 (21)
was a potent inverse agonist at α5 subtypes in oocytes with a much weaker efficacy at
the other subtypes.

Figure 14. Subtype selective efficacy of RY-24 (21); dose response curves for RY-24 in
oocytes expressing different subunit combinations of GABAA receptors. Subtype
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp. Increasing concentrations of RY-24 were
superfused together with a GABA concentration eliciting ~ 20% of the maximal current
amplitude. RY-24 was pre-applied for 30 sec before the addition of GABA, which was
co-applied with the drugs until a peak response was observed. Data were normalized for
each curve assuming 100% for the response in the absence of RY-24. RY-24 was made
up and diluted as stock solution in DMSO. Final DMSO concentrations perfusing the
oocyte were 0.1%. Values are presented as mean ± SD of at least 4 oocytes from at least
2 batches.
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Inspection of the data in Table 4 reveals some observations worth noting. While the
lipophilic substituent at R8 of RY-24 21 and RY-80 23 decreased the affinity for
α1, α2 and α3 subtypes, it retained affinity for α5 and actually increased affinity for the
α6 subtype. This data again supports the importance of the occupation of the lipophilic
pocket L2 for potent selectivity at the α5 subtype.

Table 5. In Vitro Receptor Binding Data of α5 ligands. Binding Affinity at αxβ3γ2
GABAA/BzR Receptor Subtypes (Values are Reported in nM)

Ki (nM)a
Ligand

a

R8

R3

α1

α2

α3

α5

α6
5.1

RY-24 (21)

H

t-Bu 26.9 26.3 18.7 0.4

RY-23 (20)

TMS

t-Bu 197

RY-80 (23)

H

Et

28.4 21.4 25.8 0.49 28.8

RY-79 (22)

TMS

Et

121

143

142

255

198

2.61 58.6

5.0

114

"Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzo-diazepines:

High Affinity, Selective Probes for α5 Containing GABAA Receptors,"Liu, R.; Hu, R.; Zhang,
P.; Skolnick, P.; Cook, J. M., J. Med. Chem., 39, 1928-1934 (1996).
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In agreement with previous studies,61 these α5 selective ligands were highly selective in
suppressing ethanol-maintained responding (Figure 25).96 As previously stated, the
hippocampus contains the greatest concentration of α5-containing receptors in the
CNS,90,97 and it is possible that these hippocampal α5 receptors may regulate alcoholmotivated responding following systemic administration of an α5-selective agent.
Furthermore, RY-24 also antagonized the motor-impairing and sedative effects of
ethanol in Long-Evans rats. Combined with additional studies within the ventral
pallidum (VP), it has been proposed that the GABAergic systems within the VP and
hippocampal pathways may represent new extensions of the mesolimbic ethanol reward
circuitry. Although these data do not strongly support a direct role for the modulatory
influences of intrinsic efficacy in the behaviors examined, the synthesis of α5 subtype
selective ligands provides researchers a unique opportunity to explore the role of this
subtype in the neurobehavioral effects of alcohol.61,98 However, the efficacy (inverse
agonist, negative modulation) of RY-23 and RY-24 at α1 and α2 subtypes precludes
potential clinical uses of such agents for both agents are proconvulsant and RY-24 is
also convulsant.
Additional behavioral studies of RY-24 were performed by Helmstetter et al. and
provided further support for the role of the hippocampus in anxiety and learning.91
Moreover, the data suggested that Bz BSs within the hippocampus are important for the
acquisition of fear conditioning. Although this subtype selective ligand has been shown
to be an inverse agonist at the α5 subtype,62,99 this study suggested that RY-24 may act
as an agonist at other alpha subtypes because larger doses of RY-24 were not as
anxiogenic as the smaller doses and resulted in decreased learning. Consistent with the
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studies of Stephens et al. using α5 knock-out mice100 and the efficacy studies of
Lüddens, June and Cook et al.,101 these findings support the concept that the
pharmacology observed depends upon the dose, behavioral paradigm employed and
subunit composition activated. Ligands such as RY-24 have proven to be valuable in
the study of the biochemical and pharmacological properties of GABAA receptors and
have permitted insight into the role this protein plays in anxiety and learning.
In brief, isatoic anhydride 25 and sarcosine were heated in DMSO to form
benzodiazepine 26 in 84% yield. Benzodiazepine 26 was treated with bromine in the
presence of CH3COOH and H2SO4 to provide the bromide 27 in 80% yield as illustrated
in Scheme 3. Deprotonation of 27 with KOtBu in THF followed by treatment with
diethyl chlorophosphate provided the intermediate enol phosphate.102 The enol
phosphate was stirred with a solution of t-butyl isocyanoacetate and KOtBu to yield the
imidazobenzodiazepine 28 in 70% yield. This bromide was converted into 20 by a
Heck-type coupling reaction60,62using bis(acetate) bis(triphenylphosphine) palladium(II)
to provide TMS analog RY 23 (20) and the silyl group was removed in high yield on
treatment with TBAF/H2O/THF to provide RY 24 (21).60
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Scheme 3: Synthesis of RY-23 and RY-24
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4. Synthesis of α5 selective BzR bivalent ligands
Bivalent ligands have been termed as compounds that contain two pharmacophores
joined through a connecting unit. The general structure for bivalent ligands is P-X-P (P:
pharmacophore; X: spanner).103-105 They may exhibit enhanced selectivity and potency
relative to their monovalent analogues (P-X) when a suitable spanner X is employed.
The study by Portoghese et al. on bivalent ligands that bind to different opioid receptor
subtypes was among one of the most successful reported to date.103-105
A linker of 3 CH2- groups is often called the Leonard linker from its founder Nelson J.
Leonard.
To enhance subtype selectivity, the bivalent form103,104,106 of RY024 (17),60,62 that is
1,3-bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester, (33, XLi093) was designed and prepared. The
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synthesis, α5 subtype selectivity and antagonist properties of this ligand are described
below.
Deprotonation of 27 with KOtBu in THF followed by treatment with diethyl
chlorophosphate provided the intermediate enol phosphate. The enol phosphate was
stirred with a solution of ethyl isocyanoacetate and KOtBu to yield the
imidazobenzodiazepine 29 in 70% yield.102 This bromide was converted into 22 by a
Heck-type coupling reaction60,62 and the silyl group was removed to provide acetylene
23 in high yield on treatment with TBAF/H2O/THF.60 Hydrolysis of the ester function of
23 provided the acid 32 in excellent yield and this material was subjected to a standard
CDI-mediated coupling reaction with a three carbon linker to furnish bivalent ligand
XLi093 33 in 73.4% yield on gram scale.
Scheme 4: Synthesis of Bivalent Ligand XLi-093
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The binding affinity of XLi093 (33) in vitro was determined on α1-6β3γ2 Ltk- cells and
is illustrated in Table 6. This ligand XLi093 33 bound to α5β3γ2 subtypes with a Ki of
15 nM, but exhibited little or no affinity at other BzR/GABAA subtypes. Although the
efficacy at all receptor subtypes was decreased by incorporation of the pharmacophore
of 23 into the bivalent structure, the loss of affinity at α1, α2, α3, α4 and α6 subtypes
was profound. Presumably, since the second unit of XLi093 33 lies in the extracellular
domain of the BzR, the enriched selectivity is entropic. This has been the most selective
α5 subtype selective ligand reported, to date. Depicted in Figure 15 is the ORTEP
drawing of the crystal structure of XLi093 (see Appendix VI for coordinates). The J
values (J = 5.38) calculated from the dihedral angles were in excellent agreement with
those from the solution determined NMR spectrum (J=6.39), hence support for the
conformation as shown (Figure 16) derives from the NMR data. This conformation of
XLi093 was then placed in the BzR/GABAA α5 pharmacophore receptor model
previously reported42,72,76 from this laboratory; the fit was excellent.
Based on the binding affinity of XLi093 (33) and the fit at the α5 subtype, a study of the
efficacy of Xli093 was then pursued in oocytes by Sieghart, Furtmueller, Li, Cook et
al.107 The effects of XLi093 (33) on chloride currents in GABAA receptors was
determined.108 The activity of XLi093 on GABAA receptors was characterized using
Xenopus oocytes expressing the GABAA receptor subunits alpha 1 to alpha 6 in
combination with beta 3 and gamma 2 subunits. Using the two electrode voltage clamp
method, currents in the µA range were measured for all subunits.

169

Figure 15. Crystal Structure of Bivalent Ligand XLI093 (33).

Figure 16. XLi093(33) Aligned in the Included Volume of the Pharmacophore/Receptor
Model for the α5β3γ2 Subtype.
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Table 6. In Vitro Binding Affinities at GABAA/BzR Subtypes. aValues Reported are in
nM.

a

Ligand

α1

α2

α3

α4

α5

α6

RY079 (22)

121

142

198

159

5.0

114

RY080 (23)

28.4

21.4

25.8

53

0.49

28.8

XLi093 (33)

>1000

>1000

858

1550

15

>2000

Ki values represent the mean of two determinations which differed by less than 10%.

Data were generated using Ltk- cell membranes expressing human αxβ3γ2 receptors
combinations in response to application of a saturating concentration of GABA (10
mM). Two electrode voltage clamp experiments were performed to test whether XLi093
triggered chloride currents,108,109 modulated GABA-induced currents or antagonized the
effects of benzodiazepines in oocytes that express GABAA receptors.
Bivalent ligand XLi093 33 at concentrations up to 1 µM did not trigger chloride
currents in any of the tested subtypes of the GABAA receptor. This dimer, however, at
micromolar concentrations modulated GABA-induced currents in an alpha subtype
specific manner. To test for agonistic or inverse agonistic effects of XLi093, the
compound was coapplied with a concentration of GABA that induced app. 3% of the
maximum current amplitude. At concentrations of XLi093 33 up to 100 nM, this ligand
caused no significant modulation of GABA-induced currents in any subtype of GABAA
receptors tested. At a concentration of 1 µM, XLi093 33 caused a significant increase in
GABA-induced currents in the GABAA receptor subtypes α4β3γ2 [+37.6 ± 2.6 %
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(SEM), p < 0.0001 in four oocytes] and α6β3γ2 [+ 17.0 ± 2.5 % (SEM), p = 0.0014 in
four oocytes]. Furthermore, 1 µM XLi093 caused a reduction in GABA induced currents
in the subtype α5β3γ2 [-4.0 ± 1.5 % (SEM), p = 0.0075 in six oocytes]. However, 1 µM
of XLi093 caused no significant modulation of GABA-induced currents in the GABAA
receptor subtypes α1β3γ2, α2β3γ2 and α3β3γ2.
Ligand XLi093 (33) shifted the dose response curve for diazepam in a subtype specific
manner. To test for benzodiazepine antagonistic effects of XLi093, dose response
experiments for the stimulation of GABA-induced currents by diazepam in the absence
or presence of 1 µM XLi093 33 were performed. Similar conditions for different
subtypes were provided by using a concentration of GABA that induced app. 3% of the
maximum current amplitude in the respective cell. In oocytes expressing GABAA
receptors of subunit combination α5β3γ2, the presence of 1 µM XLi093 (33), shifted the
dose response curves for the stimulation of GABA induced currents by diazepam to the
right (Figure 17). Even high concentrations of diazepam could not fully overcome this
inhibition since maximum current stimulations in the presence of XLi093 (33) reached
only app. 85% of current stimulations that were seen in the absence of XLi093 (33).
The dose response curves for diazepam with and without 1 µM XLi093 (33) in oocytes
expressing different subunit combinations of GABAA receptors are depicted (Figure 17).
cRNA–Injected Xenopus oocytes were held at –60 mV under two-electrode voltage
clamp. Increasing concentrations of diazepam with or without 1 µM of XLi093 (33)
were superfused together with a GABA concentration eliciting app. 3% of the maximal
current amplitude. Diazepam and XLi093 were preapplied for 30 sec before the addition
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of GABA, which was coapplied with the drugs until a peak response was observed. Data
were normalized for each curve assuming 100% for the response in the absence of
diazepam and XLi093. Drugs were made up and diluted as stock solutions in DMSO.
Final concentrations of DMSO perfusing the oocyte were 0.1%. Values are presented as
mean ± SD of at least four oocytes from at least two batches.

Figure 17. Effects of XLi093 (33) on GABAA receptors were tested by two-electrode
voltage clamp experiments in cRNA injected Xenopus oocytes that functionally
expressed several subtype combinations of GABAA receptors. In oocytes expressing
GABAA receptors of the subtypes α1β3γ2, α2β3γ2, or α3β3γ2, 1 µM XLi093 (33)
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caused only marginal shifts of dose response curves for the stimulation of GABAinduced currents by diazepam.
Receptor binding studies indicated that the bivalent ligand XLi093 33 bound almost
exclusively to the α5 subtype of GABAA receptors. In summary, the effect of this
compound on various GABAA receptors expressed in Xenopus oocytes was fully
investigated by electrophysiological studies. Analysis of the data indicated that bivalent
ligand XLi093 up to a concentration of 1 µM did not trigger chloride currents in any one
of the tested GABAA receptor subtypes. At 1µM, XLi093 did not modulate GABA
induced chloride flux in α1β3γ2, α2β3γ2, α3β3γ2 but stimulated GABA-induced
currents in α4β3γ2 and α6β3γ2 and slightly inhibited currents in α5β3γ2. At 1 µM,
XLi093 only marginally influenced diazepam stimulation of GABA-induced current in
α1β3γ2, α2β3γ2 and α3β3γ2, but shifted the diazepam dose response curve to the right
in α5β3γ2 receptors. The slight reduction in the maximal diazepam stimulation in the
presence of 1µM XLi093 might have been due to the previously described reduction in
current stimulation at high diazepam concentration109 or might indicate interaction of
XLi093 via two different binding sites. Importantly, bivalent ligand XLi093 was able to
dose dependently and completely inhibit diazepam stimulated currents in α5β3γ2
receptors. It was a quite selective benzodiazepine receptor site antagonist at α5
receptors. As noted, ligands such as XLi093 have been important in the determination of
which physiological function(s) are subserved by this GABAA α5β3γ2 subtype. There
are many scientists who have reversed the amnesic effects of diazepam in vivo with XLi093 in rodents and primates by Savic, Rowlett and Platt et al (see below).
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4.1. Binding Studies of XLi-093 (33) in vivo by Rowlett and Cook et al.55
Recent studies by Rowlett and Cook et al.

55

have shown that diazepam significantly

impaired performance in a hole board memory task, in which mice learned the location
of 4 baited holes (out of 16 possible) over the course of 4 trials.

Figure 18: In vivo binding of Xli-093. The memory-impairing effects of diazepam were
blocked (Figure 18) by a dose of (33; 3.0 mg/kg) that occupied ~66% of α5 GABA(A)
binding sites but less than 25% (non-significant) of the α1 GABA(A) and
α2/α3GABA(A) binding sites. Memory impairment measured via the holeboard task
occurred at a dose of diazepam that resulted in a relatively high degree of α5 GABA(A)
binding site occupancy (64%). Interestingly, even at a saturating dose of diazepam (10
mg/kg), XLi-093 (33) was still able to block the memory impairing effects of diazepam.
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Figure 19: XLi-093 (3.0 mg/kg) blocked the DZ-induced suppression of performance
ratio on the holeboard task. Note that XLi-093 showed no effect when administered
with vehicle.

This performance impairment suggested that diazepam-induced a working memory
deficit. The novel antagonist XLi-093 (33) was able to antagonize this deficit and
showed appreciable subtype selectivity for the α5 GABAA receptor in vivo consistent
with previous findings. In vivo binding studies with XLi-093 showed negligible
occupancy of α1GABA(A) and α2/3GABA(A) binding sites; however, occupancy of
α5GABA(A) binding sites was significant at 1.0 mg/kg and above (see Figure 18).

The data suggests α5 GABA(A) receptors play an important role in diazepam-induced
memory impairments. Identification of compounds with reduced α5 GABA(A) activity
may result in sedative-anxiolytics that lack memory-impairing effects of classical
benzodiazepines.
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In vivo binding studies (see Table 7) with XLi-093 (33) showed negligible occupancy of
α1 GABAA and α2/3GABAA binding sites; however, occupancy of α5 GABA(A)
binding sites was significant at 1.0 mg/kg and above. The ability of a novel α5 GAB(A)
subtype selective antagonist, XLi-093 (33; 0.3-10.0mg/kg), to occupy α5 GABA
receptors in vivo (in vivo [3H]L-655,708 binding) had been evaluated. Based on percent
binding occupancy, the ability of a range of XLi-093 doses to reverse impairments
induced by the minimal effective dose of diazepam (DZ (3.0 mg/kg)) was assessed.
Ligand XLi-093 (33) reversed DZ-induced impairments at doses of 1.0 and 3.0 mg/kg,
which occupied ~50-65% of [3H]L-655,708 binding. In contrast, these doses resulted in
only ~20% occupancy of α1 GABA and α2/3 GABA(A) receptors in cerebellum and
spinal cord, respectively, (determined by in vivo [3H]flumazenil binding). These
findings are consistent with a key role for α5GABA(A) receptors in BZ agonist induced
impairments in learning and memory.

Table 7: Percent of α5GABA (A) binding sites occupied by XLi-093 and DZ at doses
used in the behavioral studies.

Ligand (Dose, i.p.)

% α5GABAA
Occupancy

XLi (3.0)

65.8

DZ (1.0)

63.8

DZ(3.0)

83.5

DZ (10.0)

99
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It had been demonstrated that bivalent ligand XLi-093 bound tightly to α5β3γ2 receptor
subtypes illustrated that bivalent ligands will bind to BzR and since the second unit of
this bivalent ligand presumably lies in the extracellular domain of the BzR, this ligand
had very poor or no affinity at the other subtypes. It is now obvious that this is the first
α5 bivalent ligand which was not only orally active, but also passed through the blood
brain barrier. This was an important result for these bivalent ligands in regard to use in
science.

Scheme 5: Synthesis of Bivalent Ligands XLi-356 and XLi-210
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The bivalent ligand XLi356 (34) was obtained from XLi093 (33) in 99% yield via
catalytic hydrogenation (Pd/C, H2). While XLi093 was found to be an antagonist, ligand
XLi356 is an inverse agonist in α5β3γ2 oocytes and a weak agonist at α1β3γ2 sites.
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Figure 20: Subtype selective efficacy of XLi356 (34), Dose response curves for XLi356
in oocytes expressing different subunit combinations of GABAA receptors. Subtype
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp by Sieghart et al.
Table 8. In Vitro Binding affinities of bivalent ligands at GABAA/BzR subtypes.
a

a

Values Reported are in nM.

Ligand

α1

α2

α3

α4

α5

α6

XLi356 (34)

1851.5

4202.5

8545

ND

100.5

5000

XLi210 (35)

231

661

2666

ND

5.4

54.22

XLi093 (33)

>1000

>1000

858

1550

15

>2000

Ki values represent the mean of two determinations which differed by less than 10%.

Data were generated using Ltk- cell membranes expressing human αxβ3γ2 receptors.
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DeLorey has recently shown that XLi-356 (34) does potently reverse scoploamine
induced memory deficits in rodents. XLi356 was found to reverse scopolamine induced
memory deficits in mice. When XLi356 was looked at in audio cued fear conditioning,
the results show no activity. This suggests that the effect of XLi356 is selective through
α5 receptors which are abundant in the hippocampus which is highly associated with
contextual memory. Audio cued memory instead is amygdale-based, and is not affected
by an α5 subtype selective compound.110

Audio Cued Memory

Contextual Memory
p>0.05

*

75

**

*
**

75

50
50

p>0.05

25
25

0
VEH

Scop

XLI356
+
Scop

0
VEH

Scop

XLi356 10mg
+
Scop

Figure 21: Visual and audio que data for XLi356

As illustrated in Figure 21, scopolamine (1 mg/kg) reduced freezing (ie. impairs
memory) typically caused by pairing the context (the cage) with a shock. The drug
XLi356 when given at 10mg/kg attenuates the impairment of memory returning the
freezing to the level that one typically sees the mouse freeze at (i.e. veh). In the audio
cued paradigm, memory was triggered by sound not the context. XLi356 was not able
to reverse this type of memory effect which is amygdale driven.
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The biology of a bivalent ligand with a 3-carbon linker XLi-093 (33) led us to
synthesize the analogous bivalent ligand with a 5-carbon linker. The synthesis of XLi210 (35) was done analogous to the conditions employed for XLi-093. The acid 32 was
subjected to a standard CDI-mediated coupling reaction using a 5-carbon linker to
furnish bivalent ligand XLi210 35 in 60% yield in dry DMF (Scheme 5).

% of control current at EC3

XLI-210
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Figure 22: Subtype selective efficacy of XLi210 (35): dose response curves for XLi210
in oocytes expressing different subunit combinations of GABAA receptors. Subtype
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp.

This bivalent ligand (35) showed 50 fold selectivity at α5 over α1 (see Table 8). The
efficacy data shows that the ligand is an agonist. This ligand should have properties
exactly opposite that of PWZ-029 which is an inverse agonist (NAM). Positive controls
and an α5 antagonist render this a very strong approach to hippocampal-mediated drug
design in regard to the development of agents to treat cognition deficits in Alzheimer’s
and age-related memory deficits.
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Table 9. EC50 and Hill Slope for Modulation of Control GABA EC3 by XLi 210 (35) in
Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results Represent
EC50 (95% Confidence Interval for EC50) and Hill Slope (Nh) ± SD from at Least Four
Cells from Two Batches.

XLi-210

α1β 3γ2

α2β 3γ2

α3β 3γ2

α5β 3γ2

EC50

262nM

>324nM

175nM

95%CI

(15-4543)

(7-4210)

Nh

0.89

0.94

Table 10. Modulation of Control GABA EC3 by XLi 210 (35) on Xenopus Oocytes
Expressing Different GABAA Receptor Subtypes. Values are Presented as Mean ± SEM
of at Least Four Oocytes from at Least Two Batches.

XLi210 (35)

α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

10nM

ns

ns

ns

ns

100nM

115±6 %

117±7%
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110±3%

1µM

143±18 %

133±9%

150±25%

111±2%

10µM

153±20%

144±4%

156±19%

123±6%

All the above values were significantly different from the respective control currents (p<0.01, Student’st-test) except where indicated (n.s.). n.s. means not significant.
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5. Synthesis of Bivalent Ligands with Oxygen Linkers
In order to enhance water solubility and potency, bivalent ligands with a oxygen atom in
the linker were synthesized. The insertion of an oxygen atom into the linker might
increase the water solubility and hence enhance the molecular hydrophilicity which
should play an important role in the pharmacokinetic properties of the ligand.
Scheme 6: Synthesis of Bivalent Ligands with Oxygen Linkers XLi-347, XLi-374
and SR-II-35
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The oxygen linked analog XLi 347 (36) and SR-II-35 (42) were synthesized analogous
to the conditions employed for the preparation of XLi-093 (33), the synthesis of the 5carbon atom linked dimer 35 (XLi210) had been was carried out. The acid (32) available
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from Scheme 4, was subjected to a standard CDI-mediated coupling reaction to furnish
bivalent ligands XLi 347 (36) and SR-II-35 (39) in 60% yield in dry DMF (see Scheme
6).
For the synthesis of XLi 374 (39) , the preparation of the required oxygen-substituted
linker (a dibromodimethylether) was based on the method of Tischtschenki

and

Rabcevitsch-Zubkovski111,112. Bromine was added slowly to water over a four hour
period, to which a mixture of paraformaldehyde (37) and red phosphorus was also added
at a comparable rate. The reaction mixture was ice-water-cooled during this process. The
temperature was maintained at 0°C. The final reaction mixture was allowed to stand for
20 hours. The heavy crude dibromo ether layer was then separated, saturated with
hydrogen bromide, and dried over P2O5 for one day. Distillation at 158°C at 1 atm
provided the ether from one fraction as pure dibromodimethyl ether (a colorless liquid).
With the dibromodimethyl ether in hand, acid 32 was dissolved in dry dimethylformamide (DMF). To this solution the dibromodimethyl ether (38) was added, and this
was followed by addition of TEA. After the mixture stirred for 26 hours at ambient
temperature, the solvent was removed under reduced pressure and the residue was
distributed between CH2Cl2 and water. The organic layer was washed multiple times
with water and dried over Na2SO4, and the solvent was removed under reduced pressure
almost to dryness. Subsequent flash chromatography of the crude oil provided the
bivalent oxygen (C-O-C) dimer XLi374 (39) as a white solid.
The nature of the functional groups in a ligand plays an important role in receptor
binding, of course, as well as the conformation in solution. The more the information
about the stable conformation(s) of molecules, the better is the understanding of the
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structure-activity relationships. It was essential from the beginning of the present study
to determine the conformation of these bivalent ligands, which contained 3 to 5 atom
linkers, since the steric requirements for affinity to the Bz receptor must be satisfied. In
traditional medicinal chemistry, computer assisted molecular modeling programs and Xray analysis contribute greatly in the search for stable conformations. However, some
problems with these methods should not be neglected. Using computer modeling to
determine the stable conformation of molecules containing many freely rotating bonds,
such as those contained in bivalent ligands is difficult. Although X-ray crystallography
is the ultimate arbiter of chemical structure, it has many limitations beyond the obvious
need for crystals: it often does not reflect accurately the conformation in solution, nor is
it informative regarding conformational equilibria. This information is crucial in drug
design. However, NMR spectroscopy is a powerful technique in drug discovery and its
role in conformational analysis cannot be surpassed by other spectroscopic
methods.42,113

5.1. Low Temperature NMR studies and X-ray Analysis
Herein is described a method utilizing low temperature NMR for the determination of
the solution stable conformation of a series of GABAA-benzodiazepine bivalent ligands
with different monomeric units and linkers. The conformations in solution were
determined by NMR spectroscopy and compared with those in the crystal structure. The
combination of low temperature NMR and X-ray analysis provided accurate structural
information required for understanding structure-activity relationships and drug design.
The influence of the molecular structure of the linker on the conformation is also
discussed.
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5.2. Results
Recently it was shown the active dimers XLi093 (33) and DMH-D-053 (31) existed in a
linear conformation in the solid state while dimer

dm-III-96 (43) with a oxygen

containing linker folded back upon itself, as illustrated in Figure 23.114
Since the bioactive conformation in solution may or may not parallel that in the crystal
structure, the lowest energy solution structure must be established in order to correlate
conformation with biological activity. Thus, NMR experiments at variable temperatures
were performed and data were collected in different solvents. In methylene chloride or
chloroform at room temperature, only a single set of signals was detected for both
bivalent ligands 33 and 42.
Table 11. In Vitro binding affinities of bivalent ligands at GABAA/BzR subtypes.
a

Values Reported are in nM.

Ligand
RY-080 (23)
XLi-093 (33)
XLi-374 (39)
XLi-347 (36)
SR-II-35 (42)
XHe-II-053 (30)
dm-III-96 (43)
DMH-D-053 (31)

α1
28.4
>1000
3795
828.05
200.7
287
460
236

α2
21.4
>1000
2694
690.2
47.03
45
5000
7.4

α3
25.8
858
1864
ND
94.66
96
ND
272

α4
5.3
1550
ND
ND
ND
1504
ND
>5000

α5
0.49
15
76.14
13.87
38.38
13.8
5000
194.2

α6
28.8
>2000
ND
ND
ND
1000
5000
>5000
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(XLi-093)
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7 (dm-III-96)
(43,
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8 (31,
(DMH-D-053)

Figure 23. Crystal structures of XLi-093, DMH-D-053, and DM-III-96.

At low temperature, it was found that the linear dimer 33 exhibited only a small splitting
of about 3 Hz for some of the aromatic protons in the 1HNMR spectra( see Figure 24),114
while two clearly separated sets of signals were observed for the folded dimer 43 (Figure
25). For example, as seen in Figure 25 for 43, the signal of 1H (7.92 ppm at 298 K) was
split into two peaks at δ7.91 and 7.88 ppm, respectively, at 273° K. The doubling of the
signals is consistent with disruption of the symmetry between the two domains of the
molecule as expected if 43 adopted a static folded structure similar to the crystalline
state.
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Table 12. The molecular composition and stable conformation of various Bz BS
bivalent ligands. ND = not determined yet.

N

O

N

N
N

O

N

O
N

N

O
N
O

A

Ligand

O
N

Cl

O

O

C

B

Monounit 1 Monounit 2

Linker

Conformation Crystal
in solution
structure

32, RY-080

A

-

-

-

-

33, XLi-093

A

A

(CH2)3

linear

linear

35, XLi -210

A

A

(CH2)5

linear

ND

36, XLi -347

A

A

(CH2)2O(CH2)2

folded

ND

39, XLi-374

A

A

CH2OCH2

folded

ND

30, XHe-II-053

B

-

-

-

31, DMH-D-053

B

B

(CH2)3

linear

43, dm-III-96

B

B

(CH2)2O(CH2)2

folded

folded

42, SR-II-35

C

C

CH2OCH2

folded

ND

linear
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Figure 24. Aromatic region of 1HNMR spectra of XLi-093 (33) in CD2Cl2 at variable
temperatures.
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Figure 25. Aromatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable
temperatures.
However, the possibility could not be ruled out that the split in the signals was caused by
slowing a dynamic process within each domain, such as conformational interconversion
of the seven-membered ring.
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Figure 26. Aliphatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable
temperatures.
The analysis of these data indicated that the line broadening at the lowest temperature
was due to one of the conformational processes mentioned above, whereas the doubling
of the peaks in 42 was caused by the presence of two domains. Certainly an interdomain
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interaction existed between the two heterocyclic units of 42. It was therefore concluded
the internal mobility of the molecule decreased as expected, when the temperature was
lowered which permitted observation of the two sets of signals of 42 on the NMR time
scale. It was thus suggested that only when the molecule preferred the folded
conformation in solution were two sets of signals observed. The preferred conformations
of the molecules in CDCl3 and CD2Cl2 correlated quite well with those observed in the
crystal structures (Table 12).
The study was then expanded by varying the nature of the linker and monomer. It was
found that 31, 33, 34, and 35 exhibited only one set of NMR signals at low temperature,
whereas the NMR signals of ligands 43 and 42 split into two sets at low temperature.
Low temperature NMR studies were performed in CD2Cl2. It was concluded that 43 and
42 preferred a folded conformation, while 32, 33, 34, and 35 assumed a linear
conformation.

These conclusions are supported by a crystal structure obtained for

bivalent ligand 33 which indicated 33 was present in a linear conformation in the solid
state. These results are illustrated in Table 12.
Attempts to run the NMR experiments in water failed since the ligands were not
sufficiently soluble in D2O. However, the spectra of both the linear and folded dimer 33
and 42 respectively could be carried out in MeOH-d4. The solvating properties of
methanol, of course, more closely resemble those of water and this more closely mimics
aqueous physiological conditions as well. The conformations of dimers in MeOH-d4
were consistent with conformations in hydrophobic solvents.
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5.3. Discussion
From the results described above, it is clear that dimers which contain an oxygen atom
in the linker tend to adopt a folded conformation. Analysis of these data indicated in the
hydrophilic solvent, 43 also had a higher tendency to fold back upon itself than 33, as it
did in the hydrophobic media (Figure 23). In fact, the tendency of 43 to assume a folded
structure appeared to be higher in methanol than in CD2Cl2 or CDCl3, as the free rotation
of the molecule was limited (Figure 25). On the other hand, for dimer 33, which
preferred a linear structure in the solid state and in lipophilic solvents, only one set of
signals was observed at room temperature in MeOH-d4 (Figure 27).
It is interesting to note that in the preparation of the samples, dimer 33 was less soluble
in MeOH-d4 than was 42 and 43. It has been established that ligands are easier to
dissolve in a solvent when the ligands surface energy can be minimized. Bivalent
ligands 42 and 43 were more polar than dimer 33 and had a higher tendency to fold
back. Consequently, 42 was presumably, easier to dissolve in methanol because its
surface energy was minimized. On the other hand, when ligand 33 was dissolved in a
more polar solvent such as methanol, the surface energy may be forced to be minimized.
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Figure 27. Aromatic region of 1H NMR spectra of XLi-093 (33) in MeOH-d4 at
different temperatures.
Since the conformation of molecules XLi-093 (33) and SR-II-35 (42) in methanol agree
with those in CD2Cl2 or CDCl3, the behavior of these ligands in CD2Cl2 or CDCl3 should
reflect those in aqueous solution. The stable conformation of the compounds determined
in CD2Cl2 or CDCl3 were correlated with the newly generated receptor binding data
(Table 11). In the pharmacophore/receptor model, the bivalent ligands in the linear
conformation align well (Figure 28).

194

Figure 28. Bivalent ligand XLi093 (33) aligned in the included volume of the
pharmacophore/receptor model for the α5β3γ2 subtype.

Importantly, bivalent ligands 31, 33, 34, and 35 with carbon only linkers preferred the
linear conformation as the stable conformation, independent of the number of linker
atoms. In contrast, replacing the middle carbon of either linker (CH2)3 or (CH2)5 with an
oxygen atom altered the stable conformation of the molecules 42 and 43 from linear to
folded. The only difference between bivalent pairs 33 and 39 with linear and folded
conformations as the stable ones, respectively, was the center atom. In compound 33
(XLi-093) the middle atom was carbon, while in 39 (XLi-374) oxygen was present.
Consequently, it was decided to focus attention on the conformational difference
between carbon and oxygen containing linkers.
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It was well-known115,116 that the carbon chain in both small molecules and polymers
favored the anti-conformation which results in a linear arrangement of atoms. From
examination of the linkers (Figure 29), it was easily seen that linkers C and D can be
regarded as oligomers of oxymethylene (OCH2)2 and oxyethylene (OCH2CH2)2.
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Figure 29. The linkers of the bivalent ligands.

It was well documented that the preference for the gauche-gauche conformation117-119 of
a simple open-chain acetal such as dimethoxymethane (CH3OCH2OCH3) could be
predicted on the basis of the anomeric effect and related stereoelectronic effects. In this
conformation the polar Χ−Ο bonds are favorably oriented such that a lone pair orbital of
the oxygen atom was almost antiperiplanar to the Χ−Ο bond (Figure 30, lone pair orbital
and Χ−Ο bond in same color). This permitted maximum overlap of the n orbital of the
oxygen atom with the σ* orbital of the Χ−Ο bond. This was not possible in the anti-anti
or gauche-trans conformations and the two rabbit-ear interactions117-121 (Figure 30)
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engendered by each pair of adjacent oxygen atoms in the anti-anti conformer are
avoided.
H3C
O

O
H3C

H
O

CH3

O

CH3

H

ant i-ant i

gauche-gauche

Figure 30. The conformations for dimethoxymethane.
Furthermore, in the related polymer of dimethoxymethane with the two-bond repeating
sequence, poly(oxymethylene) (POM), the gauche conformation was, in fact, markedly
preferred over trans and the polymer existed in a helical (all gauche) conformation116,122124

rather than in the all-anti one.

Similarly, much effort has been spent on the investigation of the conformational
characteristics of 1,2-dimethoxyethane (glyme, CH3OCH2CH2OCH3) as a model
molecule for understanding the conformations of poly(oxyethylene) , POE. It had long
been established that POE chains have a large fraction of bonds in gauche conformation
and assumed a helical conformation overall.115,116,122-124 It has been proposed that the
oxygen gauche effect116,125,126 and 1, 5-CHO interaction127-129 within the molecule were
responsible for the gauche-rich conformations.
Based on this pioneering work, the correlation was made that the conformation of the
linkers in the bivalents 33-39 and 42-43 adopt anti (B), gauche-gauche (C), trans-
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gauche-trans (D) conformations, respectively, regardless of the monomeric units which
comprise them. The arrangement in space (disregarding the direction) of every unit in
the linkers is depicted in Figure 31. The end-to-end distance of each unit (C and D)
which adopted the gauche conformation was shorter than the one in the anti-conformer.
The more units in the linker, the shorter the gauche linker becomes. Moreover, it was
recognized that the Χ−Ο bond length (1.43Å) is often appreciably shorter than the C-C
bond (1.54 Å).130 Therefore, it was believed that the linkers with the oxygen atom in the
middle favored the helical conformation and rendered the two monomeric units in each
dimer sufficiently close to each other with suitable dihedral angles to facilitate the
intramolecular lipophilic-lipophilic (aromatic-aromatic) interaction. This was regarded
as one of the most important factors to stabilize the folded structure as the preferred
conformation.131-135 For these same reasons, bivalent ligands with the linker B adopted
the linear conformation.
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Figure 31. Newman projection for linkers B, C and D.

For the higher analog of POM and POE, namely, poly(trimethylene oxide) [(CH2)3O]x
(POM3), trans-gauche-gauche-trans was slightly preferred over all-trans and trans-
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trans-gauche-trans comformers in the crystalline state.116 The preference for the gauche
state in this case was only 0.2 kcal/mol were as in the POM and POE examples was 1.5
and 0.4 kcal/mol, respectively.122

Since the energy difference between gauche and

trans was low, the linker A had more flexibility than the other linkers (C and D) to
rotate freely and less tendency to occur as gauche. This could lead to improper end-toend distances or dihedral angles for the interaction between the aromatic monounits.
Hence dimers connected with linker A could not be stabilized in the folded
conformation even though the same aromatic monomeric units were contained in the
molecules.
Bivalent ligands were evaluated in competition binding assays for specific GABAA
membrane proteins using [3H] flunitrazepam as the radiolabel. This assay measured the
ability of the ligand to displace flunitrazepam. Data is reported as Ki according to the
Cheng-Prusoff equation.136

Biological data are presented in Table 11 for dimers

synthesized using different spanners (or linkers). The linkers in 42 (SR-II-35) and 43
(dm-III-96) contained an oxygen atom. Compounds 31, 33, 34, and 35 contained all
carbon linkers. Binding data indicated decreased affinity when bivalents contained an
oxygen atom in the linker. Bivalent Ligand 33 (XLi-093) and 35 (XLi-210) showed
increased selectivity for the α5 subtype as compared to parent monomer 23. Bivalent
ligand 39 (XLi-374) which was analogous to 33 (XLi-093) with the exception of the
oxygen atom present in the linker, bound with less affinity at the α5 subtype. Likewise
bivalent ligand 31 (DMH-D-053) showed increased selectivity versus monomer 30
(XHe-II-53). However, the bivalent 43 (dm-III-96) containing an oxygen atom in the
linker did not bind. The data suggests that dimers which contain a single oxygen atom
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in the linker bind less (decreased affinity) to the Bz/GABA (A) receptor. This is due to
their propensity to adopt a folded conformation. One strategy to increase hydrophilicity
and avoid a folded conformation is to extend the linker length and insert two opposing
oxygen atoms. This approach is currently underway.
Comparison of the results of low temperature NMR studies to crystal structures has
provided enough information to demonstrate that low temperature NMR can be used as
a quick method to identify dimeric ligands with a tendency to fold back upon
themselves, as compared with those preferring a linear conformation. A correlation with
binding data shows that the suitability of a ligand in the α5 BzR/Gabaergic subtype is
heavily influenced by its conformation in solution. Variable temperature NMR thus can
be used as a tool for screening bivalent ligands for their in vivo suitability. It was also
clear the presence of one oxygen atom in the linker was the principle cause for the dimer
to fold back onto itself.

6. Synthesis of α5 subtype selective inverse agonist PWZ-029 on
multigram scale
PWZ-029 (47) was effective in improving memory and cognition, especially in models
with baseline cognitive deficits. The high specificity of PWZ-029 (47) for α5-containing
GABAA receptors has successfully mitigated adverse side effects of seizures and
sedation, which are commonly observed with typical benzodiazepines (BZ) and
nonselective inverse agonists of the GABAA complex. The novel ligand PWZ-029,
which was synthesized on large scale and characterized electrophysiologically,
possesses in vitro binding selectivity and moderate inverse agonist functional selectivity
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at α5-containing GABAA receptors. This ligand has also been examined in rats in the
passive and active avoidance, spontaneous locomotor activity, elevated plus maze and
grip strength tests, primarily predictive of the effects on the memory acquisition, basal
locomotor activity, anxiety level and muscle tone, respectively. The improvement of
task learning was detected at the dose of 5 mg/kg in the passive, but not the active
avoidance test. The inverse agonist PWZ-029 had no effect on anxiety nor muscle tone,
whereas at higher doses (10 and 20 mg/kg) it decreased locomotor activity in this one
paradigm. This effect was antagonized by flumazenil and also by the lower (but not the
higher) dose of an agonist (SH-053-2’F-R-CH3) selective for GABAA receptors
containing the α5 subunit. The hypolocomotor effect of PWZ-029 was not antagonized
by the antagonist ß-CCt exhibiting a preferential affinity for α1-subunit containing
receptors. These data suggest that moderate negative modulation at GABAA receptors
containing the α5 subunit is a sufficient condition for eliciting enhanced
encoding/consolidation of declarative memory, while the influence of higher doses of
modulators at these receptors on motor activity shows an intricate pattern whose
relevance and mechanism wait to be defined.
One desirable property in this regard is the pro-amnesic activity of BZ site inverse
agonists, repeatedly reported in animal models,137,138 as well as in human
volunteers.139,140 However, this desirable effect is confounded by different concomitant
psychomotor effects (increased vigilance, anxiogenic and/or proconvulsant state), some
of which have been described in memory studies with non-selective inverse agonists in
humans, urging their early termination.139 Point mutated mice could not be used to
identify the receptor subtypes mediating the promnesic activity of inverse agonists
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because an unexplained switch to the agonist mode of action occurs when an inverse
agonist at wild type diazepam-sensitive recombinant GABAA receptors is tested at the
respective point-mutated receptors.141,142 Thus, inverse agonists exerted agonistic-like
sedative and anticonvulsant effects in mice with the point-mutated α1 subunits,142 while
the corresponding experiments in models of learning and memory were not
performed.142 Nevertheless, behavioral examination of genetically modified animals
conducted to date has indicated the α1 and α5 subunit-containing GABAA receptors
comprise the ‘memory-modulating’ population of these receptors.143,144 It is notable that
GABAA receptors containing the α5 subunit are abundantly expressed in the
hippocampus,11,145,146 the structure substantially involved in memory formation.147
Recent evidence from animal studies with affinity-selective148 or efficacy-selective
ligands149-151 has confirmed that the α5 subunit was significantly involved in cognition
enhancement mediated by the negative modulation of GABAA receptor functions.
Moreover, it was shown in humans that pre-treatment with an α5 efficacy-selective
inverse agonist significantly reduces the amnesic effect of alcohol on learning a word
list.152 However, the affinity- or efficacy-selectivity of the ligands, as well as the
diversity of the behavioral tasks used in their characterization to date, were of limited
extent, which necessitated screening of newer BZ site negative modulatory ligands, to
determine the putative therapeutic role of such compounds in various disorders with
diminished cognitive capabilities in humans.56
In this regard, the BZ site ligand PWZ-029 was synthesized (Scheme 7) and prepared on
large scale. A mixture of 5-chloroisatoic anhydride 44 and sarcosine in DMSO was
heated to reflux to furnish benzodiazepine 45 in 84% yield. Potassium t-butoxide was

202

added to a solution of 45 in THF at 0 oC and stirred for 20 min. The reaction was cooled
to -35oC and diethylchlorophosphate was added slowly. After stirring at 0oC for 30 min,
the reaction mixture was cooled to -78oC and ethyl isocyanoacetate was added followed
by potassium t-butoxide to form 40 in 89% yield. A solution of imidazobenzodiazepine
40 can be reduced with LiBH4 to furnish alcohol 46 in 67% yield as colorless crystals.
To a slurry of KOH in DMSO at room temperature were added alcohol 46 and CH3I to
give PWZ-029 (47) , as an off-white powder in 95% yield on 1-15 gram scale. The
alcohol was dissolved in a solution of KOH in DMSO and treated with CH3CH2I at
room temperature to give SR-II-81 (48).

Scheme 7: Synthesis of PWZ-029
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Electrophysiology experiments in Xenopus oocytes demonstrated that PWZ-029, at a
concentration of 1 μM, significantly reduced GABA initiated control currents, thereby
indicating a partial inverse agonist effect of PWZ-029 on GABAA receptors possessing
the α5 isoforms (Figure 32). Illustrated in Figure 32, are the concentration–effects curve
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for modulation of GABAA elicited currents by PWZ-029 on Xenopus oocytes expressing
GABAA receptor subtypes α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2. Concentrations of
GABAA that elicit 3% of the maximum GABAA-triggered current of the respective cells
were applied alone and with various concentrations of PWZ-029. Control currents
represent responses in the absence of PWZ-029. Data points represent means±SEM from
4 oocytes from ≥2 batches [1 μMPWZ-029 resulted in 114±4%, 105±8%, 118±5% and
80±4% of control current (at GABAA EC3) in α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2
receptors, respectively]. All these values except the one for α2β3γ2 receptors were
significantly different from that of the respective control currents (p<0.01, Student's ttest). Note that 100 nM is the pharmacologically relevant concentration.
Table 13. In Vitro Binding Affinities of bivalent ligands at GABAA/BzR subtypes.

a

α2

α3

α4

291.73 >300

>300

>300

ND 38.8

>300

Moltech

291.73 920

ND

ND

ND 30

ND

UNC-Roth

291.73 362.4 180.330 328.2 ND 6.185 ND

Code

MW

Merck

Values Reported are in nM.

α1

α5

α6

204

Figure 32. Oocyte data for PWZ-029 by Sieghart et al.153
This ligand as mentioned, has also been examined in rats in the passive and active
avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests,
primarily predictive of the effects on the memory acquisition, basal locomotor activity,
anxiety level and muscle tone, respectively. The improvement of task learning was
detected at the dose of 5 mg/kg in the passive avoidance task (Figure 33). The passive
avoidance task is a one trial fear-motivated avoidance task in which the mouse learns to
refrain from stepping through a door to an apparently safer but previously punished dark
compartment. The latency to refrain from crossing into the punished compartment serves
as an index of the ability to avoid, and allows memory to be assessed.
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Figure 33. Fear conditioned contextual memory of PWZ-029

The PWZ-029 at 5 mg/kg, administered before the acquisition session, significantly
increased retention session latency relative to the control group.154
The inverse agonist PWZ-029 (47) had no effect on anxiety or muscle tone, whereas at
higher doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was
antagonized by flumazenil and also by the lower (but not the higher) dose of an agonist
(SH-053-R-CH3-2′F) selective for GABAA receptors containing the α5 subunit. The
hypolocomotor effect of PWZ- 029 (47) was not antagonized by the antagonist βCCt,
which exhibits a preferential affinity for α1- subunit-containing receptors. These data
suggest that moderate negative modulation at GABAA receptors containing the α5
subunit is a sufficient condition for eliciting enhanced encoding/consolidation of
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declarative memory, while the influence of higher doses of modulators at these receptors
on motor activity shows an intricate pattern whose relevance and mechanism await to be
defined.154 In fact, in the conflict paradigm in Rowlett’s lab in rhesus monkeys, PWZ029 was a weak anxiolytic with no sedation observed in either the suppressed or
nonsuppressed portion of the test. Recently, Stables et al. at NINDS has shown PWZ029 to be a weak anticonvulsant. The PWZ-029 (47) an α5 inverse agonist cannot be
proconvulsant or convulsant (see Appendix IV) and consequently will not exhibit the
side effects of other inverse agonists (NAM).

Figure 34. Passive avoidance task154

The effects of DMCM (0.2 mg/kg) and PWZ-029 (2, 5 and 10 mg/kg) on retention
performance in a passive avoidance task (*p<0.05 compared to solvent (SOL) group).
Number of animals per treatment group: 10.
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6.1. CANTAB Approach (Rowlett, Rallapalli and Cook et al.)155
Recent studies by Rowlett, Rallapalli and Cook et al. on PWZ-029 showed that this
ligand acted as an inverse agonist at α5GABAA receptor subtypes which enhanced
memory. Rowlett’s used several primate models, including the Cambridge
Neuropsychological Test Automated Battery, or CANTAB. A clear strength of the
CANTAB approach is that its tasks are based on corresponding procedures developed
for human patients, which greatly facilitate the ultimate goal of translating findings from
monkeys to humans.
Because PWZ-029 has been shown to be safe and to have cognitive-enhancing effects in
rodents154 experiments were initiated with this compound in rhesus monkeys as
mentioned. Initial results, shown in Figure 35, are quite provocative and exciting:
PWZ-029 enhanced performance in the DNMS (Delayed non-matching to sample) to
task using the 10-min delay with distracters (Figure 35A) and although it had no effect
alone, PWZ-029 completely reversed the scopolamine-induced deficit in the ORD
(Object Retrieval with Detours ) task (Figure 35B). Interestingly, PWZ-029 induced
anti-conflict (anxiolytic) effects in monkeys without the concomitant response ratesuppressing effects characteristic of BZ-type drugs (Figure 35C). It is felt that these
latter effects are due to PWZ-029’s partial agonist effects at α2/3GABAA receptor
subtypes, whereas the cognition-enhancing effects of this compound are due to inverse
agonist (NAM) action at α5GABAA receptors.
PWZ-029 (47) provides an important lead compound based not only on potential
effectiveness against cognitive impairment, but also as a potential treatment for anxiety
and agitation in patients with dementias, similar to the anxiolytic effects of classical BZs
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(Meehan et al. 2002). Studies will continue with PWZ-029 and expand them to include
comparative studies with non-selective agonists and α5GABAA-preferring agonists; as
well as with pre-treatments with α5GABAA-preferring antagonists such as XLi-093
(33). In addition, in our initial screens compounds will be sought with similar, and
hopefully improved, efficacy profiles. For example, a compound that is an α5GABAA
partial inverse agonist, an α2/3GABAA-preferring partial agonist, but ineffective at
α1GABAA receptors is both desirable and feasible in our synthesis/screening program.

Figure 35: Preliminary profile of cognitive enhancing and anxiolytic like effects of
PWZ-029 in monkeys. Data are from n=2 monkeys (A &C) and n=4 monkeys (B). Red
arrow indicates the dose (0.01mg/kg, i.v.) of PWZ-029 tested in A & B
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Importantly, in the ORD task, PWZ-029 showed only a modest trend for enhancement
of performance (Fig. 36A), but when task difficulty was increased by testing with
difficult trials only, PWZ-029 robustly increased performance (Fig. 36B).

This

enhancement was reversed by administration of the α5GABAA-preferring antagonist
XLi-093, and this antagonism, in turn, was reversed by increasing the dose of PWZ-029
(Fig. 36C). Finally, PWZ-029 completely reversed deficits in performance induced by

% Correct (mean +/- SEM)

the memory-impairing anti-cholinergic scopolamine (Fig. 36D).
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Figure 36. Cognitive-enhancing effects of PWZ-029 in the rhesus monkey Object
Retrieval with Detours (ORD) task (N=5 monkeys). A. Effects of PWZ-029 on ORD
tests consisting of both easy and difficult trials .No effect of the compound was observed
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(mean % correct first reaches, p>0.05, repeated measures ANOVA).

B. PWZ-029

enhanced performance in the ORD task when tested with difficult trials only (*p<0.05
vs. vehicle, V, Bonferroni t-tests). C. Enhancement of ORD performance by 0.018
mg/kg of PWZ-029 was attenuated by the α5GABAA-preferring antagonist XLi-093,
and this antagonism was surmountable by increasing the PWZ-029 dose (*p<0.05 vs.
vehicle, **p<0.05 vs. 0.018 mg/kg PWZ-029, Bonferroni t-tests).

D.

PWZ-029

reversed performance impaired by 0.01 mg/kg of scopolamine. (*p<0.05 vs. vehicle;
**p<0.05 vs. scopolamine alone, Bonferroni t-tests).

6.2. Synthesis of PWZ-029 analogs
The chemistry used to design fluoro analogs of PWZ-029 (47) can be adapted to design
ligands of XHE-II-053 (30) with less potential for metabolization by esterases. Fluorine
atoms in place of the carbonyl group satisfy current included volumes and
electronegativity requirements of the Milwaukee-based pharmacophore receptor model.
The covalent radius of a hydrogen is 37 pm whereas a fluorine is 71 pm.
This approach is in agreement by a recent compounds patented by Roche.156 Several
new analogs have been proposed and docked in the Milwaukee based pharmacophore by
Clayton et al. 157
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Figure 37: Binding affinity data of PWZ-029 (47) and Roche difluoro ligand 49
The new analogs of PWZ-029 are of strong interest due to the recent contextual memory
impairment data wherein doses of scopolamine decreased memory while the α5 ligand
reversed this (see Scheme 8).
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Scheme 8: Synthesis of various analogs of PWZ029
N

N
COOEt
N

CH3

N

N

X

CH3

49 O

CH3

46 O

tO
,E
HF
4,T

iB
H
1)
L

N

H

2

,
id
ac
,
ic
on , ine
or te h e,
l b ta s p at
p y ce h o p h C
ro a l p o s 0 °
op m x y h 0
cl diu e p , 1
cy alla cloh ium 2O
p cy ss , H
tri ota ne
p lu e
to

2

1. DIBAL-H, THF
(aldehyde formation)
2. DAST, CH Cl

O

50

CH2OH

N

X

N

N

CF2H

N

COOEt

N
N

X

O
29 (X = Br)
40 (X = Cl)

N

CH3
N

COOEt
N
N
CH3

O

50

CH2OCH3

N

1) LiBH4, EtOH

N

2) DMSO, KOH
CH3I, rt

51

CH3

O

N

N

N
CHO

COOEt
N

N

1) MgBrCF2CF2H, THF

DIBAL-H, THF
N

X
29 (X = Br)
40 (X = Cl)

O

N

X
CH3

N

N
54 O

CH3

2. CH3COCl,
glyme,
Ni or Mn

O

55 O

( X = Br, Cl, -C

CH2CF2CH3

N

DAST, CH2Cl2
N

X

N

X

CH3

N
CH3

N

1. SOCl2, THF

N

X
O
53

N
OH

N
X

2) Et3SiH, TFA

CH3

O
52

CH2CF2CF2H

N

CH3
56

O

CH3

CH )

The synthesis of amine analog of PWZ-029 can be seen in Scheme 9. A mixture of
imidazobenzodiazepine was refluxed with methyl amine in anhydrous CH2Cl2 to give
SR-II-097 (57) in 78% yield. The efficacy data evaluated by Sieghart et al. (shown in
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Figure 38) indicated that the ligand SR-II-097 (57) was an inverse agonist at α5 and was
an agonist at α1 when compared to PWZ-029 (see Figure 38 and Table 15).

Scheme 9: Synthesis of SR-II-097
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Figure 38: Oocyte data of SR-II-097
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Table 14. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-II-097 (57)
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent
EC50 (95% confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four
cells from two batches.

SR-II-097 (57)

α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

EC50

378nM

>6µM

>18µM

95nM

95%CI

(58-2426)

(0.01-6000)

Nh

0.80

-3.5

Table 15. Modulation of Control GABA EC3 by SR-II-097 (57) on Xenopus Oocytes
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM
of at least four oocytes from at least two batches.

SR-II-097(57)

α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

10nM

ns

ns

ns

ns

100nM

ns

ns

ns

ns

1µM

121±2 %

ns

ns

88±5%

10µM

123±5%

119±1%

125±13%

88±4%

All the above values were significantly different from the respective control currents (p<0.01, Student’st-test) except where indicated (n.s.). n.s. means not significant.
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The fluoro analog SR-III-38 was prepared using DAST (diethylaminosulfur trifluoride)
in anhydrous CH2Cl2 at room temperature in 70 % yield.

Scheme 10: Synthesis of SR-III-38
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Examination of the oocyte data (shown in Figure 39) indicated no significant subtype
selective efficacy.
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Figure 39: Oocyte data on SR-III-38 by Sieghart et al.
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Table 16. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-38 (58)
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent
EC50 (95% confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four
cells from two batches.
α1β3γ2
EC50
SR-III-38 (58)

α2β3γ2

α3β3γ2

>0.6µM

>43µM

0.4

1.5

α5β3γ2

95%CI
Nh

Table 17. Modulation of Control GABA EC3 by SR-III-38 (58) on Xenopus Oocytes
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM
of at least four oocytes from at least two batches.

SR-III-38 (58)

α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

10nM

ns

ns

ns

ns

100nM

105±1 %

ns

ns

ns

1µM

112±10 %

ns

105±3%

ns

10µM

115±7%

ns

115±17%

ns

All the above values were significantly different from the respective control currents (p<0.01, Student’st-test) except where indicated (n.s.). n.s. means not significant.
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To improve the selectivity, the difluoro analog SR-III-61 was synthesized from an
aldehyde (59). The alcohol 46 was treated with Dess Martin periodinane in dry CH2Cl2
to afford aldehyde 59 in 96% yield. Treatment of aldehyde in dry CH2Cl2 with DAST
resulted in the difluro analog SR-III-61 (49) in 65% yield.

Scheme 11: Synthesis of SR-III-61
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Figure 40: Oocyte data of SR-III-61 by Sieghart et al.
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Table 18. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-61 (49)
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent
EC50 (95% Confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four
cells from two batches.

α1β3γ2

α2β3γ2

>10µM

>3nM

EC50
SR-III-61 (49)

95%CI

(1-27nM)

Nh

0.8

α3β3γ2

α5β3γ2
>0.03µM

Table 19. Modulation of Control GABA EC3 by SR-III-61 (49) on Xenopus Oocytes
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM
of at least four oocytes from at least two batches.

SR-III-61(49)

α1β3γ2

α2β3γ2

α3β3γ2

α5β3γ2

10nM

ns

109±4 %

ns

102±7 %

100nM

ns

119±6%

112±2 %

107±5%

1µM

110±4 %

116±1%

116±2%

109±8%

10µM

113±4%

113±1%

144±16%

110±9%

All the above values were significantly different from the respective control currents (p<0.01, Student’st-test) except where indicated (n.s.). n.s. means not significant.
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Data of SR-III-61 (49) from the electrophysiology indicated (in oocytes) was an agonist
at α3 subtypes at high concentrations. However at a pharmacologically relevant
concentration (100nM, -7) the ligand demonstrated efficacy at all subtypes.
Unfortunately, the efficacy data showed no significant subtype selectivity. The synthesis
of the other PWZ analogs is currently underway.

7. Conclusions
In this study, it was clear that QH-II-066 (11) which is α5 subtype selective ligand is an
agonist. It was shown88 that QH-II-066 (11) exhibited functional selectivity in vivo with
potent diazepam-like efficacy at α5 subtypes and partial efficacy at the α1 subtype.
Recent studies by Weiss and Cook et al.89 have shown that activation of GABA (A) by
QH-II-066 (11) induces apoptosis in neuroblastoma. This is very important finding. The
mechanism by which GABA-A activation inhibited the growth of neuroblastoma cells
was assessed by Cho, Cook et al. QH-II-066 (11), an α5 agonist passes through the
blood brain barrier which opens up the potential to apply in neurology and psychology
as chemotherapeutic agent. These results also highlight a possible connection between
the role of neurotransmitters in nervous system development and the regulation of
neuroblastoma growth as shown by Weiss, Rallapalli and Cook et al. (unpublished, see
Appendix III).
Bivalent ligand XLi-093 (33) has clearly been shown to be the first subtype selective
antagonist at α5 subtypes which is known (Rowlett, Savic et al.) to cross the blood brain
barrier. Rowlett showed that the memory impairing effects of diazepam were blocked by
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a dose of XLi-093 (3.0mg/kg) that occupied about 66% of the α5 GABAA binding sites.
A series of bivalent ligands with oxygen linker were synthesized based on α5 selectivity
of XLi-093 (33). Comparison of the results of low temperature NMR studies to crystal
structures has provided enough information to demonstrate that low temperature NMR
can be used as a quick method to identify dimeric ligands with a tendency to fold back
upon themselves, as compared with those preferring a linear conformation.

A

correlation with binding data shows that the suitability of a ligand in the α5
BzR/Gabaergic subtype is heavily influenced by its conformation in solution. Variable
temperature NMR thus can be used as a tool for screening bivalent ligands for their in
vivo suitability. It is also clear the presence of one oxygen atom in the linker was the
principle cause for the dimer to fold back onto itself, consequently resulted in
diminished activity. From the recent work of Rowlett, it was demonstrated that novel α5
selective inverse agonist PWZ-029 (47) enhanced cognition in rhesus monkeys in the
CANTAB paradigm. This ligand had the ability to reverse cholinergic deficits in
performance induced by the antimuscarinic scopolamine under mixed trial conditions. In
the ORD task, PWZ-029 showed only a modest trend for enhancement of performance.
But when task difficulty was increased by testing with difficult trials only, PWZ-029
robustly increased performance. This enhancement was reversed by administration of
the α5 GABA (A) subtype selective antagonist XLi-093 and this antagonism in turn was
reversed by increasing the dose of PWZ-029. In addition, PWZ-029 enhanced
performance in the DNMS task using the 10 minute delay with distracters. This ligand
also exhibited anxiolytic activity in some primates and was a weakly active
anticonvulsant in rats (NINDS, Jim Stables et al. see Appendix IV).These findings are
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consistent with a role for PWZ-029 (47) α5 GABAA receptors in the treatment of ageassociated memory impairment and Alzheimer’s disease. It is the subject of an SBIR
grant submitted December 5th, 2012 by Physiogenix (see Appendix VII).

8. General Experimental Details
All reactions were carried out under an argon atmosphere with dry solvents using
anhydrous conditions unless otherwise stated. Tetrahydrofuran (THF) and diethyl ether
were freshly distilled from Na/benzophenone ketyl prior to use. Dichloromethane was
distilled from calcium hydride prior to use. Methanol was distilled over magnesium
sulfate prior to use. Benzene and toluene were distilled over sodium and acetonitrile was
distilled over CaH2 prior to use. Reagents were purchased of the highest commercial
quality and used without further purification unless otherwise stated. Thin layer
chromatography (TLC) was performed using Dynamic Adsorbents Inc. UV active silica
gel, 200 µm, plastic backed; Dynamic Adsorbents Inc. UV active alumina N, 200 µm, F254 plastic backed plates. Flash and gravity chromatography were performed using
silica gel P60A, 40-63 µm purchased from Silicycle. Elemental analyses were performed
on a Carlo Erba model EA-1110 carbon, hydrogen, and nitrogen analyzer. All samples
submitted for CHN analyses were first dried under high vacuum for a minimum of six
hours using a drying pistol with isopropyl alcohol or benzene as the solvent with
potassium hydroxide pellets in the drying bulb. Melting points were taken on a Stuart
melting point apparatus SMP3 manufactured by Barloworld Scientific US Ltd. Proton
(1H NMR) and carbon high resolution nuclear magnetic resonance spectra (13C NMR)
were obtained on a Bruker 300-MHz or a GE 500-MHz NMR spectrometer. 1H NMR
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data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t =
triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of
doublet of doublet, td = triplet of doublets, qd = quartet of doublets, sex = sextet, m =
multiplet), integration, and coupling constants (Hz). 13C NMR data are reported in parts
per million (ppm) on the δ scale. The low resolution mass spectra (LRMS) were
obtained as electron impact (EI, 70eV), which were recorded on a Hewlett-Packard
5985B gas chromatography-mass spectrometer, while high resolution mass spectra
(HRMS) were recorded on a VG Autospec (Manchester, England) mass spectrometer.
HRMS recorded by electrospray ionization (ESI) methods were performed at the
Laboratory for Biological Mass Spectrometery at Texas A&M University on an API
QStar Pulsar model, manufactured by MDS Sciex.
5-Phenyl -1,4 benzodiazepine-2-one (7) : The 2-amino-benzophenone 5 (100.6g,
0.51mol) and NaHCO3 (128.6g, 1.5mol) were suspended in dry CH2Cl2 (1.3L) at rt. A
solution of bromoacetyl bromide (113.2g, 0.56mol, 48.9mL) in dry CH2Cl2 (200mL)
was added dropwise over 30 min and the mixture was allowed to stir for another 3h. The
reaction was allowed to stir until analysis by TLC (silica gel) indicated the absence of
starting material, after which the above reaction mixture was concentrated under vacuum
to provide amide intermediate 6 which was added directly to a saturated solution of
anhydrous ammonia in CH3OH (1.5L). The mixture was heated to reflux for 6h until
analysis by TLC (silica gel) indicated the absence of the 2-bromoacetyl intermediate 6
prepared above. After the solvent was removed under reduced pressure, the solid which
remained was washed with hexane/EtOH (1:4) to provide pure benzodiazepine 7 (107g,
95%) as a white powder. 3: mp: 135-145 °C; IR (KBr) 3454, 3185, 3063, 2891, 1681,
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1614, 1467 cm-1 ; 1H NMR (CDCl3, , 300MHz) δ 9.68 (s, 1H), 7.09-7.59 (m, 9H), 4.31
(s, 2H) MS (EI) m/e 236 (M+, 93), 208 (100), 180 (28), 152 (19); Anal. Cald for
C15H12N2O: C, 76.25; H, 5.12; N, 11.86; Found C, 76.21; H, 5.19; N, 11.94. The
spectral data were in agreement with the literature.65
7-Bromo-5-phenyl-1,4-benzodiazepine-2-one 8: Benzodiazepine 7 (61.4g, 0.274mol)
was dissolved in acetic acid (1L) and was treated with H2SO4 (15.2mL, 0.55mol, 36N)
and bromine (87.1 g, 0.55mol). After stirring at rt for 10d, the reaction mixture was
poured into ice water and brought to pH 5-6 with an aq solution of 6N NaOH. The crude
bromide 4 precipitated and was collected by vacuum filtration and recrystallized from
EtOH to provide the bromide 8 as a white solid in 90% yield. 8: mp: 188-194 °C; IR
(KBr) 3466, 3173, 3075, 2953, 1687, 1602, 1480 cm-1: 1H NMR (DMSO-d, 300MHz) δ
10.95(s, 1H), 7.11-7.89 (m, 8H), 4.25 (s, 2H). MS (CI) m/e 316 (M+ +1, 78), 265 (15),
237 (100), Anal. Cald for C15H12N2O: C, 57.16; H, 3.52; N, 8.89; Found C, 57.56; H,
3.49; N, 8.82. This material was identical to that reported in the literature. 65
7-Trimethylsilylacetyleno-5-phenyl-1,3-dihydrobenzo[e]-1,4-diazepine-2-one 9:The
6- Bromo-benzodiazepine 8 (5g, 15.86mmol) was dissolved in dry triethyl amine
(108mL) and acetonitrile (68mL). This mixture was degassed 3-4 times under vacuum
and back filled with argon. To this degassed mixture, bis (triphenylphosphine) palladium
(II) acetate (0.713g, 1.1mmol) and trimethylsilylacetylene (4.48mL, 31.72 mmol) was
added and the mixture was heated to reflux under argon. After 12 h the reaction mixture
was cooled to rt and filtered through a bed of celite with EtOAc. The filtrate was
concentrated in vacuuo and the residue was purified via flash chromatography [silica
gel, EtOAc:hexane (1:1)] to furnish the TMS analog 9 as a yellow powder (4.5g, 85%):
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mp: 190.0-191.5 °C; IR (KBr) 3011, 2281, 1686, 1610, 1486 cm-1: 1H NMR (CDCl3,
300 MHz) δ10.17 (s, 1H), 7.21-7.61 (br, 7H), 7.09 (d, 1H, J=8.25Hz), 4.31 (s, 2H), 0.21
(s, 9H) ; MS (CI) m/e (relative intensity) 333 (M+ +1, 100). Anal. Cald for
C20H20N2OSi: C, 72.25; H, 6.06; N, 8.43; Found C, 72.20; H, 6.11; N, 8.52
1-Methyl- 7 - trimethylsilylacetyleno-5- phenyl - 1,3-dihydrobenzo[e]-1,4-diazepine2-one 10: The acetyleno amine 9 (1g, 3mmol) was dissolved in dry THF (15mL) at 15°C and NaH (60% mineral oil, 144mg, 3.6mmol) was added to the solution in one
portion. The slurry was then stirred for 30 min and then CH3I (0.28mL, 4.5mmol) was
added to the mixture and this mixture was allowed to warm to rt. After the mixture was
allowed to stir overnight, the reaction was quenched with water (200mL) and EtOAc
(100mL). The mixture was extracted with EtOAc and then washed with brine and dried
(Na2SO4). After the removal of the solvent under reduced pressure, the residue was
purified by flash chromatography [hexane:EtOAc (75:25)] to provide the TMS-analog
10 (0.9g, 85%) as a white solid : mp: 177-178 °C; IR (KBr) 2954, 2147, 1687, 1612,
1491 cm-1: 1H NMR (CDCl3, 300 MHz,) δ 7.20-7.27 (m, 3H), 7.07 (d, 1H, J=8.58Hz),
7.05 (s,1H), 4.60 (d, 1H, J=10.8Hz), 3.54 (d, 1H, J=10.8 Hz), 3.18 (s, 3H); MS (EI) m/e
346 (M+, 90), 318 (100), 303 (19), 165 (22), 151 (20). Anal. Cald for C21H22N2OSi: C,
72.79; H, 6.40; N, 8.08; Found C, 72.50; H, 6.68; N, 8.04
1-Methyl-7-acetyleno-5- phenyl- 1,3-dihydrobenzo[e]-1,4-diazepine-2-one 11: A
solution of trimethylsilyl acetyleno benzodiazepine 10 (0.87g, 2.5 mmol) was dissolved
in THF (200mL) and the solution was cooled to -30°C . A solution of TBAF (1.0M in
THF; 3.01mL, 3mmol) was then added to the mixture and it was allowed to warm to rt.
After stirring at rt for 20min the reaction mixture was quenched with water (200mL) and
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extracted with EtOAc (200mL), washed with brine and dried (Na2SO4). After removal of
the solvent under reduced pressure the residue was purified by flash chromatography
[EtOAc : hexane (1:1)] to provide the target compound 11 (QH-II-066) (0.62g, 90%) as
light yellow crystals. mp: 163-165 °C; IR (KBr) 2965, 1680, 1605 cm-1: 1H NMR
(CDCl3, 300 MHz) δ 7.62 (dd, 1H, J=8.5Hz, 2.0Hz), 7.35-7.45 (m, 4H), 7.27-7.42 (d,
1H, J=8.5Hz), 4.80 (d, 1H, J=10.9Hz), 3.85 (d, 1H, J = 10.8Hz), 3.46 (s, 3H), 3.11 (s,
3H); MS (EI) m/e 274 (M+, 100), 259(12), 246 (10), 189 (12), 122 (19), 105 (42). Anal.
Cald for C18H14N2O.2/3H2O: C, 75.51; H, 4.89; N, 9.78; Found C, 75.59; H, 5.17; N,
9.62. This material was identical to that reported in the literature. 47,65
(Z)-8-Bromo-2-((4-methylpiperidin-1-yl)methylene)-6-phenyl-2,4-dihydro-1Hbenzo[f]imidazo[1,2-a][1,4]diazepin-1-one 16: A suspension of 7-bromo-1,3-dihydro5-phenyl-2H-1,4-benzodiazepin-2-thione 12 (1.6g, 4.83mmol), glycine (1.81g,
24.2mmol) and Na2CO3 (1.84g, 17.4mmol) in EtOH (38mL)-H2O (16mL) was stirred at
reflux for 1 h and then poured into water (100mL), after which the mixture was filtered
to remove a small amount of 7-bromo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2one which remained. The filtrate was extracted with CHCl3. The CHCl3 extract was
discarded and then the aq layer was adjusted to pH 4 with a solution of aq 2N HCl after
which it was extracted with CHCl3 (3x25mL). Evaporation of the CHCl3 solution gave
pure acid 13 (1.2g, 67%) as a yellow solid. Acid 13 (350mg, 0.941mmol) was suspended
in dry CH2Cl2 (10mL) and DCC (223mg, 1.08mmol) was added. The suspension which
resulted was stirred at 40°C for 2h and then cooled to 0°C. The mixture which resulted
was filtered and the solvent was removed under vacuum to give 8-bromo-2,4-dihydro-6phenyl-1H-imidazo[1,2-a][1,4] benzodiazepine-1-one 14 as a brown oil. The cyclized
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amide 14 (250mg) was dissolved in dry benzene (6mL), after which dimethylformamide
diethylacetal (130mg, 0.883 mmol) and triethyl amine (89mg, 0.883 mmol) were added.
The solution which resulted was stirred at rt for 1 h and the solvent was removed under
vacuum. The residue was crystallized from EtOAc-MeOH to give 15 (200mg, 70%). A
solution of 15 (180mg, 0.440 mmol) in dry toluene (5mL) was treated with 1-methyl
piperazine (1mL) and heated to reflux for 5h. The solvent was removed under vacuum to
give a gum which crystallized from CH2Cl2-Et2O to furnish 16 (146mg, 72%) as a
yellow solid. mp >250 °C; IR (KBr) 3324, 2932, 2787, 1692, 1624, 1475, 1402, 1297,
1137, 933 cm-1; 1H NMR (CDCl3, 300MHz) δ 7.95 (d, 1H, J=8.8Hz), 7.72 (dd, 1H,
J1=8.8Hz, J2=2.3Hz), 7.58-7.55 (m, 2H), 7.49-7.37 (m, 4H), 7.17 (s, 1H), 5.01 (d, 1H,
J=12Hz), 4.50-4.60 (m, 1H), 4.20-4.30 (m, 1H), 4.16 (d, 1H, J=12Hz), 3.50-3.58 (m,
2H), 2.40-2.60 (m, 4H), 2.34 (s, 3H); MS (m/z) 465 (100). Anal. Calcd. for
C23H22N5OBr. 1/3H2O: C, 58.79; H, 4.95; N, 14.89. Found: C, 58.73; H, 4.86; N, 14.83.
The spectral data of 16 were identical to the published results.158
(Z)-2-((4-Methylpiperidin-1-yl)methylene)-6-phenyl-8-((trimethylsilyl)ethynyl)-2,4dihydro-1H-benzo[f]imidazo[1,2-a][1,4]diazepin-1-one 17: To a suspension of amide
16 (140mg, 0.302mmol) in dry acetonitrile (4mL) and triethylamine (3mL) was added
bis (triphenylphosphine)-palladium (II) acetate (22.6mg, 0.03mmol). The solution which
resulted was degassed and trimethylsilyl acetylene (0.1mL, 0.7mmol) was added. The
mixture was heated to reflux and stirred overnight. After removal of the solvent under
vacuum, the residue was dissolved in CH2Cl2 and washed with a saturated aq solution of
NaHCO3 and brine. The organic layer was dried (Na2CO3), filtered and concentrated
under vacuum. The residue was purified by flash column chromatography (EtOAc:
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MeOH 9:1) to furnish the trimethylsilyl analog 17 (100mg, 69%) as a pale yellow solid.
mp >250 °C; IR (KBr) 3436, 2936, 2794, 2154, 1682, 1625, 1489, 1136, 847cm-1; 1H
NMR (CDCl3, 300MHz) δ 8.80 (d, 1H, J=8.5Hz), 7.68 (dd, 1H, J=1.9Hz, 8.5Hz), 7.557.59 (m, 2H), 7.37-7.49 (m, 4H), 7.16 (s, 1H), 4.99 (d, 1H, J=12Hz), 4.50-4.60 (m, 1H),
4.20-4.30(m, 1H), 4.13 (d, 1H, J=12.4Hz), 3.48-3.58(m, 2H), 2.4-2.6 (m, 4H), 2.35 (s,
3H), 0.23 (s, 9H); MS (m/z) 482 (100). Anal. Calcd. for C28H31N5OSi. H2O: C, 67.60;
H, 6.54; N, 13.59. Found: C, 67.30; H, 6.66; N, 14.01.
(Z)-8-Ethynyl-2-((4-methylpiperidin-1-yl)methylene)-6-phenyl-2,4-dihydro-1Hbenzo [f]imidazo[1,2-a][1,4]diazepin-1-one 18 (PS-1-37): A solution of the
trimethylsilyl analog 17 (65mg, 0.135mmol) in THF (15mL) was stirred with TBAF
hydrate (45mg, 0.175mmol) at -5°C for 5min. After this, H2O (5mL) was added to the
solution to quench the reaction and stirring continued at -5°C for one half h. The solution
was then extracted with EtOAc (3x40mL) and the organic layer was washed with water.
After removal of the solvent under reduced pressure, diethyl ether was added to the
residue to precipitate a solid. The solid was filtered and washed with CHCl3-Et2O (1:15)
to provide the acetyl target 18 (40mg, 73%). mp 223-224 °C;

IR (KBr) 3298, 2935,

2786, 1695, 1628, 1364, 1136, 1002, 778cm; 1H NMR (CDCl3, 300MHz) δ 8.04 (d, 1H,
J=8.5Hz), 7.71 (dd, 1H, J=1.9Hz, 8.5Hz), 7.55-7.58 (m, 2H), 7.36-7.48 (m, 4H), 7.17 (s,
1H), 5.0 (d, 1H, J=12.1Hz), 4.5-4.6 (m, 1H), 4.2-4.3 (m, 1H), 4.16 (d, 1H, J=12.1Hz),
3.5-3.6 (m, 2H), 3.08 (s, 1H), 2.4-2.6 (m, 4H), 2.35 (s, 3H); MS (m/z) (100). The
spectral data of 14 were identical to the published results.159
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4-Methyl-3,4-dihydro-1H- benzo[e][1,4]diazepine-2,5-dione(26): A mixture of isatoic
anhydride 25 (20g, 101 mmol) and sarcosine (9.02g, 101 mmol) in DMSO (160mL) was
heated at 150°C for 5 hr, after which the solution was cooled to rt and poured into ice
water (750mL) to furnish a light brown solid. This solid was collected by filtration,
washed with water (3x200mL) and dried. The benzodiazepine 26 was obtained as a light
brown solid (19g, 84%). This material was used directly in the next experiment.
7-Bromo-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione(27):
Benzodiazepine 26 (32.4g, 0.17mol) was added to a solution of acetic acid (400mL) in a
3-neck reaction flask. Sodium acetate (27.9g, 0.34mol) was added to this solution.
Bromine (13.1mL, 0.255mol) was added using an addition funnel and the solution which
resulted was allowed to stir for 18h and then poured into ice water (200mL) to provide a
white solid. This solid was collected by filtration and then washed (3x200mL) and dried
(Na2SO4). The bromobenzodiazepine 27 (36.6g, 80%) was used directly in the next
experiment. mp 240-242 °C; 1H NMR (DMSO-d6, 300MHz) δ10.54 (br s, 1H), 7.81 (d,
1 H, J = 2.2 Hz), 7.67 (dd, 1 H, J = 2.4,8.6 Hz), 7.04 (d,l H,J = 8.7 Hz),3.87 (s,2 H),3.09
(s,3 H); MS (CI) m/z 269 (M + H).
tert-Butyl-8-bromo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxylate (28): The t-BuOK (7.50 g, 66.91 mmol) was
added to a solution of benzodiazepine 27 (15 g, 55.76 mmol) in anhydrous THF (1500
mL) at 0 °C and the mixture which resulted was stirred for 20 min. The reaction mixture
was cooled to –35 °C and diethyl chlorophosphate (10.47 mL, 72.48 mmol) was added
slowly. After stirring at 0°C for 30 min the mixture was cooled to –78°C and t-butyl
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isocyanoacetate (8.926 mL, 61.33 mmol) was added, and this was followed by the
addition of t-BuOK (6.88g, 61.33 mmol) at -78°C. After stirring at rt for 4 h the reaction
was quenched with a saturated aq NaHCO3 solution (500 mL) and extracted with EtOAc
(3 × 1000 mL). The combined organic layers were dried (Na2SO4) and concentrated to
give a solid residue. This solid residue was triturated with Et2O (250 mL) and the ester
28 precipitated as an off-white solid. The mother liquor was further purified by flash
chromatography on silica gel (gradient elution 40– 60% EtOAc in hexane) to afford
additional ester 28 in a combined yield of (15.3g, 70%). mp 180-183 °C; 1H NMR
(CDCl3, 300MHz) δ 8.33 (s, 1H), 7.90 (s, 1H), 7.62 (d, 1H, J =10.8 Hz), 7.03 (d, 1H, J
= 8.6 Hz), 4.71 (br, s, 1H), 4.13 (br, s, 1H), 3.10 (s, 3H), 1.56 (s, 9H); MS (EI) m/e 394
(M+, 100). The spectral data for 28 were identical to the published values.
tert-Butyl-8-(trimethylsilyl)-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine3-carboxylate (20): A mixture of imidazobenzodiazepine 28
(7.5g, 19.12mmol) was dissolved in dry triethyl amine (223mL ) and

acetonitrile

(149mL; 3:2 ratio). This mixture was degassed under argon three times. To this
degassed mixture, bis (triphenylphosphine)-palladium (II) acetate (1g, 7 mol %) was
added. The mixture was again degassed (with vacuum) three times under argon.
Trimethylsilyl acetylene (5.52mL, 38.24mmol) was added and this reaction mixture was
heated to reflux for 8h under argon. The reaction mixture was cooled to rt and the
solvents were concentrated under reduced pressure. This concentrated mixture was
dissolved in ethyl acetate and passed through a bed of celite. After the removal of
solvent under reduced pressure the residue was purified by flash chromatography (silica
gel, EtOAc) to afford a yellow solid of RY-23 (20) (6.5g, 83%). mp 199-200 °C. IR
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(KBr) 2971, 2156, 1723, 1662, 1500 cm -1 ; 1H NMR (CDCl3, 300MHz) δ 8.13 (s, 1H),
7.84 (s, 1H), 7.64 (d, 1H, J = 8.2 Hz), 7.32 (d, 1H, J = 8.2 Hz), 5.11 (br, 1H), 4.31 (br,
1H), 1.63 (s, 9H), 0.25 (s, 9H); MS (EI) m/e 409 (M+, 4), 354 (19), 353 (82), 335 (45),
307 (100), 279 (23), 251 (16), 143 (13), 160 (21), 107 (14); Anal. Calcd for
C22H27N3O3Si: C, 64.52; H, 6.64; N, 10.26; Found C, 64.57; H, 6.70; N, 10.46. The
spectral data for 20 were in excellent agreement with the literature. 85
tert-Butyl-8-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine3-carboxylate (21): A solution of 20 (1.2g, 2.93 mmol) in THF
(360mL) was treated with a solution of TBAF solution (1.0M in THF;
3.52mL,3.51mmol) at -30°C. The mixture which resulted was allowed to stir for 30 min
at rt, after which the mixture was added to H2O (50mL) and extracted with EtOAc
(3x100mL). The combined organic extracts were washed with brine (50mL) and dried
(Na2SO4). After removal of the solvent under reduced pressure, the residue was purified
by a wash column (silica gel, EtOAc) to give 21 (RY-24) as a yellow solid (0.89g,
90%): mp 213-214 °C. 1H NMR (CDCl3, 300MHz) δ 8.16 (s, 1H), 7.85 (s, 1H), 7.69 (d,
1H, J = 8.3 Hz), 7.35 (d, 1H, J = 8.3 Hz), 5.15 (br, 1H), 4.32 (br, 1H), 3.23 (s, 3H), 3.20
(s, 1H), 1.63 (s, 9H); MS (EI) m/e 337 (M+, 2), 282(15), 281 (78), 264 (31), 263(56),
235 (100), 229(22), 207 (36), 138 (16), 101(19); Anal. Calcd for C19H19N3O3: C,
67.64; H, 5.68; N, 12.45; Found C, 67.50; H, 5.78; N, 12.41. The spectral data for 21
were in excellent agreement with the reported values.
8-Ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3carboxylic acid 32 :

Ethyl-8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-

a][1,4] benzodiazepine-3-carboxylate 23 (1.5g, 5.3mmol),available from the literature,
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was dissolved in EtOH (100mL), after which an aq solution of 2N NaOH (15mL) was
added to the solution. The mixture which resulted was heated to 70°C and allowed to stir
for 1hr. The mixture was then allowed to cool to rt and the EtOH was removed under
reduced pressure. Aq 2N HCl was added to the residue to bring the pH to approximately
3-4. A precipitate formed which was removed by filtration, washed with water
(3x50mL) and dried. The 3-carboxylic acid 32 was obtained as a white solid in 90%
yield; mp 315-316 °C. 1H NMR (CD3OD, 300MHz) δ 8.20 (s, 1H), 7.80 (dd, 1H, J
=2.5Hz, 10 Hz), 7.69 (s, 1H), 5.22 (br, 1H), 4.50 (br, 1H), 3.74 (s, 1H), 3.28 (s, 3H), ;
MS (EI) m/e 281 (M+, 80), 277(100), 263 (60), 235 (84), 207(55) Anal. Calcd for
C15H11N3O3: C, 64.04; H, 3.94; N, 14.95; Found C, 64.40; H, 4.12; N, 14.76. The
spectral data for 20 were in excellent agreement with the published reports. 160
1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4Himidazo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 33 (XLi-093) : To a
solution of carbonyl diimidazole (230.3mg, 0.57mmol) in anhydrous DMF (5mL) was
added 8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3carboxylic acid 24 (200mg, 0.71mmol). The solution which resulted was allowed to stir
for 2h at rt. Analysis of the material by TLC (silica gel) indicated the absence of starting
material. To this solution, 1, 3 propanediol (27.1mg, 0.36mmol) in dry DMF (0.5mL)
and DBU (114.2mg, 0.75mmol) in dry DMF (0.5mL) were added to the solution at rt.
The mixture was allowed to stir for 12h until analysis by TLC (silica gel) indicated the
absence of starting material. The reaction mixture was then poured into ice water
(30mL) and extracted with EtOAc (3x50mL). The combined organic layers were washed
with H2O (5x50mL) and dried (Na2SO4). The solvent was removed under reduced
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pressure and the residue was purified by flash chromatography (silica gel,
EtOAc/MeOH: 4:1) to provide the dimer 33 ( XLi-093 ; 157mg, 74%) as white solid.
mp >230 °C (dec);

IR (NaCl) 3247, 1725, 1641, 1359, 1253, 1061 cm-1; 1H NMR

(CD3OD, 300MHz) δ 8.20 (d, 2H, J=1.76Hz), 7.89 (s, 2H), 7.72 (dd, 2H, J =6.43Hz,
1.86 Hz), 7.41 (d, 2H, J=8.3Hz), 5.31 (br, 2H), 4.57 (t, 4H, J=6.2Hz), 4.40 (s, 2H), 3.26
(s, 6H), 3.24 (s, 2H), 2.37 (m, 2H);

C NMR (CD3OD, 300MHz) δ 26.2, 34.4, 40.7,

13

60.2, 78.7, 79.7, 120.4, 121.6, 127.1, 127.7, 130.1, 133.4, 134.1, 134.9, 161.3, 164.1;
MS (FAB) m/e 603 (M+ +1, 100) Anal. Calcd for C33H26N6O6.2/3 CH3OH: C, 64.81;
H, 4.63; N, 13.47; Found C, 64.56; H, 4.72; N, 13.76. The spectral data for XLi-093
were identical to the published values. 160
1,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4] benzodiazepine3-carboxy) propyl diester 34: Bis (8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4Himidazo[1,5a][1,4]-benzodiazepine-3-carboxy) propyl diester 33 (500mg, 0.83mmol)
was dissolved in EtOH (150mL) and degassed 3-4 times with a balloon of hydrogen
after which Pd/C (176mg) was added to the solution at rt. The slurry was allowed to stir
for 12h under H2. The catalyst was removed by filtration and washed with EtOH. The
EtOH was removed under reduced pressure to furnish a residue. This material was
purified by flash chromatography (silica gel, EtOAc:MeOH, 9:1) to provide (34)XLi356 (504mg, 99%) as white crystals: mp 125-133°C; IR (NaCl) 3407, 2964, 2358,
1725, 1640, 1499 cm-1; 1H NMR (CDCl3, 300MHz) δ 8.15 (s, 1H), 7.89 (t, 4H,
J=3.2Hz, 5.3Hz), 7.48 (d, 2H, J=1.8Hz), 7.33 (d, 2H, J=8.2Hz), 5.16 (br, 2H), 4.56 (t,
4H, J=6.1, 12.2 Hz), 4.48 (br, 2H), 3.26 (s, 6H), 2.78 (dd, 4H, J=7.5, 15.1Hz), 2.39 (m,
2H), 1.29 (m, 6H) ; MS (EI) m/e (relative intensity) 611 (M++1, 100); Anal Calcd for
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C33H34N6O6.2H2O: C, 61.33; H, 5.92; N, 13.00. Found: C, 61.74; H, 5.91; N, 12.63.
The spectral data of XLi-356 were identical to the published values. 160
1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4Himidazo[1,5a][1,4]benzodiazepine-3-carboxy) pentyl diester 35: To a solution of
carbonyl diimidazole (173mg, 1.06mmol) in anhydrous DMF (5mL) was added 8-ethyl5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3-carboxylic acid
32 (150mg, 0.534mmol). The solution which resulted was stirred for 2h at rt. Analysis of
the mixture by TLC (silica gel) indicated the absence of starting material. To this
solution, 1,5 pentanediol (27.8mg, 0.267mmol) in dry DMF (0.5mL) and DBU
(114.2mg, 0.75mmol) in dry DMF (0.5mL) were added at rt. The mixture was allowed
to stir for 12h until analysis by TLC (silica gel) indicated absence of starting material.
The reaction mixture was then poured into ice water (30mL) and extracted with EtOAc
(3x50mL). The combined organic layers were washed with H2O (5x50mL) and dried
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified
by flash chromatography (silica gel, EtOAc/MeOH: 4:1) to provide the dimer 35 XLi210 (123mg, 89.2%) as a white solid. mp 132-138 °C ; IR (NaCl) 3422, 3280, 2931,
1714, 1635, 1487, 1249, 1064 cm-1; 1H NMR (CD3OD, 300MHz) δ 8.18 (s, 2H), 7.86
(s, 2H), 7.70 (m, 2H), 7.36 (dd, 2H, J=8.1, 16Hz), 5.29 (s, 2H), 4.39 (s, 8H), 3.52 (s,
2H), 3.24 (s, 6H), 1.90 (m, 4H); MS (FAB) m/e 631 (M+ +1, 100) Anal. Calcd for
C35H30N6O6.5/3 H2O: C, 63.61; H, 4.83; N, 12.72; Found C, 63.16; H, 4.72; N, 13.06.

Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine3-carboxy) diethylene glycol diester 36 (XLi-347). To a solution of carbonyl
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diimidazole (243 mg, 1.50 mmol) in anhydrous DMF (8 mL) was added 8-ethynyl-5, 6dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 32
(351.4 mg, 1.25 mmol). This solution was stirred for 2 h at rt until analysis by TLC
(silica gel) indicated the absence of starting material. To the solution which resulted was
then added diethylene glycol (66.3 mg, 0.62 mmol) in dry DMF (0.5 mL) and also DBU
(190 mg, 1.25 mmol) in dry DMF (0.10 mL) at rt. The mixture was stirred at rt for 8 h
until analysis by TLC (silica gel) indicated the reaction was complete. The reaction
mixture was then poured into ice water (30 mL) and extracted with CH2Cl2 (3 x 50 mL).
The combined organic layer was washed with H2O (5 x 50 mL), brine and dried
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified
by flash chromatography (silica gel, EtOAc/CH3OH, 4 : 1) to provide 36 (150 mg) as a
white solid in 60% yield. 28: mp 118-121°C (dec.); IR (NaCl) 3247, 2880, 1725, 1639,
1

1496, 1253, cm-1; H NMR (500 MHz, CDCl3) δ 8.19 (d, 2H, J=1.76Hz), 7.90(s, 2H),
7.72(dd, 2H, J=1.8 Hz and J=8.3 Hz) , 7.39 (d, 2H, J=6.1 Hz), 5.20(br, 2H), 4.37(br,
2H), 3.67 (t, 4H, J=5.1Hz), 3.23(s,6H), 3.21(s, 2H);

C NMR (53.4 MHz, CD2Cl2) δ

13

35.4, 42.3, 63.5, 68.9, 79.6, 81.3, 122.2, 122.4, 128.4, 129.4, 131.9, 135.1, 135.7, 135.8,
136.0, 162.5, 165.2; MS (FAB,NBA) m/e (relative intensity) 633(M++1, 11). Anal.
Calcd for C34H28N6O7 •1/3 C2H5OH: C, 61.38; H, 4.45; N, 12.39. Found: C, 60.99; H,
4.62; N, 12.16.
Dibromodimethyl ether 38111. Bromine (120 g) was added slowly via an addition
funnel to a capped three-neck flask containing water (22.4 ml) in equal portion intervals
over a 2 h period. Paraformaldehyde (120 g) and red phosphorus (27.2 g) were added to
the bromine/water solution at a comparable rate in equal portions after each bromine
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addition. The reaction vessel and vials containing the starting material were kept capped
and only opened briefly to allow sample removal and addition. The reaction mixture
was ice water-cooled during the addition period of the process. After completing the
addition of all the starting material the final reaction mixture was set aside for 20 h. The
heavy crude ether layer, dibromodimethyl ether, was separated, saturated with hydrogen
bromide, and dried with phosphorus pentaoxide (P2O5) for 24 h. Simple distillation at
atmospheric pressure afforded the colorless dibromo-dimethyl ether 38 as a fraction with
b. p. = 146-159 oC. The data for 38 were identical to the literature values.112
Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine3-carboxy) dimethyl glycol diester 39 (XLi374). 8-Ethynyl-5, 6-dihydro-5-methyl-6oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 32 (100 mg, 0.356 mmol)
was dissolved in DMF (10 mL) and to this solution dibromodimethyl ether (36.3 mg,
0.178 mmol) was added, followed by TEA(2.0 mL). After 26 h of stirring at ambient
temperature the solvent was removed under reduced pressure and the residue was
distributed between CHCl3 and water. The organic phase was washed multiple times
with water and dried over Na2SO4. The dried crude ether was applied on a column of
silica gel to afford dimer 39 (86 mg) in 80% yield. 39: mp >220 °C (dec.); IR (KBr)
1

3419, 3237, 2910, 1714, 1635, 1561, 1498 cm-1; H NMR (500 MHz, CD2Cl2) δ 8.15 (s,
2H), 7.90 (s, 2H), 7.74(dd, 2H, J=1.6Hz , J=8.2Hz), 7.40(d, 2H, J=8.1 Hz), 5.74 (s,
4H), 5.29(br, 2H), 4.37 (br, 2H), 3.31(s,2H), 3.18(s, 6H); MS(FAB,NBA) m/e (relative
intensity) 605(M++1, 100). Anal. Calcd for C32H24N6O7 •3/2 CH3COOC2H5: C, 61.99;
H, 4.93; N, 11.41. Found: C, 61.36; H, 4.52; N, 11.96.
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8-Chloro-5-methyl-6-Oxo-5,6-dihydro-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]dizaepine-3-carboxylic acid (41). The ester 40 (2 g, 6 mmol) was dissolved in EtOH
(150 mL) to form a solution and then 10% aq sodium hydroxide solution (40 mL) was
added to the mixture. The mixture was heated to reflux for 0.5 h and the EtOH was
removed under reduced pressure, after which the solution was allowed to cool. The pH
was then adjusted to 4 by adding 10% aq HCl dropwise. The solid which precipitated
was filtered and the solid acid was washed with water and ether. The solid was dried to
provide acid 41: mp >260oC; IR (neat) 3100, 2424, 1661, 1642, 1562 cm-1; 1H NMR
(300 MHz, DMSO) δ 8.35 (s, 1H), 7.77-7.88 (m, 3H), 5.28 (br s, 1H), 4.55 (br s, 1H),
3.09 (s, 3H); MS (EI) m/e (relative intensity) 291 (M+, 44), 273 (61), 245 (100), 230
(47), 217 (62), 75 (37). Anal. Calcd. for C13H10ClN3O3• 0.3CH2Cl2: C, 50.57; H, 3.37;
N, 13.32. Found: C, 50.64; H, 3.25; N, 13.12. This material was used directly in a later
step.
Bis(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3carboxy) diethylene glycol diester 42(SR-II-35). To a solution of carbonyl diimidazole
(0.197g, 1.22 mmol) in anhydrous DMF (8 mL) was added 8-ethynyl-5,6-dihydro-5methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 41 (0.297g,
1.01 mmol). The solution which resulted was stirred for 2 h at rt until analysis by TLC
(silica gel) indicated the absence of starting material. To the solution which resulted was
then added diethylene glycol (48 mg, 0.46 mmol) in dry DMF (0.5 mL) and also DBU
(186mg, 1.22 mmol) in dry DMF (0.10 mL) at rt. The mixture was stirred at rt for 8 h
until analysis by TLC (silica gel) indicated the reaction was complete. The reaction
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mixture was then poured into ice water (30 mL) and extracted with CH2Cl2 (3 x 50 mL).
The combined organic layer was washed with H2O (5 x 50 mL), brine and dried
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified
by flash chromatography (silica gel, EtOAc/CH3OH, 4: 1) to provide 41 (177 mg) as a
1

white solid in 60% yield. 41: H NMR (300 MHz, CDCl3) δ 8.03 (d, 2H, J=2.4Hz),
7.83(s, 2H), 7.72(dd, 2H, J=3.3 Hz and J=9.3 Hz) , 7.40 (s,1H), 7.35(s, 1H), 5.18 (br,
2H), 4.55 (s,4H), 4.36 (br, 2H), 3.93 (t, 4H, J=4.8 Hz), 3.26 (s,6H); MS (EI) m/e 652
(M+).
7-Chloro-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (45): A mixture
of 5-chloroisatoic anhydride 44 (20g, 101 mmol) and sarcosine (9.02g, 101 mmol) in
DMSO (160mL) was heated at 150°C for 5 hr, after which it was cooled to rt and poured
into ice water (750mL) to furnish a light brown solid. This solid was collected by
filtration, washed with water (3x200mL) and dried (Na2SO4). The benzodiazepine 45
was obtained as a light brown solid (19g, 84%). This material was used directly in the
next experiment.
Ethyl-8-chloro-5, 6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-][1,4]benzodiazepine3carboxylate (40): t-BuOK (8.99 g, 80.14 mmol) was added to a solution of amide 45
(15 g, 66.77 mmol) in anhydrous THF (1500 mL) at 0 °C and the solution allowed to stir
for 20 min. The reaction mixture which resulted was cooled to –35 °C and diethyl
chlorophosphate (12.48 mL, 86.80 mmol) was added slowly. After stirring at 0 °C for 30
min, the mixture was cooled to –78 °C and ethyl isocyanoacetate (8.027 mL, 73.44
mmol) was added and this was followed by the addition of t-BuOK (8.24g, 73.44
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mmol). After stirring at rt for 4 h, the reaction mixture was quenched with a saturated aq
solution of NaHCO3 (500 mL) and extracted with EtOAc (3 × 1000 mL). The combined
organic layers were dried (Na2SO4) and concentrated to give a solid residue. This solid
residue was treated with Et2O (250 mL) and the ester 40 was precipitated as an off-white
solid. The mother liquor was further purified by flash chromatography on silica gel
(gradient elution, 40– 60%, EtOAc in hexane) to afford additional ester 40 with an
overall yield of (19g, 89%). mp 192-193 °C; 1H NMR (CDCl3, 300MHz) δ 8.1 (d, 1H, J
= 2.4 Hz), 7.90 (s, 1H), 7.62 (dd, 1H, J = 8.7, 2.5 Hz), 7.40 (d, 1H, J = 8.6 Hz), 5.23
(br, s, 1H), 4.46 (q, 2H, J=7.12Hz), 4.13 (br, s, 1H), 3.27 (s, 3H), 1.47 (t, 3H, J=7.12Hz);
MS (EI) m/e 319 (M+, 100). The data for this material were identical to the published
values.161
8-Chloro-5,

6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4]benzodiazepine-3-

methyl alcohol (46). A solution of imidazobenzodiazepine 40 (5 g, 15.6 mmol) in a
mixture of ethyl ether (50 mL), and THF (50 mL) was stirred with LiBH4 (2.0 M in
THF, 9 mL, 18 mmol). The mixture which resulted was then heated to reflux for 30 min,
after which it was cooled to rt and treated with a saturated aq solution of NaHCO3 (5
mL). The solvent was concentrated and the residue was taken up in EtOAc (100 mL).
The organic layer was washed with water (2 × 20 mL), brine (20 mL) and dried
(MgSO4). After removal of the solvent under reduced pressure the residue was purified
by flash chromatography (silica gel, EtOAc) to afford alcohol 46 as colorless crystals
(2.9 g, 67%): mp 252-253 °C; IR (KBr) 3500 (br, OH), 3100, 1667, 1612, 823 cm-1; 1H
NMR (CDCl3, 300MHz) δ 8.00 (d, 1H, J = 2.4 Hz), 7.80 (s, 1H), 7.55 (dd, 1H, J = 8.7,
2.4 Hz), 7.30 (d, 1H, J = 8.6 Hz), 4.70 (d, 2H, J = 4.2 Hz), 4.40 (s, 2H), 3.20 (s, 3H);
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MS (EI) m/e 279 (M+, 41), 277 (M+, 100), 259 (84), 246 (55), 231(41). The data for this
material were identical to the published values.19
Methyl(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4]
benzodiazepin-3-yl)methyl ether (47). To a slurry of KOH (2.41g, 44 mmol) in DMSO
(56 mL) at rt were added alcohol 46 (3g, 11 mmol) and excess CH3I. The mixture which
resulted was stirred for 5-10 min and then poured into ice water (100 mL) after which it
was extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed
with brine (50mL) and dried (MgSO4). After removal of solvent under reduced pressure,
the residue was purified by a wash column on silica gel (EtOAc) to give ether 47 (PWZ029) as an off-white powder (2.83g, 90%): mp 193-194 °C; IR (KBr) 3122, 2973, 1632,
1611, 811 cm-1; 1H NMR (CDCl3, 300MHz) δ 8.00 (d, 1H, J = 2.4 Hz), 7.80 (s, 1H),
7.55 (dd, 1H, J = 8.7, 2.5 Hz), 7.30 (d, 1H, J = 8.6 Hz), 4.55 (br, 2H), 4.38 (s, 2H), 3.42
(s, 3H), 3.18 (s, 3H). The data for this material were identical to the published values.
Ethyl (8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4] benzodiazepin3-yl)methyl ether (48). To slurry of KOH (2.41g, 44 mmol) in DMSO (56 mL) at rt
were added alcohol 46 (3g, 11 mmol) and excess C2H5I. The mixture which resulted was
allowed to stir for 5-10 min, poured into ice water (100 mL), and extracted with EtOAc
(3 × 100 mL). The combined organic extracts were washed with brine (50mL) and dried
(MgSO4). After removal of the solvent under reduced pressure the residue was purified
by a wash column on silica gel (EtOAc) to give ether 48 (SR-III-81) as an off-white
powder (2.98g, 90%): mp 137-138 °C; IR (KBr) 31282, 2973, 1634, 1601, 810 cm-1; 1H
NMR (CDCl3, 300MHz) δ 7.92 (d, 1H, J=2.4Hz), 7.86 (s, 1H), 7.50 (dd, 1H, J=8.5, 2.4
Hz), 7.30 (d, 1H, J=8.6Hz), 4.55 (s, 2H), 3.60 (q, 2H, J=7.0Hz), 3.12 (s, 3H), 1.22 (t,
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3H, J=7.0Hz). Anal. Calcd. For C15H16ClN3O2. 0.0235 H2O, C 58.84, H 5.28, N
13.72. Found 58.94, H 5.40, N 13.32
8-Chloro-N,5-dimethyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo-[1,5a][1,4]diazepine-3-carboxamide( 57): The ester 40 (100mg, 0.313 mmol) was
dissolved in anhydrous CH2Cl2 (5mL). To this mixture, a solution of CH3NH2
(0.147mL, 1.56 mmol) was added. This reaction mixture (in a sealed tube) was placed in
a preheated oil bath at 45°C overnight. The solvent was then removed under reduced
pressure and the residue was purified by flash chromatography with CH2Cl2/MeOH
(4.5:0.5) to provide 3-N-methyl amide 57 (74mg, 78% yield).

1

H NMR (CDCl3,

300MHz) δ 8.1 (d, 1H, J = 2.4Hz), 7.90 (s, 1H), 7.62 (dd, 1H, J = 8.6, 2.5 Hz), 7.40 (d,
1H, J = 8.6Hz), 5.23 (br, 1H), 5.23 (br, 1H), 3.28 (s, 3H), 3.02 (d, 3H, J=3.9Hz) ; MS
(EI) m/e 304 (M+, 100). Anal. Calcd. For C14H13ClN4O2 . 0.28 H2O, C 54.25, H 4.41,
N 18.07. Found 54.39, H 4.52, N 17.69
8-Chloro-3-(fluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-6(5H)one (58) : The alcohol 46 (100mg, 0.360mmol) was dissolved in anhydrous CH2Cl2 (5
mL). At 0oC, DAST (diethylaminosulfur trifluoride, 0.07mL, 0.720mmol) 162 was added
very slowly and the reaction was allowed to stir for 2h. The reaction mixture was then
quenched with aq solution of NaHCO3 and allowed to stir for 1h at 0oC and then
extracted with CH2Cl2. The combined organic layers were washed with brine and dried
(MgSO4). After removal of the solvent under reduced pressure the residue was purified
by a wash column on silica gel (gradient elution 4:1 EtOAc: hexane) to afford the fluoro
analog 58 (SR-III-38; 0.070mg, 70%). 1H NMR (CDCl3, 300MHz) δ 8.05 (dd, 1H,
J=2.3Hz, 1.4Hz), 7.89 (d, 1H, J=1.4Hz), 7.62 (m, 1H), 7.37 (dd, 1H, J = 8.4, 1.2 Hz),
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5.57 ( s, 1H), 5.41 (s, 1H), 4.40 (br, 2H ), 3.25 (d, 3H, J=1.3Hz);

19

F NMR (CDCl3,

282MHz) δ -205.21 (t, 1F, J=52Hz); MS (EI) m/e 279 (M+, 100). Anal. Calcd. For
C13H11ClFN3O.0.13 (C2H5)2O, C 56.11, H 4.28, N 14.54. Found 55.86, H 3.97, N 14.17
8-Chloro-3-(difluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin6(5H)-one 49: The alcohol 46 (1g, 3.6mmol) was dissolved in dry CH2Cl2 (100mL) and
Dess-Martin periodinane163 (2.29g, 5.41mmol) was added in one portion at 0oC. This
solution which resulted was stirred at rt for 2 h. The reaction mixture which resulted
was then quenched with a saturated aq solution of Na2S2O3, washed with NaHCO3 and
extracted with CH2Cl2. The combined organic layers were washed with brine and dried
(MgSO4). After removal of the solvent under reduced pressure, the residue was purified
by a wash column on silica gel (gradient elution 1:9 EtOAc: hexane ) to afford the
aldehyde 59 (0.953g, 96%). 1H NMR (CDCl3, 300MHz) δ 10.35 (s, 1H), 8.09 (d, 1H
,J=2.43Hz), 7.94 s, 1H), 7.64 (dd, 1H, J=8.55, 2.41Hz), 7.41 (d, 1H, J=8.6Hz), 5.23 (br,
s, 1H), 4.6 (br, s, 1H), 3.25 (s, 3H); HRMS (ESI) calculated for C13H11ClN3O2 :
276.0540; found : 276.0536 The aldehyde 59 (100mg, 0.363mmol) was dissolved in
anhydrous CH2Cl2 (5 mL). At 0oC DAST (diethylaminosulfur trifluoride, 0.07mL,
0.725mmol) was added very slowly and the reaction was allowed to stir for 2h at 0oC.
The reaction mixture was then quenched with an aq solution of NaHCO3 and allowed to
stir for 1hr and extracted (CH2Cl2). The combined organic layers were washed with
brine and dried (MgSO4). After removal of the solvent under reduced pressure, the
residue was purified by a wash column on silica gel (gradient elution 4:1 EtOAc:
hexane) to afford the difluoro analog 49 (0.070mg, 65%). 1H NMR (CDCl3, 300MHz) δ
8.05 (dd, 1H, J=2.4Hz), 7.88 (s, 1H), 7.62 (dd, 1H, J = 8.6 Hz, 2.4 Hz), 7.37 (d, 1H, J =
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8.5Hz), 6.83 (t, 1H, J=55Hz), 4.55 (d, 1H, J= 14Hz), 4.45 (d, 1H, J=14Hz), 3.2 (s, 3H);
13

C NMR (CDCl3, 300MHz) δ 35.41, 42.01, 112.52 (t, J = 234Hz), 123.2, 128.11,

130.38 (d, J=31.8Hz), 132.43, 132.67, 134.50, 134.80, 165.14;

19

F NMR (CDCl3,

282MHz) δ -111.76 (dd, J(F-F)=309Hz, J(H-F) =55Hz), -109.78 (dd, J(F-F)=309Hz, J(H-F)
=55Hz); HRMS (ESI) Calculated for C13H11ClF2N3O : 298.0559; found: 298.0561.
8-Chloro-3-(difluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin6(5H)-one 60: The acid 41 (300mg, 1.02 mmol) was dissolved in dry CH2Cl2 (5mL) and
at 0oC, excess SOCl2 was added in one portion. The reaction mixture was heated to
reflux for 2h until analysis of the mixture by TLC indicated the absence of starting
material. The reaction mixture was concentrated under reduced pressure on a rotavapor a
few times with CH2Cl2 to remove the excess SOCl2 and dried under vacuum. The solid
which resulted was stirred in dry THF at -60oC. In a separate flask, bis[2-(N,Ndimethylamino)ethyl] ether37 (0.239mL, 1.25mmol) was stirred in dry THF (5mL) and at
0oC, EtMgBr (0.419mL, 1.25mmol) was slowly added over 15min. After stirring the
reaction mixture for 5min, the mixture which resulted was quenched with an aq solution
of NH4Cl and extracted with EtOAc (3x10mL). The combined organic layers were
washed with brine and dried (MgSO4). After removal of the solvent under reduced
pressure the residue was purified by a wash column on silica gel (gradient elution 4:1
EtOAc: hexane) to afford the ketone 60 (0.167g, 53 %). HRMS (ESI) Calculated for
C15H14ClN3O2 : 304.0853; found:304.0861. The ketone 60 (100mg, 0.360mmol) was
dissolved in anhydrous CH2Cl2 (5 mL). At 0oC, DAST (diethylaminosulfur trifluoride,
0.07mL, 0.720mmol) 162 was added very slowly and the reaction was allowed to stir for
2h. No product formation was observed. Addition of excess DAST (diethylaminosulfur
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trifluoride) did not work either. When various fluorinating agents such as Xtal-fluor or
Deoxo-fluor were employed they did not yield the product. Excess addition of these
fluorinating agents also was futile.

9. Computer Modeling
The core structures of the ligands were taken from available X-ray crystallographic
coordinates or generated using the SYBYL fragment library.164 The structures which
resulted were energy minimized using MM2 (molecular mechanics program 2) or
MMFF (Merck molecular force field), and the subsequent Monte Carlo conformational
searches were carried out on MacroModel 6.0 on a Silicon Graphics Personal Iris 4D/35
workstation or a Silicon Graphics Octane SI 2P 175 R10000 workstation, respectively.
The low energy conformations were then fully optimized via molecular orbital
calculations at the 3-21G basis set with torsional angles fixed. The structures which
resulted were further calibrated with 6-31G* single point calculations at an
“SCF=TIGHT” convergence criteria via Gaussian 92165 on a Silicon Graphics Indigo
R4400 workstation, or Gaussian 94166 on a Silicon Graphics Octane SI2P175R10000
workstation.43

9.1. Competition Binding Assays (With Dr. Majumder and Dr. Roth)
Competition binding assays were performed in a total volume of 0.5 mL at 4 °C for 1 h
using [3H] flunitrazepam as the radiolabel. A total of 6 µg of cloned human GABAA
receptor DNA containing the desired α subtype along with the β2 and γ2 subunits were
used for transfecting the HEK 293T cell line using Fugene 6 (Roche Diagnostic)
transfecting reagent. Cells were harvested 48 h after transfection, washed with Tris-HCl
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buffer (pH 7.0) and Tris Acetate buffer (pH 7.4) and the resulting pellets were stored at 80 °C until assayed. On the day of the assay, pellets containing 20-50 µg of GABAA
receptor protein were resuspended in (50 mM Tris-acetate pH 7.4 at 4 °C) and incubated
with the radiolabel as previously described.167 Nonspecific binding was defined as
radioactivity bound in the presence of 100 μM diazepam and represented less than 20%
of total binding. Membranes were harvested with a Brandel cell harvester followed by
three ice-cold washes onto polyethyleneimine-pretreated (0.3%) Whatman GF/C filters.
Filters were dried overnight and then soaked in Ecoscint A liquid scintillation cocktail
(National Diagnostics; Atlanta, GA). Bound radioactivity was quantified by liquid
scintillation counting. Membrane protein concentrations were determined using an assay
kit from Bio-Rad (Hercules, CA) with bovine serum albumin as the standard.

10. Experimental procedures for the electrophysiology using the twoelectrode voltage clamp (with Dr. R. Furtmüller and Dr. W.
Sieghart)168-171
Ligand effects on GABAA receptors were tested by two-electrode voltage clamp
experiments in cRNA injected Xenopus oocytes that functionally expressed several
subtype combinations of GABAA receptors.168
10.1.1 Preparation of cloned mRNA
Cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8 expression vectors
(Invitrogen, CA) has been described elsewhere.172 GABAA receptor subunit α4 was
cloned in an analogous way. cDNAs for subunits α2, α3 and α5 were gifts from P.
Malherbe and were subcloned into a pCI-vector. cDNA for subunit α6 was a gift from P.
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Seeburg and was subcloned into the vector pGEM-3Z (Promega). After linearizing the
cDNA vectors with appropriate restriction endonucleases, capped transcripts were
produced using the mMessage mMachine T7 transcription kit (Ambion, TX). The
capped transcripts were polyadenylated using yeast poly(A) polymerase (USB, OH) and
were diluted and stored in diethylpyrocarbonate-treated water at –70 °C.
10.1.2 Functional expression of GABAA receptors
The methods used for isolating, culturing, injecting and defolliculating of the oocytes
were identical to those as described previously.109,168,173 Briefly, mature female Xenopus
laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-maminobenzoate, Sigma, MO) before decapitation and removal of the frog ovary. Stage 5
to 6 oocytes with the follicle cell layer around them were singled out of the ovary using
a platinum wire loop. Oocytes were stored and incubated at 18 °C in modified Barths
medium (MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM
NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM Ca(NO3)2) that was
supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Oocytes with
follicle cell layers still around them were injected with a total of 2.25 ng of cRNA. This
solution contained the transcripts for the different α subunits and the β 3 subunit at a
concentration of 0.0065 ng/nL as well as the transcript for the γ2 subunit at 0.032 ng/nL.
After injection of the cRNA, oocytes were incubated for at least 36 h before the
enveloping follicle cell layers were removed. To this end, oocytes were incubated for 20
min at 37 °C in MB that contained 1 mg/mL collagenase type IA and 0.1 mg/mL trypsin
inhibitor I-S (both Sigma). This was followed by osmotic shrinkage of the oocytes in
doubly concentrated MB medium supplied with 4 mM Na-EGTA. Finally, the oocytes
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were transferred to a culture dish containing MB and were gently pushed away from the
follicle cell layer which stuck to the surface of the dish. After removal of the follicle cell
layer, oocytes were allowed to recover for at least 4 h before being used in
electrophysiological experiments.
10.1.3. Electrophysiological experiments171,174
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath of
Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 7.4),
1 mM MgCl2, 1 mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a
flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs.
Drugs were diluted into XR from DMSO solutions resulting in a final concentration of
0.1 % DMSO perfusing the oocytes. Drugs were preapplied for 30 sec before the
addition of GABA, which was coapplied with the drugs until a peak response was
observed. Between the two applications, oocytes were washed in XR for up to 15 min to
ensure full recovery from desensitization. For current measurements the oocytes were
impaled with two microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. All
recordings were performed at rt at a holding potential of –60 mV using a Warner OC725C two-electrode voltage clamp (Warner Instruments, Hamden, CT). Data were
digitized, recorded and measured using a Digidata 1322A data acquisition system (Axon
Instruments, Union City, CA). Results of concentration response experiments were fitted
using GraphPad Prism 3.00 (GraphPad Software, San Diego, CA). The equation used for
fitting

the

concentration

response

curves

was

Y=Bottom

+

(Top-

Bottom)/(1+10^((LogEC50-X)*HillSlope)); X represents the logarithm of concentration,
Y represents the response; Y starts at Bottom and goes to Top with a sigmoid shape.
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10.2. Anticonvulsant screen (with Dr. James Stables)174
The standard models incorporated into anticonvulsant screening include the maximal
electroshock test (MES), the subcutaneous Metrazol test (scMET), and evaluations of
toxicity (TOX)-which is sedation in this study. The data for each condition is presented
as a ratio of either the number of animals protected or toxicity (loss of locomotor
activity) over the number of animals tested at a given time point and dose. Experiments
were performed in male rodents (albino Carworth Farms No. 1 mice (intraperitoneal
route, ip) and albino Sprague-Dawley rats (oral route and ip). The mice weighed
between 18 and 25 g, while rats were between 100 and 150 g. All animals had free
access to food and water except during the actual testing period. Housing, handling, and
feeding were all in accordance with recommendations contained in the “Guide for the
Care and Use of Laboratory Animals”. All of the test ligands were administrated in
suspensions of 0.5% (w/v) of methyl cellulose in water. The volumes administered were
0.01 mL/g of body weight for mice and 0.04 mL/10 g for rats. Anticonvulsant activity
was established using the maximal electroshock seizure (MES) and subcutaneous
metrazole seizure threshold (scMET) tests.175,176

10.3. In Vivo Experiments (with S. Lelas)88
10.3.1. Subjects
All animals were maintained in accordance with the guidelines of the Committee on
Animals of the Bristol-Myers Squibb Company and the “Guide for Care and Use of
Laboratory Animals” (Institute of Animal Laboratory Resources, 1996).

Research
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protocols were approved by the Bristol-Myers Squibb Company Institutional Animal
Care and Use Committee.
Male CDF rats weighing approximately 350 g at the time of the experiment (conflict),
male Sprague-Dawley rats weighing 180-300 g (locomotor activity, rotorod studies, and
drug discrimination studies) and male CF1 mice weighing 20-22 g at the time of the
experiment (seizure studies) were purchased from Charles River Laboratories
(Wilmington, Mass., USA). For the conditioned fear studies, male Sprague-Dawley rats
weighing approximately 225 g at the time of the experiment were purchased from
Harlan (Indianapolis, Ind., USA). Animals were housed in pairs or fours in clear plastic
shoebox cages with Beta Chip bedding in rooms maintained at constant temperature (2123°C) and humidity (50 ± 10%) with a 12 h light/dark cycle (lights on at 0600 h, except
for mice lights were on at 0500 h), except for the drug discrimination study for which
animals were housed individually in suspended wire cages.
Animals had ad libitum access to food and water throughout the studies, except for the
conflict and drug discrimination studies in which animals were restricted to 9 g
(conflict) or 12 g (drug discrimination) of laboratory rodent chow (Bio-Serv,
Frenchtown, NJ) per day in addition to the food earned in operant box, with unlimited
access to water. All training and testing was done between 0600 and 1300 h Monday
through Friday of each week.
10.3.2. Procedures
10.3.2.1. GABAA Binding Assay
HEK293 cells were trypsinized and counted. Cells were transfected using the Amaxa
electroporator and 3 million cells per sample. Each transfection was performed in
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Amaxa solution “V” using electroporation program Q-01 (Amaxa Inc., Gaithersburg,
Md., USA). 1 µg of each GABA subunit (α, β, and γ) was used per transfection.
Following electroporation, cells were plated onto poly-lysin coated glass coverslips and
used for the experiments.
10.3.2.2. Electrophysiological Studies
Whole-cell patch-clamp experiments were performed using HEK cell lines transiently
expressing two different configurations of GABAA constructs, on the first or second day
after the transfection. Cells were plated onto 25 mm Petri dishes and viewed using
Nikon TE200 inverted microscope, equipped with the mercury lamp to monitor GFP
fluorescence. Cells were continuously perfused with extracellular physiological solution
containing (in mM): NaCl 140, KCl 2.5, CaCl2 2, MgSO4 2, Na2HPO4 1.25, HEPES 10,
Glucose 11, pH 7.4 and 340 mOsm (modified from Brown et al., 2002). Patch pipettes
were pulled using Narishige vertical puller from fire-polished borosillicate glass
capillaries. Pipette resistance was between 3.5 and 6 MOm. The intracellular solution
contained (in mM): CsCl 140, HEPES 10, EGTA 5, MgATP 2, MgCl2 3, pH 7.3 and 340
mOsm.
Cells were voltage-clamped at -20 mV via an EPC10 amplifier (HEKA Electronics,
Southboro, Mass.). Preliminary experiments have shown that amplitude of the GABAinduced current in these cells was not significantly different at -60, -40 or -20 mV
holding potentials.

At the same time, -20 mV holding potential facilitated longer

experimental time which enabled testing of several concentrations of the test
compounds. Drug solutions were applied to the cells via a multi-channel local perfusion
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system (AutoMate Scientific, Inc., San Francisco, Calif.) with the estimated solution
change time of 20 ms.
GABA was applied to the cell for 20 s with a 60 s washout period between applications,
which was found to be a sufficient time period to reverse any desensitization that may
occur. In addition, to ensure that there is no desensitization that may affect GABA
responses at any given concentration of a GABA modulator, GABA was applied twice
during control (no drug) and once at each concentration of the test compound. Test
compounds were applied in increasing concentrations (1, 10, 100, or 1000 nM) 60 s
prior to GABA (3 µM) applications.
10.3.3. Geller Conflict with Incremental Shock in Rats
Experiments were conducted in 8 model E10-10 Coulbourn operant chambers
(Coulbourn Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) with an electrified
grid floor which were housed in light-proof, sound-attenuated, and fan-ventilated
chambers. On one wall of each operant chamber is a house light and a centrally placed
food hopper 3 cm from the floor that delivered one 45-mg food pellet (Dustless
Precision Pellets, Bio-Serv, Frenchtown, N.J., USA). To the left was mounted a lever
response module with cue lights above. Foot-shock was delivered using an H13-16
Universal Shocker. Experiments were controlled with a Compaq DeskPro computer
running Graphic State Notation software through Habitest Universal Linc interface
equipment (Coulbourn Instruments).
Rats were trained to stability on an alternating multiple Random Interval 30 s/Fixed
Ratio 1 Food +Shock paradigm (RI15/FR1 F+S). The paradigm ran through four cycles
beginning with the Random Interval (RI) schedule which ran for 12 minutes then
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switched to the Fixed Ratio (FR) schedule which was cued and ran for 3 minutes. The
RI had a range of 15 to 45 s with the food pellet being delivered with the first lever press
after the expiration of the interval. The FR schedule delivered a food pellet after each
lever press along with a foot-shock that increased with each lever press beginning at
zero on the first lever press then increasing to 0.05 mA on the second lever press and
incrementing by 0.05 mA with each subsequent lever press. The shock was reset to zero
at the beginning of each RI/FR cycle.
10.3.4. Protection against Pentylenetetrazole- and Shock-Induced Seizures in Mice
Pentylenetetrazole (PTZ) was administered at 125 mg/kg s.c. The number of animals
surviving was recorded at 30 minutes and 60 minutes after administration of PTZ.
Electroshock is administered using an Ugo Basile ECT, Unit 7801 seizure apparatus
(Ugo Basile, Italy) and corneal electrodes soaked in 0.9% saline. Mice received a shock
of 30 mA for 0.3 s. The number of animals that exhibited the hind-limb extensor
component of the seizure was recorded.
10.3.5. Conditioned Fear in Rats
Experiments were conducted in standard modular test chambers (ENV-008, Med
Associates, St. Albans, Vt., USA, 30.5 x 24.1 x 21 cm) with an electrified grid floor
which were housed in light-proof, sound-attenuated, and fan-ventilated chambers. Footshock was delivered using a shocker/scrambler module (ENV-414). Experiments were
controlled with a desktop computer using Med-PC software through Smart Ctrl
interface equipment (Med-Associates).
On day 1, rats were placed in the test chambers for a 7-minute conditioning session
consisting of 2.5 minutes of habituation, a 2-s foot-shock at 0.7 mA, followed by 2.5
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minutes of no foot-shock, another 2-s, 0.7 mA foot-shock, and another 2 minutes with
no foot-shock. Twenty-four hours after the conditioning session, rats were placed in the
test chamber again for 7 minutes with no foot-shocks and percent time freezing was
quantified by video image analysis (Freezeview software using filter 25 and bout length
of 0.75 s; Actimetrics and Coulbourn Instruments, Allentown, Penn., USA).
10.3.6. Spontaneous Locomotor Activity in Rats
The testing apparatus consisted of Plexiglas chambers (42 x 42 x 30 cm) equipped with
Digiscan activity monitors (Omnitech Electronics, Columbus, Ohio, USA) that detect
interruptions of eight photobeams spaced 5 cm apart and 2.5 cm above the floor.
Horizontal activity was recorded in 5-minute bins for a total of 60 minutes and
expressed as total distance covered (in cm).
10.3.7. Rotorod Performance in Rats
The degree of motor coordination or balance was determined using a standard
accelerating rotorod treadmill (Ugo Basile, Comerio-Varese, Italy) that was 6 cm in
diameter and 24 cm above the base. The speed was increased gradually from 2 rpm to a
maximum speed of 20 rpm. The time each animal remained on the rotating rod was
automatically recorded, up to a maximum of 5 minutes. Three acclimation trials were
conducted for each animal prior to administration of drugs. The time on rotorod from
the third trial was used to counterbalance animals for subsequent drug testing.
10.3.8. Chlordiazepoxide Discrimination in Rats
Twelve model E10-10 Coulbourn operant conditioning chambers (Coulbourn
Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) were housed in light-proof,
sound-attenuated, and fan-ventilated chambers. Each operant conditioning chamber was
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equipped with two non-retractable levers, requiring a downward force equivalent to 15 g
(0.15 N), that were mounted 3 cm from the side wall, 3 cm above the metal grid floor,
and 5 cm from a centrally placed food tray that delivered one 45-mg food pellet
(Dustless Precision Pellets, Bio-Serv, Frenchtown, N.J.). The experimental chambers
were connected to a Micro PDP11/73 computer using a LAB LINC interface. A SKED11 operating system (State System, Kalamazoo, Mich.) was used to record and control
behavior.
After habituation to the operant conditioning chamber, rats were trained to alternate
daily between response levers on an FR 1 schedule of food reinforcement. Once lever
pressing was well established, the reinforcement contingency was increased
incrementally to an FR 10 schedule of food reinforcement, while maintaining the lever
alternation.

Rats were then trained to discriminate between an intraperitoneal (IP)

injection of drug (5.0 mg/kg CDP) and vehicle (0.25% methylcellulose) administered 30
minutes prior to the start of the session. Ten consecutive responses on the injectionappropriate lever resulted in food delivery. Responses on the incorrect lever did not
result in pellet delivery. Following an injection of CDP, responding on the right lever
was reinforced for half the rats and responding on the left lever was reinforced for the
other rats. In each two-week period there were five drug days and five saline days, with
the constraint that there not be more than three consecutive drug or vehicle days.
Drug test sessions were conducted once a week (Fridays) with training sessions
scheduled on intervening days (Monday – Thursday). The criterion for testing was
achieved if no more than three incorrect responses occurred prior to the first reinforcer
for at least 9 out of 10 consecutive sessions. During test sessions, the lever on which the
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rat first made 10 consecutive responses resulting in delivery of the first food pellet was
designated the “selected “ lever and subsequent pellet delivery was made contingent on
responding on this selected lever on an FR10 schedule. The selected lever, the number
of responses prior to the first food pellet delivery, and the total number of responses in
the session were recorded for each rat. The duration of test sessions was ten minutes.
Dose-response functions were determined for CDP, diazepam, and QH-ii-066.

11. Experiments of GABA signaling in neuroblastoma (Weiss and Cook
et al.)89
11.1. Methods Summary:
Backcross mice were generated by crossing TH-MYCN transgenic FVB/N mice to wildtype 129/SvJ, and subsequently crossing F1 offspring to wild-type 129/SvJ. Mice were
observed for at least one year to be considered tumor-free. DNA was isolated from
spleen and genotyped using a combination of microsatellite and SNP markers. RNA
from SCG was analyzed using Affymetrix Mouse Exon arrays. Susceptibility linkage
was analyzed using R-QTL.

Differential gene expression was assessed using

Significance Analysis of Microarrays, and eQTL were calculated using custom software
as described previously.
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11.2. Supplementary Methods:

11.2.1. Mice All mice were obtained from the Jackson Labs (Bar Harbor, ME), and
were housed and treated following UCSF IACUC guidelines. Tumor-negative backcross
mice were followed until one year of age (the latest tumor was detected at 342 days).
Superior cervical ganglia (SCG) were surgically isolated and snap-frozen in liquid
nitrogen. SCG were isolated from the parental control groups at 21 days.
11.2.2. Taqman analysis of transgene expression: Taqman expression analysis was
performed on 6 mice (3 female, 3 male) from each strain. Proprietary assays for human
MYCN and controls L18 and mGUS were obtained from Applied Biosystems (Carlsbad,
CA).
11.2.3. Genotyping DNA was isolated from spleen tissue using a proteinase K lysis
followed by phenol chloroform extraction.

Microsatellite marker genotyping was

carried out by the Marshfield Clinic (Marshfield, WI), and CIDR (Baltimore, MD).
SNP genotyping was performed using template-directed primer extension with
fluorescence polarization detection (FP-TDI, Acycloprime II, Perkin Elmer, Waltham,
MA) and SNPStream2 48-plex (Beckman Coulter, Brea, CA). The marker set had an
average spacing of 8 MB genome-wide (excluding the high density of markers on
chromosome 10).
11.2.4. Linkage analysis Interval mapping was performed using the R-QTL3 package
in the R statistical language. Genotypes flagged as probable errors by R-QTL were
discarded. The genetic map positions were determined using the physical map positions
(NCBI 37/mm9), followed by re-estimation of the map using R-QTL, and likely mis-
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mapped markers were discarded. Linkage analysis was performed on a 1-cM grid.
Genome-wide significance thresholds were determined by running 1000 permutations
for each dataset. Interval analysis was performed using the binary mode of the “EM”
model. All results reported as significant were significant at a 5% genome-wide error
rate. 95% confidence intervals (CI) were determined using the lodint function in RQTL. Genes within the confidence intervals were determined by counting all genes in
the UCSC genome assembly mapping between markers flanking the 95% CI.
11.2.5. Expression Arrays RNA from superior cervical ganglia was isolated using the
RNEasy kit (QIAGEN, Valencia, CA), as we found these buffers were more effective at
disrupting the ganglia than Trizol. 1µg of RNA was used as a starting template for the
RiboMinus rRNA subtraction (Invitrogen, Carlsbad, CA) followed by the ST labeling
protocol (Affymetrix, Santa Clara, CA).

Labeled samples were hybridized to

Affymetrix Mouse Exon 1.0 arrays. Array quality control was performed using the
Affymetrix Expression Console. 2-way comparisons between homogenous groups (e.g.
male vs. females or 129/SvJ vs FVB/N males) were performed using the Significance
Analysis of Microarrays (SAM) package4 using a 5% false discovery rate.
11.2.6. eQTL analysis

Arrays were normalized using RMA in the XPS package

(http://www.bioconductor.org/packages/2.6/bioc/html/xps.html). eQTL were calculated
as described in 5; briefly, linkage between gene expression and loci was assessed by
linear regression with genome-wide significance assessed using a FDR-based method.
11.2.7. Cell Culture Neuroblastoma cell lines were grown in RPMI media with 10%
serum and antibiotics with the exception of SK-N-BE(2) (DMEM/F12, 10% serum) and
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IMR-32 (DMEM, 10% serum plus non-essential amino acids).

Nor-NOHA was

obtained from Bachem (Torrance, CA) and dissolved in DMSO. GABA was obtained
from Sigma (St. Louis, MO) and dissolved in H2O. Picrotoxin and bicuculline were
obtained from Sigma and dissolved in DMSO.
11.2.8. Western blotting

Equal amounts of total protein were loaded for 4%–12%

SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes.
After blocking, membranes were blotted with Arg1 (R&D Systems, Minneapolis MN),
GABA B R1, Erk (Santa Cruz Biotech, Santa Cruz, CA) , GABA A Rβ2/3, GABA B
R2, β-tubulin (Millipore, Billerica, MA), cleaved-PARP (Asp214), p-Akt (Ser473), Akt,
pErk (Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA), and GAPDH
(Upstate Biotechnology, Lake Placid NY). Antibodies were detected with HRP-linked
anti-mouse,

anti-rabbit

(Amersham/GE,

Piscataway,

NJ),

or

anti-sheep

IgG

(Calbiochem/EMD, Gibbstown, NJ), followed by enhanced chemiluminescence
(Amersham/GE, Piscataway, NJ).
11.2.9. WST-1 assay Cells were grown in 12-well plates and treated for 72 hours prior
to the addition of WST-1 reagent (100µl per 1ml media). Absorbance was read after 60
minutes.

Results were plotted using Graphpad Prism software, and p-values were

calculated using a two-tailed Student’s t-test.
11.2.10. FACS

Cells were plated on 6-well dishes and treated as indicated for 24

hours. They were then harvested, fixed in 70% ethanol for 30 minutes, then stained with
a propidium iodide (PI) dye and RNase solution. All samples were analyzed on a
FACSCaliber flow cytometer (Becton Dickenson, Franklin Lakes, NJ) and analyzed
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using ModFit (Verity Software, Topsham ME).

Apoptosis was detected by flow

cytometry for annexin V-FITC per manufacturer’s protocol (Annexin V-FITC detection
kit, BioVision, Milpitas, CA) using FlowJo software (Tree Star, Inc, Ashland, OR).

12. Behavioral experiments (with Savic et al.)154
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, Serbia),
weighing 220-250 g. All procedures in the study conformed to EEC Directive 86/609
and were approved by the Ethical Committee on Animal Experimentation of the Medical
Faculty in Belgrade. The rats were housed in transparent plastic cages, six animals per
cage, and had free access to pelleted food and tap water. The temperature of the animal
room was 22±1ºC, the relative humidity 40-70%, the illumination 120 lux, and the 12/12
h light/dark period (light on at 6:00 h). All handling and testing took place during the
light phase of the diurnal cycle. Throughout the study the animals were used only once,
with the exception of the grip strength measurement, which was done immediately after
the tracking of behavior on the elevated plus maze. Spontaneous locomotor activity and
elevated plus maze behavior were analyzed by the ANY-maze Video Tracking System
software (Stoelting Co., Wood Dale, IL, USA). All drugs were dissolved/suspended with
the aid of sonication in a solvent containing 85% distilled water, 14% propylene glycol,
and 1% Tween 80, and were administered intraperitoneally in a volume of 1 ml/kg, 15
min before behavioral testing (for active and passive avoidance test, before the
acquisition session). Time of administration, as well as, the doses of DMCM in various
tests were chosen based on our previous studies (Savić et al., 2005a; 2005b; 2006). For
interaction studies in the locomotor activity assay, the first treatment indicated in
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combination was administered into the lower left quadrant of the peritoneum 20 minutes
before testing, and the second treatment 5 minutes later into the lower right quadrant of
the peritoneum.

12.1. Passive Avoidance (PA) Paradigm
The experiments were performed in an adapted Automatic reflex conditioner (Ugo
Basile, Milan, Italy, Model 7051), as described earlier.177

In short, the apparatus

consisted of a shuttle-box, equipped with a grid floor and divided with a sliding door
into a lit and a dark compartment, and a programming unit. The animals were submitted
to two, 24 hour – separated sessions. The acquisition session started by placing
individual subjects in the illuminated compartment. After 30 seconds, the entrance to
the dark compartment was opened, and as soon as the rat had entered it with all four
paws, the footshock (2 s, 0.3 mA) was delivered. Immediately afterwards, the rat was
returned to its home cage. The same procedure was repeated 24 hours later (retention
session), without footshock. A cut-off time of 180 seconds was used on the training day,
whereas, on the retention trial, a ceiling of 300 seconds was imposed.

13. Two-Way Active Avoidance (AA) Paradigm (with Savic
et al.)154
The AA test was performed in automated two-way shuttle-boxes (Campden Instruments,
Sileby, UK), as described earlier.177 In short, the animals were submitted to two, 24-hour
separated sessions. Training and test sessions were procedurally identical. Animals were
placed singly into the shuttle box and left to freely explore for 15 minutes, and
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habituation crossings were automatically counted. Afterward, they received 30 tone foot
shock trials. During the first 5 seconds of each trial, a sound signal was presented
(broadband noise of 69 dB), allowing the animal to avoid shocks by moving to the other
compartment (avoidance response). If the animal did not respond within this period, a
foot shock of 0.5 mA (7-s duration) was applied. Crossing to the adjacent compartment
during the shock discontinued its delivery. The animal could move freely in the
apparatus between trials (18-s intertrial intervals), and the intertrial crossings were
automatically counted.

14. Measurement of Locomotor Activity (with Savic et al.)
Activity of single rats in a clear Plexiglas chamber (40 x 25 x 35 cm) under dim red light
(20 lux) was recorded for a total of 30 minutes, without any habituation period, using
ANY-maze software (as described above). For purposes of improving data analysis, the
central 20% of the chamber (200 cm2) was virtually set as a central zone. The minimum
percentage of animal that must have been in the zone for an entry to occur was set at
70%, and 50% of the animal must have remained in the zone for an exit not to occur.

15. Behavior on the Elevated Plus Maze (EPM) (with Savic
et al.)
The apparatus consisted of two open (50 x 10 cm, with a ledge of 0.3 cm) and two
enclosed arms (50 x 10 x 40 cm), connected by a junction area (10 x 10 cm). The
illumination in the experimental room was 10 lux on the surface of the arms. At the
beginning of the experiment, single rats were placed in the center of the maze, facing
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one of the enclosed arms, and their behavior was recorded for 5 min. An entry into an
open or closed arm was scored when 90% of the animal crossed the virtual line
separating the central square of the maze from the arm, whereas an exit occurred when
more than 90 % of the animal left the respective arm. After each trial, the maze was
cleaned with dry and wet towels.

16. Grip Strength Test (with Savic et al.)
Muscle strength was assessed by the grip strength meter (Ugo Basile, Milan, Italy,
model 47105). When pulled by the tail, the rat grasps the trapeze connected to a force
transducer, and the apparatus measures the peak force of experimenter’s pull (in g)
necessary to overcome the strength of the animal’s forelimbs grip. Each animal was
given three consecutive trials, and the median value was used for further statistics.

16.1. Statistical Analysis
All numerical data presented in the figures were given as the mean ± SEM, except for
results from the PA test (median latency with 25th, 75th interquartile range; data were
non-parametric because the procedure involved a cut-off). For electrophysiological data
Student´s t-test was used for statistical analysis. Data from PA test were assessed by a
Kruskal-Wallis non-parametric ANOVA, with post-hoc comparison relative to solvent
control by a Dunn's test (α=0.05). Data from the AA, EPM, grip strength and activity
assay were assessed by a one-way ANOVA. If the ANOVA was significant, each
treatment condition was compared with control by a Dunnett's test (α=0.05). Where
appropriate, the assessment of the antagonist influence on the inverse agonist effect was

262

conducted by a student’s t-test. Statistical analyses were performed with ANY-maze
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA) and SigmaStat
2.0 (SPSS, Inc., Chicago, IL, USA).

17. In vivo studies on XLi-093 in mice (Rowlett and Cook
et al)55
Subjects
C57BL/6 Male Mice, 6 weeks old, n=8-10 per group

17.1. Drugs
1. Diazepam, Xli-093, flumazenil, bretazenil, and flunitrazepam were injected at doses
between 03. and 30.0 mg/kg, i.p. and dissolved in a 50% PG and 50% distilled water
vehicle
2. [3H]Flumazenil (1.5µCi/30g mouse, i.v), [3H]L655-708 (1.5µCi/30g mouse, i.v.),
both were dissolved in a saline vehicle

17.2. HOLEBOARD MEMORY TASK
Apparatus: Holeboard insert containing 16 holes in a sound attenuated locomotor
activity chamber (Med Associates, Inc.)
Same 4 holes were baited for 4 consecutive 5-min sessions. Baited holes are changed
daily. Mice were trained for 14 days or until they reached criteria. After training, testing

263

with DZ, XLi-093(XLi), DZ+ flumazenil (FLZ), or DZ+XLi-093 began. Performance
was measured as a ratio of the number of novel correct holes (i.e., correct hole visited
only once) /Total holes visited. Perfect performance was indicated by a ratio of 1.0.

17.3. IN VIVO BINDING ASSAY
1. To determine binding site occupancy at α1 and α2/3GABAA receptors, mice were
injected with [3H] flumazenil ([3H]FLZ) (1.5 µCi/mouse, i.v.). Pretreatments (30 min):
DZ (0.3-10.0 mg/kg, i.p.), XLi-093 (0.03-10.0 mg/kg, i.p.), flunitrazepam (30.0mg/kg,
i.p., used to determine non-specific binding). Mice were sacrificed 3 min after i.v.
injection of tritiated ligand.

Cerebellum and spinal cord were quickly removed,

homogenized, and stored in ScintiSafe. All samples were processed with a Packard
1900CA liquid scintillation analyzer.
2. For binding site occupancy at α5GABA(A)receptors, methods followed those above
using [3H]L655,708 (1.5µCi/mouse, i.v.). Non-specific binding was determined using
bretazenil (5.6 mg/kg, i.p.). Mice were sacrificed 1 min after injection with tritiated
ligand and the forebrain was quickly removed and prepared as described above.
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18.

CANTAB

work

(Rowlett

and

Cook

et

al.)155:

Preferential inverse agonist action at α5GABAA receptors
resulted in enhancement of performance on memory
tasks.
18.1. Subjects: Experiments were conducted with adult male rhesus monkeys
(Macaca mulatta), aged 10-15 years (corresponding roughly to “middle aged”
monkeys), born and reared at the New England Primate Research Center breeding
facility.

The monkeys were experimentally naïve at the beginning of the study.

Monkeys were prepared with a non-allergic nylon vest (Lomir) and seated in primate
chairs (Crisp Instruments) enclosed in ventilated, sound-attenuating chambers (Med
Associates); or prepared with the non-allergic nylon vest attached to a flexible, stainless
steel tether (Lomir) connected to the top of the monkey's home cage. The restraint chair
system was used in CANTAB studies, and the tether system was used in ORD,
observational and MAP studies.

All monkeys were housed in a temperature- and

humidity-controlled housing room and maintained on a 12-hr on/12-hr off light/dark
schedule (lights on at 0600 hr). Water was available continuously in the home cage.

18.2. Food availability: The protocol for food restriction developed by Taffe
(2004) was used. Briefly, the monkeys in all studies were weighed weekly, and these
weights were used to calculate food (LabDiet 5038) allotments based on metabolic
energy requirements for rhesus monkeys. The calculation was based on the equation:
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y=15.504x-0.8219, in which y=food biscuits/kg/day and x=body weight in kg (Taffe 2004).
Monkeys were maintained at 100% of this allotment for at least 3 weeks or until weights
are stable (no upward or downward trend over three weight determinations). Once
stable, the monkeys’ food allotments were gradually reduced to 70 to 85% (note that this
was not a reduction in weight, rather a reduction in food allotment), an amount shown to
result in stable and accurate performance in CANTAB tasks. Weekly weighing occured
throughout the studies to adjust feeding (within the 70-85% range) based on a
combination of weight, performance, and overall health (as determined by routine
physical exams conducted by the Clinical Veterinary Staff).

18.3. Surgery and drug delivery: All compounds were administered via the
intravenous (i.v.) route. We used this route in order to minimize pharmacokinetic
variables and to allow direct comparisons with other procedures at Harvard Medical
School (NERPC) designed to study BZ effects in rhesus monkeys (e.g., i.v. selfadministration models of abuse potential).

Monkeys were implanted with venous

catheters using the surgical procedures described by Platt et al. (2005). Surgery was
conducted under aseptic conditions using isoflurane/oxygen anesthesia. Catheters were
passed by way of a jugular, femoral or brachial vein to the level of the right atrium. The
distal end of the catheter was passed subcutaneously to a mid-scapular exit point.
Catheters were flushed routinely with saline containing Heparin (100-150 U/ml), and
physical exams were conducted that occasionally included contrast-dye infusion into the
catheter, followed by X-ray to verify catheter patency and proper placement. Using
these procedures, catheters can remain patent for up to 3 years.
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18.4. General design and data analyses: Separate groups of 6-8 monkeys were
used in the CANTAB vs. the ORD/MAP/observation studies, with each monkey in a
group receiving all treatments whenever possible.
Dependent measures for the studies depended on the individual tasks, as described
below. The studies employed within-subjects design, in which each subject serves as its
own control. This design permits scientifically meaningful results to be obtained with
fewer animals than would be required using most other approaches. For individual
subject analysis, data during test sessions were compared to data from control sessions
and significance of effects were determined on the basis of 95% confidence intervals
established under baseline conditions. For comparison of doses within individual tasks,
repeated-measures ANOVAs were used to evaluate statistical reliability when
warranted. For all studies, multiple comparisons were assessed for statistical reliability
using a priori Bonferroni t-tests, when applicable. Comparisons of drug potencies were
conducted by computing ED50 values (dose engendering 50% of the maximum effect).
The ED50s were computed using non-linear regression analysis techniques.

18.5. CANTAB Tasks in Monkeys.
18.5.1 Apparatus: As described above, monkeys were trained to sit in primate chairs
that will be placed in a sound-attenuating chamber.

Inside this chamber were a

computer-controlled touch-screen monitor (Campden or Lafayette Instruments, Inc,),
equipped with a dispenser to deliver 190-mg flavored food pellets (BioServe, Inc.).
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Experimental events were controlled by the CANTAB software system on a computer in
an adjacent room.

18.5.2. Delayed non-matching to sample (DNMS). The DNMS task was a
short-term recognition memory task involving sets of visual discriminations. A sample
stimulus is presented in the center of the screen, and the animal must touch this stimulus
within 30 sec. After a touch, the screen was blanked and following a variable retention
interval, two stimuli were presented on the lower left and right of the screen. The
retention interval consisted of 0, 1, 3, or 10 min; if performance was highly variable, the
delays were adjusted for individual monkeys based on performance such that short,
medium, and long delays were tested. Of the two “matching” stimuli, one stimulus was
identical to the sample stimulus (“matching” stimulus) and the other was novel (“nonmatching” stimulus). A touch directed to the non-matching stimulus was followed by
reinforcer delivery. In addition to the four retention interval conditions, a simultaneous
condition was included in which the sample stimulus remained present while the
matching and non-matching stimuli were present. A session consisted of 10 trials of
each retention interval, presented in a randomly intermixed fashion (total trials=50).
The CANTAB software used 469 shapes and 7 colors to ensure that discriminations
were unique for approximately 120,000 trials. The primary dependent measured for the
DNMS task are the percent correct responses at each delay and the latency to respond at
each delay.

The number of trials completed also was recorded as a measure of

motivation and/or ability to perform the task.

18.5.3. Paired associated learning (PAL). Large colored abstract stimuli were
displayed in one of 4 positions (top center, bottom center, left middle, right middle).
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The subject was required to touch the sample stimulus, which then disappeared. After a
1-sec delay, the same pattern reappears (choice phase) in two or more locations on the
screen (the original location plus one or more novel locations).

The subject was

required to touch the stimulus that was presented in the same location as the sample item
to obtain a food pellet. Task difficulty was increased by increasing the number of
stimulus-location associations required on each trial.

Training was initiated with

sessions that present 25 1-stimulus trials and 25 2-stimulus trials until performance
averaged >50% correct trials on the 2-stimulus trials. Next, monkeys received sessions
of 25 2-stimulus trials and 25 3-stimulus trials until performance averaged >25% correct
trials on the 3-stimulus trials. This part of the PAL task measured memory for stimuluslocation associations.
Next, a learning component is introduced in which a trial repeats if a mistake was made
in attempting to complete this trial (i.e. the monkey gets 0-2 of 3 stimulus-locations
correct in a 3-stimulus trial). Up to 6 attempts at a given trial were allowed. Finally, 4stimulus trials were added when performance of 3-stimulus trials exceeded 50% correct
(thus, the PAL task measured both memory and learning of stimulus-location
associations). The dependent measures were the percent correct at each difficulty level
and the latencies to respond.

18.5.4. Intradimensional/extradimensional set shifting (ID/ED).

The

ID/ED shift task evaluated the ability of a subject to attend to specific attributes of a
stimulus, as well as the ability to shift attention to other attributes when required. This
task consisted of a series of eight discrimination learning stages wherein touching only
one of two stimuli presented on the screen resulted in food pellet delivery. Within any
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given stage of the task, a pair of stimuli was presented and the same stimulus was
associated with reinforcement (S+ stimulus) until the performance criteria were met (18
of 20 consecutive trials correct). Correct choices must be made within 30 sec, and
following a correct choice the screen was blanked for 5 sec while an incorrect choice (Sstimulus) resulted in a 0.2 sec tone and a 9-sec period of blank screen.

The task consisted of 4 levels of stimulus sets, each progressively more difficult. In the
first stimulus set (Level 1), two distinctly shaped stimuli were presented, with touches
on one shape resulting in food pellet delivery. This level (and all subsequent levels)
included a stimulus reversal, in which the same two shapes are retained but pressing the
S+ stimulus now does not result in reinforcement, whereas touching the former Sstimulus did result in food pellet delivery. In Level 2, a compound discrimination was
presented.

For this discrimination, the two shapes from Level 1 are present, but

additional stimuli, consisted of lines, were superimposed onto the existing shapes.
Because the shape discrimination from the previous stage did not change, the lines are
irrelevant to this discrimination. Level 3 consisted of the intra-dimensional (ID) shift
stage. For this discrimination, two new shapes with new lines were presented. This was
considered an ID shift due to the fact that despite new shapes and lines being introduced,
the shape remained the relevant dimension for the discrimination. In the final level, the
extra-dimensional (ED) shift will be introduced. Thus, in Level 4, new shapes and lines
were presented; however, the lines—not the shape—were the relevant discriminative
stimulus. Performance was determined as the number of errors at each stage, and the
data were subjected to a square root transformation to achieve normal distributions.
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18.5.5. Progressive-Ratio (PR). PR procedures consisted of response requirements
that progressively increased across a session until responding ceases. The last response
requirement completed, termed “break point”, provided a quantitative measure of the
reinforcing effectiveness of a stimulus. For these studies, a session was initiated by a
colored box appearing in the middle of the screen. Touching the box once resulted in
food pellet delivery, and the response requirement were progressively increased
following each reinforcer by an incremental value beginning at 1 and doubling after 8
response requirements were completed successfully. Thus, the response requirement
sequences consisted of: Increment= 1, response requirements= 1, 2, 3, 4, 5, 6, 7, 8;
Increment = 2, response requirements = 10, 12, 14, 16, 18, 20, 22, 24; Increment = 4,
response requirements = 28, 32, 36, 40, 44, 48, 52, 56; and so on. Sessions were a
maximum of 30 min, and were terminated if 3 min elapses without a response.
Performance was measured as the break point and number of food pellets delivered per
session. This procedure provided a measure of the ability of the animal to respond, as
well as an assessment of “motivation” to perform.

18.5.6. Training. Initial training began with shaping the basic response of touching
the screen. A large colored square was displayed that occupied most of the screen.
Touching the screen inside the box was a “correct” response and results in food
reinforcement. With each correct response, the size of the square decreased until the
monkey readily pressed a 1-in box in any location on the screen. This initial training
typically required up to 5 sessions.
Currently 4 monkeys were trained at various stages of the DNMS and ID/ED task.
These monkeys initiated training on PAL (a task that requires a lengthy training period,
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Taffe et al. 2004) with “reminder” trials for DNMS and ID/ED scheduled one day per
week. We anticipated approximately 5-6 more months of training for PAL performance
to reach acceptable performance.
For new monkeys, CANTAB training was initiated by gradually introducing different
tasks, and also incorporate training on the ORD task. In the first phase of training, the
PAL task was introduced 5 days/week. After approximately 6 months, the DNMS task
was introduced on days 1-4 of the week, with PAL training continuing on day 5. In our
experience, DNMS training typically took up to 3 months, once criterion performance
was met, DNMS training was initiated on days 1-3, with PAL training scheduled for
days 4 and 5, respectively. PAL training may take up to and over 12 months, therefore,
after 9 months the ID/ED task was introduced into the sequence once or twice per week
on randomly chosen days (this task did not require special training, Weed et al., 1999).
In the final phase of training, two tasks per day were introduced and the PR schedule
introduced according to the schedule: day 1: PR/PAL; day 2: DNMS/PR; day 3: PAL;
day 4: DNMS/PR; day 5: ID/ED/PR.

Table 20: Schedule of CANTAB tests for a single dose of compound plus vehicle
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18.5.7. Testing. Once training criteria were reached on all tasks, the 8-day cycles
shown in Table 20 were initiated. The two cycles shown in the Table allowed a dose of
test compound and vehicle to be determined twice in all tasks. For each compound,
vehicle plus at least 4 doses were evaluated. All doses of a compound (or dose of
compound plus antagonist) were tested in irregular order, with a compound finished
prior to moving to the next compound. A test session consisted of i.v. injections of
compound(s) at an appropriate pretreatment time prior to the session. Based on the
scheduling shown in Table 20, for CANTAB a dose-response function was required
approximately 10 weeks to complete.

19. Object Retrieval with Detours (ORD) Task.

To augment

CANTAB-based testing, parallel assessments were conducted using the ORD Task,
which was a manual test sensitive to frontostriatal deficits (Taylor et al. 1990; Jentsch et
al. 1999) and has been validated in pharmacological studies at NERPC. The task
required the monkey to retrieve a small piece of palatable food from a transparent box
that was open on one side only. The box was attached to a tray that can be positioned
within easy reach of the monkey. Different levels of task complexity were achieved by
varying the orientation of the open side of the box, the position of the box on the tray,
and the position of the food relative to the opening. The level of cognitive complexity
and motor difficulty of each task was rated a priori using the criteria of Taylor et al.
(1990). The 12 task configurations varied from those characterized by high cognitive
complexity/low motor difficulty to low cognitive complexity/high motor difficulty.

273

Training on the ORD task typically required 14-21 sessions, and tests were scheduled as
described above in Table 20. The primary dependent measure for the ORD task was
“percent success”, which was the total number of reaches minus “incorrect” (i.e., a reach
in which the food item was not obtained) and “barrier” reaches (i.e., a reach in which the
monkey contacted a closed side of the box), divided by total reaches and then multiplied
by 100. Barrier reaches were also analyzed separately as a measure of perseverative
behavior, and reach latencies (i.e., time to obtain food or maximum trial length of 20
seconds) were recorded as a measure of motor impairment.

20. Assessment of Motor Coordination and Behavioral
Effects in Monkeys.
20.1. MAP apparatus and procedure. To evaluate fine motor coordination,
monkeys were trained using the movement assessment panel (MAP) system developed
by Gash and colleagues (Gash et al. 1999). The MAP (Quanteon, Inc.) consists of a
Lexan® box attached to a clear Lexan® panel that was mounted on to home cage
(Figure 41). Portals in the front panel and on the sides of the food receptacle allowed
monkeys to retrieve small food objects (e.g., miniature marshmallows or raisins).
Arrays of photocells are attached to the portals on the front panel (Portal A) and food
receptacle (Portal B). The amount of time that the photobeams for Portal A were broken
was considered a measure of gross motor coordination, whereas the amount of time that
the photobeams for Portal B were broken was considered a measure of fine motor
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coordination (Gash et al. 1999). MAP studies occurred in the home cage of monkeys
prepared with the tether system. The MAP apparatus fit the cage door, and monkeys
received initial training by placing food treats in different parts of the apparatus until
they consistently retrieved treats from the food receptacle.

B

A

Figure 41. Movement Assessment Panel
for rhesus monkeys.

Training occurred 5 days per week until latencies retrieved the treat are stable (no
upward or downward trends over 3 consecutive sessions) and testing occurred on day 2
and day 5 of this 5-day cycle.

20.1.1. Observation studies. Observers were trained in the use of the behavioral
scoring instrument developed in previous studies at NERPC. Each observer will undergo
at least 20 hrs of observational training until they reached a > 90% reliability criterion
based on percent agreement scores.

The scoring system included 19 categories
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encompassing a wide range of species-typical and drug-induced behaviors including
locomotion,

environmental

manipulation,

foraging,

self-grooming,

scratching,

stereotypic behavior such as self-grasping, back flipping, and hair pulling, ataxia, sleep
posture, moderate and deep sedation. These behavioral categories have proven to be
useful for characterization of the sedative and motoric effects of BZ-type compounds in
previous research at NERPC.
Observation studies occurred in the same monkeys that were trained on the MAP task.
Observation studies were conducted in these monkeys in alternate weeks, on the 2nd and
3rd day of the 5-day cycle (i.e., MAP testing occurred one week, observation tests
occurred the following week, and so on). Video cameras were used to record the
monkeys’ behavior during observation sessions. This provided an archival record of
experimental sessions, permitted subsequent scoring of videotapes by independent
observers, and eliminated the possibility that an observer’s presence disturbed the
monkeys’ behavior.

All behaviors were scored during 5-min sampling periods as

described above. Each 5-min period was subdivided into twenty 15-s intervals, and
frequency scores were calculated as the proportion of 15-s intervals in which a particular
behavior occurred. Data was analyzed separately in individual subjects and for the group
when appropriate used the statistical approach described earlier at NERPC.
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III. Appendix I: Crystal Data for 110 and 111
X-ray Crystal Structure Determination for 110 and 111

Single-crystal X-ray diffraction data on 110 and 111 were collected at 296 and 100 °K
respectively. All data were collected using MoKα radiation (λ = 0.71073 Å) and a
Bruker APEX 2 CCD area detector. Samples were prepared for data collection by
coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oilcoated crystal was mounted on a MicroMesh mount (MiTeGen, Inc.) and transferred
immediately to the diffractometer. Corrections were applied for Lorentz, polarization,
and absorption effects. All structures were solved by direct methods and refined by fullmatrix least squares on F2 values using the programs found in the SHELXTL suite
(Bruker, SHELXTL v6.10, 2000, Bruker AXS Inc., Madison, WI). Parameters refined
included atomic coordinates and anisotropic thermal parameters for all non-hydrogen
atoms.
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Full information on data collection, refinement, and results of the x-ray studies are given
in Tables 1 to 14
Table 1. Crystal data and structure refinement for 110.
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 29.23°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole

C19H20N2O2
308.37
296(2) K
0.71073 Å
Orthorhombic
P 212121
a = 9.6247(4) Å
α= 90°
b = 11.6485(5) Å
β= 90°
c = 13.7072(5) Å
γ = 90°
1536.76(11) Å3
4
1.333 Mg/m3
0.087 mm-1
656
0.549 x 0.141 x 0.104 mm3
2.29 to 29.23°
-12<=h<=13, -15<=k<=15, -18<=l<=18
17885
4117 [R(int) = 0.0313]
99.4 %
Semi-empirical from equivalents
0.9910 and 0.9537
Full-matrix least-squares on F2
4117 / 0 / 208
1.051
R1 = 0.0441, wR2 = 0.1120
R1 = 0.0560, wR2 = 0.1197
0.9(14)
0.275 and -0.226 e.Å-3
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 110.
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________
x
y
z
U(eq)
________________________________________________________________________________
N(1)
1218(2)
4427(1)
8185(1)
37(1)
C(2)
2099(2)
5027(2)
8752(1)
33(1)
C(3)
3328(2)
5685(2)
8403(1)
34(1)
N(4)
3535(1)
6617(1)
9129(1)
34(1)
C(5)
3857(2)
6092(1)
10089(1)
34(1)
C(6)
2664(2)
5348(2)
10454(1)
35(1)
O(6)
2569(2)
5140(1)
11332(1)
47(1)
C(7)
1757(2)
4884(2)
9725(1)
33(1)
C(8)
551(2)
4152(2)
9753(1)
33(1)
C(9)
-305(2)
3714(2)
10488(1)
42(1)
C(10)
-1425(2)
3030(2)
10227(2)
47(1)
C(11)
-1703(2)
2774(2)
9258(2)
49(1)
C(12)
-880(2)
3187(2)
8508(2)
43(1)
C(13)
242(2)
3876(2)
8775(1)
35(1)
C(14)
4643(2)
4903(2)
8333(1)
39(1)
C(15)
5780(2)
5425(2)
8987(1)
37(1)
C(16)
5253(2)
5408(2)
10054(1)
37(1)
C(17)
6311(2)
5866(2)
10792(2)
53(1)
O(17)
6185(2)
7054(1)
10952(1)
60(1)
C(18)
8403(2)
6398(2)
7934(2)
60(1)
C(19)
7098(2)
7033(2)
8158(1)
44(1)
C(20)
6001(2)
6639(2)
8636(1)
37(1)
C(21)
4712(2)
7351(2)
8821(2)
41(1)
________________________________________________________________________________
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Table 3. Bond lengths [Å] and angles [°] for 110.
________________________________________________________________________________
N(1)-C(2)
1.345(2)
N(1)-C(13)
1.395(2)
N(1)-H(1A)
0.8600
C(2)-C(7)
1.384(2)
C(2)-C(3)
1.489(2)
C(3)-N(4)
1.485(2)
C(3)-C(14)
1.562(3)
C(3)-H(3A)
0.9800
N(4)-C(21)
1.480(2)
N(4)-C(5)
1.484(2)
C(5)-C(6)
1.523(2)
C(5)-C(16)
1.563(2)
C(5)-H(5A)
0.9800
C(6)-O(6)
1.231(2)
C(6)-C(7)
1.432(2)
C(7)-C(8)
1.441(2)
C(8)-C(9)
1.398(2)
C(8)-C(13)
1.411(2)
C(9)-C(10)
1.387(3)
C(9)-H(9A)
0.9300
C(10)-C(11)
1.387(3)
C(10)-H(10A)
0.9300
C(11)-C(12)
1.384(3)
C(11)-H(11A)
0.9300
C(12)-C(13)
1.395(3)
C(12)-H(12A)
0.9300
C(14)-C(15)
1.541(3)
C(14)-H(14A)
0.9700
C(14)-H(14B)
0.9700
C(15)-C(20)
1.509(3)
C(15)-C(16)
1.548(2)
C(15)-H(15A)
0.9800
C(16)-C(17)
1.531(3)
C(16)-H(16A)
0.9800
C(17)-O(17)
1.406(3)
C(17)-H(17A)
0.9700
C(17)-H(17B)
0.9700
O(17)-H(17C)
0.8200
C(18)-C(19)
1.490(3)
C(18)-H(18A)
0.9600
C(18)-H(18B)
0.9600
C(18)-H(18C)
0.9600
C(19)-C(20)
1.325(3)
C(19)-H(19A)
0.9300
C(20)-C(21)
1.514(3)
C(21)-H(21A)
0.9700
C(21)-H(21B)
0.9700
C(2)-N(1)-C(13)
109.18(14)
C(2)-N(1)-H(1A)
125.4
C(13)-N(1)-H(1A)
125.4
N(1)-C(2)-C(7)
110.16(15)
N(1)-C(2)-C(3)
125.62(14)
C(7)-C(2)-C(3)
124.10(15)
N(4)-C(3)-C(2)
105.51(13)
N(4)-C(3)-C(14)
111.05(14)
C(2)-C(3)-C(14)
111.26(14)
N(4)-C(3)-H(3A)
109.6
C(2)-C(3)-H(3A)
109.6
C(14)-C(3)-H(3A)
109.6
C(21)-N(4)-C(5)
109.31(14)
C(21)-N(4)-C(3)
109.49(14)
C(5)-N(4)-C(3)
108.68(13)
N(4)-C(5)-C(6)
111.59(14)
N(4)-C(5)-C(16)
111.26(13)
C(6)-C(5)-C(16)
111.64(13)
N(4)-C(5)-H(5A)
107.4
C(6)-C(5)-H(5A)
107.4
C(16)-C(5)-H(5A)
107.4
O(6)-C(6)-C(7)
124.21(16)
O(6)-C(6)-C(5)
119.25(16)
C(7)-C(6)-C(5)
116.46(14)
C(2)-C(7)-C(6)
118.78(15)
C(2)-C(7)-C(8)
106.74(14)
C(6)-C(7)-C(8)
134.12(15)
C(9)-C(8)-C(13)
118.55(16)
C(9)-C(8)-C(7)
135.20(16)
C(13)-C(8)-C(7)
106.24(14)
C(10)-C(9)-C(8)
118.74(18)
C(10)-C(9)-H(9A)
120.6
C(8)-C(9)-H(9A)
120.6
C(11)-C(10)-C(9)
121.41(18)
C(11)-C(10)-H(10A)
119.3
C(9)-C(10)-H(10A)
119.3
C(12)-C(11)-C(10)
121.72(18)
C(12)-C(11)-H(11A)
119.1
C(10)-C(11)-H(11A)
119.1
C(11)-C(12)-C(13)
116.67(18)
C(11)-C(12)-H(12A)
121.7
C(13)-C(12)-H(12A)
121.7
C(12)-C(13)-N(1)
129.41(16)
C(12)-C(13)-C(8)
122.91(16)
N(1)-C(13)-C(8)
107.67(15)
C(15)-C(14)-C(3)
108.01(14)
C(15)-C(14)-H(14A)
110.1
C(3)-C(14)-H(14A)
110.1
C(15)-C(14)-H(14B)
110.1
C(3)-C(14)-H(14B)
110.1
H(14A)-C(14)-H(14B)
108.4
C(20)-C(15)-C(14)
106.53(15)
C(20)-C(15)-C(16)
111.10(15)
C(14)-C(15)-C(16)
108.14(14)
C(20)-C(15)-H(15A)
110.3
C(14)-C(15)-H(15A)
110.3
________________________________________________________________________________
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Table 3. (continued)
________________________________________________________________________________
C(16)-C(15)-H(15A)
110.3
C(17)-C(16)-C(15)
113.68(15)
C(17)-C(16)-C(5)
111.96(15)
C(15)-C(16)-C(5)
107.71(13)
C(17)-C(16)-H(16A)
107.8
C(15)-C(16)-H(16A)
107.8
C(5)-C(16)-H(16A)
107.8
O(17)-C(17)-C(16)
112.84(17)
O(17)-C(17)-H(17A)
109.0
C(16)-C(17)-H(17A)
109.0
O(17)-C(17)-H(17B)
109.0
C(16)-C(17)-H(17B)
109.0
H(17A)-C(17)-H(17B)
107.8
C(17)-O(17)-H(17C)
109.5
C(19)-C(18)-H(18A)
109.5
C(19)-C(18)-H(18B)
109.5
H(18A)-C(18)-H(18B)
109.5
C(19)-C(18)-H(18C)
109.5
H(18A)-C(18)-H(18C)
109.5
H(18B)-C(18)-H(18C)
109.5
C(20)-C(19)-C(18)
127.06(19)
C(20)-C(19)-H(19A)
116.5
C(18)-C(19)-H(19A)
116.5
C(19)-C(20)-C(15)
126.46(17)
C(19)-C(20)-C(21)
123.16(16)
C(15)-C(20)-C(21)
110.16(14)
N(4)-C(21)-C(20)
111.02(14)
N(4)-C(21)-H(21A)
109.4
C(20)-C(21)-H(21A)
109.4
N(4)-C(21)-H(21B)
109.4
C(20)-C(21)-H(21B)
109.4
H(21A)-C(21)-H(21B)
108.0
________________________________________________________________________________
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Table 4. Anisotropic displacement parameters (Å2 x 103) for 110. The anisotropic displacement factor
exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ]
______________________________________________________________________________
U22
U33
U23
U13
U12
U11
______________________________________________________________________________
N(1)
39(1)
46(1)
27(1)
0(1)
1(1)
-5(1)
C(2)
33(1)
36(1)
30(1)
1(1)
2(1)
1(1)
C(3)
34(1)
38(1)
30(1)
2(1)
2(1)
-4(1)
N(4)
33(1)
33(1)
38(1)
2(1)
2(1)
1(1)
C(5)
36(1)
34(1)
32(1)
-3(1)
0(1)
-4(1)
C(6)
37(1)
36(1)
30(1)
-2(1)
3(1)
-1(1)
O(6)
54(1)
58(1)
27(1)
-1(1)
2(1)
-13(1)
C(7)
33(1)
37(1)
30(1)
1(1)
3(1)
-3(1)
C(8)
33(1)
35(1)
31(1)
2(1)
1(1)
2(1)
C(9)
42(1)
48(1)
36(1)
4(1)
5(1)
-1(1)
C(10)
41(1)
47(1)
53(1)
8(1)
13(1)
-8(1)
C(11)
40(1)
47(1)
59(1)
3(1)
0(1)
-11(1)
C(12)
41(1)
43(1)
45(1)
-2(1)
-4(1)
-6(1)
C(13)
34(1)
37(1)
34(1)
0(1)
1(1)
1(1)
C(14)
42(1)
36(1)
39(1)
-4(1)
10(1)
-2(1)
C(15)
32(1)
32(1)
47(1)
2(1)
5(1)
3(1)
C(16)
37(1)
33(1)
41(1)
5(1)
-1(1)
-2(1)
C(17)
50(1)
54(1)
54(1)
7(1)
-13(1)
-5(1)
O(17)
42(1)
63(1)
76(1)
-22(1)
1(1)
-12(1)
C(18)
48(1)
61(1)
72(2)
-5(1)
20(1)
-5(1)
C(19)
44(1)
42(1)
47(1)
1(1)
9(1)
-6(1)
C(20)
35(1)
35(1)
42(1)
2(1)
0(1)
-3(1)
C(21)
39(1)
33(1)
50(1)
8(1)
5(1)
-2(1)
______________________________________________________________________________
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 110.
________________________________________________________________________________
x
y
z
U(eq)
________________________________________________________________________________
H(1A)
1251
4390
7559
44
H(3A)
3128
6019
7762
41
H(5A)
3978
6719
10557
40
H(9A)
-127
3878
11140
50
H(10A)
-2001
2738
10711
56
H(11A)
-2462
2312
9109
58
H(12A)
-1066
3013
7859
52
H(14A)
4421
4131
8550
47
H(14B)
4963
4863
7663
47
H(15A)
6643
4984
8929
44
H(16A)
5050
4609
10225
44
H(17A)
6188
5466
11407
63
H(17B)
7241
5701
10558
63
H(17C)
6767
7260
11352
91
H(18A)
9023
6889
7577
90
H(18B)
8190
5733
7548
90
H(18C)
8838
6162
8531
90
H(19A)
7048
7787
7939
53
H(21A)
4904
7913
9325
49
H(21B)
4462
7761
8231
49
________________________________________________________________________________
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Table 6. Torsion angles [°] for cook106.
________________________________________________________________________________
C(13)-N(1)-C(2)-C(7)
0.8(2)
C(13)-N(1)-C(2)-C(3)
176.81(16)
N(1)-C(2)-C(3)-N(4)
152.43(16)
C(7)-C(2)-C(3)-N(4)
-32.1(2)
N(1)-C(2)-C(3)-C(14)
-87.0(2)
C(7)-C(2)-C(3)-C(14)
88.4(2)
C(2)-C(3)-N(4)-C(21)
-177.83(13)
C(14)-C(3)-N(4)-C(21)
61.50(17)
C(2)-C(3)-N(4)-C(5)
62.83(16)
C(14)-C(3)-N(4)-C(5)
-57.84(17)
C(21)-N(4)-C(5)-C(6)
178.61(14)
C(3)-N(4)-C(5)-C(6)
-61.93(16)
C(21)-N(4)-C(5)-C(16)
-55.97(17)
C(3)-N(4)-C(5)-C(16)
63.48(16)
N(4)-C(5)-C(6)-O(6)
-158.11(16)
C(16)-C(5)-C(6)-O(6)
76.7(2)
N(4)-C(5)-C(6)-C(7)
25.1(2)
C(16)-C(5)-C(6)-C(7)
-100.12(18)
N(1)-C(2)-C(7)-C(6)
173.05(16)
C(3)-C(2)-C(7)-C(6)
-3.0(3)
N(1)-C(2)-C(7)-C(8)
-1.0(2)
C(3)-C(2)-C(7)-C(8)
-177.07(16)
O(6)-C(6)-C(7)-C(2)
-169.54(18)
C(5)-C(6)-C(7)-C(2)
7.1(2)
O(6)-C(6)-C(7)-C(8)
2.5(3)
C(5)-C(6)-C(7)-C(8)
179.14(18)
C(2)-C(7)-C(8)-C(9)
-178.1(2)
C(6)-C(7)-C(8)-C(9)
9.1(4)
C(2)-C(7)-C(8)-C(13)
0.80(19)
C(6)-C(7)-C(8)-C(13)
-171.94(19)
C(13)-C(8)-C(9)-C(10)
-0.2(3)
C(7)-C(8)-C(9)-C(10)
178.7(2)
C(8)-C(9)-C(10)-C(11)
0.2(3)
C(9)-C(10)-C(11)-C(12)
-0.1(3)
C(10)-C(11)-C(12)-C(13)
-0.1(3)
C(11)-C(12)-C(13)-N(1)
-178.39(19)
C(11)-C(12)-C(13)-C(8)
0.2(3)
C(2)-N(1)-C(13)-C(12)
178.43(18)
C(2)-N(1)-C(13)-C(8)
-0.3(2)
C(9)-C(8)-C(13)-C(12)
0.0(3)
C(7)-C(8)-C(13)-C(12)
-179.15(17)
C(9)-C(8)-C(13)-N(1)
178.81(16)
C(7)-C(8)-C(13)-N(1)
-0.32(19)
N(4)-C(3)-C(14)-C(15)
-4.76(18)
C(2)-C(3)-C(14)-C(15)
-121.97(15)
C(3)-C(14)-C(15)-C(20)
-56.62(17)
C(3)-C(14)-C(15)-C(16)
62.88(17)
C(20)-C(15)-C(16)-C(17)
-65.57(19)
C(14)-C(15)-C(16)-C(17)
177.85(16)
C(20)-C(15)-C(16)-C(5)
59.09(18)
C(14)-C(15)-C(16)-C(5)
-57.49(17)
N(4)-C(5)-C(16)-C(17)
121.05(16)
C(6)-C(5)-C(16)-C(17)
-113.56(17)
N(4)-C(5)-C(16)-C(15)
-4.63(18)
C(6)-C(5)-C(16)-C(15)
120.75(15)
C(15)-C(16)-C(17)-O(17)
90.4(2)
C(5)-C(16)-C(17)-O(17)
-31.9(2)
C(18)-C(19)-C(20)-C(15)
-5.5(4)
C(18)-C(19)-C(20)-C(21)
-179.5(2)
C(14)-C(15)-C(20)-C(19)
-108.6(2)
C(16)-C(15)-C(20)-C(19)
133.8(2)
C(14)-C(15)-C(20)-C(21)
65.96(18)
C(16)-C(15)-C(20)-C(21)
-51.6(2)
C(5)-N(4)-C(21)-C(20)
65.37(19)
C(3)-N(4)-C(21)-C(20)
-53.6(2)
C(19)-C(20)-C(21)-N(4)
164.91(18)
C(15)-C(20)-C(21)-N(4)
-9.9(2)
________________________________________________________________________________

301

Table 7. Hydrogen bonds for 110 [Å and °].
____________________________________________________________________________
D-H...A
d(D-H)
d(H...A)
d(D...A)
<(DHA)
____________________________________________________________________________
N(1)-H(1A)...O(6)#1
0.86
2.10
2.8409(19)
143.7
O(17)-H(17C)...N(4)#2
0.82
2.25
2.743(2)
119.5
____________________________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 -x+1/2,-y+1,z-1/2 #2 x+1/2,-y+3/2,-z+2
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Table 8. Crystal data and structure refinement for 111.
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 29.14°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole

C21H30N2O4
374.47
100(2) K
0.71073 Å
Orthorhombic
P 21 21 21
a = 8.3186(7) Å
α= 90°
b = 12.4731(10) Å
β= 90°
c = 19.1532(16) Å
γ = 90°
1987.3(3) Å3
4
1.252 Mg/m3
0.086 mm-1
808
0.463 x 0.429 x 0.091 mm3
1.95 to 29.14°
-11<=h<=11, -17<=k<=16, -24<=l<=26
22977
5326 [R(int) = 0.0221]
99.6 %
Semi-empirical from equivalents
0.9931 and 0.9658
Full-matrix least-squares on F2
5326 / 2 / 252
1.103
R1 = 0.0356, wR2 = 0.1041
R1 = 0.0367, wR2 = 0.1055
0.3(7)
0.329 and -0.273 e.Å-3
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Table 9. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 111.
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________
x
y
z
U(eq)
________________________________________________________________________________
N(1)
8034(1)
7267(1)
1454(1)
19(1)
C(2)
9226(1)
6894(1)
1016(1)
16(1)
C(3)
9215(1)
5825(1)
663(1)
16(1)
N(4)
10222(1)
5969(1)
23(1)
14(1)
C(5)
11870(1)
6313(1)
231(1)
14(1)
C(6)
11787(1)
7506(1)
449(1)
14(1)
O(6)
13218(1)
7827(1)
813(1)
18(1)
C(7)
10356(1)
7674(1)
908(1)
15(1)
C(8)
9838(1)
8606(1)
1287(1)
17(1)
C(9)
10416(1)
9662(1)
1352(1)
21(1)
C(10)
9558(2)
10381(1)
1759(1)
25(1)
C(11)
8144(2)
10067(1)
2108(1)
26(1)
C(12)
7541(2)
9036(1)
2053(1)
23(1)
C(13)
8393(1)
8315(1)
1633(1)
19(1)
C(14)
9850(1)
4886(1)
1124(1)
19(1)
C(15)
11491(1)
4539(1)
832(1)
18(1)
C(16)
12574(1)
5545(1)
793(1)
17(1)
C(17)
14318(1)
5261(1)
620(1)
22(1)
O(18)
15055(1)
4601(1)
1132(1)
29(1)
C(19)
12250(2)
2212(1)
268(1)
40(1)
C(20)
11531(2)
3126(1)
-134(1)
27(1)
C(21)
11204(1)
4106(1)
107(1)
19(1)
C(22)
10360(1)
4933(1)
-348(1)
18(1)
O(1S)
5487(1)
6196(1)
2188(1)
26(1)
C(1S)
6066(2)
6072(2)
2882(1)
39(1)
O(2S)
13630(1)
7920(1)
2198(1)
34(1)
C(2S)
12416(2)
8163(1)
2687(1)
34(1)
________________________________________________________________________________
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Table 10. Bond lengths [Å] and angles [°] for 110.
________________________________________________________________________________
N(1)-C(2)
1.3796(14)
N(1)-C(13)
1.3849(16)
N(1)-H(1A)
0.8800
C(2)-C(7)
1.3681(15)
C(2)-C(3)
1.4956(15)
C(3)-N(4)
1.4957(14)
C(3)-C(14)
1.5580(15)
C(3)-H(3A)
1.0000
N(4)-C(22)
1.4790(13)
N(4)-C(5)
1.4898(14)
C(5)-C(6)
1.5469(14)
C(5)-C(16)
1.5569(15)
C(5)-H(5A)
1.0000
C(6)-O(6)
1.4362(13)
C(6)-C(7)
1.4942(14)
C(6)-H(6A)
1.0000
O(6)-H(6B)
0.8400
C(7)-C(8)
1.4366(15)
C(8)-C(9)
1.4073(16)
C(8)-C(13)
1.4191(16)
C(9)-C(10)
1.3856(17)
C(9)-H(9A)
0.9500
C(10)-C(11)
1.4089(19)
C(10)-H(10A)
0.9500
C(11)-C(12)
1.384(2)
C(11)-H(11A)
0.9500
C(12)-C(13)
1.3988(16)
C(12)-H(12A)
0.9500
C(14)-C(15)
1.5377(16)
C(14)-H(14A)
0.9900
C(14)-H(14B)
0.9900
C(15)-C(21)
1.5081(17)
C(15)-C(16)
1.5462(16)
C(15)-H(15A)
1.0000
C(16)-C(17)
1.5302(16)
C(16)-H(16A)
1.0000
C(17)-O(18)
1.4209(15)
C(17)-H(17A)
0.9900
C(17)-H(17B)
0.9900
O(18)-H(18A)
0.8400
C(19)-C(20)
1.4994(19)
C(19)-H(19A)
0.9800
C(19)-H(19B)
0.9800
C(19)-H(19C)
0.9800
C(20)-C(21)
1.3352(17)
C(20)-H(20A)
0.9500
C(21)-C(22)
1.5219(16)
C(22)-H(22D)
0.9900
C(22)-H(22E)
0.9900
O(1S)-C(1S)
1.4221(17)
O(1S)-H(1S)
0.8400
C(1S)-H(1SC)
0.9800
C(1S)-H(1SB)
0.9800
C(1S)-H(1SA)
0.9800
O(2S)-C(2S)
1.4099(17)
O(2S)-H(2S)
0.8402(10)
C(2S)-H(2SA)
0.9800
C(2S)-H(2SB)
0.9800
C(2S)-H(2SC)
0.9800
C(2)-N(1)-C(13)
108.26(10)
C(2)-N(1)-H(1A)
125.9
C(13)-N(1)-H(1A)
125.9
C(7)-C(2)-N(1)
110.26(10)
C(7)-C(2)-C(3)
124.79(10)
N(1)-C(2)-C(3)
124.78(10)
C(2)-C(3)-N(4)
105.01(8)
C(2)-C(3)-C(14)
114.34(9)
N(4)-C(3)-C(14)
111.40(9)
C(2)-C(3)-H(3A)
108.6
N(4)-C(3)-H(3A)
108.6
C(14)-C(3)-H(3A)
108.6
C(22)-N(4)-C(5)
107.98(8)
C(22)-N(4)-C(3)
109.36(8)
C(5)-N(4)-C(3)
109.37(8)
N(4)-C(5)-C(6)
107.96(8)
N(4)-C(5)-C(16)
110.68(8)
C(6)-C(5)-C(16)
114.89(9)
N(4)-C(5)-H(5A)
107.7
C(6)-C(5)-H(5A)
107.7
C(16)-C(5)-H(5A)
107.7
O(6)-C(6)-C(7)
109.63(8)
O(6)-C(6)-C(5)
111.23(8)
C(7)-C(6)-C(5)
109.26(9)
O(6)-C(6)-H(6A)
108.9
C(7)-C(6)-H(6A)
108.9
C(5)-C(6)-H(6A)
108.9
C(6)-O(6)-H(6B)
109.5
C(2)-C(7)-C(8)
107.02(10)
C(2)-C(7)-C(6)
122.41(10)
C(8)-C(7)-C(6)
130.54(10)
C(9)-C(8)-C(13)
119.14(10)
C(9)-C(8)-C(7)
134.35(11)
C(13)-C(8)-C(7)
106.46(10)
C(10)-C(9)-C(8)
118.66(11)
C(10)-C(9)-H(9A)
120.7
C(8)-C(9)-H(9A)
120.7
C(9)-C(10)-C(11)
121.11(12)
C(9)-C(10)-H(10A)
119.4
C(11)-C(10)-H(10A)
119.4
C(12)-C(11)-C(10)
121.62(11)
C(12)-C(11)-H(11A)
119.2
C(10)-C(11)-H(11A)
119.2
C(11)-C(12)-C(13)
117.21(12)
________________________________________________________________________________
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Table 10. (continued)
________________________________________________________________________________
C(11)-C(12)-H(12A)
121.4
C(13)-C(12)-H(12A)
121.4
N(1)-C(13)-C(12)
129.79(11)
N(1)-C(13)-C(8)
107.97(10)
C(12)-C(13)-C(8)
122.22(11)
C(15)-C(14)-C(3)
107.85(9)
C(15)-C(14)-H(14A)
110.1
C(3)-C(14)-H(14A)
110.1
C(15)-C(14)-H(14B)
110.1
C(3)-C(14)-H(14B)
110.1
H(14A)-C(14)-H(14B)
108.5
C(21)-C(15)-C(14)
107.15(9)
C(21)-C(15)-C(16)
109.83(9)
C(14)-C(15)-C(16)
107.80(9)
C(21)-C(15)-H(15A)
110.7
C(14)-C(15)-H(15A)
110.7
C(16)-C(15)-H(15A)
110.7
C(17)-C(16)-C(15)
111.98(9)
C(17)-C(16)-C(5)
110.40(9)
C(15)-C(16)-C(5)
108.26(9)
C(17)-C(16)-H(16A)
108.7
C(15)-C(16)-H(16A)
108.7
C(5)-C(16)-H(16A)
108.7
O(18)-C(17)-C(16)
113.16(10)
O(18)-C(17)-H(17A)
108.9
C(16)-C(17)-H(17A)
108.9
O(18)-C(17)-H(17B)
108.9
C(16)-C(17)-H(17B)
108.9
H(17A)-C(17)-H(17B)
107.8
C(17)-O(18)-H(18A)
109.5
C(20)-C(19)-H(19A)
109.5
C(20)-C(19)-H(19B)
109.5
H(19A)-C(19)-H(19B)
109.5
C(20)-C(19)-H(19C)
109.5
H(19A)-C(19)-H(19C)
109.5
H(19B)-C(19)-H(19C)
109.5
C(21)-C(20)-C(19)
126.91(14)
C(21)-C(20)-H(20A)
116.5
C(19)-C(20)-H(20A)
116.5
C(20)-C(21)-C(15)
127.85(11)
C(20)-C(21)-C(22)
121.13(11)
C(15)-C(21)-C(22)
110.94(9)
N(4)-C(22)-C(21)
110.67(9)
N(4)-C(22)-H(22D)
109.5
C(21)-C(22)-H(22D)
109.5
N(4)-C(22)-H(22E)
109.5
C(21)-C(22)-H(22E)
109.5
H(22D)-C(22)-H(22E)
108.1
C(1S)-O(1S)-H(1S)
109.5
O(1S)-C(1S)-H(1SC)
109.5
O(1S)-C(1S)-H(1SB)
109.5
H(1SC)-C(1S)-H(1SB)
109.5
O(1S)-C(1S)-H(1SA)
109.5
H(1SC)-C(1S)-H(1SA)
109.5
H(1SB)-C(1S)-H(1SA)
109.5
C(2S)-O(2S)-H(2S)
110.8(3)
O(2S)-C(2S)-H(2SA)
109.5
O(2S)-C(2S)-H(2SB)
109.5
H(2SA)-C(2S)-H(2SB)
109.5
O(2S)-C(2S)-H(2SC)
109.5
H(2SA)-C(2S)-H(2SC)
109.5
H(2SB)-C(2S)-H(2SC)
109.5
________________________________________________________________________________
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Table 11. Anisotropic displacement parameters (Å2 x 103) for 110. The anisotropic displacement factor
exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ]
______________________________________________________________________________
U22
U33
U23
U13
U12
U11
______________________________________________________________________________
N(1)
13(1)
25(1)
18(1)
-1(1)
4(1)
-1(1)
C(2)
13(1)
21(1)
13(1)
1(1)
1(1)
1(1)
C(3)
12(1)
19(1)
15(1)
3(1)
1(1)
-2(1)
N(4)
13(1)
16(1)
14(1)
0(1)
0(1)
-1(1)
C(5)
12(1)
17(1)
13(1)
1(1)
0(1)
0(1)
C(6)
11(1)
19(1)
12(1)
0(1)
1(1)
-1(1)
O(6)
14(1)
26(1)
14(1)
0(1)
0(1)
-5(1)
C(7)
13(1)
19(1)
14(1)
0(1)
1(1)
1(1)
C(8)
14(1)
22(1)
14(1)
-2(1)
-1(1)
2(1)
C(9)
19(1)
24(1)
21(1)
-3(1)
-1(1)
-1(1)
C(10)
24(1)
25(1)
28(1)
-8(1)
-3(1)
2(1)
C(11)
23(1)
33(1)
23(1)
-10(1)
-1(1)
8(1)
C(12)
18(1)
34(1)
18(1)
-5(1)
2(1)
4(1)
C(13)
14(1)
26(1)
15(1)
-2(1)
0(1)
3(1)
C(14)
18(1)
21(1)
18(1)
6(1)
2(1)
-1(1)
C(15)
17(1)
19(1)
20(1)
5(1)
0(1)
1(1)
C(16)
13(1)
20(1)
16(1)
5(1)
-2(1)
2(1)
C(17)
14(1)
27(1)
25(1)
5(1)
-1(1)
3(1)
O(18)
24(1)
32(1)
32(1)
5(1)
-8(1)
9(1)
C(19)
41(1)
25(1)
54(1)
3(1)
-6(1)
13(1)
C(20)
27(1)
24(1)
32(1)
-1(1)
-3(1)
6(1)
C(21)
17(1)
18(1)
23(1)
3(1)
0(1)
0(1)
C(22)
20(1)
16(1)
17(1)
-1(1)
-2(1)
-1(1)
O(1S)
19(1)
37(1)
21(1)
6(1)
0(1)
-1(1)
C(1S)
33(1)
57(1)
25(1)
9(1)
-5(1)
0(1)
O(2S)
29(1)
56(1)
18(1)
-3(1)
-2(1)
11(1)
C(2S)
38(1)
41(1)
23(1)
5(1)
7(1)
13(1)
______________________________________________________________________________
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Table 12. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 110.
________________________________________________________________________________
x
y
z
U(eq)
________________________________________________________________________________
H(1A)
7191
6900
1596
22
H(3A)
8089
5657
516
19
H(5A)
12571
6265
-192
16
H(6A)
11666
7957
21
17
H(6B)
13840
8142
535
26
H(9A)
11375
9876
1123
25
H(10A)
9928
11098
1802
30
H(11A)
7592
10575
2390
31
H(12A)
6589
8826
2290
28
H(14A)
9965
5125
1614
23
H(14B)
9087
4278
1111
23
H(15A)
11990
3979
1136
22
H(16A)
12547
5916
1256
20
H(17A)
14347
4886
164
26
H(17B)
14946
5931
572
26
H(18A)
15198
4957
1500
44
H(19A)
12363
1588
-40
60
H(19B)
11547
2028
661
60
H(19C)
13309
2421
445
60
H(20A)
11281
2993
-610
33
H(22D)
10974
5035
-785
21
H(22E)
9274
4670
-472
21
H(1S)
4845
6716
2172
39
H(1SC)
6968
6564
2959
58
H(1SB)
6429
5333
2951
58
H(1SA)
5202
6236
3213
58
H(2S)
13284(9)
7984(18)
1788(1)
51
H(2SA)
12095
8915
2635
51
H(2SB)
12826
8045
3161
51
H(2SC)
11485
7699
2606
51
________________________________________________________________________________
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Table 13. Torsion angles [°] for 110.
________________________________________________________________________________
C(13)-N(1)-C(2)-C(7)
0.34(13)
C(13)-N(1)-C(2)-C(3)
-175.08(10)
C(7)-C(2)-C(3)-N(4)
-20.77(14)
N(1)-C(2)-C(3)-N(4)
153.99(10)
C(7)-C(2)-C(3)-C(14)
101.63(12)
N(1)-C(2)-C(3)-C(14)
-83.61(13)
C(2)-C(3)-N(4)-C(22)
177.07(9)
C(14)-C(3)-N(4)-C(22)
52.78(11)
C(2)-C(3)-N(4)-C(5)
59.02(10)
C(14)-C(3)-N(4)-C(5)
-65.27(11)
C(22)-N(4)-C(5)-C(6)
166.16(8)
C(3)-N(4)-C(5)-C(6)
-74.93(10)
C(22)-N(4)-C(5)-C(16)
-67.31(10)
C(3)-N(4)-C(5)-C(16)
51.60(11)
N(4)-C(5)-C(6)-O(6)
165.99(8)
C(16)-C(5)-C(6)-O(6)
41.96(12)
N(4)-C(5)-C(6)-C(7)
44.82(10)
C(16)-C(5)-C(6)-C(7)
-79.21(11)
N(1)-C(2)-C(7)-C(8)
-1.32(13)
C(3)-C(2)-C(7)-C(8)
174.09(10)
N(1)-C(2)-C(7)-C(6)
-179.39(10)
C(3)-C(2)-C(7)-C(6)
-3.98(17)
O(6)-C(6)-C(7)-C(2)
-130.32(11)
C(5)-C(6)-C(7)-C(2)
-8.19(14)
O(6)-C(6)-C(7)-C(8)
52.11(15)
C(5)-C(6)-C(7)-C(8)
174.24(11)
C(2)-C(7)-C(8)-C(9)
-175.80(13)
C(6)-C(7)-C(8)-C(9)
2.1(2)
C(2)-C(7)-C(8)-C(13)
1.77(12)
C(6)-C(7)-C(8)-C(13)
179.63(11)
C(13)-C(8)-C(9)-C(10)
0.58(17)
C(7)-C(8)-C(9)-C(10)
177.92(12)
C(8)-C(9)-C(10)-C(11)
0.79(19)
C(9)-C(10)-C(11)-C(12)
-1.1(2)
C(10)-C(11)-C(12)-C(13)
-0.09(19)
C(2)-N(1)-C(13)-C(12)
178.83(12)
C(2)-N(1)-C(13)-C(8)
0.81(12)
C(11)-C(12)-C(13)-N(1)
-176.27(12)
C(11)-C(12)-C(13)-C(8)
1.51(18)
C(9)-C(8)-C(13)-N(1)
176.43(10)
C(7)-C(8)-C(13)-N(1)
-1.59(12)
C(9)-C(8)-C(13)-C(12)
-1.78(17)
C(7)-C(8)-C(13)-C(12)
-179.79(11)
C(2)-C(3)-C(14)-C(15)
-109.10(11)
N(4)-C(3)-C(14)-C(15)
9.75(12)
C(3)-C(14)-C(15)-C(21)
-64.15(11)
C(3)-C(14)-C(15)-C(16)
54.00(11)
C(21)-C(15)-C(16)-C(17)
-72.68(12)
C(14)-C(15)-C(16)-C(17)
170.90(9)
C(21)-C(15)-C(16)-C(5)
49.27(12)
C(14)-C(15)-C(16)-C(5)
-67.15(11)
N(4)-C(5)-C(16)-C(17)
135.38(9)
C(6)-C(5)-C(16)-C(17)
-102.04(11)
N(4)-C(5)-C(16)-C(15)
12.47(12)
C(6)-C(5)-C(16)-C(15)
135.05(10)
C(15)-C(16)-C(17)-O(18)
-62.10(13)
C(5)-C(16)-C(17)-O(18)
177.19(10)
C(19)-C(20)-C(21)-C(15)
0.8(2)
C(19)-C(20)-C(21)-C(22)
-175.55(14)
C(14)-C(15)-C(21)-C(20)
-120.57(14)
C(16)-C(15)-C(21)-C(20)
122.61(13)
C(14)-C(15)-C(21)-C(22)
56.12(12)
C(16)-C(15)-C(21)-C(22)
-60.71(12)
C(5)-N(4)-C(22)-C(21)
56.56(11)
C(3)-N(4)-C(22)-C(21)
-62.36(11)
C(20)-C(21)-C(22)-N(4)
-176.72(11)
C(15)-C(21)-C(22)-N(4)
6.34(13)
________________________________________________________________________________
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Table 14. Hydrogen bonds for 110 [Å and °].
____________________________________________________________________________
D-H...A
d(D-H)
d(H...A)
d(D...A)
<(DHA)
____________________________________________________________________________
N(1)-H(1A)...O(1S)
0.88
2.02
2.8717(13)
163.7
O(6)-H(6B)...N(4)#1
0.84
1.92
2.7569(12)
172.2
O(18)-H(18A)...O(1S)#2
0.84
2.05
2.8593(15)
162.8
O(1S)-H(1S)...O(2S)#3
0.84
1.81
2.6472(15)
173.4
O(2S)-H(2S)...O(6)
0.8402(10)
1.880(3)
2.6783(13)
158.3(7)
____________________________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 x+1/2,-y+3/2,-z #2 x+1,y,z #3 x-1,y,z
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IV. Appendix II: Data on QH-II-066

In vivo and in vitro profiles of the GABAA/α5-preferring agonist QH-ii-066 and the nonselective agonist diazepam
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ABSTRACT
In order to investigate the possible role of GABAA/α5 receptors in behavioral
effects of benzodiazepines (BZ), the effects of QH-ii-066, the GABAA/α5-preferring
agonist, were compared with diazepam in binding and electrophysiology assays and
behavioral models of anxiety, epilepsy, and side effects (activity, motor coordination, and
subjective effects). QH-ii-066, while having similar affinity for BZ-sensitive GABAA
receptor subtypes, showed functional selectivity for GABAA/α5 receptors over
GABAA/α1 receptors. QH-ii-066 increased punished responding in the Geller conflict
test in rats and protected against pentylenetetrazole (PTZ)-induced seizures in mice at
doses similar to those of diazepam, but was less potent than diazepam in protecting
against electroconvulsive shock (ECS)-induced seizures, suggesting that GABAA/α1
receptors may play a bigger role in ECS- than PTZ-induced seizures. QH-ii-066 showed
a larger separation between doses effective in the conflict model and those effective in the
conditioned fear, locomotor activity, rotorod, and chlordiazepoxide drug discrimination.
In the case of locomotor activity and chlordiazepoxide drug discrimination, the decreased
potency of QH-ii-066 compared with diazepam indicate that GABAA/α1 receptors play a
more prominent role in sedative and chlordiazepoxide-like subjective effects of BZs.
These data suggest that compounds like QH-ii-066 with reduced efficacy at GABAA/α1
receptors may be effective anxiolytics with a reduced potential for side effects.
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Although benzodiazepines (BZ) are the most frequently prescribed anxiolytics, their use is
accompanied by significant side effects, most notably, sedation, ataxia, memory
impairment, potentiation of their effects by ethanol, development of tolerance and
dependence, and abuse liability. Efforts to discover anxiolytics with reduced side effect
profiles have centered on two types of compounds, those acting by a different mechanism
(e.g., 5-HT1A receptor agonists and CRF1 receptor antagonists) and BZ-like compounds
showing functional selectivity, i.e., acting with high efficacy at some GABAA receptors
and with low or no efficacy on other GABAA receptors. The latter approach assumes that
the therapeutic and adverse effects of classical BZs are mediated by different GABAA
receptors and that reducing binding affinity and/or efficacy at receptors mediating adverse
effects will result in a superior anxiolytic compared with classical BZs.
Zolpidem and zaleplon, two compounds with selectivity for GABAA/α1 receptors,
decrease sleep latency and increase sleep duration (e.g., Fry et al., 2000) and are marketed
for treatment of insomnia. In addition, recent studies with transgenic mice and GABAA
receptor-selective compounds have indicated that GABAA/α1 receptors mediate
sedative/ataxic effects of classical BZs (Rudolph et al., 1999; McKernan et al., 2000;
Kralic et al., 2002).
The role of other BZ-sensitive GABAA receptors, containing α2, α3, or α5
subunits, in the behavioral effects of classical BZs is less clear. Mice with a point
mutation rendering GABAA/α2 receptors insensitive to diazepam (GABAA/α2 receptor
knock-in mice) do not exhibit anxiolytic or myorelaxant effects when treated with
diazepam, whereas GABAA/α3 receptor knock-in mice showed a normal anxiolytic
response to diazepam, with reduced myorelaxant effects (Löw et al., 2000; Crestani et al.,
2001). However, selective GABAA/α3 receptor inverse agonists appear to be anxiogenic
(Collins et al., 2002), indicating that GABAA/α3 receptors may be involved in anxiolytic
effects of BZs. In addition, compounds with higher intrinsic efficacy at GABAA/α2 and
GABAA/α3 receptors, and lower or no efficacy at GABAA/α1 and GABAA/α5 receptors,
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show anxiolytic and anticonvulsant effects in rodents (Griebel et al., 2001). These studies
suggest that both GABAA/α2 and GABAA/α3 receptors may play a role in the anxiolytic
effects of classical BZs. Thus, an ideal compound, an anxiolytic with reduced motoric
side effect profile, would have no affinity or, at least, no efficacy at the GABAA/α1
receptors and high affinity and high efficacy at GABAA/α2 and GABAA/α3 receptors.
The role of GABAA/α5 receptors remains to be elucidated. Thus far, only one
study used GABAA/α5 receptor knock-in mice to investigate the role of GABAA/α5
receptors. Collinson et al. (2002) showed that these mice show no overt phenotype: their
baseline anxiety-related response, as measured by elevated plus maze, did not differ from
those of wild-type mice, they showed no spontaneous seizures, no impairment in rotorod
performance, and normal anxiolytic-like responses to chlordiazepoxide (CDP). These
animals did show faster learning of a Morris water maze task, suggesting that GABAA/α5
receptors may play a role in the memory-impairing effects of classical BZs. This result is
consistent with the finding that most GABAA/α5 receptors are located in the hippocampus,
a brain region shown to be involved in learning and memory. Furthermore, inverse
agonists at this site show memory-enhancing effects in animals (Chambers et al., 2003),
and some of these compounds also show anxiogenic and proconvulsant effects (Navarro et
al., 2002).
As is the case with GABAA/α2- and GABAA/α3 receptor-selective compounds,
studies with agonists selective for GABAA/α5 receptors are scarce.

QH-ii-066 (7-

acetyleno-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one), a compound with
6-fold selectivity for GABAA/α5 receptors compared with GABAA/α2 and GABAA/α3
receptors and 11-fold selectivity compared with GABAA/α1 receptors (Huang et al.,
2000), differs from classical BZs in that it did not share subjective effects with triazolam
in squirrel monkeys (Lelas et al., 2002). Like classical BZs, QH-ii-066 protected against
seizures induced by BZ inverse agonists DMCM and RY-24 (Skolnick et al., 1997).
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The present studies were designed to compare the effects of QH-ii-066 and
diazepam in an array of in vitro and in vivo assays. QH-ii-066 is a 7-acetyleno congener of
diazepam (Figure 1) and thus, diazepam was chosen as the classical BZ for comparison.
The two compounds were characterized in binding and electrophysiology functional assays
(HEK whole-cell patch clamp) and in models of anxiety (conflict), pentylenetetrazole
(PTZ)- and electroconvulsive shock (ECS)- induced seizures, learning and memory
(conditioned fear), sedation (locomotor activity), ataxia (rotorod performance), and BZlike subjective effects (CDP drug discrimination) in rodents.

Differences observed

between QH-ii-066 and diazepam in these assays would provide an indication of the
potential contribution of GABAA/α5 receptors to these effects of classical BZs.
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METHODS
Subjects
All animals were maintained in accordance with the guidelines of the Committee
on Animals of the Bristol-Myers Squibb Company and the “Guide for Care and Use of
Laboratory Animals” (Institute of Animal Laboratory Resources, 1996).

Research

protocols were approved by the Bristol-Myers Squibb Company Institutional Animal Care
and Use Committee.
Male CDF rats weighing approximately 350 g at the time of the experiment
(conflict), male Sprague-Dawley rats weighing 180-300 g (locomotor activity, rotorod
studies, and drug discrimination studies) and male CF1 mice weighing 20-22 g at the time
of the experiment (seizure studies) were purchased from Charles River Laboratories
(Wilmington, Mass., USA). For the conditioned fear studies, male Sprague-Dawley rats
weighing approximately 225 g at the time of the experiment were purchased from Harlan
(Indianapolis, Ind., USA). Animals were housed in pairs or fours in clear plastic shoebox
cages with Beta Chip bedding in rooms maintained at constant temperature (21-23°C) and
humidity (50 ± 10%) with a 12 h light/dark cycle (lights on at 0600 h, except for mice
lights were on at 0500 h), except for the drug discrimination study for which animals were
housed individually in suspended wire cages.
Animals had ad libitum access to food and water throughout the studies, except for
the conflict and drug discrimination studies in which animals were restricted to 9 g
(conflict) or 12 g (drug discrimination) of laboratory rodent chow (Bio-Serv, Frenchtown,
NJ) per day in addition to the food earned in operant box, with unlimited access to water.
All training and testing was done between 0600 and 1300 h Monday through Friday of
each week.
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Procedures
GABAA Binding Assay
HEK293 cells were trypsinized and counted. Cells were transfected using the
Amaxa electroporator and 3 million cells per sample. Each transfection was performed in
Amaxa solution “V” using electroporation program Q-01 (Amaxa Inc., Gaithersburg, Md.,
USA). 1 µg of each GABA subunit (α, β, and γ) was used per transfection. Following
electroporation, cells were plated onto poly-lysin coated glass coverslips and used for the
experiments.
Electrophysiological Studies
Whole-cell patch-clamp experiments were performed using HEK cell lines
transiently expressing two different configurations of GABAA constructs, on the first or
second day after the transfection. Cells were plated onto 25 mm Petri dishes and viewed
using Nikon TE200 inverted microscope, equipped with the mercury lamp to monitor GFP
fluorescence. Cells were continuously perfused with extracellular physiological solution
containing (in mM): NaCl 140, KCl 2.5, CaCl2 2, MgSO4 2, Na2HPO4 1.25, HEPES 10,
Glucose 11, pH 7.4 and 340 mOsm (modified from Brown et al., 2002). Patch pipettes
were pulled using Narishige vertical puller from fire-polished borosillicate glass
capillaries. Pipette resistance was between 3.5 and 6 MOm. The intracellular solution
contained (in mM): CsCl 140, HEPES 10, EGTA 5, MgATP 2, MgCl2 3, pH 7.3 and 340
mOsm.
Cells were voltage-clamped at -20 mV via an EPC10 amplifier (HEKA
Electronics, Southboro, Mass.). Preliminary experiments have shown that amplitude of
the GABA-induced current in these cells was not significantly different at -60, -40 or -20
mV holding potentials. At the same time, -20 mV holding potential facilitated longer
experimental time which enabled testing of several concentrations of the test compounds.
Drug solutions were applied to the cells via a multi-channel local perfusion system
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(AutoMate Scientific, Inc., San Francisco, Calif.) with the estimated solution change time
of 20 ms.
GABA was applied to the cell for 20 s with a 60 s washout period between
applications, which was found to be a sufficient time period to reverse any desensitization
that may occur. In addition, to ensure that there is no desensitization that may affect
GABA responses at any given concentration of a GABA modulator, GABA was applied
twice during control (no drug) and once at each concentration of the test compound. Test
compounds were applied in increasing concentrations (1, 10, 100, or 1000 nM) 60 s prior
to GABA (3 µM) applications.
Geller Conflict with Incremental Shock in Rats
Experiments were conducted in 8 model E10-10 Coulbourn operant chambers
(Coulbourn Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) with an electrified grid
floor which were housed in light-proof, sound-attenuated, and fan-ventilated chambers.
On one wall of each operant chamber was a houselight and a centrally placed food hopper
3 cm from the floor that delivered one 45-mg food pellet (Dustless Precision Pellets, BioServ, Frenchtown, N.J., USA). To the left was mounted a lever response module with cue
lights above. Foot-shock was delivered using an H13-16 Universal Shocker. Experiments
were controlled with a Compaq DeskPro computer running Graphic State Notation
software through Habitest Universal Linc interface equipment (Coulbourn Instruments).
Rats were trained to stability on an alternating multiple Random Interval 30
s/Fixed Ratio 1 Food +Shock paradigm (RI15/FR1 F+S). The paradigm ran through four
cycles beginning with the Random Interval (RI) schedule which ran for 12 minutes then
switched to the Fixed Ratio (FR) schedule which was cued and ran for 3 minutes. The RI
had a range of 15 to 45 s with the food pellet being delivered with the first lever press after
the expiration of the interval. The FR schedule delivered a food pellet after each lever
press along with a foot-shock that increased with each lever press beginning at zero on the
first lever press then increasing to 0.05 mA on the second lever press and incrementing by
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0.05 mA with each subsequent lever press. The shock was reset to zero at the beginning
of each RI/FR cycle.
Protection against Pentylenetetrazole- and Shock-Induced Seizures in Mice
Pentylenetetrazole (PTZ) was administered at 125 mg/kg s.c. The number of
animals surviving was recorded at 30 minutes and 60 minutes after administration of PTZ.
Electroshock is administered using a Ugo Basile ECT, Unit 7801 seizure apparatus (Ugo
Basile, Italy) and corneal electrodes soaked in 0.9% saline. Mice received a shock of 30
mA for 0.3 s. The number of animals that exhibited the hind-limb extensor component of
the seizure was recorded.
Conditioned Fear in Rats
Experiments were conducted in standard modular test chambers (ENV-008, Med
Associates, St. Albans, Vt., USA, 30.5 x 24.1 x 21 cm) with an electrified grid floor which
were housed in light-proof, sound-attenuated, and fan-ventilated chambers. Foot-shock
was delivered using a shocker/scrambler module (ENV-414).

Experiments were

controlled with a desktop computer using Med-PC software through Smart Ctrl interface
equipment (Med-Associates).
On day 1, rats were placed in the test chambers for a 7-minute conditioning session
consisting of 2.5 minutes of habituation, a 2-s foot-shock at 0.7 mA, followed by 2.5
minutes of no foot-shock, another 2-s, 0.7 mA foot-shock, and another 2 minutes with no
foot-shock. Twenty-four hours after the conditioning session, rats were placed in the test
chamber again for 7 minutes with no foot-shocks and percent time freezing was quantified
by video image analysis (Freezeview software using filter 25 and bout length of 0.75 s;
Actimetrics and Coulbourn Instruments, Allentown, Penn., USA).
Spontaneous Locomotor Activity in Rats
The testing apparatus consisted of Plexiglas chambers (42 x 42 x 30 cm) equipped
with Digiscan activity monitors (Omnitech Electronics, Columbus, Ohio, USA) that detect
interruptions of eight photobeams spaced 5 cm apart and 2.5 cm above the floor.
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Horizontal activity was recorded in 5-minute bins for a total of 60 minutes and expressed
as total distance covered (in cm).
Rotorod Performance in Rats
The degree of motor coordination or balance was determined using a standard
accelerating rotorod treadmill (Ugo Basile, Comerio-Varese, Italy) that was 6 cm in
diameter and 24 cm above the base. The speed was increased gradually from 2 rpm to a
maximum speed of 20 rpm. The time each animal remained on the rotating rod was
automatically recorded, up to a maximum of 5 minutes. Three acclimation trials were
conducted for each animal prior to administration of drugs. The time on rotorod from the
third trial was used to counterbalance animals for subsequent drug testing.
Chlordiazepoxide Discrimination in Rats
Twelve model E10-10 Coulbourn operant conditioning chambers (Coulbourn
Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) were housed in light-proof, soundattenuated, and fan-ventilated chambers.

Each operant conditioning chamber was

equipped with two non-retractable levers, requiring a downward force equivalent to 15 g
(0.15 N), that were mounted 3 cm from the side wall, 3 cm above the metal grid floor, and
5 cm from a centrally placed food tray that delivered one 45-mg food pellet (Dustless
Precision Pellets, Bio-Serv, Frenchtown, N.J.).

The experimental chambers were

connected to a Micro PDP11/73 computer using a LAB LINC interface. A SKED-11
operating system (State System, Kalamazoo, Mich.) was used to record and control
behavior.
After habituation to the operant conditioning chamber, rats were trained to
alternate daily between response levers on an FR 1 schedule of food reinforcement. Once
lever pressing was well established, the reinforcement contingency was increased
incrementally to an FR 10 schedule of food reinforcement, while maintaining the lever
alternation.

Rats were then trained to discriminate between an intraperitoneal (IP)

injection of drug (5.0 mg/kg CDP) and vehicle (0.25% methylcellulose) administered 30
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minutes prior to the start of the session. Ten consecutive responses on the injectionappropriate lever resulted in food delivery. Responses on the incorrect lever did not result
in pellet delivery. Following an injection of CDP, responding on the right lever was
reinforced for half the rats and responding on the left lever was reinforced for the other
rats. In each two-week period there were five drug days and five saline days, with the
constraint that there not be more than three consecutive drug or vehicle days.
Drug test sessions were conducted once a week (Fridays) with training sessions
scheduled on intervening days (Monday – Thursday).

The criterion for testing was

achieved if no more than three incorrect responses occurred prior to the first reinforcer for
at least 9 out of 10 consecutive sessions. During test sessions, the lever on which the rat
first made 10 consecutive responses resulting in delivery of the first food pellet was
designated the “selected “ lever and subsequent pellet delivery was made contingent on
responding on this selected lever on an FR10 schedule. The selected lever, the number of
responses prior to the first food pellet delivery, and the total number of responses in the
session were recorded for each rat. The duration of test sessions was ten minutes. Doseresponse functions were determined for CDP, diazepam, and QH-ii-066.

Drugs
GABA, diazepam, PTZ, and CDP HCl were purchased from Sigma (St. Louis,
Mo., USA). QH-ii-066 was synthesized by Xiaoyan Li, Wenyuan Yin, and Dongmei Han
at the University of Wisconsin. Compounds were prepared as suspensions in an aqueous
vehicle of 0.25% methylcellulose (Type A15c, Dow Chemicals), except for diazepam in
the conditioned fear study which was prepared in 40% propylene glycol / 10% ethanol /
50% benzoic acid solution. Stock suspensions were bead-milled overnight using three
layers of 4-mm glass beads.
vehicle.

Dilutions were made using the 0.25% methylcellulose

Compounds were administered orally by gavage (PO) 60 minutes before
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behavioral testing in a volume of 2 ml/kg body weight. Doses of all drugs were calculated
and are expressed in terms of the free base weight.

Data Analysis
In the electrophysiology experiments, the amplitude of the IGABA in each cell was
normalized to IGABA produced by 3 μM GABA in the absence of drug in the same cell.
Data (% increase of IGABA) from 3-6 cells for each concentration were averaged and
concentration-response curves for each test compound were constructed using ExcelFit.
All data are presented as mean ± 1 SEM.
Results for conflict, locomotor activity, and rotorod performance are expressed as
the mean ± 1 SEM. Results for the PTZ- and ECS-induced seizures are presented as the
percent of animals protected from death and percent of animals protected from the hindlimb extensor component of the seizure, respectively. Results for the drug discrimination
study are expressed as the percent of animals selecting the CDP-appropriate lever. A drug
was considered to substitute fully for CDP if 75% of the animals selected the CDPappropriate lever. Response rates were expressed as percentage of control rate (average of
the vehicle training session immediately before and the vehicle session immediately after
the test) for individual animals, averaged across animals, and plotted as a function of dose
(mean ± 1 SEM). All data were subjected to analysis of variance (ANOVA) followed by
individual mean comparisons using Fisher’s Least Significant Difference Test (Kirk,
1968) where appropriate. The significance level was set at P<0.05. ED50 values were
calculated by linear regression.
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RESULTS
GABAA Binding Assay
Binding affinities of QH-ii-066 and diazepam at different rat GABAA receptor
subtypes are shown in Table 1. QH-ii-066 showed similar affinity for the six rat GABAA
receptors examined (range of Ki = 40-72 nM). Similarly, diazepam showed comparable
binding affinity at all GABAA receptor subtypes studied (range of Ki values was 20-28
nM). QH-ii-066 had a 2- to 3-fold lower affinity than diazepam at the six receptors
studied.
Electrophysiological Studies
Application of GABA resulted in a dose-dependent increase in Cl- currents in
GABAA/α1β2γ2 and GABAA/α5β2γ2 receptors transiently expressed in HEK cells (data
not shown). The EC50 value for GABA was 7.55±0.58. Diazepam and QH-ii-066 both
potentiated GABA-induced Cl- currents at both GABAA/α1β2γ2 and GABAA/α5β2γ2
receptors in a concentration-dependent manner (Figure 2).

At the GABAA/α1β2γ2

receptors, maximum potentiation of IGABA by diazepam occurred at 1 µM and reached
389% of control, whereas maximum potentiation of IGABA by QH-ii-066 occurred at 100
nM and reached only 200% (at 1 µM, the potentation of IGABA by QH-ii-066 reached 180%
of control). In contrast, at the GABAA/α5β2γ2 receptors, maximum potentiation of IGABA
by diazepam and QH-ii-066 occurred at the same concentration (1 µM) and reached
similar levels (282% and 289% of control, respectively).
Geller Conflict with Incremental Shock in Rats
Diazepam and QH-ii-066 increased punished responding without altering the rate
of responding in the unpunished component (Figure 3). Diazepam significantly increased
responding in the punished component to 178% of control at the dose of 3.0 mg/kg PO
[F(3,21)=3.38, P=0.04]. QH-ii-066 significantly increased punished responding to 149%
of control at the dose of 10 mg/kg PO [F(3,15)=3.7, P=0.04]. Thus, QH-ii-066 is 3-fold
less potent than diazepam in increasing punished responding in rats.

The doses of
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diazepam and QH-ii-066 that produced a significant increase in punished responding did
not alter rates of responding in the punished component [F(3,21)=1.72, P=0.19 for
diazepam; F(3,15)=3.14, P=0.06 for QH-ii-066].
Protection from Pentylenetetrazole- and Shock-Induced Seizures in Mice
Diazepam and QH-ii-066 both fully protected against both PTZ- (at 1.0 and 10
mg/kg PO, respectively) and ECS- (10 and 100 mg/kg PO, respectively) induced seizures
in mice (Figure 4). The ED50 values for the protective effects of diazepam and QH-ii-066
are 0.27 mg/kg and <3 mg/kg against PTZ-induced seizures, respectively. The ED50
values for the protective effects of diazepam and QH-ii-066 are 0.88 mg/kg and 18.57
mg/kg against ECS-induced seizures, respectively. Thus, QH-ii-066 is approximately 11fold and 21-fold less potent in protecting against PTZ- and ECS-induced seizures,
respectively, than diazepam. Both compounds are more potent in protecting against PTZthan ECS-induced seizures, 3-fold more potent in the case of diazepam and more than 6fold more potent in the case of QH-ii-066.
Conditioned Fear in Rats
For both diazepam and QH-ii-066 experiments, vehicle-treated rats showed an
increase in freezing observed on test day (day 2) compared with animals who did not
receive

shock

(diazepam

study:

F(1,95)=19.88,

P<0.0001;

QH-ii-066

study:

F(1,95)=13.27, P<0.0004). Diazepam significantly decreased freezing on test day relative
to the vehicle-treated group (Figure 5, left panel). A dose of diazepam comparable to that
which was effective in the conflict model (2.5 mg/kg) decreased percent freezing by 44%
(F(1,95)=6.46, P=0.01) and a higher dose (5.0 mg/kg) also significantly decreased percent
freezing by 39% (F(1,95)=5.11, P=0.03).

Unlike diazepam, QH-ii-066 did not alter

freezing on test day relative to the vehicle-treated group at doses up to and including 10
mg/kg (Figure 5, right panel; F(1,95)=0.5, P=0.48), the lowest effective dose in the
conflict model.
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Spontaneous Locomotor Activity in Rats
Diazepam and QH-ii-066 dose-dependently decreased spontaneous locomotor
activity recorded 60-120 minutes after oral administration (corresponding to the 60-min
pretreatment time and 60-min test duration in the conflict test) [diazepam F(5,42)=16.66,
P<0.0001, Figure 6, left panel; QH-ii-066 F(6,49)=4.17, P=0.002, Figure 6, right panel].
The lowest effective dose of diazepam in the conflict model (3.0 mg/kg) did not alter
locomotor activity; however, a 3-fold higher dose (10 mg/kg) resulted in a significant
reduction of locomotor activity (by 34%, P=0.001), as did the doses of 30 and 100 mg/kg
(38%, P=0.0004 and 75%, P<0.0001, respectively). In comparison, the lowest effective
dose of QH-ii-066 in the conflict model (10 mg/kg) also did not alter locomotor activity;
however, a 10-fold higher dose (100 mg/kg) resulted in a significant decrease in locomotor
activity (by 49%; P=0.04).
Rotorod Performance in Rats
Diazepam dose-dependently decreased motor coordination in rats as measured by
time on rotorod [F(3,28)=5.43, P<0.005, Figure 7, left panel]. The dose of 100 mg/kg of
diazepam resulted in a significant decrease in time on rotorod to 72% of control
(P=0.001). The dose of 3.0 mg/kg of diazepam, the lowest effective dose of diazepam in
the conflict model, did not alter the time on rotorod (P=0.84); thus, the difference between
the lowest effective dose of diazepam in the conflict model compared with rotorod
performance is 33-fold.
Unlike diazepam, QH-ii-066 did not alter time on rotorod in rats up to 100 mg/kg
[F(3,27)=1.0, P=0.41, Figure 7, right panel]. The lowest effective dose of QH-ii-066 in
the conflict model (10 mg/kg) did not alter rotorod performance (P=0.96) and neither did
the highest dose of QH-ii-066 tested (100 mg/kg, P=0.44). Thus, the difference between
the lowest effective dose of QH-ii-066 in the conflict model compared with rotorod
performance is greater than 10-fold.
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Chlordiazepoxide Discrimination in Rats
All rats acquired stimulus control with the training dose of CDP of 5.0 mg/kg (IP,
administered 30 minutes before session). These data were reported by Lelas et al. (2003).
Briefly, the mean response rates (responses/min ± SEM) for vehicle and CDP were 67.1 ±
8.5 and 91.7 ± 9.8, respectively. The ED50 value for CDP was 1.7 mg/kg. All three doses
of CDP significantly increased response rates relative to vehicle control rates.
Both diazepam and QH-ii-066 dose-dependently increased the percent of rats
selecting the CDP lever (Figure 8). At the lowest effective dose of diazepam in the
conflict model (3.0 mg/kg) 86% of animals selected the CDP lever, and at 10 mg/kg 100%
of animals selected the CDP lever. The ED50 value for diazepam is 2.82 mg/kg. In
comparison, the lowest effective dose of QH-ii-066 in the conflict model (10 mg/kg)
resulted in 63% of animals selecting the CDP lever, and at 30 mg/kg 100% of animals
selected the CDP lever. The ED50 value for QH-ii-066 is 8.56 mg/kg. Thus, in the case of
diazepam, there is no separation between the doses effective in the conflict model and
those resulting in CDP-lever selection, whereas for QH-ii-066 this separation is 3-fold.
Diazepam increased mean response rates, expressed as percent of control, at 5.0
mg/kg to 158% of control [t(6)=2.69, P=0.04)], but did not alter rates of responding at the
lower (1.0 mg/kg) or the higher (10 mg/kg) dose tested. The highest dose of QH-ii-066
tested (30 mg/kg) decreased response rates to 77% of control [t(8)=2.38, P=0.04].
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DISCUSSION
The purpose of the present studies was to compare the in vitro and in vivo profiles
of diazepam, a non-selective classical BZ agonist, and QH-ii-066, a 7-acetyleno congener
of diazepam. In contrast to the previously published data (Huang et al., 2000), the present
study showed that QH-ii-066 did not bind selectively to any GABAA receptor subtype.
Affinity of QH-ii-066 at GABAA/α1, GABAA/α2, GABAA/α3, and GABAA/α5 receptors
was similar, ranging between 40 and 72 nM. Binding affinity of QH-ii-066 and diazepam
at the GABAA/α1 and GABAA/α5 receptors was similar in the presence of either β2 or β3
subunits. In the previous publication (Huang et al., 2000), QH-ii-066 showed a 6-fold
selectivity for GABAA/α5 over GABAA/α2 and GABAA/α3 receptors and 11-fold
selectivity over GABAA/α1 receptors. Thus, the difference in binding affinity for the
GABAA/α5 receptors between the two studies is 6-fold. It is possible that this discrepancy
is due to the fact that the Huang et al. (2000) study used cells expressing human GABA
receptors, whereas the present study used rat GABA receptors. When compared with
diazepam, binding data from the present study show that the 7-acetyleno congener of
diazepam exhibits approximately 2-fold lower affinity for all BZ-sensitive GABAA
receptor subtypes.
In contrast to the binding data, electrophysiology studies showed a functional
selectivity of QH-ii-066 compared with diazepam. The intrinsic efficacy of QH-ii-066 at
the GABAA/α5 receptor was similar to the efficacy of diazepam, as measured by
potentiation of GABA-induced Cl- currents in HEK cells transiently expressing
GABAA/α5 receptors. However, QH-ii-066 was approximately half as efficacious as
diazepam in HEK cells transiently expressing GABAA/α1 receptors. Thus, while QH-ii066 did not show binding selectivity, it did exhibit functional selectivity, with diazepamlike efficacy at GABAA/α5 receptors and partial efficacy at GABAA/α1 receptors.
In vivo, the effects of QH-ii-066 and diazepam were compared directly in
behavioral models of anxiety, epilepsy, and side effects (sedation, motor incoordination,
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and subjective effects).

QH-ii-066 and diazepam administered orally significantly

increased punished responding in the Geller conflict test with incremental shock, an index
of anxiolytic-like activity in rats.

QH-ii-066 was 3-fold less potent in this model

compared with diazepam. This loss of potency could be accounted for by lower affinity of
QH-ii-066 at all BZ-sensitive GABAA receptors. The present data suggest that QH-ii-066
retained anxiolytic-like activity despite loss of efficacy at the GABAA/α1 receptors. These
data support the conclusion from studies using the GABAA/α1 receptor knock-out or
knock-in mice showing normal anxiolytic-like response to diazepam in these animals
(Kralic et al., 2002; Rudolph et al., 1999; McKernan et al., 2000), suggesting that
GABAA/α1 receptors do not play an important role in the anxiolytic effects of BZs. While
efficacy of QH-ii-066 at the GABAA/α2 or GABAA/α3 receptors was not investigated in
the present study, the similar effects of QH-ii-066 and diazepam in the conflict model
suggest that QH-ii-066 retained diazepam-like intrinsic efficacy at these receptors.
In addition to the anxiolytic-like effects, QH-ii-066 and diazepam also showed
protective effects against PTZ- and ECS-induced seizures. Diazepam was 3-fold less
potent in protecting against ECS-induced seizures compared with PTZ-induced seizures;
this difference was increased to 6-fold in the case of QH-ii-066.

When the two

compounds are compared in potency in protecting against each type of seizures, diazepam
was 11-fold more potent than QH-ii-066 in protecting against PTZ-induced seizures and
21-fold more potent against ECS-induced seizures. Thus, it appears that the 7-acetyleno
substituted diazepam analog QH-ii-066 showed a greater loss of potency in protecting
against ECS-induced seizures relative to diazepam than against PTZ-induced seizures.
These data may suggest that GABAA/α1 receptors play a more prominent role in the ECSinduced seizures than in PTZ-induced seizures.

SL651498, a compound with lower

efficacy at GABAA/α1 receptors (Griebel et al., 2001), and bretazenil, a low-efficacy
agonist at many GABAA subtypes including GABAA/α1 receptors (Martin et al., 1988),
were also more potent in reversing PTZ- than ECS-induced seizures. In addition, Griebel
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et al. (1999) showed that β-CCT, an GABAA/α1 receptor-preferring antagonist, did not
alter protective effects of diazepam and zolpidem against PTZ-induced seizures, whereas
it blocked the effects of the agonists against isoniazid-induced seizures. Taken together,
these data suggest that PTZ-induced seizures are less dependent on the activity at the
GABAA/α1 receptors than ECS-induced seizures.
The conditioned fear model has been used to study “cognitive-affective” processes
in anxiety disorders (e.g., Uys et al., 2003). In this model, animals are exposed to pairings
of a neutral stimulus (conditioned stimulus (CS); e.g., tone or context) with an aversive
stimulus (unconditioned stimulus (UCS); e.g., shock). Following acquisition, behaviors
typically seen after the presentation of UCS (e.g., startle, freezing, or suppression of waterdrinking) are now seen when the CS is presented alone. BZs reduced expression of UCSappropriate behaviors in the presence of the CS (e.g., Davis, 1979; Sanger and Joly, 1985).
The same effects are obtained following administration of scopolamine (e.g., Rudy, 1996;
Lindner et al., 2003), a memory-impairing agent without any anxiolytic-like activity,
suggesting that the conditioned fear assay is more sensitive to memory-impairing rather
than anxiolytic-like effects of BZs. In the present study, diazepam at the doses of 2.5 and
5.0 mg/kg PO resulted in a decrease in freezing, whereas QH-ii-066 did not affect freezing
at the doses up to and including 10 mg/kg, PO. Thus, QH-ii-066 appears to be 2-fold less
potent in producing memory deficits in the conditioned fear test. It has been suggested
that GABAA/α5 receptors mediate memory-impairing effects of BZs (e.g., Collinson et al.,
2002).

Our electrophysiology studies showed comparable efficacy of QH-ii-066 and

diazepam in potentiating the GABA currents through the GABAA/α5 receptors. The
observed difference in potency in the conditioned fear assay could be due to lower affinity
of QH-ii-066 at all GABAA receptors studied. Therefore, higher doses of QH-ii-066
would need to be tested to determine if lower efficacy of QH-ii-066 at GABAA/α1
receptors compared with diazepam would result in lower potential to produce memory
deficits in animals. However, the present study indicates that QH-ii-066 may have a better
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therapeutic index than diazepam with respect to memory impairment since the doses of
diazepam effective in the conflict and conditioned fear models effects were, whereas QHii-066 showed at least a 3-fold separation between doses effective in these tests.
Effects of QH-ii-066 and diazepam on motoric behaviors were assessed using the
locomotor activity assay as an index of sedative effects and the rotorod performance as an
index of motor incoordination. QH-ii-066 was 10-fold less potent than diazepam in
reducing locomotor activity and at least 3-fold less potent in reducing time on rotorod.
These differences in potency to produce sedation and motor incoordination lead to a better
therapeutic index for QH-ii-066 compared with diazepam, despite a 3-fold loss of potency
in producing anxiolytic-like effects (Table 2). Thus, QH-ii-066 shows a 10-fold or greater
separation between its effects on motoric behavior and its anxiolytic-like effects in rats.
By comparison, diazepam showed only a 3-fold separation in dose between the sedative
and anxiolytic-like effects and a better (33-fold) separation in dose between the ataxic and
anxiolytic-like effects.
Since QH-ii-066 has only 2-fold lower affinity for the six GABAA receptors
compared with diazepam, the 10-fold loss of potency of QH-ii-066 in reducing locomotor
activity suggests that diminished intrinsic efficacy of QH-ii-066 at the GABAA/α1
receptors also contributed to its reduced potency in producing sedative effects. These data
support studies with transgenic mice and GABAA/α1-selective agonists in indicating that
GABAA/α1 receptors mediate sedative/ataxic effects of classical BZs (e.g., Rudolph et al.,
1999; McKernan et al., 2000; Kralic et al., 2002; Fry et al., 2000).
Finally, effects of QH-ii-066 and diazepam were compared in animals trained to
discriminate CDP. Drug discrimination may be used as an index of abuse liability when
compounds of the same pharmacological class are compared. In the present studies,
animals were trained to discriminate CDP, a classical BZ with no apparent receptor
selectivity. Diazepam at 3.0 mg/kg and QH-ii-066 at 30 mg/kg fully substituted for CDP,
suggesting that at some dose, both compounds produce CDP-like subjective effects. As
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was the case for locomotor activity, lower affinity of QH-ii-066 at GABAA receptors alone
does not account entirely for the lower potency of QH-ii-066 compared with diazepam in
substituting for CDP, suggesting that GABAA/α1 receptors may be an important part of
the CDP stimulus in rat drug discrimination. In addition, these data also suggest that
compounds like QH-ii-066 with lower efficacy at GABAA/α1 receptors may have reduced
abuse liability compared with classical BZs.
In summary, QH-ii-066, the 7-acetyleno congener of diazepam, showed a 2-fold
loss of affinity at all GABAA receptors studied relative to diazepam. However, QH-ii-066
also showed a loss of efficacy at the GABAA/α1 receptors compared with diazepam, while
retaining diazepam-like efficacy at the GABAA/α5 receptors. In vivo, QH-ii-066 showed
anxiolytic-like and protective effects against PTZ-induced seizures in rodents at doses
similar to those of diazepam. QH-ii-066 was less potent than diazepam in protecting
against ECS-induced seizures, indicating that ECS-induced seizures are mediated by
GABAA/α1 receptors to a greater extent than PTZ-induced seizures. QH-ii-066 was also
less potent than diazepam in reducing activity and in producing CDP-like subjective
effects, suggesting that QH-ii-066 and other compounds with lower intrinsic efficacy at
the GABAA/α1 receptors may be effective anxiolytics in humans with a reduced potential
for side effects.
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Table 1.
Binding affinity of QH-ii-066 and diazepam for rat GABAA receptors.
GABAA Receptor Ki (nM)
Compound

α1β2γ2

α1β3γ2

α2β3γ2

α3β3γ2

α5β2γ2

α5β3γ2

QH-ii-066

52±3*

56±1***

51±2**

72±8**

44±1**

40±8***

Diazepam

18

20

20

28

22

20

Ratioa

2.9

2.8

2.6

2.6

2.0

2.0

* n=5 determinations
** n=3 determinations
*** n=2 determinations
a

Ratio of binding affinity, QH-ii-066:diazepam
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Table 2.
Lowest effective doses (mg/kg) and therapeutic indices for QH-ii-066 and
diazepam in behavioral models.
Assay

QH-ii-066

Diazepam

Ratio

Conflict

10

3.0

3-fold

Conditioned Fear

>10

2.5

>4-fold

Locomotor Activity (LMA)

100

10

10-fold

Rotorod

>100

100

≥3-fold

Chlordiazepoxide

30

3.0

10-fold

Conflict:LMA Ratio

10-fold

3-fold

Conflict:Rotorod Ratio

>10

33-fold

Conflict:DD Ratio

3-fold

0

Drug Discrimination (DD)
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LEGENDS FOR FIGURES
Figure 1. Chemical structures of QH-ii-066 and diazepam.

Figure 2. Effects of diazepam and QH-ii-066 on GABA-induced Cl- currents in two
GABAA constructs (α1β2γ2 and α5β2γ2).

Abscissae: concentration (log, nM).

Ordinates: Percent control (3 µM GABA without drug) IGABA for n=3-6 cells per
concentration.

Figure 3. Anxiolytic-like effects of diazepam and QH-ii-066 in the Geller conflict with
incremental shock test in rats.

Abscissae: dose (mg/kg). Ordinates: mean (±SEM)

response rates expressed as percent of control rates (vehicle training days) for n=6-8
animals per dose. Diazepam and QH-ii-066 were administered in 0.25% methylcellulose
PO, 60 minutes prior to testing. * P<0.05.

Figure 4. Effect of diazepam and QH-ii-066 on pentylenetetrazole- and electroconvulsive
shock-induced seizures in mice. Abscissae: dose (mg/kg). Ordinates: percent animals
protected for n=12 animals per dose. Diazepam and QH-ii-066 were administered in
0.25% methylcellulose PO, 60 minutes prior to testing.

Figure 5. Effect of diazepam and QH-ii-066 in conditioned fear test in rats. Abscissae:
dose (mg/kg). Ordinates: mean (±SEM) percent time spent freezing for n=16-24 animals
per dose. Diazepam and QH-ii-066 were administered in 0.25% methylcellulose PO, 60
minutes prior to behavioral testing. * P<0.05.
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Figure 6. Effect of diazepam and QH-ii-066 on spontaneous locomotor activity in rats.
Abscissae: dose (mg/kg). Ordinates: mean (±SEM) distance traveled (in cm) for n=8
animals per dose. Diazepam and QH-ii-066 were administered in 0.25% methylcellulose
PO, 60 minutes prior to behavioral testing. * P<0.05.

Figure 7. Effect of diazepam and QH-ii-066 on motor coordination in the rotorod test in
rats. Abscissae: dose (mg/kg). Ordinates: mean (±SEM) time on rotorod (in seconds) for
n=7-8 animals per dose.

Diazepam and QH-ii-066 were administered in 0.25%

methylcellulose PO, 60 minutes prior to behavioral testing. * P<0.05.

Figure 8.

Discriminative stimulus and rate-decreasing effects of chlordiazepoxide,

diazepam, and QH-ii-066 in rats (n=7-12) discriminating between chlordiazepoxide and
vehicle.

Abscissae: dose (mg/kg).

Ordinates: percent of rats selecting the

chlordiazepoxide lever (upper panel) and mean response rates (± SEM) expressed as
percent control rates (vehicle training days) (lower panel).

Chlordiazepoxide was

administered in 0.25% methylcellulose IP, 30 minutes before testing. Diazepam and QHii-066 were administered in 0.25% methylcellulose PO, 60 minutes prior to behavioral
testing.

* P<0.05. The dashed line in the upper panel refers to 75% of animals selecting

the drug lever (criterion for substitution).
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Conditioned fear model

Figure 5
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Figure 7
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V. Appendix III: Data on QH-II-066
eQTL and receptor pharmacology implicate GABA signaling in neuroblastoma
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Summary
The signaling pathways driving neuroblastoma, a tumor derived from neural
progenitors, remain largely unidentified.

In an engineered mouse model for

neuroblastoma, susceptibility to tumors is strain-specific and genetically complex.
To identify genes involved in tumor susceptibility, we analyzed genetic control of
gene expression (eQTL) in the peripheral sympathetic nervous system. Here we
show that genes controlling GABA neurotransmitter signaling, including arginase
(Arg1), co-localized with susceptibility loci. Activation of GABA-A receptors in
human neuroblastoma cells induced apoptosis, while inhibition of arginase slowed
proliferation.

These results demonstrate the ability of a neurotransmitter to

regulate cell growth, and present novel neuroblastoma therapeutic targets.
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Introduction
Neuroblastoma, a pediatric tumor of the peripheral nervous system, arises from
sympathetic neural progenitors that normally differentiate into post-mitotic neurons
shortly after birth. Mutations that drive myeloid, epithelial, and glial tumors are largely
not present in neuroblastoma, suggesting this tumor arises from disruption of growth
pathways specific to the neural lineage. In a transgenic model driven by the MYCN
proto-oncogene, amplification of which is a hallmark of high-risk neuroblastoma1,2, mice
develop tumors with histological and genomic characteristics of human neuroblastoma3,4.
In this model, tumor incidence varies among mouse strains, and we exploited this genetic
variance to identify novel molecular pathways driving neuroblastoma development.
In this study, genetic linkage analysis revealed a locus on chromosome 10 that
interacted with numerous secondary loci to influence tumor susceptibility. To identify
candidate genes at these loci, we superimposed expression quantitative trail loci (eQTL)
in sympathetic superior cervical ganglia (SCG) from backcross mice. Liver arginase
(Arg1), a component of both the urea cycle and the gamma-amino butyric acid (GABA)
biosynthetic pathway, was the strongest eQTL at the primary chromosome 10 locus.
Multiple genes and eQTL involved in GABA neurotransmitter signaling were located at
the secondary susceptibility loci, providing an intriguing genetic link between

this

pathway and neuroblastoma biology. We tested this link using compounds targeting the
Arg1-GABA pathway in human neuroblastoma cell lines. Both nor-NOHA, an Arg1
inhibitor, and, more strikingly, nanomolar concentrations of the neurotransmitter GABA,
inhibited cell growth and viability in vitro.

The GABA response was dependent on

GABA-A receptor expression and was rescued with GABA-A-specific antagonists.
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Activation of GABA-A signaling induced apoptosis and was associated with decreased
activity of PI3K/AKT and MAPK signaling, two central pathways in cell growth and
survival.

The implication of arginine metabolism and GABA signaling in the

pathogenesis of neuroblastoma presents a combination of therapeutic targets.
Additionally, the demonstration that the neurotransmitter GABA inhibits growth of tumor
cells derived from a neural lineage highlights an emerging role for neurotransmitters in
regulating development of the peripheral nervous system.
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Results
Neuroblastoma penetrance in TH-MYCN mice is strain-dependent
Transgenic mice were generated on a Balb/c x C57B6/J background and showed
~10% incidence of tumors.

As mice were crossed into strain FVB/NJ, incidence

decreased to zero by 2 generations (Supplementary Figure 1A). Conversely, penetrance
of tumors steadily increased with each successive backcross into strain 129/SvJ, leveling
out at ~60%5. Levels of transgene expression were similar between genetic backgrounds
(Supplementary Figure 1B).
We next crossed resistant transgenic FVB/NJ mice to susceptible wild-type
129/SvJ.

The resulting F1 mice showed 4% incidence of tumors, suggesting that

resistance was genetically dominant. To generate a genetically diverse population for
linkage mapping, we backcrossed transgenic F1 animals to wild-type 129/SvJ mice.
Incidence of tumors in the resulting N1 backcross generation was 38% (N=203), with an
average survival (109 days) identical to that of mice carrying the transgene in a pure
129/SvJ background 5

Linkage analysis identifies a tumor susceptibility modifier on chromosome 10
To identify genomic loci associated with tumor susceptibility, we genotyped 203
mice using a combination of microsatellite and SNP markers (see Supplementary
Methods). Interval mapping for linkage to tumor susceptibility produced a maximum
LOD (log of odds) score on chromosome 10 at marker RS36323433 (LOD=4.1, Figure
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1A, B, significant at a 5% genome-wide error rate, see Supplementary Methods).
However, at this locus, heterozygous mice were tumor prone (55%), while mice
homozygous for the 129/SvJ allele were resistant (25% incidence) (Figure 1C).
Additionally, tumor susceptibility was strongly influenced by gender. Performing the
analysis using sex as an interacting covariate increased the LOD score to 4.9. When mice
were segregated by sex and analyzed independently, this locus was not significant in
female mice but was in males (LOD=4.3, N=82). It may be relevant in this regard that
neuroblastoma is slightly more prevalent in boys (1.3:1) than in girls6.
Since the segregation of genotypes with tumor susceptibility at the chromosome
10 locus did not match the patterns of tumor susceptibility in the parent strains, we next
considered a more complex genetic model to explain susceptibility.

A 2-QTL test

identified several loci that interacted with the chromosome 10 locus, with similar LOD
scores (Figure 1D, Supplementary Table 1).

Interestingly, while all of these loci

interacted with the chromosome 10 locus, they did not interact with each other.

Expression QTL analysis identifies Arg1 as a candidate modifier
The 95% confidence interval of the peak on chromosome 10 spanned 47Mb and
contained over 281 genes (see Supplementary Methods), complicating identification of
candidates. Hypothesizing that susceptibility to tumors may be governed by differential
expression of genes within this locus, we narrowed our field of candidates by comparing
mRNA expression levels in neural crest-derived sympathetic superior cervical ganglia
(SCG) from transgenic male and female 129/SvJ and FVB/NJ mice using Affymetrix
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Mouse Exon arrays. Surprisingly, only 8 genes were differentially expressed between
sexes, and with the exception of a RIKEN clone on chromosome 2, all mapped to either
the X or Y chromosomes (Supplementary Figure 1C, Supplementary Table 3),
excluding gender-specific gene expression as a mechanism for the gender effect at the
chromosome 10 locus. When males of the two strains were compared, however, 9,820
genes were differentially expressed genome-wide (Supplementary Figure 1D,
Supplementary Table 3), including 137 within the 95% confidence interval for the
chromosome 10 susceptibility locus (representing almost half of all genes within the
locus).
Gene expression levels can be influenced by complex interactions among cis- and
trans- acting factors. One method for distinguishing these factors involves generating a
genetically heterogeneous population (such as our backcross population), measuring gene
expression levels, and treating the expression level of each gene as a quantitative trait
(expression QTL or eQTL7,8). Using this method, the cis- and trans- acting alleles
influencing gene expression are decoupled from each other, and genes whose differential
expression is due to cis-acting factors at a locus can be distinguished from genes under
the control of trans-acting factors at other loci. Genes with eQTL overlapping with QTL
for physiological phenotypes have been shown to control these phenotypes8,9. We thus
utilized this technique to identify eQTL within our chromosome 10 locus, as well as at
the numerous other secondary loci identified in the 2-QTL tumor susceptibility analysis.
We measured mRNA expression levels in 116 SCG from the backcross
population and tested for linkage between gene-level expression calls for each gene and
germline variation, to identify 342 eQTL acting both locally and on another
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chromosomes (Supplementary Table 4). Four eQTL mapped to the susceptibility locus
on chromosome 10, with Arg1 (liver arginase) showing the strongest eQTL . When this
measurement was refined by interval mapping, Arg1 expression was linked to a QTL at
chromosome 10 with a LOD score of 18.2 (Figure 2A). Arg1 overlapped directly with
our tumor susceptibility locus, making Arg1 our top candidate gene (Figure 2C, Table
1).

Mice heterozygous at that locus had almost 2-fold higher expression of Arg1

compared to mice homozygous for the 129/SvJ allele (Figure 2B). Notably, among 137
genes differentially expressed at the chromosome 10 locus in parental strains, only four
showed significant eQTL mapping to the locus, with Arg1 showing the strongest eQTL in
backcross animals. These data suggest that differential expression of the other genes in
the parents was due in part to trans-acting factors, illustrating the power of eQTL
analysis in dissecting control of gene expression at a genetic locus and filtering candidate
genes.

eQTL for GABA-related genes map to secondary susceptibility loci
We next looked for eQTL that mapped to the secondary tumor susceptibility loci
that interacted with the chromosome 10 locus, and noted eQTL for genes related to
GABA neurotransmitter signaling at two of the loci (Table 1). Notably, a trans-eQTL on
chromosome 2 controlled expression of the Gabra3 receptor subunit on the X
chromosome (Figure 3A-C).

This eQTL overlapped directly with the secondary

susceptibility locus on chromosome 2 (Figure 3G, Supplementary Figure 2A, Table 1).
Mice harboring alleles resulting in high Arg1 expression and low Gabra3 expression
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showed the strongest susceptibility to tumors (Figure 3C). Similarly, an eQTL for the
GABA transporter Slc6a1 (Figure 3D-F) mapped to a secondary susceptibility locus on
chromosome 4 (Figure 3G, Supplementary Figure 2B, Table 1), though the gene was
on chromosome 6. Importantly, the chromosome 2 and 4 secondary susceptibility loci
showed the highest LOD scores in male mice (Supplementary Table 2).
We next investigated secondary susceptibility loci that lacked GABA-related
eQTL candidates and found several GABA-related genes mapping within 10Mb of
susceptibility peaks.

The locus on chromosome 1 (LOD 7.8) flanked by markers

RS5056599 (116MB) and D1MIT1001 (131Mb) , LOD 7.8) is in close proximity to Dbi
(diazepam binding inhibitor, 122Mb), a gene that modulates GABA receptor activity10.
Similarly, the locus on chromosome 9 centered near 117Mb (D9MIT201, LOD 7.9) is 4
Mb from the Trak1 gene, which encodes a trafficking factor that modulates GABA
receptor homeostasis11. The locus on chromosome 7 centered at 144Mb (RS13479509,
LOD 6.4) is 4 MB from ornithine aminotransferase (Oat), which converts ornithine to
glutamate (the substrate for GABA synthesis). Finally, the locus on chromosome 17
centered near 35Mb (D17MIT231, LOD 6.7) is 2 Mb from the GABA-B receptor 1.
Together, at least 6 secondary susceptibility loci co-localized with genes in the GABA
pathway, and/or eQTL controlling these genes (Table 1).

Inhibition of Arg1 decreases viability of human neuroblastoma cells
The higher-expressing Arginase allele conferring tumor susceptibility is nested
within an overall resistant genetic background in purebred mice (either FVB/NJ or
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FVB/NJ x 129/SvJ F1).

The allelic variation in the secondary loci (harboring

components of the GABA pathway) only showed an effect in combination with alleles at
other loci. This genetic complexity precluded validation in vivo.

The association of a

gene with susceptibility to tumors does not necessarily imply an ongoing role in tumor
maintenance. Nevertheless, since our ultimate goal was to identify clinically-relevant
biochemical pathways, we next analyzed Arg1 and GABA in human neuroblastoma cell
lines. As there is little precedent for these pathways in regulation of cell growth and thus
little basis for the specific downstream pathways involved, we assessed the effect of
compounds targeting this pathway on overall growth and viability.
We detected Arg1 by western blot across a panel of human neuroblastoma cell
lines (Figure 4A). We treated this panel with the reversible arginase inhibitor norNOHA (N-Omega-hydroxy-nor-arginine)12 to test whether inhibition of arginase could
impair tumor growth. Viability was decreased in CHP-126, SY5Y, and Kelly cells at
100µM (Supplementary Figure 3A). Both Kelly and SY5Y cultures accumulated in G1
phase with decreased numbers of cells in S phase, without a significant apoptotic fraction
assessed by flow cytometry (Supplementary Figure 3B). In SY5Y cells this effect was
nearly equivalent to the potent PI3K/mTOR inhibitor PI-103. We conclude that Arg1
expression modulates viability and proliferation in human neuroblastoma cells.

GABA-A activation induces apoptosis in neuroblastoma
We next investigated the role of GABA signaling in the control of viability.
While all neuroblastoma cell lines tested expressed the two human GABA-B receptors,
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expression of the GABA-A receptor subunits was variable (Figure 4A). In response to
GABA, viability was unchanged in cell lines CHP-126, Kelly and SY5Y, all of which
expressed low levels of the GABA-A receptor (Supplementary Figure 3C). In contrast,
the cell line LAN-5, which expressed high levels of the GABA-A receptor, was
particularly sensitive to GABA, showing a 40% decrease in viability at doses as low as
100nM. To demonstrate that this effect was specific to the GABA-A receptor, we cotreated cells with GABA and either picrotoxin or bicuculline.

Picrotoxin, a non-

competitive GABA-A channel blocker, was able to fully rescue the effects of both
100nM and 1mM GABA. In contrast, the competitive inhibitor bicuculline was able to
reverse the effects of GABA in a dose-dependent manner; 10µM bicuculline reversed the
effects of 100nM but not 1mM GABA treatment (Figure 4B). The dose-dependent and
independent effects of bicuculline and picrotoxin, respectively, are consistent with the
pharmacological mechanisms of each molecule on the GABA-A receptor, and
demonstrate the specificity of the GABA-A receptor’s role in cell viability.
We next assessed the mechanism by which GABA-A activation inhibited the
growth of neuroblastoma cells. To enhance the signal readout of this pathway, we
utilized the potent, selective GABA-A receptor agonist QHii066, a benzodiazepine
derivative13,14. Apoptosis was induced in both LAN-5 (high GABA-A expression levels)
and Kelly cells (low GABA-A expression levels) (Figure 4 C and D), as assessed by
annexin V flow cytometry. Immunoblotting revealed that upon addition of GABA and
QHii066, cleaved PARP, an indicator of apoptosis, was increased.

Notably,

immunoblotting revealed a decrease in activity of the PI3K/AKT and MAPK pro-growth
and survival pathways, indicated by decreased phosphorylation levels of Akt and Erk,
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respectively (Figure 4E). Together these data suggest that specific activation of the
GABA-A receptor decreases cell viability, induces apoptosis, and suppresses pro-growth
and survival signaling pathways in neuroblastoma cell lines.
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Discussion
The pathways regulating development of the peripheral nervous system are
distinct from those controlling epithelial and other cell types. Perhaps as a consequence,
common genomic aberrations driving tumorigenesis in epithelial and glial tumors rarely
show abnormalities in neuroblastoma, a tumor of the sympathetic peripheral nervous
system.
Mouse model systems have provided a tremendous resource for the identification
and validation of genes involved in cancer. Though the influence of strain background
on tumor penetrance is frequently observed in mouse models of cancer, only a handful of
genes underlying this susceptibility have been identified15-20, mostly due to the limited
resolution of quantitative trait linkage mapping. To decipher biological mechanisms
underlying genetic linkage to tumor susceptibility in our mouse neuroblastoma model, we
investigated patterns of gene expression in peripheral sympathetic nervous tissue.
Analysis of gene expression as a function of genotype (in other words, treating gene
expression levels as heritable traits and performing linkage analysis) has facilitated
identification of candidate genes for quantitative trait loci underlying physiological
differences7-9. Genetic control of gene expression is more direct than genetic influence
over complex physiological phenotypes. Thus, analysis of expression quantitative trait
loci or eQTL provides a relatively strong signal in linkage analysis, enabling the direct
identification of specific candidate genes among hundreds of genes at an overlapping
QTL for a physiological phenotype.

eQTL analysis has identified several genes

modifying tumor susceptibility in mouse models for cancer21-23. In the current study,
eQTL suggested candidate genes from a common biological pathway at multiple loci
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simultaneously, including genes located on chromosomes that were controlled in trans by
unidentified elements at the QTL loci, a phenomenon that would have been missed by
conventional analysis of candidate genes at the susceptibility loci.
eQTL analysis identified Arg1 as a candidate neuroblastoma modifier gene at
chromosome 10.

One of the strongest secondary susceptibility loci, a locus on

chromosome 2, overlapped with a particularly prominent eQTL governing expression of
a GABA-A neurotransmitter receptor subunit.

Numerous other susceptibility loci

overlapped with other GABA-related genes, suggesting a mechanism for the pattern of
genetic linkage to tumor susceptibility and implicating an interaction between upregulation of arginase activity and down-regulation of GABA receptors as cooperating
mechanisms promoting susceptibility to tumors.
While Arg1 is associated with the urea cycle in liver, it is also expressed in a
number of tissues that do not carry out the urea cycle, including sympathetic nerve
ganglia24, suggesting a role in other biochemical pathways. In neurons, Arg1 is part of
the GABA synthesis pathway, producing ornithine, a precursor of glutamate and of
GABA. The biochemical link between Arg1 and the GABA pathway potentially explains
our unique genetic pattern of several secondary loci interacting with a single gene/locus.
Only one cytoplasmic arginase gene exists (Arg1).

However, the GABA signaling

pathway may be perturbed at several genomic loci, including several components of the
GABA-A receptor, genes for which are dispersed throughout the genome. Thus, in a
genetic model involving perturbation of arginase and GABA signaling, many GABArelated genes could interact with the single Arg1 gene on chromosome 10 with similar
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effects (disrupting two connected pathways), while GABA genes may not interact with
each other (as multiple disruptions would have redundant effects on the same pathway).
While emerging evidence supports the role for GABA signaling in the control of
neural cell growth (see below), a role for Arg1 is less obvious. Several downstream
outputs could account for increased expression of Arg1 predisposing mice to tumors.
Arginase may act as an immunosuppressant25,26, a competitor for the substrate arginine
with the growth-inhibitory nitric oxide synthases (NOSs) 27-30, or a producer of ornithine,
the substrate for polyamine synthesis linked to tumorigenesis31 and neural proliferation32.
The rate-limiting polyamine synthetic enzyme, ornithine decarboxylase (ODC), is a wellestablished target for c-myc and MYCN33.

ODC inhibitors inhibit neuroblastoma

development in vitro and in TH-MYCN mice34,35, and are currently in clinical trials for
neuroblastoma (http://www.nmtrc.org/phase-i-dfmo/). Ornithine is also a substrate for
synthesis of glutamate and GABA. Notably, ornithine aminotransferase (Oat), which
converts ornithine to glutamate, maps to a susceptibility locus. GABA inhibits neuronal
growth and promotes differentiation36. Thus, at least one ultimate output of Arg1 activity
(GABA) could inhibit both induction and further growth of tumors, driving selection for
secondary genetic lesions that disable this pathway.
While Arg1 activity has not been studied extensively in cancer, inhibition of
arginase has been shown to disrupt growth of breast cancer cells37. Arginase expression
has also been linked to neuronal viability. Clinically, Arg1 mutations cause arginemia,
characterized by neurodegeneration (OMIM 207800).

While hepatic production of

neurotoxic metabolites are speculated to cause this neurodegeneration38,39, our data,
coupled with detection of Arg1 expression in neural tissues24,40,41, suggest that Arg1 may
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be involved in growth and survival signaling in neuroblasts, and inhibition of Arg1 may
have an intrinsic cytotoxic effect in neurons and neuroblastoma cells.
The observation that mice with lower expression of GABA-A receptor subunits
are tumor prone is consistent with GABA’s known role in neuronal cell growth and
differentiation36,42, and suggest that the association of down-regulation of GABA-A
receptors with more aggressive human neuroblastomas has biological significance43.
However, since the receptor is formed as a pentameric combination of 19 possible
subunits, with changing expression patterns and biological roles42, testing this hypothesis
is not straightforward. GABA signaling has been shown to negatively regulate growth of
neural crest stem cells36. In our hands, neuroblastoma cells expressing the GABA-A
receptor showed decreased viability, increased apoptosis, and diminished activity of
mitogenic signaling pathways in response to GABA-A activation, supporting a role of
GABA signaling in tumor cell growth and survival.

These results parallel the

neurotrophin model, based on the observation that dysregulation of TRK neurotrophin
receptors correlates with clinical outcome in neuroblastoma

44

. Our results are consistent

with this paradigm, suggesting that decreased signaling through the GABA pathway
(rather than TRKs) may promote neuroblastoma development.
Neuroblastoma is a common pediatric tumor with a unique biology, making the
development of novel targeted therapeutics problematic. As a result, improvements in
clinical outcomes have been modest over the last several decades. Arginase inhibitors are
under investigation for highly prevalent diseases such as hypertension27. Additionally,
the implication of GABA and other neurotransmitters in regulating growth of
neuroblastoma opens up the potential to apply numerous clinically-approved drugs used
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in neurology and psychology as chemotherapeutic agents. These results also highlight a
possible connection between the role of neurotransmitters in nervous system development
and the regulation of neuroblastoma growth.
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Methods Summary:
Backcross mice were generated by crossing TH-MYCN transgenic FVB/N mice to
wild-type 129/SvJ, and subsequently crossing F1 offspring to wild-type 129/SvJ. Mice
were observed for at least one year to be considered tumor-free. DNA was isolated from
spleen and genotyped using a combination of microsatellite and SNP markers. RNA
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from SCG was analyzed using Affymetrix Mouse Exon arrays. Susceptibility linkage
was analyzed using R-QTL.

Differential gene expression was assessed using

Significance Analysis of Microarrays, and eQTL were calculated using custom software
as described previously21. Cell viability and cell-cycle status were assessed using a
WST-1 assay and flow cytometry. For details see Supplementary Methods.
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Table 1: Candidate genes at susceptibility loci
A. Candidate eQTL at susceptibility loci
susceptibility
chromosome
locus (Mb)
LOD eQTL gene
10
28
5.0
Arg1
2
166
7.0
Gabra3
4
115
7.4
Slc6a1

eQTL locus
(Mb)
25
178
129

eQTL p-val
2.92E-20
5.57E-34
2.81E-05

perm. p-val
<0.001
<0.001
0.001

B. GABA genes at susceptibility loci
chromosome
1
9
17
7

susceptibility
locus (Mb)
131
117
35
144

C. Gene descriptions
location
gene
(chromosome)
Arg1
10
Gabra3
X*
Slc6a1
6*
Dbi
1
Trak1
9
Gabbr1
17
Oat
7
*controlled by trans eQTL

LOD
7.8
7.8
6.9
6.3

gene
Dbi
Trak1
Gabbr1
Oat

gene location (Mb)
122
121
37
140

description
liver arginase
GABA-A receptor, subunit alpha 3
GABA transporter, removes GABA from synaptic cleft
diazepam binding inhibitor; modulates the action of the GABA receptor
trafficking protein, kinesin binding 1, regulates GABA receptor
GABA-B receptor, 1
ornithine aminotransferase (produces glutamate, a GABA precursor)
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Figure 1. A locus on chromosome 10 and multiple secondary loci are linked to
tumor susceptibility. (A) LOD plot for tumor susceptibility shows a single significant
locus on chromosome 10. Dotted line indicates 5% genome-wide significance threshold
(LOD=2.81, 1000 permutations). (B) LOD plot of chromosome 10 only. Hash marks on
the horizontal axis indicate marker positions. Dotted line indicates 5% genome-wide
significance threshold (LOD=2.81, 1000 permutations). (C) Effect plot for the marker
closest to the maximum LOD score (RS36323433) showing incidence of tumors as a
function of genotype.

(D) Two-QTL analysis using sex as an interacting covariate

reveals that multiple secondary loci interact with the chromosome 10 locus. The top left
half shows the results of the additive model (no epistatic interactions), and the bottom
right half shows results of the “full” model, which accounts for epistatic interactions.
The bar on the right displays the correspondence between color on the chart and LOD
scores (the left side of the bar corresponds to the additive analysis on the top left half of
the plot, while the right side of the bar, with a different scale, corresponds to the full
model analysis on the bottom right). Locations of the maximum LOD scores are shown
in Supplementary Table 1.

Figure 2. An eQTL for Arg1 co-localizes with the tumor susceptibility locus on
chromosome 10. (A) Interval mapping for Arg1 expression, the most significant eQTL
in the chromosome 10 region, showing a LOD score of 18.2 on chromosome 10, centered
at the physical location of the Arg1 gene. Line indicates 5% genome-wide significance
threshold. (B) Log2 Arg1 expression level as a function of genotype. (C) A plot of LOD
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scores on chromosome 10 for susceptibility (black line) and the Arg1 eQTL (blue line)
showing co-localization of the peaks.

Figure 3. Secondary susceptibility loci co-localize with eQTL for GABA-related
genes.
(A) A trans-eQTL on chromosome 2 controls expression of the GABA-A receptor
subunit 3 (Gabra3) on the X chromosome (arrow) (LOD=30.9). (B) Gabra3 expression
as a function of D2MIT148 genotype. (C) Plot of tumor incidence as a function of
genotypes at the chromosome 2 and 10 loci. (D) Expression QTL for the Slc6a1 GABA
transporter on chromosome 4 (LOD=4.1).

Arrow indicates the physical location of

Slc6a1 on chromosome 6. (E) Slc6a1 expression as a function of D4MIT203 genotype.
(F) Tumor incidence as a function of genotypes at loci on chromosomes 4 and 10. (G)
Genome-wide plot of LOD scores for the Gabra3 (black), Slc6a1 (green), Arg1 (blue)
eQTL and tumor susceptibility for a single-locus model (purple) and the combined effect
of the peak of the chromosome 10 locus plus points across the rest of the genome (red),
showing correspondence between eQTL peaks and primary and secondary susceptibility
loci.

Two-dimensional plots for Gabra3 and Slc6a1 are shown in Supplementary

Figure 2.
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Figure 4. GABA activation decreases viability and induces apoptosis in
neuroblastoma cells (A) Western blot for Arg1, GABA-A, and GABA-B receptors in
neuroblastoma

cell

lines.

(B) GABA treatment of LAN-5, a GABA-A expressing cell line, results in decreased
viability that is rescued by the GABA competitive inhibitor bicuculline (bic) at 10µM, in
a GABA dose-dependent manner; and

by the non-competitive channel blocker

picrotoxin (picro) at 100µM in a GABA dose-independent manner. (C) Lan5 and Kelly
cells were treated with GABA 100 μM or the selective ligand for GABA QHii066 1 μM
or both and analyzed by annexin V-FITC flow cytometry for apoptosis after 72h. (D)
Percentages of positive cells for apoptotic marker annexin V are mean ± s.e. for triplicate
samples with treatments indicated. (E) Cells analyzed by immunoblot using antisera
indicated show decreased phosphorylation of Akt and Erk.

Figure 1
A

C

B

Chromosome 10

D

367
Figure 2
B

A

C

Chromosome 10

Figure 3
A

C

Log2 expression

B

E

F

Log2 expression

D

G
Gabra3

Arg1
Secondary susceptibility
Slc6a1

Primary susceptibility

Viability (percent of control)

SKNBE2

B
SY5Y

Shep-tet

Kelly
LAN5

IMR-32

CHP-126

Figure 4
A

KCNR

368

Arg1
GABAA R β2/3
GABAB R1
GABAB R2
β-tubulin

C

Kelly
6.3%

1.7%

0.7%

DMSO

GABA

DMSO

GABA

11.0%

20.4%

3.6%

6.2%

QHii066

GABA/
QHii066

QHii066

GABA/
QHii066

FL1-H

FL1-H

Lan5
10.4%

SSC-H

SSC-H

E

D
GABA (100 μM)
QHii066 (1 μM)

Lan5
+
+

+
+

Kelly
+

Lan5

+

+
+

GABA (100 μM)
QHii066 (1 μM)
c-PARP

Annexin V (%)

p-Akt (473)
Akt
p-Erk (202/204)
Erk
GAPDH

+

+
+ +

Kelly

+

+
+ +

369
Supplementary Figure 1
A

C

B

D

370

Supplementary Figure 3
A
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S 30.5
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Supplementary Methods:

Mice: All mice were obtained from the Jackson Labs (Bar Harbor, ME), and were housed
and treated following UCSF IACUC guidelines. Tumor-negative backcross mice were
followed until one year of age (the latest tumor was detected at 342 days). Superior
cervical ganglia (SCG) were surgically isolated and snap-frozen in liquid nitrogen. SCG
were isolated from the parental control groups at 21 days.
Taqman analysis of transgene expression: Taqman expression analysis was performed
on 6 mice (3 female, 3 male) from each strain. Proprietary assays for human MYCN and
controls L18 and mGUS were obtained from Applied Biosystems (Carlsbad, CA).
MYCN relative to mGUS is shown in Supplementary Figure 1B.
Genotyping: DNA was isolated from spleen tissue using a proteinase K lysis followed
by phenol chloroform extraction. Microsatellite marker genotyping was carried out by
the Marshfield Clinic (Marshfield, WI), and CIDR (Baltimore, MD).

SNP genotyping

was performed using template-directed primer extension with fluorescence polarization
detection (FP-TDI1, Acycloprime II, Perkin Elmer, Waltham, MA) and SNPStream2 48plex (Beckman Coulter, Brea, CA).

Markers and map positions are shown in

Supplementary Table 5. The marker set had an average spacing of 8 MB genome-wide
(excluding the high density of markers on chromosome 10).
Linkage analysis: Interval mapping was performed using the R-QTL3 package in the R
statistical language. Genotypes flagged as probable errors by R-QTL were discarded.
The genetic map positions were determined using the physical map positions (NCBI
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37/mm9), followed by re-estimation of the map using R-QTL, and likely mis-mapped
markers were discarded. Linkage analysis was performed on a 1-cM grid. Genome-wide
significance thresholds were determined by running 1000 permutations for each dataset.
Interval analysis was performed using the binary mode of the “EM” model. All results
reported as significant were significant at a 5% genome-wide error rate. 95% confidence
intervals (CI) were determined using the lodint function in R-QTL. Genes within the
confidence intervals were determined by counting all genes in the UCSC genome
assembly mapping between markers flanking the 95% CI.
Expression Arrays: RNA from superior cervical ganglia was isolated using the RNEasy
kit (QIAGEN, Valencia, CA), as we found these buffers were more effective at disrupting
the ganglia than Trizol. 1µg of RNA was used as a starting template for the RiboMinus
rRNA subtraction (Invitrogen, Carlsbad, CA) followed by the ST labeling protocol
(Affymetrix, Santa Clara, CA). Labeled samples were hybridized to Affymetrix Mouse
Exon 1.0 arrays. Array quality control was performed using the Affymetrix Expression
Console. 2-way comparisons between homogenous groups (e.g. male vs. females or
129/SvJ vs FVB/N males) were performed using the Significance Analysis of
Microarrays (SAM) package4 using a 5% false discovery rate. Results are presented in
Supplementary Table 3 and plotted in Supplementary Figures 1C and 1D.
eQTL analysis: Arrays were normalized using RMA in the XPS package
(http://www.bioconductor.org/packages/2.6/bioc/html/xps.html). eQTL were calculated
as described in 5; briefly, linkage between gene expression and loci was assessed by
linear regression with genome-wide significance assessed using a FDR-based method.
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Cell Culture: Neuroblastoma cell lines were grown in RPMI media with 10% serum and
antibiotics with the exception of SK-N-BE(2) (DMEM/F12, 10% serum) and IMR-32
(DMEM, 10% serum plus non-essential amino acids). Nor-NOHA was obtained from
Bachem (Torrance, CA) and dissolved in DMSO. GABA was obtained from Sigma (St.
Louis, MO) and dissolved in H2O. Picrotoxin and bicuculline were obtained from Sigma
and dissolved in DMSO.
Western blotting: Equal amounts of total protein were loaded for 4%–12% SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After
blocking, membranes were blotted with Arg1 (R&D Systems, Minneapolis MN), GABA
B R1, Erk (Santa Cruz Biotech, Santa Cruz, CA) , GABA A Rβ2/3, GABA B R2, βtubulin (Millipore, Billerica, MA), cleaved-PARP (Asp214), p-Akt (Ser473), Akt, pErk
(Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA), and GAPDH (Upstate
Biotechnology, Lake Placid NY).
mouse,

anti-rabbit

Antibodies were detected with HRP-linked anti-

(Amersham/GE,

Piscataway,

NJ),

or

anti-sheep

IgG

(Calbiochem/EMD, Gibbstown, NJ), followed by enhanced chemiluminescence
(Amersham/GE, Piscataway, NJ).
WST-1 assay: Cells were grown in 12-well plates and treated for 72 hours prior to the
addition of WST-1 reagent (100µl per 1ml media).
minutes.

Absorbance was read after 60

Results were plotted using Graphpad Prism software, and p-values were

calculated using a two-tailed Student’s t-test.
FACS: Cells were plated on 6-well dishes and treated as indicated for 24 hours. They
were then harvested, fixed in 70% ethanol for 30 minutes, then stained with a propidium
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iodide (PI) dye and RNase solution. All samples were analyzed on a FACSCaliber flow
cytometer (Becton Dickenson, Franklin Lakes, NJ) and analyzed using ModFit (Verity
Software, Topsham ME).

Apoptosis was detected by flow cytometry for annexin V-

FITC per manufacturer’s protocol (Annexin V-FITC detection kit, BioVision, Milpitas,
CA) using FlowJo software (Tree Star, Inc, Ashland, OR).
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Supplementary Figure Legends
Supplementary Figure 1. Incidence of neuroblastoma and SCG gene expression,
but not MYCN transgene expression, are dependent on strain. (A) Incidence of
tumors in FVB/NJ and 129/SvJ as a function of backcross number.

(B) Taqman

expression showing equivalent levels of TH-MYCN transgene expression in all tissues
tested. Analysis of brain, adrenal gland, and superior cervical ganglia from each strain
showed equivalent levels of expression (C) SAM analysis showing 3 genes differentially
regulated between male and female FVB/NJ mice (N=5 in each group) (D) SAM
analysis showing 9,820 genes differentially expressed between strains in male ganglia
Supplementary Figure 2.

Correspondence between Gabra3 and Slc6a1 eQTL and

secondary susceptibility loci. (A) 2-qtl lod scores are plotted for the intersection of
chromosomes 10 (vertical) and 2 (horizontal) in the top panel, with the scale at right
indicating LOD scores for the full (additive plus interaction) model. The contour line
indicates a 1.5 LOD drop from the maximal value for the chromosome (See Table 1).
The bottom panel shows the eQTL LOD plot for Gabra3 expression, indicating that the
peak LOD score falls within a 1.5-LOD (95%) confidence interval for the susceptibility
locus. (B) plot similar to A, showing chromosome 4 on the horizontal axis and the eQTL
lod score for Slc6a1 in the bottom panel.
Supplementary Figure 3.

Treatment of neuroblastoma cell lines with arginase

inhibitors inhibits proliferation, while the effect of GABA on viability is GABRA-A
expression dependent.

(A)

WST-1 assay showing a dose-dependent decrease in

viability following 72h treatment of neuroblastoma cells with varying doses of the Arg1
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inhibitor nor-NOHA. (C) FACS plot showing increased G1 phase in Kelly and SY5Y
cells treated with nor-NOHA for 24 hours. The dual PI3K/mTOR inhibitor PI103 is
shown for comparison.

(C)

Three neuroblastoma cell lines with low GABA-A

expression show no change in viability in response to GABA. Viability was assessed by
WST-1 assay at 72h.

Supplementary Tables:
Supplementary Table 1: Tumor susceptibility interaction LOD scores, all mice, sex
as an interacting covariate.
Supplementary Table 2: Tumor susceptibility interaction LOD scores, male mice
only.
Supplementary Table 3: Genes differentially expressed between 129/SvJ and
FVB/N
Supplementary Table 4: eQTL significant at a 5% genome-wide error rate
Supplementary Table 5: Markers and map positions

Supplementary References:
1.

Hsu, T.M., Chen, X., Duan, S., Miller, R.D. & Kwok, P.Y. Universal SNP
genotyping assay with fluorescence polarization detection. Biotechniques 31, 560,
562, 564-8, passim (2001).

382

2.

Bell, P.A. et al. SNPstream UHT: ultra-high throughput SNP genotyping for
pharmacogenomics and drug discovery. Biotechniques Suppl, 70-2, 74, 76-7
(2002).

3.

Broman, K.W., Wu, H., Sen, S. & Churchill, G.A. R/qtl: QTL mapping in
experimental crosses. Bioinformatics 19, 889-90 (2003).

4.

Tusher, V.G., Tibshirani, R. & Chu, G. Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98, 5116-21
(2001).

5.

Quigley, D.A. et al. Genetic architecture of mouse skin inflammation and tumour
susceptibility. Nature 458, 505-8 (2009).

383

VI. Appendix IV: Anticonvulsant Screening Data

384

385

VII. Appendix V: Data on QH-II-066
Modulation of α5 subunit-containing GABAA receptors alters alcohol drinking by
rhesus monkeys

Daniela Rüedi-Bettschen, PhD1, James K. Rowlett, PhD, Sundari Rallapalli, PhD, Terry
Clayton, PhD, James M. Cook, PhD, and Donna M. Platt, PhD

Harvard Medical School, New England Primate Research Center, Southborough, MA,
USA (DR-B, JKR, DMP)
Department of Chemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA
(SR, TC, JMC)

1

Current address: Department of Pharmacology and Toxicology, College of Medicine,

University of Arkansas for Medical Sciences, 4301 W. Markham, #611, Little Rock, AR,
72205, USA

Correspondence: Donna M. Platt, Ph.D., Harvard Medical School, New England Primate
Research Center, One Pine Hill Drive, PO Box 9102, Southborough, MA 01772-9102,
USA; phone: 508-624-8090; fax: 508-624-8197; e-mail: donna_platt@hms.harvard.edu

Supported by: AA16179 (DMP), RR00168 (DMP), DA11792 (JKR), MH46851 (JMC),
The Lynde and Harry Bradley Foundation (JMC)

386
Abstract
Background: Alcohol’s ability to potentiate the activity of γ-aminobutyric acid (GABA) at
GABAA receptors has been implicated as a key mechanism underlying the behavioral
effects of alcohol. The complex molecular biology of these receptors raises the
possibility that particular receptor subtypes may play unique roles in alcohol’s abuserelated effects and that subtype-selective ligands with therapeutic specificity against
alcohol might be developed. This study evaluated the capacity of α5GABAA receptor
ligands to alter selectively the reinforcing effects of alcohol. Methods: Two groups of
rhesus monkeys were trained to orally self-administer alcohol or sucrose under fixedratio schedules and limited daily access conditions. Additionally, following daily selfadministration sessions, the behavior of each monkey was scored for both speciestypical and drug-induced behaviors. Results: Concentrations of 1-6% alcohol
maintained self-administration above water levels, engendered pharmacologicallyrelevant blood alcohol levels ranging from 90-160 mg/dl, and produced changes in
behavior typical of alcohol intoxication. Concentrations of 0.3-3% sucrose also reliably
maintained self-administration. The α5GABAA receptor agonist QH-ii-066 enhanced and
the α5GABAA receptor inverse agonist L-655,708 inhibited alcohol but not sucrose
drinking. The changes in alcohol drinking could be reversed with the α5GABAA receptor
antagonist XLi-093. However, L-655,708 increased yawning in both alcohol- and
sucrose-drinkers, possibly indicative of an anxiogenic effect. Conclusions: These
findings suggest a prominent and specific role for α5GABAA receptor mechanisms in the
reinforcing effects of alcohol. Moreover, these results suggest that α5GABAA receptors
may represent a novel pharmacological target for the development of medications to
reduce drinking. Of ligands modulating this receptor, α5GABAA receptor inverse
agonists may hold the most promise as alcohol pharmacotherapies.
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Introduction
Alcohol’s ability to potentiate the activity of γ-aminobutyric acid (GABA) at GABAA
receptors has been implicated as a key mechanism underlying the abuse-related effects
of alcohol in both human and non-human subjects (e.g., Hyytiä and Koob, 1995; June et
al., 1995; 1998; Korpi, 1994; Söderpalm and Hansen, 1998). Molecular biological
studies have shown that the mammalian GABAA receptor is a pentamer consisting of
subunits from at least five different families, including the α, β, and γ subunits (McKernan
and Whiting, 1996; Pritchett et al., 1989; Rudolph et al., 2001). In addition, most of
these subunits have a number of different isoforms (e.g., α1-α6, β1-β3, γ1-γ3; Olsen and
Sieghart, 2008). The complex molecular biology of GABAA receptors raises the
possibility that subtype-selective agents with therapeutic specificity against alcohol might
be developed.
GABAA receptors expressing the α5 subunit (α5GABAA receptors) comprise only
a small proportion of native GABAA receptors and are found primarily in the
hippocampus (Sur et al., 1999; Uusi-Oukari and Korpi, 2010). Projections from the CA1
and CA3 hippocampal fields have been shown to innervate brain regions implicated in
the reinforcing effects of alcohol (e.g., Sesack and Grace, 2010). Several lines of
evidence support a potential role for α5GABAA receptor mechanisms in the abuserelated effects of alcohol. In this regard, using data from the Collaborative Study on the
Genetics of Alcoholism, Song and colleagues (2003) reported a significant association
between GABRA5 (the gene encoding the α5 subunit of the GABAA receptor) and
alcohol dependence. In alcohol discrimination studies in squirrel monkeys, we have
shown that the α5GABAA receptor-selective agonists QH-ii-066 and panadiplon
mimicked the discriminative stimulus effects of alcohol (Platt et al., 2005). Moreover, the
discriminative stimulus effects of alcohol and the alcohol-like discriminative stimulus
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effects of QH-ii-066 were dose-dependently blocked by L-655,708, an α5GABAA
receptor-selective inverse agonist (Platt et al., 2005). With respect to the reinforcing
effects of alcohol, intrahippocampal or i.p. administration of other α5GABAA receptorselective inverse agonists decreased alcohol self-administration in rats at doses that did
not disrupt self-administration of saccharin or water (June et al., 2001; McKay et al.,
2004). Finally, mice lacking the α5 subunit of the GABAA receptor show both reduced
preference for and reduced consumption of alcohol (Boehm et al., 2004).
The purpose of the present study was to evaluate the contribution of α5GABAA
receptor mechanisms to the reinforcing effects of alcohol in rhesus monkeys. We
determined the ability of α5GABAA receptor-selective ligands to augment and/or
attenuate alcohol self-administration. The selective ligands included the agonist QH-ii066, the antagonist XLi-093 and the inverse agonist L-655,708. Results with the
α5GABAA receptor ligands were compared with results obtained with naltrexone, an
FDA approved pharmacotherapy to treat alcohol dependence. Drugs that reduce
alcohol self-administration may have potential as candidate anti-alcohol medications. An
important consideration in the development of an alcohol pharmacotherapy is the
pharmacological specificity of the candidate medication’s effects. One technique used to
evaluate the specificity of a medication’s effect is to compare the doses of a drug to
reduce behaviour maintained by alcohol relative to behaviour maintained by a non-drug
reinforce. To that end, we investigated the extent to which L-655,708 modulated the
reinforcing effects of alcohol at doses that did not alter sucrose self-administration.
Finally, compliance with any medication regimen is tied closely with the extent to which
the medication produces untoward side effects. We evaluated the observable
behavioral effects of α5GABAA receptor ligands in both alcohol- and sucrose-drinking
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monkeys to assess the degree to which the drugs elicited behavioral effects that might
limit their clinical utility (e.g., sedation, anxiety, convulsions).

Materials and Methods
Subjects. Nine adult male rhesus monkeys (Macaca mulatta), weighing 9.5 to
12.1 kg, were studied in daily experimental sessions. Three of the monkeys (two
assigned to the alcohol group; one assigned to the sucrose group) had prior experience
in operant i.v. self-administration (either cocaine or midazolam) procedures. The
remaining monkeys were experimentally naive. Monkeys were housed in a colony room
with a 12-h light/dark cycle. Monkeys had unrestricted access to water via the standard
cage-associated automatic sipper line and were fed a diet of monkey chow (Harlan
Teklad Monkey Diet, Harlan Teklad, Madison, WI), supplemented with fresh fruit. All
animals were maintained in accordance with the guidelines of the Committee on Animals
of the Harvard Medical School and the “Guide for Care and Use of Laboratory Animals”
of the Institute of Laboratory Animal Resources, National Research Council, Department
of Health, Education and Welfare Publication No. (NIH) 85-23, revised 1996. Research
protocols were approved by the Harvard Medical School Institutional Animal Care and
Use Committee.

Apparatus. Monkeys were housed individually in stainless steel primate cages
that also served as the experimental chambers. One side of the cage was customized
to form an operant drinking panel. The panel consisted of two retractable sippers (model
#: ENV-652AM; Med Associates, Inc., Georgia, VT) equipped with solenoids to minimize
dripping. Each sipper was connected with Tygon tubing to a stainless steel liquid
reservoir mounted on the outside of the drinking panel. A response lever (Med
Associates, Inc., Georgia, VT) was positioned below each sipper. Each press of a lever
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produced an audible click and was recorded as a response. Colored lights mounted
above the sippers could be illuminated to serve as visual stimuli. In these experiments,
only one side of the drinking panel was active.

Alcohol self-administration. Five monkeys were trained to respond under a
fixed-ratio (FR) schedule of oral alcohol reinforcement. In the presence of a white light,
completion of every 10th response (FR 10) resulted in a change in illumination from white
to red light and extension of the drinking spout. Displacement of the drinking spout up,
down, left or right during extension resulted in alcohol delivery. Fluid flow continued for
as long as the monkey displaced the spout or for 30-s, whichever was shorter. Within
the 30-s sipper extension time, the monkey could stop drinking (i.e., release the spout)
and resume drinking (i.e., displace the spout) as many times as it wanted. The actual
duration and volume of intake, within the constraints of the schedule, were under the
control of the subject. Between extensions of the drinking spout, all lights were off
briefly, and responses had no scheduled consequences. Daily self-administration
sessions lasted 3-h. The reinforcing effects of a range of concentrations of alcohol (0.5
– 16% w/v), as well as water, were evaluated initially in each monkey. Each alcohol
concentration (or water) was made available for a minimum of five consecutive selfadministration sessions and until stable intake was observed (i.e., no upward or
downward trend in mls and/or g/kg consumed over a period of at least three consecutive
days).
The effects of pretreatment with varying doses of the α5GABAA agonist QH-ii066 (0.1 – 5.6 mg/kg), the α5GABAA antagonist XLi-093 (0.03 – 0.3 mg/kg) or the
α5GABAA inverse agonist L-655,708 (0.1 – 1.8 mg/kg) and their vehicles were
determined on self-administration of a 2% alcohol solution. This alcohol concentration
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was chosen because it maintained intakes significantly higher than that of water. In
addition, it was on the ascending limb of the alcohol concentration-response function,
allowing for detection of both increases and decreases in intake as a consequence of
drug pretreatment. Each dose of QH-ii-066, XLi-093 and L-655,708 was studied for a
minimum of five consecutive sessions and until intake was stable. Between evaluation
of different doses of the α5GABAA ligands, monkeys were returned to baseline selfadministration (i.e., a minimum of five days of self-administration of a 2% alcohol
solution in the absence of any pretreatment). This step allowed assessment of baseline
levels of intake over the course of the study. The α5GABAA ligands were studied in
random order in individual animals, and all doses of a given ligand were studied before
moving on to another drug. For comparison, the effects of the opioid antagonist
naltrexone (0.01 – 0.3 mg/kg) also were determined.
Subsequently, maximally effective doses of QH-ii-066 (0.3 mg/kg) and L-655,708
(1.8 mg/kg) and their vehicles were given as pretreatments before sessions in which a
wider range of alcohol concentrations were made available for self-administration.
These studies determined the degree to which the ligands altered the shape and/or
position of the alcohol concentration-response function. Finally, the capacity of XLi-093
to reverse the effects of QH-ii-066 and L-655,708 was determined. In all instances, the
effects of the α5GABAA ligands at each alcohol concentration were studied for a
minimum of five consecutive sessions and until intake was stable.

Sucrose self-administration. A separate group of four monkeys was trained to
respond under a FR 10 schedule of oral sucrose reinforcement. This schedule and
solution delivery was identical to that for alcohol self-administration, except that a
sucrose solution instead of alcohol was available for self-administration. The reinforcing
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effects of a range of concentrations of sucrose (0.1 – 3% w/v), as well as water, were
evaluated initially in each monkey. Each sucrose concentration (or water) was made
available for a minimum of five consecutive self-administration sessions and until stable
intake was observed.
The effects of pretreatment with varying doses of the QH-ii-066 or L-655,708 and
their vehicles were determined on self-administration of a 0.3% sucrose solution. This
sucrose concentration was chosen because it maintained intakes that were significantly
higher than that of water and roughly equivalent to intakes maintained by 2% alcohol in
the alcohol self-administration group. Each dose of QH-ii-066 and L-655,708 was
studied for a minimum of five consecutive sessions and until intake was stable. Between
evaluation of different doses of the α5GABAA ligands, monkeys were returned to
baseline self-administration. The α5GABAA ligands were studied in irregular order in
individual animals, and all doses of a given ligand were studied before moving on to
another test drug.

Observable behavior. Following daily self-administration sessions, the behavior
of each monkey (regardless of whether the animal self-administered alcohol or sucrose)
was scored during a five-min sampling period using a focal animal approach as
described in Platt et al. (2000; 2002) and as modified for the rhesus monkey. That is,
after the self-administration session, an observer who was not informed about the drugs
under investigation watched a specific animal for five min. During this sampling period,
the observer recorded each instance a particular behavior (Table 1) occurred in 15-s
intervals during the period. Scores were calculated from these data as the number of
15-s intervals in which a particular behavior occurred (maximum possible score for each
behavior was 20). A randomization schedule was employed so that order effects
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between animals were minimized. Eight observers performed the scoring across the
duration of the study. Typically, two observers were used daily – one observing the
alcohol drinkers, one observing the sucrose drinkers. To ensure reliability across
observers, each individual underwent at least 20 h of training until they reached an interobserver reliability criterion of ≥ 90% based on percent agreement scores calculated
between all possible pairs.

Blood alcohol levels (BAL). At select time points across the study (e.g., once
stable intake was obtained at a particular alcohol concentration or after a particular drug
treatment), monkeys self-administering alcohol were anesthetized with ketamine
immediately following the session and three – five mls of blood were collected from the
femoral vein. Samples were immediately centrifuged at 3200 rpm for 8-12 minutes. The
plasma was drawn off, transferred to polypropylene tubes, and then frozen until analysis.
Triple determinations of BALs were conducted using a rapid high performance plasma
alcohol analysis using alcohol oxidase with an AM1 series analyzer and Analox Kit
GMRD-113 (Analox Instruments USA, Lunenberg, MA). This process detects BAL
ranges from 0 to 350 mg/dl using an internal standard of 100 mg/dl.

Data analysis. After each alcohol self-administration session, intake for
individual subjects was determined in two ways: volume (mls) and alcohol dose (g/kg)
consumed. Dose was calculated as: [volume consumed (mls) X alcohol concentration
(g/ml)]/weight (kg). After each sucrose self-administration session, intake for individual
subjects was the volume consumed (mls). Data are expressed as mean intake over the
last three sessions of water or alcohol/sucrose availability. Because the intake
measurements for alcohol self-administration are correlated, with the exception of Fig. 1,
we present only the data representing alcohol dose. A one-way repeated measures
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ANOVA was used to evaluate the effect of alcohol/sucrose concentration on total volume
consumed.
To compare the effects of the α5GABAA ligands and naltrexone on alcohol selfadministration, intakes following pretreatment with QH-ii-066, XLi-093; L-655,708 or
naltrexone were converted to % of baseline intake. Baseline intake was considered to
be the mean dose of alcohol consumed across the three days of no pretreatment
immediately prior to tests with a given dose of a compound. Separate one-way repeated
measures ANOVAs followed by Bonferroni t-tests compared the effects of the
pretreatment drugs to the effect of vehicle on intake. In curve-shifting experiments,
separate two-way repeated measures ANOVAs compared the effects of either QH-ii-066
or L-655,708, alone or combined with XLi-093, to the effect of vehicle on intake.
To compare the effects of the α5GABAA ligands on sucrose self-administration,
intakes following pretreatment with QH-ii-066 or L-655,708 were converted to % of
baseline intake. Baseline intake was considered to be the mean mls of sucrose
consumed across the three days of no pretreatment immediately prior to tests with a
given dose of a compound. Separate one-way repeated measures ANOVAs compared
the effects of the pretreatment drugs to the effect of vehicle on intake.
Observational data were treated in two ways. To evaluate the effect of
increasing intake of alcohol on observable behavior, frequency scores for each behavior
were averaged across the alcohol self-administration subjects to obtain group means.
Mean scores (± SEM) for each behavior then were plotted as a function of intake. For
these analyses, intake (g/kg) was converted to “number of drinks”. We use an
operational definition of a “drink” as 0.25 g/kg alcohol or 17 g alcohol in a 70 kg human,
representing the upper range of worldwide definitions of a drink (cf. Grant and Bennett,
2003; Kalant and Poikolainen, 1999). To determine statistical reliability of treatment
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effects on each behavior, the effect of drink number was determined by separate oneway ANOVAs. Only the behavioral data generated during determination of the alcoholconcentration response function were included in these analyses. To evaluate the effect
of α5GABAA ligands on observable behavior, frequency scores for each behavior were
averaged separately across the alcohol self-administration subjects and the sucrose
self-administration subjects to obtain means. For each group, mean scores (± SEM) for
each behavior were plotted as a function of dose. For normally distributed data (as
assessed using the Shapiro-Wilk test), separate two-way mixed factor ANOVAs
determined the effects of the between-group factor (alcohol vs. sucrose) and withingroup factor (dose) and their interaction on each behavior. In all cases, significant main
effects were examined post-hoc with Bonferroni t-tests. The alpha level for all tests was
P≤0.05.

Drugs. Ethanol (95%; Pharmco Products. Brookfield, CT) and diluted to the
appropriate concentrations with tap water. QH-ii-066 and XLi-093 were synthesized as
described in Huang et al. (2000) and Li et al. (2003), respectively. These compounds
were dissolved in 50-80% propylene glycol/20-50% 0.9% saline solution. L-655,708
(Tocris Bioscience, Ellsville, MO) was dissolved in 50% propylene glycol/50% 0.9%
saline solution. Naltrexone HCl (Sigma/RBI, St. Louis, MO) was dissolved in 0.9%
saline solution. Intramuscular injection volumes were 0.02 – 0.05 ml/kg body weight.
Pretreatment times were 10 min for the α5GABAA ligands and 30 min for naltrexone.

Results
Alcohol self-administration. Oral presentation of alcohol maintained selfadministration in all monkeys under the FR schedule of alcohol delivery and limited
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access conditions (Fig. 1). As the concentration of alcohol was increased, intake first
increased and then decreased, resulting in an inverted u-shaped concentration-response
function. For the group, alcohol concentrations between 1 and 6% (w/v) maintained
intakes significantly higher than that during water availability (Fig. 1A; F(7,28)=17.6,
P<0.001, Bonferroni t-tests, P<0.05). At these concentrations, monkeys drank
approximately 0.8 – 1.9 g/kg of alcohol (Fig. 1B). Analysis of blood samples verified that
the volumes consumed when concentrations ≥ 2% (w/v) were available produced BALs
in excess of 80 mg/dl in all monkeys (Fig. 1C).
In addition to producing orderly effects on drinking behavior, alcohol altered
several observable behaviors (Fig. 2). All five self-administration monkeys had selfadministration episodes resulting in intake of 1 – 8 drinks; while three of the five
monkeys had self-administration episodes resulting in intake of nine or more drinks.
These higher intakes were observed after 13% of the self-administration sessions.
While intakes below the equivalent of 7 drinks failed to alter any observable behavior,
intakes of at least 7 drinks produced reliable changes in measures of passive visual,
locomotion, tactile/oral exploration, stereotypy, scratching, and ataxia compared to levels
of these behaviors observed during water availability. Locomotion, across a range of 7 –
9 drinks, was significantly increased compared to levels observed during water
availability (F(10,716)=6.2, P<0.001, Bonferroni t-tests, P<0.05). At the highest intake (≥
10 drinks), though, locomotion returned to water levels, likely coinciding with a significant
increase in passive visual behavior (F(10,716)=2.0, P<0.05, Bonferroni t-tests, P<0.05).
During water availability, ataxia was not observed. However, a significant drinkdependent increase in ataxia occurred at intakes of ≥8 drinks (F(10,716)=4.0, P<0.001,
Bonferroni t-tests, P<0.05). Significant drink-dependent decreases in behaviors also
were observed. At intakes ≥7 drinks, scratching was significantly reduced compared to
water levels (F(10,716)=8.0, P<0.001, Bonferroni t-tests, P<0.05). Alcohol also
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produced an overall drink-dependent decrease in levels of tactile/oral exploratory
behavior (F(10,716)=2.2, P<0.05, Bonferroni t-tests, n.s.) and stereotypic behavior
(F(10,716)=2.4, P<0.01, Bonferroni t-tests, n.s.). Alcohol had no other significant effects
on observable behavior over the range of intakes observed during determination of the
alcohol concentration-response function.

α5GABAA ligands and alcohol self-administration. Daily pretreatment with
the α5GABAA ligands or naltrexone produced qualitatively different effects on alcohol
(2% w/v) intake depending on the compound (Fig. 3). For example, the two lowest
doses (0.1 and 0.3 mg/kg) of QH-ii-066 induced small but significant increases in alcohol
consumption (125 – 135% of the baseline intake of 1.4±0.2 g/kg) compared to vehicle
(F(5,20)=18.2, P<0.001, Bonferroni t-tests, P<0.05). At higher doses of QH-ii-066,
intake returned to baseline levels and did not differ from that following vehicle
administration. Problems with solubility prohibited testing higher doses of QH-ii-066. In
the case of XLi-093, none of the doses evaluated altered self-administration of alcohol
compared to vehicle, and intake was maintained at baseline levels (1.8±0.02 g/kg). In
contrast, daily pretreatment with L-655,708 resulted in dose-dependent reductions in
alcohol self-administration compared to vehicle (F(4,16)=37.6, P<0.001), with the two
highest doses (1 and 1.8 mg/kg) producing significant decreases in intake (Bonferroni ttests, P<0.05). At the highest dose of L-655,708, intake was suppressed maximally to
approximately 40% of the baseline intake of 1.6±0.2 g/kg. The suppression of alcohol
self-administration by L-655,708 was similar to that induced by naltrexone. As expected,
naltrexone engendered dose-dependent decreases in alcohol self-administration that
reliably differed from vehicle at doses of 0.1 and 0.3 mg/kg (F(4,16)=7.7, P<0.01,
Bonferroni t-tests, P<0.05). The highest dose of naltrexone maximally suppressed
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alcohol self-administration to 38% of the baseline intake of 1.7±0.2 g/kg. In general, for
all drugs, the effect observed on the first day of a given pretreatment was similar to that
observed on the final day of administration (5 – 7 days), providing no evidence of the
development of tolerance to the effects of QH-ii-066, L-655,708 or naltrexone (data not
shown).
Based on the results of the study described above, doses of the α5GABAA
ligands that maximally altered alcohol self-administration were studied in combination
with a wider range of alcohol concentrations (Fig. 4). In general, pretreatment with QHii-066 (0.3 mg/kg) enhanced self-administration of 0.5 – 4% (w/v) alcohol solutions and
resulted in a leftward shift in the ascending limb of the alcohol concentration-response
function (Fig. 4, left). By and large, this leftward shift could be reversed if the animals
also received a pretreatment of the highest dose of XLi-093 (0.3 mg/kg). These findings
are confirmed by a significant alcohol concentration X treatment interaction (F(6,24)=5.2,
P<0.01, Bonferroni t-tests, P<0.05). In contrast, pretreatment with L-655,708 (1.8
mg/kg) attenuated self-administration of 1 – 6% (w/v) alcohol solutions and resulted in
an overall rightward shift in the ascending limb of the alcohol concentration-response
function (Fig. 4, right). As with QH-ii-066, pretreatment with the highest dose of XLi-093
completely reversed the L-655,708-induced rightward shift in the alcohol concentrationresponse function. These findings are confirmed by a significant alcohol concentration X
treatment interaction (F(6,24)=3.9, P<0.01, Bonferroni t-tests, P<0.05).

α5GABAA ligands and sucrose self-administration. Oral presentation of
sucrose maintained self-administration in all monkeys under the FR schedule of sucrose
delivery and limited access conditions (Fig. 5A). As the concentration of sucrose was
increased, intake also increased. Patterns of responding were comparable to those
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observed during alcohol self-administration (data not shown). For the group, sucrose
concentrations between 0.3 and 3% (w/v) maintained intakes significantly higher than
that during water availability (F(4,12)=9.5, P<0.01, Bonferroni t-tests, P<0.05). At 0.3%
(w/v), individual subjects displayed intakes ranging from ~ 450 to 1100 mls. The
average intake (± SEM) for the group at this concentration was 839±157 mls and did not
differ significantly from the intake of the alcohol self-administration group at 2% (w/v)
(906 ± 92 mls; t(7)=0.4, P=n.s.). Daily pretreatment with either QH-ii-066 or L-655,708
did not markedly alter sucrose self-administration at any dose compared to their
respective vehicles (Fig. 5B).

α5GABAA ligands and observable behavior. In the absence of drug
pretreatment and under water availability, the alcohol- and sucrose-drinking monkeys did
not differ from each other for the majority of behaviors (Supplemental Figure 1).
However, the sucrose drinkers did exhibit significantly higher levels of tactile/oral
exploration (t(7)=-4.3, P<0.005) and locomotion (t(7)=-2.4, P<0.05) and tended to
present more (t(7)=-2.5, P<0.05). Neither QH-ii-066 nor L-655,708, at any dose
evaluated, markedly altered the majority of observable behaviors. Likewise, naltrexone
failed to alter any of the behaviors. There were, however, two exceptions (Fig. 6A and
6B). QH-ii-066 dose-dependently decreased tactile/oral exploration in both the alcoholdrinking and sucrose-drinking monkeys, with a dose of 3 mg/kg significantly reducing
this behavior compared to vehicle levels. This effect was confirmed by a significant main
effect of QH-ii-066 dose on this behavior (Shapiro-Wilk Normality test – passed;
F(4,28)=4.6, P<0.01, Bonferroni t-tests, P<0.05). On the other hand, L-655,708 dosedependently increased yawning in both self-administration groups, with the highest dose
(1.8 mg/kg) engendering significantly more yawning compared to vehicle (Shapiro-Wilk
Normality test – passed; F(4,28)=2.8, P<0.05, Bonferroni t-tests, P<0.05).
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Discussion
In the present study, alcohol served as a reinforcer in all monkeys, maintaining
intake levels above those of water. At concentrations of ≥ 2% (w/v), monkeys selfadministered pharmacologically relevant doses of alcohol and produced BALs ranging
from 90 – 160 mg/dl. The overall intakes (i.e., g/kg) observed in this study are generally
typical of intakes observed for macaques self-administering alcohol under limited access
conditions (Grant and Johanson, 1988; Henningfield and Meisch, 1978; 1979; 1981;
Katner et al., 2004; Vivian et al., 1999). Differences in intake between the present study
and those cited could be due to a number of methodological differences including length
of self-administration session, addition of flavorants, induction techniques,
concentrations of alcohol made available for self-administration, and the selfadministration apparatus itself. In fact, the latter difference could be especially important
in the cases where the intakes observed in the present study are higher than those of
the cited studies. In our procedure, the monkey must press a lever to gain access to a
drinking spout connected to an alcohol reservoir. Depression of the drinking spout
during extension results in alcohol delivery and fluid flow continues for as long as the
monkey displaces the spout or for 30-s, whichever is shorter. The actual duration and
volume of intake, within the constraints of the schedule, is under the control of the
subject. Depending upon the available alcohol concentration, we observed average
volumes of 12.5 mls of alcohol delivered per spout extension (range: ~3.5 mls/extension
at 16% w/v; ~21 mls/extension at 2% w/v; data not shown). This average
volume/delivery is much larger than the volumes/delivery in the cited studies in which the
drinking spouts are designed to deliver a set amount of alcohol (typically 0.5 – 1 ml)
each delivery. Evidence from rats would suggest that alcohol intake should increases as
the volume per reinforcement increases (Henningfield and Meisch, 1975).
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When given the opportunity to consume a wide range of alcohol concentrations,
monkeys drank sufficient quantities of alcohol to alter observable behavior. In many
instances, these behavioral changes mirrored the effects of alcohol in intoxicated
humans or those exposed to an acute alcohol challenge. For example, it is wellestablished that alcohol has a biphasic effect on activity (e.g., Martin et al., 1993;
Morean and Corbin, 2010) such that, in human subjects, alcohol-induced stimulant
effects (e.g., feelings of energized, stimulated, vigorous) are generally observed at lower
BALs on the ascending limb of the blood alcohol curve, and alcohol-induced sedative
effects (e.g., feelings of heavy head, inactive, sluggish) are reported at higher BALs on
the descending limb of the blood alcohol curve. In monkeys, we observed a reliable
increase in locomotor activity across a lower range of drinks (and presumably lower
BALs) compared to the range where we observed increases in passive visual behavior
and decreases in tactile/oral exploration, possible indices of sedative-like effects.
Alcohol also is known to reduce the response to stressors and can produce anxiolyticlike effects in humans (e.g., Eckardt et al., 1998; Thomas et al., 2003). Similarly, alcohol
produced a drink-dependent decrease in stereotypy and scratching, two behaviors that
have been associated with anxiety in nonhuman primates and which are amenable to
reduction by typical anxiolytics (e.g., Birkett et al., 2005; Castles et al., 1999; Schino et
al., 1996; Tiefenbacher et al., 2005a; 2005b; Troisi, 2002). Finally, alcohol has been
shown to dose-dependently increase the amount of body sway or static ataxia in
humans (e.g., Schuckit, 1985); likewise, in monkeys, observable ataxia increased in a
drink-dependent manner. Together, these findings illustrate and reinforce the
translational nature of our non-human primate drinking model.
Using this model and GABAA receptor subtype-selective ligands, we assessed
the contribution of α5GABAA receptor mechanisms to the reinforcing effects of alcohol.
We found that the agonist QH-ii-066 modestly increased, and the inverse agonist L-
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655,708 decreased, intake of alcohol (2% w/v). Subsequently, the maximally effective
dose of QH-ii-066 was found to enhance intake of a wider range of alcohol
concentrations; whereas, the maximally effective dose of L-655,708 was found to inhibit
intake of a wider range of alcohol concentrations. Both leftward (QH-ii-066) and
rightward (L-655,708) shifts in the alcohol concentration-response function were
abolished by XLi-093, despite it not altering drinking on its own. These observations are
in agreement with results from rodent studies showing that other α5GABAA receptor
inverse agonists can reduce drinking (June et al., 2001; McKay et al., 2004). In
conjunction with observations that α5GABAA receptor-subunit knockout mice exhibit
reduced preference for and consumption of alcohol (Boehm et al., 2004), these findings
suggest a prominent role for α5GABAA receptor mechanisms in the reinforcing effects of
alcohol. Moreover, the lack of effect on drinking behavior with XLi-093 alone raises the
possibility that neutral efficacy (i.e., antagonism) at this specific GABAA receptor subtype
is not sufficient to inhibit drinking, rather inverse efficacy is required.
In our hands, L-655,708 was as effective as the prototypical alcohol
pharmacotherapy naltrexone in reducing drinking in the monkeys. Coupled with the
observation that L-655,708 also can attenuate the subjective/interoceptive effects of
alcohol (Platt et al., 2005), a growing body of research suggests that α5GABAA receptor
inverse agonists may have potential as candidate anti-alcohol medications. An
important consideration in the development of an alcohol pharmacotherapy is the
pharmacological specificity of the candidate medication’s effect. One technique used to
evaluate the specificity of a medication’s effect is to compare the doses of a drug
needed to reduce behavior maintained by alcohol relative to behavior maintained by a
non-drug reinforcer. For example, if a drug reduces alcohol-maintained behavior to a
greater extent than it reduces behavior maintained by the non-drug reinforcer, then the
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drug may have selective effects on alcohol self-administration (c.f. Mello and Negus,
1996). In the present study, L-655,708, across the same dose range studied in the
alcohol drinkers, did not alter drinking in the sucrose drinkers. This result suggests that
the inhibitory effects of L-655,708 are selective for alcohol. Moreover, that sucrose
drinking also was not modified by QH-ii-066 provides additional support for a key role for
α5GABAA receptor mechanisms in modulating the abuse-related effects of alcohol in
particular, rather than drinking behavior in general.
Because adverse side effects can limit the utility of a pharmacotherapy, and
because non-selective inverse agonists at the GABAA/benzodiazepine site often can
have convulsant/proconvulsant effects (e.g., Braestrup et al., 1983), it was of interest to
determine the behavioral profile of L-655,708. In both alcohol- and sucrose-drinkers, L655,708 was relatively benign and there was no indication of any interaction between L655,708 and alcohol. Notably, even with repeated administration, L-655,708 was devoid
of convulsant activity. This agrees with studies in rats showing that L-655,708 does not
induce seizures on its own, nor does it alter the dose of pentylenetetrazole required to
induce seizures (Atack et al., 2006). The sole observable effect of L-655,708 was to
increase yawning in both groups of monkeys. In nonhuman primates, increases in
yawning often have been interpreted as indicating increased stress and anxiety (Castles
et al., 1999; Lutz et al., 2004), and yawning can be induced in monkeys with
administration of an anxiogenic drug (Major et al., 2009). Likewise, L-655,708 exhibited
anxiogenic-like activity in mice in an elevated plus-maze procedure (Navarro et al.,
2002). While the effects of L-655,708 have not been determined in alcoholics, there is
evidence for transient anxiogenic effects of flumazenil, a benzodiazepine receptor
antagonist, in alcoholics in early withdrawal (Nutt et al., 1993). Taken together, these
findings certainly would suggest that an α5GABAA receptor inverse agonist is likely to
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have anxiogenic effects in humans. While a relatively mild side effect, anxiogenesis
would likely limit how an L-655,708-type drug might be used effectively in a treatment
setting. For example, given that stress-induced negative affective states and
withdrawal-induced anxiety are important facilitators of relapse to excessive alcohol use
(e.g., Breese et al., 2005; Heilig et al., 2010), a drug that induces anxiety would not be a
practical anti-relapse medication. Rather, our results would suggest that an α5GABAA
receptor inverse agonist may be most useful as a pharmacotherapy to assist individuals
with achieving abstinence.
In summary, our findings suggest a prominent and selective role for α5GABAA
receptor mechanisms in the reinforcing effects of alcohol. The results implicate
α5GABAA receptors as potential pharmacological targets for medications to reduce
drinking and assist individuals in achieving abstinence. In particular, α5GABAA receptor
inverse agonists may hold the most promise as alcohol pharmacotherapies.
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Table 1. Behavioral categories, abbreviations, and definitionsa.
SPECIES-TYPICAL:
Passive visual
(VIS)
Animal is standing or sitting motionless with eyes open
Rest/Sleep posture
(RSP)
Idiosyncratic posture adopted by monkeys during rest or sleep; eyes closed, easily
roused by external stimulation (e.g., tapping on cage)
Locomotion
(LOC)
At least two directed steps in the horizontal and/or vertical plane
Tactile/oral exploration
(TAC)
Any tactile or oral manipulation of the cage or environment
Forage
(FOR)
Sweeping and/or picking through wood chip substrate
Self-groom
(GRM)
Picking, scraping, spreading or licking of an animal’s own hair
Scratch
(SCR)
Vigorous strokes of the hair with the finger or toenails
Vocalization
(VOC)
Species-typical sounds emitted by monkey (not differentiated into different types)
Yawn
(YWN)
To open mouth wide and expose teeth
Present
(PRE)
Posture involving presentation of rump, belly, flank, and/or neck) to observer or other
monkey
Threat/aggress
(THR)
Multifaceted display involving one or more of the following: open mouth stare with teeth
partially exposed, eyebrows lifted, ears flattened or flapping, rigid body posture,
piloerection, attack (e.g., biting, slapping) of inanimate object or other monkey
Fear grimace
(FGR)
Grin-like facial expression involving the retraction of the lips exposing clenched teeth;
may be accompanied by flattened ears, stiff, huddled body posture, screech/chattering
vocalizations
Body spasm
(BSP)
An involuntary twitch or shudder of the entire body; also “wet dog” shake
Lip smack
(LIP)
Pursing the lips and moving them together to produce a smacking sound; often
accompanied by moaning
Cage shake
(CSH)
Any vigorous shaking of the cage that may or may not make noise
Stereotypy
(STY)
Any repetitive, ritualized pattern of behavior that serves no obvious function
Other
(OTH)
Any notable behavior not indicated above (e.g., masturbation, nose rub, lip droop,
vomit/retch)
PROCEDURE-RELATED:
Lever press
(LVR)
Depression of lever manipulanda on the drinking panel
Drink
(DRI)
Mouth contact to fluid delivery sippers
DRUG-INDUCED:
Ataxia
(ATX)
Any slip, trip, fall or loss of balance
Procumbent posture
(PRO)
Loose-limbed posture (sitting or lying on cage bottom) accompanied by eye closure; not
easily aroused by external stimulation (e.g., tapping on cage)
a
Adapted from Novak et al., 1992; Weerts et al., 1998; Platt et al., 2000, 2002.
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Figure Legends
Figure 1

Oral self-administration of varying alcohol concentrations and water under a
fixed-ratio schedule and limited access conditions in monkeys. For each
monkey, mean intakes for the last three sessions at each concentration were
calculated. Data points represent the mean intake ± SEM (A. mls; B. g/kg) for
the group (N = 5). * P<0.05 vs. water (gray bar = SEM for water availability). C.
Mean ± SEM blood alcohol levels (mg/dl) determined once stable intake was
obtained at a particular alcohol concentration for the group (N = 5).

Figure 2

Effects of increasing number of drinks on observable behavior (one drink = 0.25
g/kg alcohol). Data points represent the mean ± SEM at each drink (N = 34 –
115). * P<0.05 vs. water (gray bar = SEM for water availability).

Figure 3

Effects of daily pretreatment with QH-ii-066, XLi-093, L-655,708 or naltrexone on
intake maintained by a 2% (w/v) alcohol solution. For each monkey, mean
intakes for the last three sessions at each dose were calculated. Data points
represent the mean intake ± SEM presented as a % of baseline g/kg for the
group (N = 5). * P<0.05 vs. vehicle. Baseline intake for QH-ii-066 = 1.4±0.2
g/kg; XLi-093 = 1.8±0.02 g/kg; L-655,708 = 1.6±0.2 g/kg; naltrexone = 1.7±0.2
g/kg (one-way ANOVA; F(3,16)=0.97, n.s.).

Figure 4

Modulation by QH-ii-066 and L-655,708, administered alone or in conjunction
with XLi-093, of alcohol self-administration in monkeys. Points are group means
± SEM based on the last three sessions at each alcohol concentration in five
monkeys. * P<0.05 vs. vehicle.

Figure 5

A. Oral self-administration of varying sucrose concentrations and water under a
fixed-ratio schedule and limited access conditions in monkeys. For each
monkey, mean intakes for the last three sessions at each concentration were
calculated. Data points represent the mean intake ± SEM (mls) for the group (N
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= 4). * P<0.05 vs. water (gray bar = SEM for water availability). B. Effects of
daily pretreatment with QH-ii-066 or L-655,708 on intake maintained by a 0.3%
(w/v) sucrose solution. For each monkey, mean intakes for the last three
sessions at each dose were calculated. Data points represent the mean intake ±
SEM presented as a % of baseline mls for the group (N = 4). Baseline intake for
QH-ii-066 = 739±178 mls; L-655,708 = 953±142 mls (t-test; t(6)=-0.94, n.s.).
Figure 6

Observable effects of QH-ii-066 on tactile/oral exploration (A) and L-655,708 on
yawning (B). Bars/points are group means ± SEM in the sucrose selfadministration group (N = 4) and the alcohol self-administration group (N = 5). *
P<0.05 vs. vehicle.

Supplemental Figure 1

Behavioral profile of alcohol and sucrose self-administration
monkeys under water availability (see Table 1 for abbreviations).
* P<0.05

Figure 1:
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VIII. Appendix VI (a). Crystal data and structure refinement for XLi093 (33).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 66.97°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole

(33)
C33 H26 N6 O6
602.60
295(2) K
1.54178 Å
Monoclinic
P2/n
a = 6.9314(1) Å
α= 90°.
b = 9.2889(1) Å
β= 95.316(1)°.
c = 22.5403(4) Å
γ = 90°.
1445.02(4) Å3
2
1.385 Mg/m3
0.809 mm-1
628
0.24 x 0.10 x 0.02 mm3
3.94 to 66.97°.
-7<=h<=7, -10<=k<=10, -22<=l<=26
7178
2450 [R(int) = 0.0286]
95.3 %
Semi-empirical from equivalents
0.984 and 0.823
Full-matrix least-squares on F2
2450 / 0 / 211
1.045
R1 = 0.0451, wR2 = 0.1276
R1 = 0.0574, wR2 = 0.1378
0.0020(6)
0.369 and -0.181 e.Å-3
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Appendix III(b). Atomic coordinates (x 104) and equivalent isotropic displacement
parameters (Å2x 103) for XLi093(33).
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
x
y
z
U(eq)
_______________________________________________________________________
C(1)
583(3)
4957(2)
3838(1)
60(1)
N(2)
-713(2)
5543(2)
4205(1)
66(1)
C(3)
302(3)
6423(2)
4553(1)
63(1)
N(4)
2206(2)
6468(2)
4437(1)
58(1)
C(5)
3729(3)
7252(2)
4757(1)
56(1)
C(6)
3678(3)
7399(2)
5366(1)
62(1)
C(7)
5123(3)
8119(2)
5706(1)
64(1)
C(8)
6661(3)
8721(2)
5433(1)
60(1)
C(9)
6658(3)
8620(2)
4822(1)
60(1)
C(10)
5230(3)
7871(2)
4466(1)
57(1)
C(11)
5409(3)
7917(2)
3806(1)
63(1)
O(11)
6076(2)
9000(2)
3588(1)
79(1)
N(12)
4863(2)
6755(2)
3477(1)
68(1)
C(13)
4333(3)
5396(2)
3747(1)
67(1)
C(14)
2394(3)
5524(2)
3978(1)
57(1)
C(15)
-123(3)
3891(2)
3389(1)
62(1)
O(15)
-1791(2)
3537(2)
3294(1)
88(1)
O(16)
1313(2)
3338(2)
3099(1)
66(1)
C(17)
735(3)
2297(3)
2632(1)
68(1)
C(18)
2500
1438(4)
2500
70(1)
C(19)
5152(4)
6746(4)
2849(1)
103(1)
C(20)
8236(3)
9416(2)
5781(1)
70(1)
C(21)
9564(4)
9941(3)
6065(1)
92(1)
________________________________________________________________________
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Appendix III(c). Bond lengths [Å] and angles [°] for XLi093(33).
_____________________________________________________
C(1)-C(14)
1.371(3)
C(1)-N(2)
1.386(3)
C(1)-C(15)
1.468(3)
N(2)-C(3)
1.295(3)
C(3)-N(4)
1.369(2)
N(4)-C(14)
1.370(3)
N(4)-C(5)
1.423(2)
C(5)-C(6)
1.384(3)
C(5)-C(10)
1.403(3)
C(6)-C(7)
1.377(3)
C(7)-C(8)
1.397(3)
C(8)-C(9)
1.379(3)
C(8)-C(20)
1.437(3)
C(9)-C(10)
1.401(3)
C(10)-C(11)
1.504(3)
C(11)-O(11)
1.229(2)
C(11)-N(12)
1.344(3)
N(12)-C(19)
1.448(3)
N(12)-C(13)
1.464(3)
C(13)-C(14)
1.491(3)
C(15)-O(15)
1.203(2)
C(15)-O(16)
1.342(2)
O(16)-C(17)
1.457(3)
C(17)-C(18)
1.513(3)
C(18)-C(17)#1
1.513(3)
C(20)-C(21)
1.177(3)
C(14)-C(1)-N(2)
C(14)-C(1)-C(15)
N(2)-C(1)-C(15)
C(3)-N(2)-C(1)
N(2)-C(3)-N(4)
C(3)-N(4)-C(14)
C(3)-N(4)-C(5)

109.99(18)
131.11(18)
118.90(17)
105.25(16)
112.49(18)
106.56(16)
126.97(17)
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C(14)-N(4)-C(5)
126.31(15)
C(6)-C(5)-C(10)
120.76(18)
C(6)-C(5)-N(4)
117.91(17)
C(10)-C(5)-N(4)
121.33(18)
C(7)-C(6)-C(5)
121.08(18)
C(6)-C(7)-C(8)
119.6(2)
C(9)-C(8)-C(7)
118.85(19)
C(9)-C(8)-C(20)
120.46(18)
C(7)-C(8)-C(20)
120.7(2)
C(8)-C(9)-C(10)
122.81(18)
C(9)-C(10)-C(5)
116.79(19)
C(9)-C(10)-C(11)
115.74(17)
C(5)-C(10)-C(11)
127.30(17)
O(11)-C(11)-N(12)
122.2(2)
O(11)-C(11)-C(10)
119.17(19)
N(12)-C(11)-C(10)
118.64(18)
C(11)-N(12)-C(19)
119.2(2)
C(11)-N(12)-C(13)
122.06(19)
C(19)-N(12)-C(13)
117.7(2)
N(12)-C(13)-C(14)
110.26(17)
N(4)-C(14)-C(1)
105.71(16)
N(4)-C(14)-C(13)
117.83(16)
C(1)-C(14)-C(13)
136.41(19)
O(15)-C(15)-O(16)
123.6(2)
O(15)-C(15)-C(1)
124.09(19)
O(16)-C(15)-C(1)
112.30(17)
C(15)-O(16)-C(17)
115.99(16)
O(16)-C(17)-C(18)
108.60(16)
C(17)#1-C(18)-C(17)
116.3(3)
C(21)-C(20)-C(8)
177.6(3)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 -x+1/2,y,-z+1/2
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Appendix III(d). Anisotropic displacement parameters (Å2x 103) for XLi093 (33).
The anisotropic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h
k a* b* U12 ]
_________________________________________________________________________
U11
U22
U33
U23
U13
U12
_________________________________________________________________________
C(1)
45(1)
62(1)
74(1)
0(1)
14(1)
-3(1)
N(2)
42(1)
77(1)
81(1)
-6(1)
17(1)
-4(1)
C(3)
43(1)
66(1)
82(1)
-6(1)
18(1)
-2(1)
N(4)
40(1)
56(1)
79(1)
-6(1)
16(1)
-4(1)
C(5)
43(1)
49(1)
77(1)
-1(1)
13(1)
0(1)
C(6)
51(1)
60(1)
78(1)
1(1)
19(1)
-6(1)
C(7)
59(1)
65(1)
70(1)
2(1)
13(1)
-6(1)
C(8)
50(1)
57(1)
74(1)
1(1)
8(1)
-3(1)
C(9)
45(1)
54(1)
81(1)
3(1)
14(1)
-4(1)
C(10)
43(1)
52(1)
77(1)
0(1)
13(1)
-1(1)
C(11)
45(1)
68(1)
79(1)
-2(1)
17(1)
-8(1)
O(11)
76(1)
81(1)
81(1)
3(1)
21(1)
-24(1)
N(12)
52(1)
80(1)
77(1)
-13(1)
23(1)
-12(1)
C(13)
48(1)
62(1)
94(2)
-16(1)
23(1)
-5(1)
C(14)
45(1)
53(1)
75(1)
-4(1)
15(1)
-1(1)
C(15)
50(1)
70(1)
68(1)
3(1)
13(1)
-5(1)
O(15)
49(1)
116(1)
100(1)
-28(1)
14(1)
-17(1)
O(16)
53(1)
72(1)
73(1)
-10(1)
15(1)
-8(1)
C(17)
63(1)
77(1)
65(1)
-4(1)
9(1)
-9(1)
C(18)
78(2)
69(2)
66(2)
0
10(1)
0
C(19)
94(2)
135(2)
87(2)
-28(2)
37(2)
-31(2)
C(20)
61(1)
73(1)
77(1)
8(1)
10(1)
-12(1)
C(21)
77(2)
114(2)
82(2)
12(2)
1(1)
-40(2)
________________________________________________________________________
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Appendix III (e). Hydrogen coordinates ( x 104) and isotropic displacement parameters
(Å2x 10 3) for XLi093 (33).
________________________________________________________________________
x
y
z
U(eq)
________________________________________________________________________
H(3)
H(6)
H(7)
H(9)
H(13B)
H(13A)
H(17B)
H(17A)
H(18)
H(19A)
H(19B)
H(19C)
H(21)

-205
2650
5076
7646
5296
4303
199
-250
3010(40)
5480
3983
6186
10530(50)

6965
7006
8205
9068
5148
4633
2793
1659
810(30)
7698
6437
6096
10430(40)

4848
5549
6116
4639
4070
3452
2276
2763
2867(10)
2726
2623
2780
6280(14)

75
75
77
72
80
80
82
82
84
155
155
155
119

425
Appendix III (f). Torsion angles [°] for XLi093(33).
________________________________________________________________
C(14)-C(1)-N(2)-C(3)
-0.3(2)
C(15)-C(1)-N(2)-C(3)
179.53(19)
C(1)-N(2)-C(3)-N(4)
0.5(2)
N(2)-C(3)-N(4)-C(14)
-0.4(2)
N(2)-C(3)-N(4)-C(5)
-176.01(19)
C(3)-N(4)-C(5)-C(6)
34.5(3)
C(14)-N(4)-C(5)-C(6)
-140.2(2)
C(3)-N(4)-C(5)-C(10)
-144.9(2)
C(14)-N(4)-C(5)-C(10)
40.4(3)
C(10)-C(5)-C(6)-C(7)
-1.9(3)
N(4)-C(5)-C(6)-C(7)
178.69(18)
C(5)-C(6)-C(7)-C(8)
0.5(3)
C(6)-C(7)-C(8)-C(9)
2.2(3)
C(6)-C(7)-C(8)-C(20)
-176.9(2)
C(7)-C(8)-C(9)-C(10)
-3.5(3)
C(20)-C(8)-C(9)-C(10)
175.54(19)
C(8)-C(9)-C(10)-C(5)
2.1(3)
C(8)-C(9)-C(10)-C(11)
177.80(18)
C(6)-C(5)-C(10)-C(9)
0.6(3)
N(4)-C(5)-C(10)-C(9)
-179.99(16)
C(6)-C(5)-C(10)-C(11)
-174.48(19)
N(4)-C(5)-C(10)-C(11)
4.9(3)
C(9)-C(10)-C(11)-O(11)
-32.8(3)
C(5)-C(10)-C(11)-O(11)
142.3(2)
C(9)-C(10)-C(11)-N(12)
145.98(19)
C(5)-C(10)-C(11)-N(12)
-38.9(3)
O(11)-C(11)-N(12)-C(19)
3.0(3)
C(10)-C(11)-N(12)-C(19)
-175.8(2)
O(11)-C(11)-N(12)-C(13)
171.04(19)
C(10)-C(11)-N(12)-C(13)
-7.7(3)
C(11)-N(12)-C(13)-C(14)
73.5(3)
C(19)-N(12)-C(13)-C(14)
-118.2(2)
C(3)-N(4)-C(14)-C(1)
0.2(2)
C(5)-N(4)-C(14)-C(1)
175.81(18)
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C(3)-N(4)-C(14)-C(13)
178.00(19)
C(5)-N(4)-C(14)-C(13)
-6.4(3)
N(2)-C(1)-C(14)-N(4)
0.1(2)
C(15)-C(1)-C(14)-N(4)
-179.8(2)
N(2)-C(1)-C(14)-C(13)
-177.1(2)
C(15)-C(1)-C(14)-C(13)
3.0(4)
N(12)-C(13)-C(14)-N(4)
-64.7(3)
N(12)-C(13)-C(14)-C(1)
112.3(3)
C(14)-C(1)-C(15)-O(15)
-176.2(2)
N(2)-C(1)-C(15)-O(15)
3.9(3)
C(14)-C(1)-C(15)-O(16)
4.6(3)
N(2)-C(1)-C(15)-O(16)
-175.23(18)
O(15)-C(15)-O(16)-C(17)
2.4(3)
C(1)-C(15)-O(16)-C(17)
-178.41(17)
C(15)-O(16)-C(17)-C(18)
-161.41(18)
O(16)-C(17)-C(18)-C(17)#1
-52.04(12)
C(9)-C(8)-C(20)-C(21)
-78(6)
C(7)-C(8)-C(20)-C(21)
101(6)
________________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 -x+1/2,y,-z+1/2

IX. Appendix VII: SBIR grant by Physiogenix
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Research Strategy
A. Significance
Alzheimer’s disease (AD) is a complex and progressive neurodegenerative pathology
that currently affects 5.4 million Americans at an estimated total cost of $200 billion
[Alzheimer’s Association, 2012]. Although the monetary costs greatly impact our
economy, the emotional and social burdens the disease imparts on individuals and their
families are immeasurable. The complexity of the disease is due in part to the multiple
stages of AD, ranging from pre-symptomatic to severe dementia. As the disease
progresses into the symptomatic phase of pathogenesis, individuals begin losing basic
cognitive and learning abilities, which eventually can lead to the complete loss of
memory, cognition, and executive functions [1, 2]; a point at which many AD sufferers
lose the freedom of independent living. Along with the complexity of defining the exact
causes of AD, there is a multitude of controversies and gaps in our understanding of the
disease progression, which has made the treatment and prevention of AD especially
difficult. Furthermore, current treatments for AD have variable successes [2-5] and
demonstrate efficacy in approximately half of the treated individuals [National Institute of
Aging, Alzheimer’s Association, 2012], thus substantiating the need for new approaches
to AD therapeutics [1, 2]. Here, we propose our ligand PWZ-029, an inverse agonist with
functional selectivity at gamma-aminobutyric acid class A (GABAA) receptors containing
α5 subunits, for the mitigation of cognitive deficits associated with AD and age-related
dementias.
Current treatments of Alzheimer’s disease are largely ineffective and recent
approaches to treating and preventing the disease have lost momentum in clinical
trials. Currently, there are five drug therapies that are FDA-approved for the treatment of
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cognitive symptoms associated with AD. Cholinesterase inhibition is the mechanism of

action utilized by four of the five AD therapies (e.g., donepezil) while N-methyl-Daspartate (NMDA) antagonism constitutes the action of memantine, which is prescribed
to treat moderate to severe AD [2]. Unfortunately, the efficacy of these drugs is variable,
with positive results reported in only half of the users [3-5]. Thus, the necessity to further
characterize the mechanism of disease progression, which will theoretically identify
novel targets for drug therapies, is increasingly evident. Since the mid-1990s, the bulk of
AD drug development efforts have surrounded the amyloid cascade hypothesis, which
postulates that the neurotoxicity associated with AD pathogenesis is largely the result of
alterations in the processing of amyloid precursor proteins in the brain. The result of
these alterations can lead to the production and eventual aggregations of plaque-forming
amyloid-beta (Aβ) peptides [2, 6-9]. Although the presence of extracellular Aβ plaques
and intracellular neurofibrillary tangles are generally recognized as hallmarks of AD,
recent attempts to commercialize compounds that reduce the accumulation of or
increase the clearance of Aβ have been met by failure during clinical trials [2]. Thus, new
approaches to treating or preventing AD are of immediate need. Recent approaches to
characterizing the neuronal processes and alterations that result in or from hallmark
anatomical changes of AD pathology are gaining momentum [10-12], thereby leading to
novel targets for treating and preventing AD, such as the GABAA receptor complex [2, 7,
8, 13-15]. To this end, we aim to develop PWZ-029, a selective inverse agonist of
α5GABAA receptors, to mitigate cognitive deficits associated with early (i.e., mild and
moderate) stages of AD, as well as age-associated dementias.
The GABAA receptor complex is the primary modulator of neuronal inhibition and
possesses diverse functionalities. The pathogenesis of AD targets neuronal networks
that are especially vulnerable to the toxic effects of disease progression. Cholinergic
neurons of the forebrain and the glutamatergic receptors and neurons in the
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hippocampus are prime examples of networks affected by AD pathology. These
excitatory networks of the brain are predominantly modulated by gamma-aminobutyric
(GABA) neurotransmissions. GABA is the chief inhibitory neurotransmitter of the
mammalian central nervous system (CNS) [7, 8, 14, 16, 17] and is regulated by three
classes of GABA receptors, GABAA, GABAB, and GABAC, with the GABAA receptor
complex being the primary regulator of GABA-induced CNS depression [7, 8, 16] and
the primary target for benzodiazepine (BZ) pharmaceuticals [7, 8, 14, 17].
The GABAA receptor complex is a pentameric, chloride-ion-gated channel through which
GABA regulates fast synaptic inhibitory neurotransmissions [7, 16]. The heterogeneity of
this ionotropic receptor is due to the diversity of subunit compositions. Characterizations
of the GABAA receptor complex define 8 subunits with a total of 20 different subtypes:
α1-6, β1-4, γ1-3, ρ1-3, δ, ε, π , and θ [13, 16-24]. Although the exact characterization of
subtype and subunit composition in relation to GABAA receptor functionality is yet
unclear, research supports that the majority of these complexes are composed of at
least two α and β subunits [14, 16, 25-27] and one γ subunit [8, 14, 16, 27]. These
findings suggest that GABAA receptors have immense structural and functional diversity,
and the implications for this diverse functioning potential have profound implications for
the specificity and resulting pharmacological effects of ligands targeting the GABAA
complex [14]. For instance, many established BZ drugs (e.g., diazepam) have nonspecific binding behaviors, which have been shown to elicit side effects like sedation,
hypnotic behavior, and affected motor coordination [14]; side effects that are not
attractive for AD therapeutics aiming to improve memory and cognition. The α1 subtype,
for example, is ubiquitously distributed in mammalian CNS [13, 14, 16] and has been
shown to play a paramount role in the sedative side effects associated with ligands of
the GABAA receptor [13, 14, 28]. Conversely, α5 subtypes, which are targeted by PWZ-
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029, are predominantly concentrated in the hippocampus, specifically in the Ammon’s
horn of the dorsal CA1 region of rodent brains [13, 14, 16], and are characterized as
modulators of memory and cognition [13, 14, 16, 24, 29-31]. These findings support the
hypothesis that highly specific ligands that selectively bind α5 subtypes are promising
targets for potent mitigators of AD-associated cognitive decline [15]. Our preliminary
data for PWZ-029 substantiates this hypothesis and shows practical evidence that our
compound significantly improves cognition without the sedative side effects common to
other BZ ligands.
Down-regulating compensatory mechanisms related to AD pathology may reduce
the cognitive impairments associated with mild and moderate stages of the
disease. Neuronal death that is commonly observed in the brains of AD patients has
been shown to be caused partly by overstimulation of NMDA and 2-amino-3-(3-hydroxy5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptors via toxic amounts of the
excitatory neurotransmitter, glutamate [32, 33]. Researchers speculate that these overstimulated pathways lead to compensatory mechanisms that aim to maintain the
excitatory/inhibitory (E/I) balance of the brain’s regulatory processes. In other words, a
pathologically overactive excitatory pathway can lead to the compensatory up-regulation
of inhibitory processes, specifically GABA-mediated CNS inhibition [7, 8]. These
findings, in combination with research showing the relative conservation of the
GABAergic hippocampal networks in AD pathology [7, 29, 34-37], suggest that inverse
agonist ligands that selectively act on GABAA receptors to inhibit the action of GABA in
the brain are excellent candidates for memory and cognition therapeutics [15], such as
PWZ-029.

B. Innovation
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Preliminary preclinical data strongly suggests that PWZ-029 is effective in improving
memory and cognition, especially in models with baseline cognitive deficits. The high
specificity of PWZ-029 for α5-containing GABAA receptors has successfully mitigated
adverse side effects of seizures and sedation, which are commonly observed with
benzodiazepines (BZ). Furthermore, the unique functional selectivity of PWZ-029 has
successfully overcome functional interference and side effects that have stopped
previous attempts to commercialize nonselective inverse agonists of the GABAA complex.
Furthermore, because the core chemical structure of PWZ-029 classifies it as a
benzodiazepine (Figure 1A) we are confident that the safety and toxicology experiments
proposed here would be consistent with the vast body of research demonstrating the
established safety and toxicological profiles of the BZ class of compounds.
Our collaborator, Dr. James Cook, synthesized PWZ-029 as part of an effort to explore
the difference between the pharmacophores for the diazepam-sensitive versus the
diazepam-insensitive GABAA receptors [38]. One of the products of his laboratory’s
research was PWZ-029, which was designed to be a partial inverse agonist with
functional selectivity for the α5 subunit-containing GABAA receptor [39]. Our approach to
mitigating the cognitive impairments of AD is innovative because PWZ-029 acts with a
novel GABA-reducing mechanism rather than targeting cholinergic, glutamatergic, or Aβ
pathways. Success in the proposed experiments will drive our team towards
commercializing a benzodiazepine drug that improves memory and cognition in AD
patients without eliciting unwanted sedative and convulsive side effects. These strides in
our research will not only lead to a marketable product with strong intellectual property,
but we will also publish our sensitive findings so that scientific understanding for
treatment and mitigation of AD will advance.

C. Approach
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C1. PHASE I FINAL REPORT/PRELIMINARY STUDIES
Our successful Phase I milestone data combined with significant findings from our
company-sponsored preliminary studies encouraged us to pursue a Phase II SBIR grant
for our cognition-enhancing compound, PWZ-029. In summary, our significant findings
demonstrate: 1) a selective binding affinity of PWZ-029 to α5 subunits on GABAA
receptors, which was substantiated by an auspicious in-vitro efficacy profile, 2) minimal
behavioral side effects of PWZ-029 compared to benzodiazepines and other inverse
agonists with non-specific binding affinities, and 3) the ability of PWZ-029 to improve
cognition and overcome impaired baseline performance in a myriad of memory tests that
were carried out in multiple species.
In-vitro characterization of binding affinity and efficacy. Extensive in vitro binding
and efficacy experiments that showed a selective affinity of PWZ-029 to α5GABAA
receptors (Figure 1.); in vitro data that were exemplified by enhanced performance in
behavioral assays [39], specifically the contextual fear conditioning paradigm [30]
(Figure 3). These data, in addition to binding and electrophysiological assays carried out
by our collaborator, Dr. James Cook (University of Wisconsin-Milwaukee), demonstrate
that PWZ-029 binds selectively (i.e., ≈20- to 30-fold greater selectivity) to α5 subunitcontaining receptors compared to the other isoforms of the GABAA receptor complex,
specifically the α1 subunit-containing receptors, which are associated with sedative side
effects of non-selective BZ ligands (Figure 1B and 1C). Electrophysiology experiments in
Xenopus oocytes demonstrated that PWZ-029, at a concentration of 1 μM, significantly
reduced GABA initiated control currents, thereby indicating a partial inverse agonist
effect of PWZ-029 on GABAA receptors possessing the α5 isoforms (Figure 1B).
Additional experiments carried out by the NIMH Psychoactive Drug Screening Program
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(PDSP) at the University of North Carolina Chapel Hill Medical School showed that
PWZ-029 is a highly selective ligand of the BZ-binding site, confidently indicating that the
observed cognitive enhancing effects elicited by this ligand are likely the result of binding
at the GABAA receptor complex and not other receptor classes, such as cannabinoids,
histamines,

prostaglandins,

Ca+ channel,

glutamate,

transporters,

acetylcholine, dopamine, serotonin, and opiates (data not shown).

A.

B.

C.

Ligand

MW

α1

α2

α3

α4

α5

α6

PWZ-029

291.7

362.4

180.3

328.2

ND

6.2

ND

Figure 1. Structural, electrophysiological, and binding
characterizations of PWZ-029 show the ligand is a partial
inverse agonist with functional selectivity and in vitro
efficacy at α5 subunit-containing GABAA receptors. Panel A.
Chemical structure of PWZ-029 classifies the compound as a
benzodiazepine, a class of compounds with a well-characterized
safety profile. Panel B. Oocyte electrophysiology data
demonstrating the selectivity of GABA attenuation by inverse
activity with α5 isoforms. Panel C. Binding affinity (Ki, nM) and
selectivity of PWZ-029 against the various α-containing GABAA
receptors.

adrenergic,
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Preliminary profiling of PWZ-029 pharmacokinetics, maximum tolerated dose, and
oral bioavailability (data not shown). In our Phase I rat experiments, we showed that
peak plasma concentrations were detected by LC/MS at 0.25 hours (h) post-dose when
PWZ-029 was administered by intravenous (1 mg/kg, i.v.) and oral gavage (5 mg/kg,
p.o.) routes. These preliminary data indicate a rapid absorption into the blood
compartment via the oral route. The concentration-time curves for both i.v. and p.o.
administrations indicated at least two separate phases of redistribution with significant
amounts of compound in the plasma compartment at 4 h and remaining detectable for
24 h post-dose. The bioavailability of PWZ-029 was found to be roughly 11% when
calculated by the area under the curve method and when accounting for the larger
concentration used for the p.o. dose. In addition, brain samples were taken from rats 2 h
after dosing to determine the potential of PWZ-029 to traverse the blood brain barrier.
PWZ-029 was detected in brain tissue at 2 h after oral dosing and represented 2.1% of
peak plasma concentration. A brain/blood ratio of 0.7 was determined for PWZ-029, with
a brain/blood ratio of greater than 0.3-0.5 serving as our reference for sufficient access
to the target organ. This was the first report showing both the oral bioavailability and
target organ accessibility of PWZ-029.
Additionally, a dose escalation experiment investigated oral doses of PWZ-029 at 30,
100, 300, and 1000 mg/kg. Doses were given in single administrations, animals were
observed for toxicological effects for 48 h post-dose, and then the next escalating dose
was administered with the same experimental design followed for all phases of the
escalation paradigm. All experimental animals survived each arm of dosing, and body
weight loss was not observed for the duration of the experiment. Although mild tremors
and facial twitches were noted, specifically at 300 and 1000 mg/kg, there were no overt
signs of toxicity observed.
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Minimal side effects observed with PWZ-029 administrations in mice, rats, and
non-human primates. Single-dose proconvulsant studies utilizing male Swiss mice
(Crl:CFW(SW)) treated with pentylenetrazole (PTZ) were conducted at NINDS and at
PsychoGenics

(Tarrytown,

NY).

Results

demonstrated

that

PWZ-029

is

not

proconvulsant at any dose (10, 20, or 40 mg/kg) in the PTZ mouse model (data not
shown). Furthermore, Harris et al. [30] found that systemic dose administrations in mice
of PWZ-029 at a dose of 30 mg/kg did not result in convulsions.
Our Phase I experiments utilized a standard battery of behavioral and motor
coordination tests to elucidate side effects that are common to the BZ class of
compounds. The rotarod test was used to assess motor coordination effects of single
oral doses of PWZ-029 at 5, 10, and 20 mg/kg versus saline- and diazepam-treated rats
in the Dahl/SS rat strain. No signs of impaired motor coordination or sedation were
observed at any of the three PWZ-029 doses (data not shown). The Dahl/SS rat strain
was also utilized for the elevated plus maze and the open field test. Oral doses of PWZ029 at 5, 10, and 20 mg/kg were tested against saline-treated and DMCM-treated rats in
both assays. The combined results of these experiments suggest that PWZ-029 activity
does not elicit anxiogenic side effects relative to the DMCM- or diazepam-treated control
rats (data not shown). We suspect that the overall data suggest a mild sedative effect of
PWZ-029; however, a sedative effect was not observed in the rotarod studies.
Targeted studies in monkeys were conducted in order to assess possible anxiolytic-like
effects, abuse potential, and sedative-motor effects. In a rhesus monkey conflict model
of the anxiolytic effects of drugs [40], PWZ-029 was ineffective over a 1000-fold dose
range (up to 1.0 mg/kg, i.v.), suggesting that although this compound is a weak agonist
at α1, α2, and α3 subunit-containing receptors, the efficacy at these subtypes is
insufficient to induce anxiolysis-like behavior or alter operant responding. Similarly,
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PWZ-029 lacked reinforcing effects over a 300-fold dose range in monkeys selfadministering the BZ, midazolam (i.v.), under a progressive-ratio procedure, suggesting
that this compound has no abuse potential (data not shown).
Figure 2 represents the results of sedation studies in rhesus monkeys treated with 3.0
mg/kg PWZ-029 (i.v., panel A) or alprazolam (i.v., panel B) and then monitored for 120
minutes (min) post-dose. PWZ-029 did not induce significant signs of sedation at doses
200-300 times higher than the lowest dose shown to enhance performance in cognitive
tasks (see below). Conversely, the non-selective BZ, alprazolam, induced significant
rest/sleep posture and deep sedation, thus providing a positive comparator.

Frequency Score

A.

Rest/Sleep Posture
3.0 mg/kg

20

Deep Sedation
3.0 mg/kg

15
10
5
0
0

7.5

15

30

60

120

0

7.5

15

30

60

120

Time after PWZ-029 Injection (min)

B.

Rest/Sleep Posture
0.1 mg/kg

Frequency Score

20

Deep Sedation
3.0 mg/kg

15
10
5
0
0

7.5

15

30

60

120

0

7.5

15

30

60

120

Time after Alprazolam Injection (min)

Figure 2. Sedation studies carried out with PWZ-029- (A) and alprazolam- (B)
treated rhesus monkeys (n=5). Data were obtained as modified frequency scores
by trained observers unaware of the treatments or purpose of the studies (interrater reliability scores > 90%). “Rest/sleep posture” was defined as the monkey
assuming a posture associated with rest or assumed sleep, with eyes closed for at
least 3 sec, but responsive to an auditory cue. “Deep sedation” was recorded if the
monkey assumed an atypical posture, with eyes closed for at least 3 sec, and nonresponsive to an auditory cue. These measures are adapted from the American
Association for Anesthesiology standards for levels of sedation. All data presented
as mean ± SEM.
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PWZ-029 demonstrates efficacy in the attenuation of cognitive deficits in mice,
rats, and NHP. Assessments of the contextual fear response (i.e., % freezing) to
stimulus (Figure 3) in scopolamine-treated, male C57BL/6 mice demonstrated that PWZ029 attenuated the scopolamine-induced impairment of contextual memory (Harris, et al.,
2008).

Figure 3. Pavlovian fear conditioned contextual memory test
in scopolamine-treated C57BL/6 mice. Each mouse was
injected via intraperitoneal injection with vehicle (white bar), 1.5
mg/kg scopolamine (black bar), or 1.5 mg/kg scopolamine plus 10
mg/kg PWZ-029 (gray bar). N=12 mice/group. *P<0.05 versus
scopolamine-treated mice (Harris et al., 2008)

In a company-sponsored Morris Water Maze (MWM) experiment, we examined the
effects of PWZ-029 in a novel rat model of Alzheimer’s disease (AD) - the FABSamaritan rat (Taconic Farms, Inc., Hudson, NY). FAB-Samaritan rats were carried
through the MWM task (1 day of visible acquistion followed by 2 days of hidden platform
tests) in subsequent weeks following brain infusions of an AD-inducing solution [41].
Infusion pumps were installed in the animals, and rats received brain infusions of saline
(positive model control) or a proprietary FAB solution (negative control and test groups).
Animals (n=8/group) were dosed for ≈28 days via p.o. gavage with vehicle (positive
model and negative controls), donepezil (positive drug control, 3 mg/kg), or PWZ-029
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(10 mg/kg) at ≈30 minutes prior to entering the maze. In the second arm of testing for

the animals, PWZ-029-treated rats performed significantly better on Day 2 of the hidden
phase in both latency to platform and distance travelled when compared to the FABSamaritan negative control animals (P<0.05 versus negative control, data not shown).
As an additional part of our SBIR Phase I project, we conducted preliminary experiments
to evaluate the extent to which PWZ-029 could alter memory processes in a
translationally-relevant primate species. Figure 3 shows very promising results with
PWZ-029 in the Object Retrieval with Detours (ORD) task in rhesus monkeys. The ORD
task in monkeys is often described as providing a measure of executive functioning [42,
43]. Impairments in executive functioning (i.e., decision making, planning, response
inhibition, cognitive flexibility) often emerge after mild cognitive impairment in the
progression to AD [44]. Importantly, Ballard et al. reported that an inverse agonist with
selectivity for α5-containing receptors enhanced performance in the ORD task, providing
initial proof-of-concept support for our studies [42].
The ORD task consists of a food-retrieval procedure in which a small food treat (e.g.,
banana slice) is placed in a transparent box with one open side, and the animal’s ability
to retrieve the treat is measured (see Figure 4). Performance in the ORD task was not
enhanced (mean percentage of successfully-completed trials in a daily session) by i.v.
injections of PWZ-029 when the task included easy trials (i.e., open side directly in front
of monkey, Figure 4A); however, performance was robustly enhanced when trials were
difficult (i.e., open side on right or left, treat deep within the box, Figure 4B). When
performance on the ORD task was attenuated by the cholinergic agent, scopolamine,
PWZ-029 treatment effectively reversed this deficit (Figure 4C). Finally, the
enhancement of ORD performance induced by PWZ-029 could be blocked by an
antagonist selective for α5-containing GABAA receptors (Figure 4D). Together, these
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findings provide strong support for PWZ-029 as a cognitive enhancer of executive
functioning in a primate species with close genetic similarity to humans.
A. Mixed Trials
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Figure 4. Effects of PWZ-029 in the
Object Retrieval with Detour (ORD)
task. Monkeys were trained to retrieve
food from an opaque box with one open
end (above right). Panel A. PWZ-029 was
ineffective
when
tested
with
a
combination of Easy and Difficult Trials.
enhanced
Panel
B.
PWZ-029
performance when only Difficult Trials
were tested (*p<0.05 vs. vehicle, V).
Panel C. Scopolamine (S, 0.01 mg/kg)
inhibited ORD performance, which was
reversed by PWZ-029 (**p<0.05 vs. S).
Panel D. Enhanced performance with
PWZ-029 in Difficult Trials was blocked
by the antagonist XLi-093 (*p<0.05 vs. V;
**p<0.05 vs. PWZ-029 alone, P).
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C2. EXPERIMENTAL APPROACH

Aim 1. Define the exposure/safety relationship of PWZ-029 in rats to determine
whether this compound exhibits a sufficient level of safety to support Phase I
clinical trials. The safety and potential target-organ toxicity of a drug must be
established to demonstrate a sufficient efficacy/safety margin prior to entering a
compound into clinical trials [45]. Here, escalating-dose and 7-day repeat dosing studies
will be carried out in rats with the goal of establishing the no observable adverse effects
level (NOAEL), dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and the
safety/exposure relationship of PWZ-029. We will use these data to support the definitive,
IND-enabling GLP safety studies needed prior to initiating a Phase I clinical trial.
Rationale: Determining the toxicology and safety of a compound prior to testing in
humans is crucial to the process of drug development [45]. As multiple benzodiazepines
are currently on the market, their general safety profile is well documented. To establish
the specific safety profile of PWZ-029, a series of safety/toxicological experiments will be
carried out to assess the MTD and NOAEL in acute and multiple dosing paradigms. The
toxicology assessments will be carried out in Sprague Dawley (SD) rats.

We will

determine the general safety profile of PWZ-029 and incorporate pharmacokinetic
measurements to establish its safety/exposure relationship. Potential differences in
toxicological responses between genders will also be evaluated. In parallel to the in vivo
safety

studies,

standard

in

vitro

assays

for

selectivity,

mutagenicity,

and

clastogenicity/aneugenicity will be conducted to assess the potential for ‘off-target’
toxicity.
Experimental Design: Information gained from the escalating-dose MTD studies will
drive the doses of PWZ-029 to be used in subsequent 7-day toxicological studies, and
the outcomes of these studies will then determine the ultimate design of the GLP-safety
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studies. A preliminary dose-ranging study in rats (using doses up to 1000 mg/kg) has

already been conducted as part of an initial safety evaluation of PWZ-029. Although no
overt findings of toxicological significance were observed, increased facial movements
(twitching) were noted, especially at 300 and 1000 mg/kg. Therefore, a second MTD
study will be conducted in rats using doses up to 2000 mg/kg, paying particular attention
to potential abnormal muscular activity (i.e., twitching/tremors).
In addition to the Phase I single dose pharmacokinetic (PK) analysis that has already
been conducted with PWZ-029 in rats, PK analysis will be carried out after a single dose
and after 4 daily doses to assess the potential for drug accumulation or the potential for
induction of liver metabolism that may affect drug exposure upon chronic dosing. Results
from these rat safety studies will be used to seek funding from other sources for further
study and to design PK, single-dose MTD, and sub-chronic safety studies in beagle dogs.
Additionally, in vitro safety assessment will be conducted by an established contract
research organization (Cerep Inc., Redmond, WA). The desired outcome of these
studies is to further define the safety and selectivity profile of PWZ-029.
PK analysis to establish safety/exposure ratio in rats. Three male SD rats (8-weeks old,
250 g) will be dosed p.o. with 10 mg/kg of PWZ-029. Blood will be sampled after 0.08,
0.25, 0.5, 1, 2, 4, 8, 18 and 24 h to assess PWZ-029 exposure and to determine single
dose PK parameters. Subsequently, rats will be dosed at 24 h intervals, and after the
fourth daily dose, blood will be sampled following the schedule utilized on Day 1 to
determine whether multiple-day dosing affects any of the PK parameters.
Escalating-dose MTD studies. Male SD rats (8-weeks old, 250 g) will be dosed via p.o.
gavage with either vehicle (n = 5) or with escalating doses of PWZ-029 (100, 500 and
2000 mg/kg; n = 5/group). On day 1 of the study, rats will be dosed with vehicle or the
lowest dose of PWZ-029 (100 mg/kg) and then observed for behavioral effects. For the
first 120 minutes, animals will be intensely monitored for signs of acute toxicity (i.e.
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morbidity and mortality) with special attention being paid toward unusual muscular
activity (i.e., twitching, tremors and/or convulsions). Animals will be subsequently
monitored for an additional 46 h for overt signs of toxicity such as ataxia, greater than
10% decrement in body weight, tremors, loss of righting response, morbidity, and
mortality. Following the initial dose, rats will be dosed at 48 h intervals with either vehicle
or the escalating doses of PWZ-029 and monitored as described for the 100-mg/kg dose.
Forty-eight hours after the final vehicle or 2000 mg/kg dose of PWZ-029, animals will be
terminated and gross pathological observations documented. Blood will be collected to
assess clinical chemistries, and the adrenals, brain, heart, kidneys, liver, spleen, thyroid
with parathyroid, skeletal muscle and thymus will be weighed, collected, and stored in
formalin for histological analysis.
In vivo safety assessment in rats (7-day repeat dose study). A low, mid, and high dose of
PWZ-029 will be established based upon the findings from the dose-ranging
experiments. A total of 32 SD rats will be distributed among 8 experimental groups.
•

16 female SD rats will be distributed into 4 experimental groups (n=4/group): Control
group, low dose group, mid dose group and high dose group.

•

16 male SD rats will be distributed among 4 dose groups as with the females.

All experimental animals will be dosed via p.o. gavage once a day for 7 consecutive
days. Detailed clinical observations including unusual muscular activity (i.e., twitching,
tremors and/or convulsions), body weights, and food consumption will be recorded daily.
On day 7, blood will be collected 1 h after administering the final dose for drug exposure
and clinical chemistries. Animals will be terminated, and the adrenals, brain, heart,
kidneys, liver, spleen, thyroid with parathyroid, skeletal muscle, and thymus will be
collected, weighed, and stored in formalin for histology. The 1 h post-dose timing was
chosen based on the PK data obtained from Phase I experiments.
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In vitro selectivity and gene safety assessment. The potential for off-target
pharmacology/toxicology will be assessed using a broad panel of ~150 human receptors
and enzymes The potential for genetic toxicity will be assessed using the Ames
fluctuation assay and the in vitro micronucleus assays run in the presence and absence
of S9 liver fractions (Cerep Inc., Redmond, WA).
Benchmark for Success. Results from the PK study will refine the PK parameters
estimated in the preliminary studies that indicated rapid oral absorption of PWZ-029 into
the blood compartment with a bioavailability of about 11% and biphasic elimination
kinetics. Success will be determined from the escalating-dose MTD studies if we
observe of a sufficiently high MTD to proceed to a multiple-dose safety assessment in
rats. Successful outcomes of the 7-day repeat dosing study will establish a relationship
between chronic dosing and DLT, define a therapeutic index (TI) sufficient for continued
development of PWZ-029, and demonstrate that PWZ-029 does not induce its own
metabolism nor show drug accumulation upon multiple-day dosing. Successful
outcomes will Finally, in vitro analyses will be successful will demonstrate that PWZ-029
does not induce its own metabolism nor show drug accumulation upon multiple-day
dosing. Finally, successful in vitro analyses will be defined as demonstration of an in
vitro selectivity profile ≥50-fold and a lack of gene toxicity.
Anticipated Problems and Solutions. The increased facial movements (i.e., twitching)
that were observed in the preliminary dose-ranging study may be confirmed or another
unanticipated DLT may be discovered. If increased facial twitching is confirmed, we will
determine whether it decreases or stops in a multiple-day dosing study (i.e., toleration).
Assessment of any toxicological observations will require their assessment in multipleday dosing studies and protocols will be designed to incorporate the necessary
measurements. Identification of off-target activity in the selectivity panel would first
require confirmation in secondary enzyme and/or cell-based assays. Confirmed off-
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target activity would require the evaluation of potential side effects and further toxicology
studies would need to incorporate assessment of these in study designs. Positive results
in the genetic toxicity assays would require the identification of a back-up compound
devoid of this activity.
Aim 2. Examine the potential of PWZ-029, an inverse agonist of α5GABAA
receptors, to mitigate cognitive deficits in a transgenic mouse model of AD.
Despite an ever-growing population of aged individuals, there are few, effective
therapeutic options for individuals suffering from cognitive deficits associated with AD.
To expand on our preliminary evidence that suggests inverse agonist action at α5subunit containing GABAA receptors can mitigate AD-associated cognitive decline, we
will test the efficacy of PWZ-029 to improve performance in the contextual-fear
conditioning assay with the APPswe Tg2576 mouse model of AD. All behavioral
experiments will be controlled with age-matched, non-transgenic littermates, as well as
positive and negative drug controls (n=10 mice/group). From these experiments, we
expect to gain proof-of-concept data that supports inverse agonist action at α5GABAA
receptors as a novel therapeutic option for improving cognition in those suffering from
AD.
Rationale: Research carried out to characterize the distribution of the various GABAA
receptor subtypes in rodent brains shows that α5GABAA subunits are highly
concentrated in the Ammon’s horn of the hippocampus, specifically in the CA1 dorsal
region [13, 14, 16]; a region of the hippocampus that is specifically targeted in contextdependent fear conditioning assays [46-50]. Furthermore, studies have shown that the
α5GABAA subunits are spared in the hippocampus, even with the pathophysiological
brain shrinkage and neuronal death that is commonly associated with AD [7, 29, 34-37].
To this end, we hypothesize that PWZ-029, an inverse agonist that has repeatedly
demonstrated high selectivity for α5GABAA receptors, will improve performance in
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context-dependent fear conditioning experiments, thereby establishing proof-of-concept
for a novel therapeutic mechanism to mitigate AD-associated cognitive decline.
Experimental Design: The following experiments will have oversight by Dr. Catherine
Kaczorowski, a leading AD expert from the Medical College of Wisconsin. The evidence
gained from these experiments will guide the direction in which impactful and successful
commercialization of PWZ-029 is most likely.
Formulation. Formulation of PWZ-029 will be carried out identically for all Aims. All
compounds will be administered via p.o. gavage 30-60 minutes prior to entering the fear
conditioning experiments. PWZ-029 will be synthesized by Cambridge Major
Laboratories (Germantown, WI). PWZ-029 will be administered to the animals only on
the day of training (see conditioning protocol below) at 10 mg/kg, a dose shown to
improve performance on memory tasks in adult mice (Figure 3) and rats (refer to MWM
data in the preliminary data section of this proposal), suggesting that a 10 mg/kg dose of
PWZ-029 will enhance cognition in the APPswe model [30, 39]. Premeasured amounts
of PWZ-029 will be dissolved in a widely used solvent that contains 85% distilled water,
14% propylene glycol, and 1% Tween 80 [30, 38, 39]. Donepezil (catalog # D6821),
which will serve as the positive drug control, will be purchased from Sigma-Aldrich (St.
Louis, MO), formulated in vehicle, and administered daily at 0.3 mg/kg for 6 weeks prior
to the fear-conditioning assay, including the training day of the behavioral assay [51, 52].
Triazolam, a non-selective BZ agonist that has been shown to inhibit performance in fear
conditioning assays [53] will serve as the negative drug control, and will also be
purchased from Sigma Aldrich (catalog # T9772), formulated in vehicle, and
administered at 0.03 mg/kg prior to the training phase of the fear conditioning protocol.
To acclimate all mice to the same handling/dosing exposure and to maintain blinded
treatments, PWZ-029 and triazolam groups will be dosed with vehicle for the 6-week
period that donepezil will be dosed prior to the conditioning assay. There will be no

doses administered on the testing day when freezing behaviors are scored.
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Research Model. Taconic Farms, Inc. (Hudson, NY) will provide male APPswe Tg2576
mice (001349-T-RD1) along with the age-matched, non-transgenic, wild type littermates
(001349-W-RD1). Prior to being shipped to the PhysioGenix Animal Facility, the mice
will be screened for the RD1 mutation, which causes blindness. Any animal carrying the
mutation will be excluded and replaced. Animals will be shipped from Taconic at ≈6
months of age and housed at PhysioGenix until the animals are aged to 9-12 months,
which is the age where Aβ deposition notably affects performance in memory tasks [54].
Body weights will be collected weekly for the entire duration that the animals are housed
at PhysioGenix as a means of monitoring animal health and to calculate dosing volumes
for each study animal.
Contextual fear conditioning assay to assess associative learning and memory.
Behavioral assays will be carried out in an isolated laboratory where traffic and sound
inference is negligible. Experiments will be carried out during the light phase of a 12/12hr
light/dark cycle, and all technicians will be blinded to the treatments of the animals. Fear
chambers will be procured from Med Associates (St. Albans, VT). Study animals will be
acclimated to the experimental room for 60-90 minutes before entering into the fearconditioning assay. After the period of acclimation, an animal will be placed into the fear
chamber, which will serve as the novel context, i.e., conditioned stimulus. The animal will
be allowed to explore the novel context for 148 s, at the end of which a foot shock
(duration of 2 s at 0.4 mA) will be introduced [55, 56]. The animal will remain in the
chamber for 30 s following the foot shock before returning to the home cage. Twentyfour hours later, the animal will be returned to the experimental room, allowed to
acclimate in the room, and placed back into the chamber. Freezing, which will be defined
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as the complete absence of movement, except for respiratory actions, will be scored
every 10 s for 4 min.
Benchmark for Success. Success will be defined as a significant increase (P<0.05) in
percent freezing at the 24-hour time point for APPswe transgenic and/or non-transgenic
mice treated with PWZ-029 relative to the negative controls (vehicle and triazolam).
Anticipated Problems and Solutions. If differences are not observed between the
treatment groups, we will consult Dr. Kaczorowski for procedural amendments that may
enhance the differentiating potential of the fear conditioning assay (e.g., condition mice
to the context prior to administering unconditioned stimulus training). We may still find
that PWZ-029 does not enhance performance in this mouse model and in this assay. If
these results are encountered, in our next round of funding, we will test the ability of
PWZ-029 to mitigate cognitive deficits in mouse models of ‘normal’ aging.
Aim 3. Examine the potential of PWZ-029 to enhance executive function and
memory in rhesus monkeys. Our research during the SBIR Phase I project showed
that PWZ-029 enhanced performance on the ORD task of executive function in a
manner consistent with a role for α5-containing GABAA receptors. We first will expand
these findings to assess specific aspects of executive function, including set-shifting and
response inhibition. In addition, we will introduce studies on working memory—a
cognitive domain regulated by and influencing executive function [57]. Notably, deficits of
this domain are considered a hallmark of AD [2, 44]. Finally, we will evaluate
fundamental processes that may influence results from executive function and memory
tasks, specifically attention and motivation.
Rationale: In order to evaluate the extent to which PWZ-029 enhances executive
function and memory, our proposal will utilize the Cambridge Neuropsychological Test
Automated Battery (CANTAB). A clear strength of the CANTAB approach is that its tasks
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are based on corresponding procedures developed for human patients, which will greatly
facilitate our ultimate goal of translating findings from monkeys to humans. For executive
function, we will use two tasks, including the intradimensional/extradimensional (ID/ED)
set-shifting task, which evaluates the ability of a subject to acquire discriminations,
attend to specific stimulus attributes, and shift attention to other attributes, thus providing
an assessment of cognitive flexibility. To evaluate “impulsivity,” a behavior shown to be
impaired in AD [58], we will use the delayed reinforcement choice (DRC) task, in which
monkeys must choose between a delayed, large reward or an immediate, small reward.
To assess memory, we will use the self-ordered spatial search (SOSS) task, which is a
short-term spatial working memory task similar to the radial-arm maze procedure used in
rodents [59]. Attention will be assessed with the serial-reaction time (SRT) task [60], and
motivational processes will be assessed with a progressive-ratio (PR) procedure.
Altogether, these tasks will provide a comprehensive evaluation of the ability of PWZ029 to enhance executive function and memory, as well as to assess the relative roles of
attentional and motivational variables that potentially contribute to PWZ-029’s ability to
enhance cognition.
Experimental Design: Our overall approach will be similar to that described for our
ORD results in the preliminary data section of this proposal (see Figure 4): (1) examine a
range of doses of PWZ-029 (0.001-1.0 mg/kg) compared to a positive control (donepezil,
0.01 or 0.03 mg/kg [61]); (2) assess the ability of PWZ-029 to reverse the performanceattenuating effects of scopolamine (0.01 mg/kg, which will serve as a negative control;
and (3) assess the ability of the preferential α5-containing receptor antagonist, XLi-093
(0.1-1.0 mg/kg), to block enhanced performance, if present, of a maximally effective
dose of PWZ-029.
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Route of Administration. In order to compare our results with the results from the Phase I
studies, we will initially administer all drugs via the i.v. route using indwelling chronic
venous catheters (implanted using the methods described in detail by Platt et al., 2011)
[62]. The use of the i.v. route will also help to minimize limitations of interpretation due to
differences in pharmacokinetic variables. Oral dosing is a key consideration, however,
and in the event that a positive effect of PWZ-029 emerges for a cognitive task, we will
evaluate targeted doses using the intragastric (i.g.) route via a nasogastric tube in awake
monkeys. Our co-PI, Dr. Rowlett, has extensive experience with this methodology [6369]. We will choose the maximally effective dose, assuming a decrease in potency when
switching from i.v. to i.g. administration, and increase (or decrease) the dose by ½ log
unit in order to adjust for potency differences across the two routes.
Subjects. Experiments will be conducted with adult male and female rhesus monkeys
(Macaca mulatta), born and reared at the New England Primate Research Center
breeding facility and/or obtained from outside sources. Based on our research during the
Phase I grant, as well as power analyses derived from the literature, we are proposing a
sample size of at least N=6 monkeys. For cognitive testing, monkeys will be prepared
with a non-allergenic nylon vest (Lomir Biomedical, Inc., Malone, NY) and seated in
primate chairs (Crist Instruments, Hagerstown, MD) enclosed in ventilated, soundattenuating chambers (Med Associates). All animals will be monitored for food intake,
and will undergo relatively mild food restriction, based on limiting caloric intake (for
detailed methods, see Taffe, 2004 [70]). The monkeys will be weighed and assessed for
body condition once per week. Weekly weighing of the conflict monkeys will occur
throughout the studies to adjust feeding based on a combination of weight, performance,
and overall health (assessed in consultation with the clinical veterinary staff).
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CANTAB tasks for assessing executive function, memory, attention, and motivation. All
monkeys to be used in this application will receive training to sit in the chair, with
different stages of training for the individual tasks (most monkeys will be trained and
ready by the project start date). During a given experimental session, the monkey will be
placed into the chair and brought to a sound-attenuated chamber (Med Associates) with
ventilation, white noise, and a CANTAB touch screen unit. Sessions typically last no
more than 2 hours, and 1 or 2 tasks are conducted per session (usually a single
session/day). During tests with PWZ-029 (administered 5-10 min before the session),
only a single task will be scheduled.

A

REWARD: SHAPE
1A. Simple
Discrimination
1B. Reversal
REWARD: SHAPE
2A. Compound
Discrimination
2B. Reversal
REWARD: SHAPE

3A. Intradimensional
Shift
3B. Reversal
REWARD: LINE
4A. Extradimensional
Shift
4B. Reversal

B

Simple
Discrimination

Intra-Dimensional
Shift

Compound
Discrimination

Extra-Dimensional
Shift

Figure 5. Attentional set-shifting in
monkeys. A. Diagram illustrating ID/ED task.
B. Representative baseline performance in a
rhesus monkey.
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Intradimensional/Extradimensional Set Shifting (ID/ED). This task consists of a series of
four discrimination learning stages, plus reversals, wherein touching only one of two
stimuli presented on the screen results in food pellet delivery (for summary, see Figure
5). Within any given stage of the task, a pair of stimuli is presented and the same
stimulus is associated with reinforcement (S+ stimulus) until the performance criteria are
met (18 of 20 consecutive trials correct). Correct choices must be made within 30 s, and
following a correct choice, the screen is blanked for 5 sec while an incorrect choice (Sstimulus) results in a 0.2 s tone and a 9-s period of blank screen. Four distinct stimulus
sets will be used in 4 stages. In the first stimulus set (stage 1A), two distinctly shaped
stimuli will be presented, with touches on one shape resulting in food pellet delivery.
Stage 1B will consist of a stimulus reversal, in which the same two shapes are retained,
but pressing the S+ stimulus now does not result in reinforcement, whereas touching the
former S- stimulus will result in food pellet delivery. In Stage 2A, a compound
discrimination is presented. For this discrimination, the two shapes from Stage 1B are
present, but additional stimuli, consisting of lines, will be superimposed onto the existing
shapes. Because the shape discrimination from the previous stage does not change, the
lines are irrelevant to this discrimination. Stage 2B will consist of a shape reversal,
similar to Stage 1B.
Stage 3A will consist of the ID shift stage. For this discrimination, two new shapes with
new lines will be presented. This is considered an ID shift due to the fact that despite
new shapes and lines being introduced, the shape remains the relevant dimension for
the discrimination. Stage 3B will consist of a reversal of the shape S+ and S- from Stage
3A. In the final two stages, the ED shift will be introduced. Thus, in Stage 4A, new
shapes and lines will be presented; however, the lines—not the shape—will be the
relevant discriminative stimulus. Stage 4B will consist of a reversal of the line S+ and S-
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contingencies. Performance is determined as the number of errors at each stage, and
the data will be subjected to a square root transformation to achieve normal distributions
[59]. Data will be analyzed with repeated measures ANOVA and Bonferroni t-tests for
multiple comparisons.
Delayed Reinforcement Choice (DRC). Our preliminary data with the ORD task
suggested the possibility that PWZ-029 enhances the ability of the monkey to withhold or
inhibit prepotent responding. The ID/ED task will allow recording of persistent incorrect
responding, similar to barrier reaches in the ORD task. A prominent interpretation of this
type of behavior is dysfunctional inhibitory control, or “impulsivity.” A more complex form
of inhibitory control involves choice behavior, which can be investigated using the DRC
task, also commonly referred to as “delayed discounting” task.
The CANTAB “Impulsive Choice” task offers subjects a choice between two reinforcers,
which can differ in magnitude, probability, and delay. We are focusing on delay of
reinforcement in the DRC task, based on pharmacological studies [71, 72]. In this task, a
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Figure 6. Delayed reinforcement choice task from the monkey CANTAB system.
A. Schematic of the task.
B. Prediction of the effects of a cognitive enhancer on data analyzed by discount
functions. The k rate is the slope of discounting for the hyperbolic function—in this
example, k is reduced by the cognitive enhancer, indicating a higher degree of choice for
the larger, but delayed, reward.
choice is offered between a relatively large reward (4 or more food pellets) and a small
reward (1 food pellet). A trial will initiate by a touch of a single stimulus, which is
replaced by two stimuli, referred to as the “delay” and “immediate” stimulus. Touching
the delay stimulus results in a blank screen for a specified duration (e.g., 0-80 s),
followed by a signaled delivery of the large reward. Touching the immediate stimulus will
result in signaled delivery of the small reward with no delay. After reward, the screen will
be blank for 10 s. Data will be analyzed initially by comparing the percentage of delay
stimulus responding as a function of delay (typical delay sequence= 0, 10, 20, 40, 80 s,
randomly presented). As the delay is increased, animals characteristically choose the
large reward less [71] (for summary, see Figure 6A). An improvement in performance by
PWZ-029 would be manifested as a significant increase in percentage of choices for the
delayed, yet larger reward, relative to control conditions. Data also may be analyzed
using a hyperbolic discounting function [73], which provides a rate (k) of discounting
value (Figure 6B). Enhancement of performance by PWZ-029 would be reflected as a
significant decrease in the k value.
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Self-Ordered Spatial Search (SOSS). The SOSS task is a short-term spatial working
memory task similar to the radial-arm maze procedure used in rodents (see Figure 7,
[59]).
Touch
(reward)
Correct
Incorrect

Touch
(reward)
Correct

Incorrect

Incorrect
Correct

Figure 7. Self-ordered spatial search (SOSS) task
from the monkey CANTAB system.

In each trial, two, three or four small, colored, rectangular boxes are displayed on the
screen in positions randomly allocated from 16 possible locations. The monkey must
touch a box within 30 s of stimulus onset. After each successful touch, the color of the
touched box is briefly (100 ms) changed and the screen is then blanked and a reinforcer
delivered. After a 2-s delay, the boxes are re-displayed and the monkey must touch a
box that was not previously touched in the trial in order to receive a food pellet. The trial
is completed when the animal has either touched all boxes without a repetition (correct),
touched a box that had previously been selected in that trial (error), or failed to touch a
box within 30 s of stimulus presentation (omission). A tone and a 4-s screen blank will
follow errors and omissions. After 5 s, another trial is presented with stimuli in new
(randomly allocated) positions. A session will consist of 40 trials grouped into 6 blocks
that differ according to the number of boxes presented. The different blocks, with
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number of trials in parentheses, will be: 2 boxes (5), 3 boxes (7), 4 boxes (7), 3 boxes
(8), 4 boxes (8), and 2 boxes (5). Accuracy scores will be calculated for each trial type
by dividing the number of correctly completed trials by the number of trials in which there
was at least one response (omissions will be excluded from the calculation). Accuracy
scores will be analyzed by repeated measures ANOVA and Bonferroni t-tests, with trial
type and PWZ-029 dose as factors.
Serial Reaction Time (SRT). This task is based on methods described in detail by Weed
and Gold [60]. Briefly, the task consists of a discrete-trials procedure in which each trial
begins with the presentation of a grid with 5 open circles (3 cm diameter) on the touch
screen. The monkeys will be trained to press and hold a lever for a variable duration
(between 0.75 to 2.5 s, randomly determined) and then to release the lever at the onset
of a 2 cm yellow stimulus presented in one of the 5 circles. If the monkey touches this
circle within 2 s, the screen will go blank and 2 food pellets will be delivered, and a 3 s
inter-trial interval will begin. The yellow stimulus duration will consist of brief flashes of
0.02, 0.1, and 1.0 s durations. If the monkey fails to press the lever or fails to respond to
the screen within the allotted time, or touches an incorrect circle, then a tone will sound
and the screen will go blank for 4 s until the next trial, with no food reward given (for
summary, see Figure 8).
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Depress Lever

Release Lever &
Touch Stimulus

Figure 8. Serial reaction time task from the monkey
CANTAB system.

Each session will consist of 45 trials with the 3 flash durations presented randomly 3
times in each of the 5 choice circles.
Data that will be analyzed include latency to release the lever following stimulus onset
and the time taken to move the hand from the lever to the screen. Failure to touch the
screen after pressing the lever will be considered an omission error, which will be
analyzed as the average number of errors per trial.

All data will be analyzed with

repeated measures ANOVA with dose and stimulus duration as factors, as well as with
Bonferroni t-tests for multiple comparisons.
Progressive-Ratio (PR) schedule of reinforcement. PR procedures consist of response
requirements that progressively increase across a session until responding ceases
(Figure 9). The last response requirement completed, termed “break point,” provides a
quantitative measure of the reinforcing effectiveness of a stimulus. For these studies, a
colored box appearing in the middle of the screen will initiate a session. Touching the
box once will result in food pellet delivery, and the response requirement will
progressively increase following each reinforcer by an incremental value beginning at 1
and doubling after 8 response requirements are completed successfully. Thus, the
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response requirement sequences will consist of: Increment=1, response requirements=1,
2, 3, 4, 5, 6, 7, 8; Increment=2, response requirements=10, 12, 14, 16, 18, 20, 22, 24;
Increment=4, response requirements=28, 32, 36, 40, 44, 48, 52, 56; and so on.

Progressive-Ratio Schedule of Reinforcement
INC: +1

+2

+3…

RR: 1, 2, 3, 4, 5, 6, 7, 8 9, 11, 13, 15, 17, 19, 21, 23 24, 27,…

#RR:

8

8

8

INC: increments in response requirements
RR: response requirement
#RR: number of response requirements

#Reinf Delivered (mean +/- SEM)

Progressive-Ratio

*

12

*

10
8
6
4
2
0
water

0.05

0.2

0.8

Saccharin Concentration (%, w/v)

Figure 9. Schematic of
progressive-ratio schedule
of food delivery, from the
monkey CANTAB system.
The left panel represents PR
data collected with the
CANTAB
system,
with
behavior maintained by liquid
saccharin delivery. Data show
N=8 rhesus monkeys.

Sessions will be a maximum of 20 min and will be terminated if 3 min elapses without a
response. Performance will be measured as the break point and number of food pellets
delivered per session. This procedure provides a measure of the ability of the animal to
respond, as well as an assessment of “motivation” to perform. We do not anticipate that
PWZ-029 will significantly alter the mean break points or number of food pellets
delivered, which would rule out changes in motivational levels as an interpretation for
changes in cognitive performance.
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Benchmark for Success. Success will be defined as α5-containing receptor mediated
enhancements in ID/ED, DRC, and SOSS performance, in the absence of robust
changes in SRT and PR.
Anticipated Problems and Solutions. SRT enhancements might suggest that broader
cognitive processes are augmented simply due to an enhancement in attention, which in
and of itself might be therapeutically useful. Change in PR performance, however, is a
more significant issue, given that increases in motivation might explain increases in task
performance by a non-cognitive mechanism (e.g., enhanced food palatability). We are
unaware of any precedent in the literature for this type of effect.
Recent evidence has suggested an age-dependency for cognitive-enhancing effects of
inverse agonists at α5 subunit-containing GABAA receptors [15]. For our ORD studies,
the monkeys generally were in the “middle-aged” category (≈15-20 years old), a time
period documented to show mostly moderate cognitive impairments [57, 74] and a
similar group of monkeys will be available for the present project. If warranted, future
plans will involve targeted cognitive tests with PWZ-029 in aged monkeys (20+ years
old) depending on availability of monkeys in this age range.
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PWZ-029 Preliminary Data Compilation
BINDING AFFINITY
Experiment
Type of Test

Functional
and subtype
selectivity
of PWZ-029

Model

Used to determine the
subtype selectivity of
PWZ-029 to the
Xenpus oocytes
GABAA receptors, electrophysiology
especially the α5
subtype.

Mouse fibroblast
Used to determine the
L(tk ) cells
Binding
affinity of PWZ-029
expressing
Affinity of
to the GABAA
recombinant
PWZ-029
receptor subtype, α5. human GABAA
receptor subunits

Figure

Summary of Results
PWZ-029 concentrations
of up to 1 μM
demonstrated a
significant 20% reduction
of control GABA elicited
current indicating a
partial inverse agonist
effect at GABAA
receptors possessing the
α5 subtype. PWZ-029
also exhibited agonistic
selectivity for the α1 and
α3 bearing GABAA
receptors. P<0.01,
Student's t-test.

PWZ-029 binding affinity
for α5 sutypes are near 60fold times that of α1
subunits.
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PWZ-029 Preliminary Data Compilation
SIDE-EFFECTS
Experiment

Type of Test

Convulsant/
Used to determine the
Proconvulsant convulsant/proconvulsant
Effects
drug side-effects.

Model
Male Swiss mice
(Crl:CFW(SW))
treated with
pentylenetetrazole
(PTZ)
A.

Summary of Results

N/A

PWZ-029 did not cause
convulsions at any
concentration (10, 20, or 40
mg/kg) in the PTZ mouse
model.

Rotarod Test: Motor Coordination in Dahl/SS
Rats

Latency to Fall (s)

200
150

Group 1:Vehicle - Saline
Group 2: Diazepam (3 mg/kg)

100

Group 3: PWZ-029 (5 mg/kg)

50

Group 4: PWZ-029 (10 mg/kg)
Group 5: PWZ-029 (20 mg/kg)

0
Treatment Groups

Rotarod Test: Percent Success in Dahl/SS Rats
100
Success Rate (%)

Rotarod

Rotarod tests are used to
assess motor coordination.
The longer an animal
stays on the rotating rod,
the more coordination
their motor skills. The
test further assesses drug
side-effects, such as
dizziness and muscle
relaxation. If these effects
are present the subject is
expected to spend less
time on the rotating rod.

Dahl Salt-Sensitive
(SS) rats
(n=12/group) were
treated per os with
either vehicle,
diazepam, or one of
three concentrations
of PWZ-029. After
a training period, the
animals were
B.
subjected to the
rotating rod test for
a maximum of 300
seconds.

Figure

No significant decrease in
motor coordination was
observed at any of the three
PWZ-029 concentrations.
However, the success rate of
rats increased with PWZ029 treatment.

Group 1:Vehicle - Saline
Group 2: Diazepam (3 mg/kg)

50

Group 3: PWZ-029 (5 mg/kg)
Group 4: PWZ-029 (10 mg/kg)
Group 5: PWZ-029 (20 mg/kg)

0
Treatment Groups
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PWZ-029 Preliminary Data Compilation

SIDE-EFFECTS Continued
Experiment
Type of Test

Model
C.

Operant
Responding

Very basically assesses
the individual's
response that is
required to carry out
cognitive tasks. This
experiment is highly
sensitve to sedativemotor effects of
conventional
benzodiazepines (e.g.
alprazolam).

Figure
Operant Responding

Summary of Results

Rhesus monkeys
treated with vehicle
and then increasing
concentrations of
alprazolam or PWZ029. This Operant
Responding task
required the animal to
press the lever 20
times to receive a
food pellet.

PWZ-029 showed no
evidence of inhibition
in the baseline levels of
operant responding
maintained by food.

Table 2. Analysis of all behavioral categories following multiple doses of the three test compounds. Significant effects were identified as
at least one dose significantly different from vehicle (N=4-5 monkeys). See Table 1 for definitions of abbreviations.

Based on defined
behaviors observed in
animals under baseline
Observational
conditions, post-dose
Studies
observations are
indicative of drug sideeffects.

Rhesus monkeys were
treated with vehicle,
alprozolam, zolpidem,
or PWZ-029. Postdose observations
were documented as
no change, increase,
decrease or increase
and decrease in
respective behavior.

Compounds

No Change

Increase

Decrease

Alprazolam

Loc, Grm, Scr, Ste, For,
Voc, Thr, Yaw, BSm, Pre,
Dri, NRu, LSm, CSh, LDr

RSP, MSe, DSe, Atx

Pas, Tac

Zolpidem

Loc*, Grm, Scr, Ste, For,
Voc, Thr, Yaw, BSm, Pre,
Dri, NRu, LSm, RSP, MSe,
CSh, LDr
Pas, Loc, Grm, Tac, Scr,
Ste, For, Voc, Thr, Yaw,
BSm, Pre, Dri, NRu, Atx,
LSm, RSP, CSh, MSe, DSe,
LDr

DSe, Atx

Pas

PWZ-029

Increase & Decrease

Tac

No increase or decrease
in behavior were
observed for PWZ-029.

*Loc was associated with a significant overall main effect of dose (ANOVA) but none of the doses were significantly different from vehicle
(Bonferroni t-tests, P>0.05).
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PWZ-029 Preliminary Data Compilation
SIDE-EFFECTS Continued
Experiment
Type of Test

Sedation
Measures

Based on defined
sedative postures
for primates,
sedative side-effects
can be measured
with these
experiments.

Model

Rhesus monkeys
were treated with 3.0
mg/kg PWZ-029
(i.v.) or one of two
concentrations of
alprazolam and then
monitored for 120minutes post-dose.

Figure

Summary of Results

PWZ-029 did not alter
either species-specific
behavior or induce
significant signs of
sedation at doses 200300 times higher than the
lowest dose that
enhanced ORD
performance.
Conversely, the nonselective benzodiazepine
alprazolam suppressed
some aspects of normal,
species-typical behavior
and engendered
rest/sleep posture,
moderate and deep
sedation; thus providing
a positive control for the
PWZ-029 data.
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IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY
Experiment

Type of Test

Model

Scopolamine-treated
C57BL/6 mice
(n=12/group) - Each
mouse received i.p.
Pavlovian
Assesses the
injections with either
Fear
contexual fear
vehicle (0.9% saline
Conditioned
response (i.e. freezing)
containing 2.5%
Contexual
to stimulus.
encapsin), 1.5 mg/kg
Memory
scopolamine, or 1.5
mg/kg scopolamine
plus 10 mg/kg PWZ029.

Figure

Summary of Results

PWZ-029 attenuated the
scopolamine-induced
impairment of contextual
memory [3]. ***p <0.05.
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IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY Continued
Experiment

Object
Retrieval
with
Detours
(ORD)

Type of Test

Model

Rhesus monkeys were
treated with vehicle or
1 of 3 concentrations
ORD is a manual
of PWZ-029 and then
test sensitive to
subjected to 15 mixed
frontostriatal
or difficult task
deficits that
configurations over 14investigates
21 experimental
executive
sessions. The percent
function.
success rate of object
retrieval was
measured.

Figure

Summary of Results

PWZ-029 enhanced cognition
under conditions in which
baseline performance was
impaired (i.e. difficult trials).
*P<0.05 vs. vehicle (V)
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Type of Test
Model

Figure

Summary of Results

Rhesus monkeys were
treated with vehicle,
ORD is a manual scopolamine, or 1 of 3
test sensitive to concentrations of PWZObject
frontostriatal
029 and then subjected
Retrieval with
deficits that
to 15 mixed or difficult
Detours
investigates
task configurations over
(ORD)
executive
14-21 experimental
function.
sessions. The percent
success rate of object
retrieval was measured.

Scopolamine-induced deficits
in ORD performance were
reduced with PWZ-029.
*P<0.05 vs. Vehicle (V);
**P<0.05 vs. scopolamine (S)

Rhesus monkeys treated
with vehicle or
increasing
concentrations of PWZ029 (n=2-3), and
subjected to DNMS
tasks with and without
delay.

Performance was not affected
by PWZ-029 without delay.
A 0.1 mg/kg dose of PWZ029 significantly enhanced
performance when a 1-minute
delay was introduced.
*P<0.05

Delayed NonMatch to
Sample Task
(DNMS)

Short-term
recognition
memory task
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Model
Figure

Summary of Results

DNMS

Rhesus monkeys
treated with vehicle or
0.01 mg/kg of PWZShort-term
029 (n=4), and
recognition memory subjected to DNMS
task
tasks without delay,
as well as with a 10minute delay and
distractors.

At 0.01 mg/kg, PWZ-029
significantly enhances
recognition memory in the
DNMS task when a 10-minute
delay and distractors are
introduced. *P<0.05

Object
Retrieval
with
Detours

Rhesus Monkeys
treated with and
Theorized to assess
without scopolamine
Executive Function
and/or PWZ-029
(n=4).

PWZ-029 appeared to recover
the scopolamine-induced deficit
of retrieving the objects.
*P<0.05 vs. no treatment (first
bar)
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Model
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MWM

MWM

PWZ-029 significantly improves
the ability of SS rats to acquire
the location of the hidden
platform after four days of
acquisition training.

Male, Dahl SS, n=10,
red bars = 10 mg/kg
PWZ-029

Male, FAB-Samaritan
rats; blue bars =
Assess spatial
positive control, red
learning and
bars = negative control,
working memory green bars = donepezil,
3 mg/kg; turquoise bars
= PWZ-029, 10 mg/kg

Male, FAB-Samaritan
rats; blue bars =
positive control, red
Assess spatial
bars = negative control,
learning and
working memory green bars = donepezil,
3 mg/kg; turquoise bars
= PWZ-029, 10 mg/kg

Distance (m)

Acquisition
Assess spatial
Phase of
learning and
MWM
working memory

Summary of Results

5.0
4.0
3.0
2.0
1.0
0.0

#
Day 1 Visible

Day 2 Hidden

Day 3 Hidden

Platform Phase

#

On the second week of the
MWM protocol, PWZ-029
significantly improved
performance in the experiment
compared to the Group 2
(negative control).

On the second week of the
MWM protocol, PWZ-029
significantly improved
performance in the experiment
compared to the Group 2
(negative control).
475

476

CURRICULUM VITAE

Full Name: Sundari K. Rallapalli

Place of birth: Secunderabad, India, March 26

Education:
University of Wisconsin-Milwaukee

08/2006-12/2012

Ph. D.

Tennessee Tech. Univ., Cookeville, TN

08/1999-08/2001

M.S.

Osmania University, Hyderabad, India

06/1996-06/1998

M.Sc.

Dissertation Title:
I.

The First Enantiospecific, Stereospecific Total Synthesis of the Indole
Alkaloid Ervincidine

II.

Synthesis.of.Alpha.5.Subtype.Selective.Ligands.for.GABA(A)/Benzodiazepine Receptors

Affiliation:
Member of the American Chemical Society
Publications
1. “A Study of the Structure-activity Relationship of GABAA-benzodiazepine
Receptor Bivalent Ligands by Conformational Analysis with low Temperature
NMR and X-ray Analysis”, Han, D., Forsterling, H.F., Li, X., Deschamps, J.R.,
Parrish, D., Cao, H., Rallapalli, S., Clayton, T. , Teng, Y., Majumder, S., Sankar,

477
S., Roth, B.L., Sieghart, W., Furtmuller, R., J.K. , Weed, M.R., Cook, J.M.
Bioorg. and Med. Chem., 16, 8853-8862 (2008).
2. “General Approach to the Total Synthesis of Macroline Related Sarpagine and
Ajmaline Alkaloids”, Edwankar, C., Edwankar, R. V., Rallapalli, S., Cook, J.
Natural Product Communications, 11, 1839-1870 (2008).
3. “Effects of a Novel Inverse Agonist Selective for Alpha5 GABA(A) Receptors on
Spatial Memory: Comparison with the Standard Non-Selective Inverse Agonist
DMCM”, Samardzic, J.,Savic, M., Clayton, T., Rallapalli, S., Obradovic, D.,
Joksimovic, S.M. Seighart, W. Cook, J. Congress of the European-College-ofNeuropsychopharmacology, Aug 30-Sept 03, 2008, Barcelona, Spain, European
Neuropsychopharmacology, S285-S-285 Supplement, Suppl.4 (18 pages),
published August 2008.
4. “An Improved Process for the Synthesis of 4H-Imidazo [1,5-a][1,4]benzodiazepines”,
Yang, J., Teng, Y., Ara, S., Rallapalli, S., Cook, J. Synthesis, 6, 1036-1040 (2009).

5. “The Differential Role of α1 and α5 Containing GABAA Receptors in Mediating
Diazepam Effects on Spontaneous Locomotor Activity and Water Maze Learning
and Memory in Rats”, Savic, M.M.; Milinkovic, M.M.; Clayton, T., Rallapalli,
S., Joksimovic, Van linn, M., Cook, J.M. International Journal of
Neuropsychopharmacology, 12, 1179-1193 (2009).
6. “Recent Progress in the Total Synthesis of Indole Alkaloids”, Edwankar, C. R.,
Edwankar, R, V., Namjoshi, O. A., Rallapalli, S. K., Yang, J., Cook, J. M. Curr.
Opin. Drug Discovery Dev. 12 (6), 752-771 (2009).
7. “The First Enantiospecific Total Synthesis of the 3-Oxygenated Sarpagine Indole
Alkaloids Affinine and 16-Epiaffinine as well as Vobasinediol and 16-

478
Epivobasinediol”, Yang, J., Rallapalli, S. K., Cook, J. M. Tetrahedron Lett., 51,
815-817 (2010).
8. “Enantiospecific Total Synthesis of the Important Biogenetic Intermediates along
the Ajmaline Pathway, (+)-Polyneuridine and (+)-Polyneuridine Aldehyde, as
well as 16-Epivellosimine and Macusine A”, Yin, W., Kabir, M. S., Wang, Z.,
Rallapalli, S. K., Ma, J., Cook, J. M. J. Org. Chem. 75, 3339-3349 (2010).
9. “α4-Containing GABA (A) Receptors are Required for Antagonism of EthanolInduced Motor in Coordination and Hypnosis by the Imidazobenzodiazepine
Ro15-4513,” Iyer, S. V.; Benavides, R. A.; Chandra, D.; Rallapalli, S.; Cook, J.;
June, H. L.; Homanics, G. E., Frontiers in Pharmacology, 2, 18, 1-7 (2011).
10. “Lifelong CRF Overproduction is Associated with Altered Gene Expression and
Sensitivity of Discrete GABAA and mGlu Receptor Subtypes,” Vinkers, C.;
Hendriksen, H.; Oorshot, R.; Cook, J.; Rallapalli, S.; Huang, S.; Millian, M.;
Oliver, B.; Groenink, L., Psychopharmacology, 219 (3), 897-908 (2012).
11. “The Role of α1 and α5 Subunit-Containing GABAA Receptors in Motor
Impairment Induced by Benzodiazepines in Rats”, Milic, M.; Divljakovic, J.;
Rallapalli, S.; Van Linn, M.L.; Timic, T.; Cook, J. M.; Savic, M. M., Behav.
Pharmacol., 23 (2), 191-197( 2012).
12. “Modulation of α5 Subunit-Containing GABAA Receptors Alters Alcohol
Drinking by Rhesus Monkeys”, Ru¨edi-Bettschen, D.; Rowlett, J. K.; Rallapalli,
S.; Clayton, T.; Cook, J. M.; Platt, D. M., Alcoholism Clin. and Exp. Res., DOI:
10.1111/acer.12018 (2012).

479
13. "Search for α3 β2/3 γ2 Subtype Selective Ligands That are Stable on Human
Liver Microsomes", Namjoshi, O.; Wang, Z.; Rallapalli, S.; Johnson, E. M.;
Johnson, Yun-Teng; Ng, H.; Ramerstorger, J.; Sieghart, W.; Roth, B.; Rowlett,
J.K.; Cook, J. M., Bioorg. and Med. Chem., accepted (2012).
14. “Cognition Impairing Effects of Benzodiazepine Type Drugs: Evaluation of the
Role of GABAA Receptor Subtypes in Spatial Recognition Memory and
Executive Function Tasks”, Makaron, L.; Moran, C.; Namjoshi, O.; Rallapalli,
S.; Cook, J.; Rowlett, J., Eur. J. Neuropsychopharmacology, 00, 0000-0000
(2013).
15. “Subtype Selectivity of α+β− Site Ligands of GABAA Receptors-Identification
of the First Highly Specific Positive Modulators at α6β (2/3)γ2 Receptors”,
Varagic, Z.; Ramerstorfer, J.; Huang, S.; Rallapalli, S.; Sarto-Jackson, I.; Cook,
J.; Sieghart, W.; Margot, E., J. British Pharmacol., 00, 0000-0000 (2013).
16. “Allosteric Modulation of GABA (A) Receptors Compared to Non-GABAergic
Compounds: Effects on Visuo Spatial Memory in Rhesus Monkeys”, P. Soto, N.
Ator, S. Rallapalli, P. Biawat, T. Clayton, C. Brayton, J. Cook, M. Weed.,
Psychopharmacology, 00, 0000-0000 (2013).
17. “The First Enantiospecific, Stereospecific Total Synthesis of Indole Alkaloid
Ervincidine”, Rallapalli, S. K.; Cook, J.M., Org. Lett., Manuscript in
preparation.
18. “eQTL and receptor pharmacology implicate GABA signaling in neuroblastoma”,
Hackett, C. S.; Quigley, D. A.; Fan, Q.;Cheng, C.;Song, Y. K.; Pawlikowska, L.;

480
Chen, J.; Bao, Y.; Goldenberg, D.D.; Nguyen, K.; Cho, Y.C.; Rallapalli, S.K.;
Cook, J. M.; Kozlov, S.; Mao, J.; Van Dyke, T.; Kwok, P. Y.; Khan, J.; Balmain,
A.; Weiss, W. A., Nature, 00, 0000-0000 (2013).
Patents
1. “GABAergic Agents to Treat Memory Deficits”, Cook, J. M. Clayton, T., Teng, Y.,
Rallapalli, S. K., Han, D.,

U. S. Patent publication no 2010/0130479 A1,

Published May 27, 2010.
2. “Gabaergic Receptor Subtype Selective Ligands and their Uses”, Cook, J. M.,
Rallapalli, S.; Clayton, T.; Jain, H.; Yang, J.; Teng, Y.; Poe, M.M., Namjoshi, O.;
Wang, Z., U.S. Patent publication no 2012/0295892 A1, Published November 22,
2012.

Major:

Organic Chemistry

Minor:

Physical Chemistry

